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   1	  
INTRODUCTION	  
	  
The	  field	  of	  Intellectual	  Property	  is	  an	  important	  and	  very	  necessary	  area	  of	  law	  that	  
provides	  protection	  to	  those	  responsible	  for	  creating	  property	  that	  will	  ultimately	  benefit	  
society.	  	  Patent	  law	  protects	  property	  within	  the	  field	  of	  science	  and	  technology.	  Research	  
and	  development	  have	  substantial	  economic	  value,	  therefore	  it	  is	  essential	  that	  their	  
growth	  be	  promoted.	  It	  is	  crucial	  that	  patent	  law	  is	  frequently	  reviewed	  as	  new	  technologies	  
are	  constantly	  emerging	  and	  existing	  patent	  frameworks	  may	  not	  sufficiently	  accommodate	  
these	  new	  and	  overly	  complex	  technologies.	  Additional	  guidelines	  may	  be	  required	  so	  as	  to	  
fill	  in	  these	  “blanks”	  and	  avoid	  problems	  ensuing	  between	  existing	  patents	  and	  new	  patent	  
applications.	  Additional	  guidelines	  may	  be	  required	  as	  to	  the	  relevant	  prior	  art,	  which	  has	  to	  
be	  taken	  into	  account	  when	  examining	  inventions	  in	  the	  area	  of	  nanotechnology,	  bearing	  in	  
mind	  the	  multi-­‐disciplinary	  character	  of	  this	  new	  technology.	  
	  	  
Patent	  systems	  are	  the	  necessary	  framework	  in	  which	  the	  protection	  of	  inventions	  is	  
regulated	  and	  innovation	  is	  encouraged	  to	  stimulate	  technological	  development	  by	  offering	  
financial	  incentives	  in	  return	  for	  public	  disclosure	  of	  the	  invention.	  This	  in	  turn	  promotes	  
competition	  ultimately	  resulting	  in	  economic	  growth,	  as	  local	  and	  foreign	  investors	  may	  be	  
interested	  in	  investing	  in	  the	  R&D	  of	  an	  invention.	  Although	  by	  the	  adoption	  of	  the	  
International	  Agreement	  on	  Trade	  Related	  Aspects	  of	  Intellectual	  Property	  Rights	  (TRIPS	  
Agreement)	  in	  1994,	  minimum	  standards	  binding	  all	  Members	  of	  the	  World	  Trade	  
Organization	  (WTO)	  as	  regards	  the	  availability	  of	  patents	  for	  any	  inventions,	  whether	  
products	  or	  processes,	  in	  all	  fields	  of	  technology,	  provided	  that	  they	  are	  new,	  involve	  an	  
inventive	  step	  and	  are	  capable	  of	  industrial	  application,1	  have	  been	  introduced,	  
governments	  continue	  to	  have	  the	  freedom	  to	  formulate	  and	  implement	  measures	  to	  
effectively	  manage	  and	  develop	  intellectual	  property	  in	  their	  national	  intellectual	  property	  
policies	  and	  strategies,	  provided	  that	  they	  are	  in	  compliance	  with	  the	  TRIPS	  Agreement	  
standards.2	  As	  a	  result	  national	  patent	  laws	  still	  differ	  from	  one	  country	  to	  another	  and	  it	  is	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  TRIPS	  Article	  27:	  Patentable	  subject	  matter.	  	  	  2	  Other	  important	  TRIPS	  patent	  provisions	  relate	  to	  the	  rights	  a	  patent	  confers	  on	  its	  owner	  (Article	  28),	  
disclosure	  requirements	  (Art.	  29),	  exceptions	  to	  rights	  conferred	  by	  a	  patent	  (Art.	  30),	  conditions	  under	  which	  
compulsory	  licenses	  can	  be	  granted	  (Art.	  31),	  the	  term	  of	  patent	  protection	  (Art.	  33),	  and,	  e.g.,	  the	  
	   2	  
decisive	  for	  inventors	  that	  they	  are	  familiar	  with	  those	  existing,	  often	  very	  important	  
differences.	  Thus,	  comparing	  the	  patent	  systems	  of	  developed	  countries,	  such	  as	  Europe	  
and	  the	  U.S.,	  to	  those	  of	  a	  developing	  country	  such	  as	  South	  Africa,	  could	  provide	  potential	  
applicants	  with	  valuable	  guidance.	  
	  
Patents	  are	  valuable	  not	  only	  to	  the	  inventor,	  as	  the	  exclusive	  holder	  of	  the	  rights	  but	  also	  
serve	  as	  a	  comprehensive	  source,	  providing	  vital	  commercial,	  legal	  and	  technical	  
information	  pertaining	  to	  the	  invention.	  This	  enables	  improvements	  and	  advancements	  of	  
technologies	  already	  described	  in	  published	  patent	  applications	  and	  patents.	  Such	  
improvements	  may	  qualify	  as	  a	  new	  invention	  provided	  that	  certain	  requirements	  are	  met.	  
The	  most	  significant	  being	  novelty	  and	  non-­‐obviousness.	  	  
	  
Patent	  law	  and	  nanotechnology,	  when	  separately	  considered,	  are	  interesting	  subjects	  but	  
when	  nanotechnology	  is	  viewed	  in	  light	  of	  patent	  law,	  certain	  characteristics	  of	  this	  
technology	  challenge	  traditional	  IP	  practices,	  making	  for	  stimulating	  inquiry.	  	  
Understandably	  this	  is	  not	  the	  first	  time	  a	  new	  technology	  has	  emerged	  and	  faced	  
challenges	  relating	  to	  its	  patentability,	  however,	  different	  technologies	  may	  present	  
different	  challenges.	  On	  the	  surface,	  nanotechnology	  may	  display	  a	  palpable	  deficiency,	  due	  
to	  its	  newness	  the	  term	  “nano”	  is	  used	  generically	  to	  describe	  anything	  of	  a	  diminutive	  
nature.	  A	  tremendous	  amount	  of	  confusion	  has	  ensued.	  For	  this	  reason	  it	  is	  essential	  that	  a	  
comprehensive	  understanding	  is	  had	  of	  nanotechnology.	  	  
	  
South	  Africa	  has	  made	  large	  financial	  contributions	  to	  further	  research	  in	  the	  field	  of	  
nanotechnology,	  making	  this	  a	  locally	  relevant	  topic.	  This	  study	  hopes	  to	  uncover	  the	  
fascinating	  science	  that	  is	  nanotechnology	  and	  determine	  the	  scope	  of	  its	  subject	  matter.	  
Essential	  elements	  necessary	  for	  drafting	  a	  comprehensive	  patent	  application	  for	  a	  nano-­‐
related	  invention	  will	  be	  examined	  in	  detail.	  The	  substantive	  requirements	  will	  be	  addressed	  
individually,	  clarifying	  the	  challenges	  that	  nanotechnology	  presents	  and	  achievable	  
solutions	  to	  overcome	  these	  challenges	  will	  be	  proposed.	  The	  application	  process	  South	  
Africa	  employs	  for	  patents	  differs	  to	  that	  of	  Europe	  and	  the	  USA.	  These	  differences	  will	  be	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
enforcement	  of	  intellectual	  property	  rights	  in	  general	  (Art.	  41	  et	  seq.).	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discussed	  in	  greater	  detail	  and	  possible	  improvements	  to	  existing	  patent	  practices	  will	  be	  
presented.	  Furthermore	  current	  nanotechnology	  projects	  in	  respect	  of	  which	  South	  Africa	  is	  
involved	  will	  be	  revealed	  as	  well	  as	  any	  international	  contributions	  to	  the	  field	  of	  
nanoscience	  and	  nanotechnology.	  Ultimately	  inferring	  whether	  South	  Africa	  is	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CHAPTER	  1	  
THE	  SCIENCE	  OF	  NANOTECHNOLOGY	  
	  
1. NEW	  ADVANCEMENTS	  IN	  TECHNOLOGY:	  THE	  DEFINITION	  AND	  SCOPE	  OF	  
NANOTECHNOLOGY	  	  
	  
Globally	  nanotechnology	  has	  become	  a	  buzzword.	  It	  has	  a	  multidisciplinary	  application	  and	  
as	  such	  this	  fascinating	  new	  technology	  is	  expected	  to	  facilitate	  great	  advances	  in	  many	  
different	  fields	  of	  science	  and	  technology,	  including	  that	  of	  medicine,	  electronics,	  
biomaterials,	  energy	  production,	  generation	  and	  storage.	  Herein	  also	  lies	  the	  potential	  for	  
all	  of	  the	  abovementioned	  fields	  to	  converge,	  creating	  infinitely	  varied	  applications	  of	  
previously	  separate	  disciplines.3	  Due	  to	  its	  uniquely	  vast	  application	  many	  questions	  
pertaining	  to	  its	  patentability	  are	  raised.	  
	  
Despite	  all	  this	  attention,	  the	  exact	  definition	  still	  remains	  perplexing	  and	  a	  challenge	  for	  
legal	  practioners	  and	  inventors	  alike.4	  The	  reason	  for	  this	  partly	  pertains	  to	  its	  newness	  and	  
rapid	  development.	  Another	  reason	  may	  be	  attributed	  to	  its	  vast	  application,	  different	  fields	  
of	  science	  and	  technology	  may	  refer	  to	  one	  term	  as	  describing	  a	  particular	  structure	  and	  
this	  same	  description	  could	  denote	  a	  completely	  different	  structure	  in	  a	  different	  field.	  
Furthermore	  multiple	  terms	  can	  be	  used	  to	  describe	  the	  same	  structure.5	  	  
	  
Attempts	  have	  been	  made	  to	  try	  and	  standardise	  the	  definitions	  and	  terms	  used	  for	  
nanotechnology.	  For	  example	  the	  EPO	  developed	  classification	  Y01N6	  and	  the	  USPTO,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)[At	  6-­‐7]	  	  4	  Berger	  “Legal	  Implications	  of	  the	  Nanotechnology	  Patent	  Land	  Rush”	  
http://www.nanowerk.com/spotlight/spotid=1919.php	  (accessed	  02/05/2012)	  [Hereinafter	  "Berger	  Nano	  
Patent	  Land	  Rush”]	  
	  5	  Mills,	  Fitzsimmons	  and	  Rodkey	  2010	  Nanotech.	  L.	  &	  Bus.	  223-­‐235	  	  	  6	  The	  EPO’	  s	  definition:“The	  term	  nanotechnology	  covers	  entities	  with	  a	  controlled	  geometrical	  size	  of	  at	  least	  
one	  functional	  component	  below	  100	  nanometres	  (nm)	  in	  one	  or	  more	  dimensions	  susceptible	  of	  making	  
physical,	  chemical	  or	  biological	  effects	  available	  which	  are	  intrinsic	  to	  that	  size.”	  See:	  
http://documents.epo.org/projects/babylon/eponet.nsf/0/623ECBB1A0FC13E1C12575AD0035EFE6/$File/nan
otech_	  (accebrochure_en.pdf	  (accessed	  08/08/2013)	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introduced	  Classification	  977	  to	  classify	  nanotechnology	  patents.7	  In	  addition,	  various	  
international	  organisations	  such	  as	  ASTM	  International,8	  British	  Standards	  Institute,	  The	  
International	  Organisation	  for	  Standardisation,9	  The	  Institute	  of	  Nanotechnology	  and	  NNI10	  	  
have	  attempted	  to	  define	  structures	  in	  nanotechnology	  by	  using	  similar	  language.	  
Unfortunately	  despite	  these	  efforts	  the	  parameters	  for	  the	  definitions	  given	  are	  not	  always	  
the	  same.11	  Therefore	  it	  becomes	  vitally	  important	  to	  understand	  the	  scope	  of	  what	  is	  in	  
fact	  covered	  by	  the	  claims	  of	  a	  specific	  patent.	  	  
	  
After	  comparing	  several	  definitions,	  the	  general,	  category	  definition	  given	  to	  identify	  this	  
technology	  is	  the	  following:	  Nanotechnology	  refers	  broadly	  to	  the	  field	  of	  applied	  science	  
and	  technology	  with	  the	  unifying	  theme	  being	  the	  manipulation	  of	  matter	  on	  an	  atomic	  and	  
molecular	  scale.12	  Scale	  is	  therefore	  the	  dominant	  feature.	  The	  term	  “nano”	  derives	  from	  
the	  Greek	  word	  for	  dwarf	  and	  refers	  to	  a	  measurement	  and	  not	  to	  an	  object.	  This	  subject	  
matter	  has	  the	  scale	  of	  approximately	  1-­‐100	  nanometres	  (nm)	  in	  at	  least	  one	  dimension,	  a	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  Class	  977	  defines	  nanotechnology	  narrowly:	  	  “This	  Nanotechnology	  art	  collection	  provides	  for	  disclosures	  
related	  to:	  
1. Nanostructure	  and	  chemical	  compositions	  of	  nanostructure;	  
2. Device	  that	  include	  at	  least	  one	  nanostructure;	  
3. Mathematical	  algorithms	  e.g.	  computer	  software,	  etc.,	  specifically	  adapted	  for	  modelling	  
configurations	  or	  properties	  of	  nanostructure;	  
4. Methods	  of	  apparatus	  for	  making,	  detecting,	  analysing	  or	  treating	  nanostructure;	  and	  
5. Specified	  particular	  uses	  of	  nanostructure.	  
As	  used	  above,	  the	  term	  “nanostructure”	  is	  defined	  to	  mean	  an	  atomic,	  molecular	  or	  macromolecular	  structure	  
that:	  
1. Has	  at	  least	  one	  physical	  dimension	  of	  approximately	  1-­‐100	  nanometres;	  and	  
2. Possesses	  a	  special	  property,	  provides	  a	  special	  function	  or	  produces	  a	  special	  effect	  that	  is	  uniquely	  
attributable	  to	  the	  structure’s	  nanoscale	  physical	  size.”	  See:	  
http://www.uspto.gov/web/patents/classification/uspc977/def977.htm	  (accessed	  21/07/2013)	  	  8	  Berger	  Nano	  Patent	  Land	  Rush	  http://www.nanowerk.com/spotlight/spotid=1919.php	  (accessed	  
02/05/2012)	  	  	  9	  Mills,	  Fitzsimmons	  and	  Rodkey	  2010	  Nanotech.	  L.	  &	  Bus.	  232	  	  	  10	  NNI’s	  definition:	  “Nanotechnology	  is	  the	  understanding	  and	  control	  of	  matter	  at	  dimensions	  between	  
approximately	  1	  and	  100	  nanometers	  (nm),	  where	  unique	  phenomena	  enable	  novel	  applications...	  
Encompassing	  nanoscale	  science,	  engineering	  and	  technology,	  nanotechnology	  involves	  imaging,	  measuring,	  
modelling	  and	  manipulating	  matter	  at	  this	  length	  scale.”	  See:	  http://www.nano.gov/nanotech-­‐
101/nanotechnology-­‐facts	  (accessed	  08/08/2013)	  
	  11	  Mills,	  Fitzsimmons	  and	  Rodkey	  2010	  Nanotech.	  L.	  &	  Bus.	  233	  	  
	  
12	  Nanodeltech	  http://nanodeltech.com/nanotechnology/nanotechnology-­‐and	  -­‐energy.html	  (accessed	  
07/05/2012)	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billionth	  of	  a	  meter.13	  Therefore	  it	  deals	  with	  developing	  materials,	  systems,	  devices	  and	  
other	  structures	  that	  possess	  novel	  properties	  and	  functions	  as	  a	  result	  of	  their	  nanoscale	  
size.	  To	  give	  a	  physical	  indication	  of	  the	  size	  of	  matter	  dealt	  with	  on	  nanoscale;	  individual	  
atoms	  are	  1	  nm	  wide,	  a	  sheet	  of	  paper	  is	  100,000	  nm	  thick;14	  a	  single	  human	  hair	  is	  about	  
10,000	  nm	  wide;15	  a	  red	  blood	  cell	  is	  about	  7,500	  nm	  wide	  and	  a	  DNA	  molecule	  2-­‐2,5	  nm	  
wide	  (falling	  within	  the	  nanoscale	  measurement).16	  
	  
With	  this	  in	  mind,	  one	  would	  assume	  that	  this	  technology	  refers	  to	  the	  mere	  reduction	  in	  
size	  of	  matter	  or	  a	  device	  and	  therefore	  one	  would	  pose	  the	  question,	  is	  the	  invention	  
“new”	  and	  therefore	  eligible	  for	  a	  patent?	  	  
	  
This	  manipulation	  of	  atoms	  and	  molecules	  can	  render	  a	  very	  different	  physical,	  chemical	  or	  
biological	  result	  on	  nanoscale	  than	  that	  same	  material	  as	  bulk	  matter.	  The	  change	  in	  
physical	  properties	  due	  to	  their	  small	  size	  is	  referred	  to	  as	  the	  “quantum	  effect”17	  or	  “scale	  
effect.”18	  Reasons	  for	  this	  difference	  can	  be	  attributed	  to	  the	  following;	  due	  to	  the	  relatively	  
larger	  surface	  area	  to	  volume	  ratio,	  nanoscale	  material	  can	  become	  more	  chemically	  
reactive	  thereby	  changing	  their	  strength	  and	  other	  properties.19	  Also,	  below	  50	  nm	  the	  
traditional	  laws	  of	  physics	  give	  way	  to	  quantum	  effects	  inciting	  different	  optical,	  electrical	  
and	  magnetic	  behaviours	  than	  from	  those	  of	  the	  same	  material	  but	  produced	  on	  a	  larger	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13	  Almeling	  2004	  STLR	  ¶1.	  Also	  see:	  Hicks,	  Grissett	  and	  Brown	  
http://www.wcsr.com/resources/pdfs/nano030310.pdf	  (accessed	  04/05/2012)	  [At	  1]	  and	  Watal	  and	  Faunce	  
http://wipo.int/wipo_magazine/en/2011/02/article_0009.html	  (accessed	  02/05/2012)	  
	  14	  Watal	  and	  Faunce	  http://wipo.int/wipo_magazine/en/2011/02/article_0009.html	  (accessed	  02/05/2012)	  
15	  Gardner	  2008	  PCOST	  3	  
16	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)[At	  15]	  
17	  Wetter	  http://www.fpif.org/articles/big_continent_and_tiny_technology_nanotechnology_and_africa	  
(accessed	  17/03/2013)	  	  18	  Zech	  2009	  SCRIPTed	  149	  
19	  Valverde	  and	  Linkov	  2011-­‐2012	  Nanotech.	  L.	  &	  Bus.	  30	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scale.20	  These	  new	  physical	  properties	  that	  emerge	  enable	  exciting	  new	  applications.	  Some	  
examples	  are	  increased	  strength,	  lighter	  weight,	  flexibility,	  conductivity,	  durability	  and	  
resistance.21	  These	  new	  properties	  are	  very	  important	  when	  determining	  the	  patentability	  
of	  a	  nanotechnology	  invention.	  This	  aspect	  will	  be	  examined	  more	  thoroughly	  in	  Chapter	  2	  
when	  determining	  novelty	  and	  non-­‐obviousness.	  
	  
2. NANOSCIENCE	  VERSUS	  NANOTECHNOLOGY	  
	  
A	  distinction	  should	  also	  be	  drawn	  between	  the	  following	  two	  concepts,	  “nanoscience”	  and	  
“nanotechnology.”	  Nanoscience	  refers	  to	  the	  science	  and	  research	  of	  nano-­‐related	  subject	  
matter.	  Once	  these	  findings	  have	  been	  developed	  and	  tested	  they	  are	  then	  reformed	  to	  
create	  nanotechnology.	  Nanotechnology	  therefore	  refers	  to	  the	  applied	  science	  and	  the	  




The	  origins	  of	  nanotechnology	  date	  back	  to	  1959	  when	  phyicist	  Richard	  Feynman	  presented	  
his	  well-­‐known	  talk	  “There’s	  Plenty	  of	  Room	  at	  the	  Bottom.”22	  He	  proposed	  a	  process	  
whereby	  one	  could	  manipulate	  individual	  atoms	  and	  molecules	  by	  using	  a	  set	  of	  precise	  
tools	  to	  build	  and	  operate	  another	  proportionally	  smaller	  set.23	  This	  process	  would	  be	  
repeated	  until	  the	  desired	  scale	  was	  achieved.	  Due	  to	  the	  direct	  manipulation	  of	  single	  
atoms,	  this	  was	  considered	  a	  more	  powerful	  form	  of	  synthetic	  chemistry.24	  He	  also	  noted	  
that	  there	  would	  be	  scaling	  issues	  due	  to	  changing	  the	  magnitude	  of	  various	  physical	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  20	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  3]	  
21	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  8-­‐10]	  
22	  Hicks,	  Grissett	  and	  Brown	  http://www.wcsr.com/resources/pdfs/nano030310.pdf	  (accessed	  04/05/2012)	  
[At	  1]	  
	  23	  Suprotec	  http://www.suprotec.ie/estore/index.php?dispatch=pages.view&page_id=9	  (accessed	  
09/12/2012)	  
	  24	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  6-­‐7]	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phenomena:	  “gravity	  would	  become	  less	  important,	  surface	  tension	  and	  Van	  der	  Waals	  
attraction25	  would	  become	  more	  important,	  etc.”26	  	  
	  
The	  term	  "nanotechnology"	  was	  defined	  in	  1974	  by	  Professor	  Norio	  Taniguchi	  from	  the	  
Tokyo	  Science	  University	  in	  his	  paper:	  "‘Nano-­‐technology'	  mainly	  consists	  of	  the	  processing	  
of,	  separation,	  consolidation,	  and	  deformation	  of	  materials	  by	  one	  atom	  or	  by	  one	  
molecule.”27	  In	  the	  1980’s,	  Dr.	  Eric	  Drexler	  explored	  the	  definition	  given	  by	  Taniguchi	  and	  
popularized	  this	  technological	  marvel	  of	  nanoscale	  by	  writing	  books	  and	  giving	  speeches	  on	  
the	  topic.	  His	  book	  entitled	  “Engines	  of	  Creation:	  The	  Coming	  Era	  of	  Nanotechnology”	  is	  
considered	  the	  first	  book	  on	  the	  topic	  of	  nanotechnology.28	  
	  
It	  can	  be	  said	  that	  nanoscience	  and	  nanotechnology	  came	  into	  being	  in	  the	  early	  1980’s	  as	  
several	  major	  developments	  occurred:	  the	  beginning	  of	  cluster	  science	  and	  the	  invention	  of	  
the	  scanning	  tunneling	  microscope	  (STM)	  and	  Atomic	  Force	  Microscope	  (AFM).29	  These	  
developments	  set	  in	  motion	  the	  possibility	  for	  further	  nanotechnology	  related	  discoveries	  
to	  be	  made.	  	  
	  
4. TYPES/	  “MAKES”	  OF	  NANOTECHNOLOGY	  	  
	  
Some	  of	  the	  most	  prominent	  nanotechnologies,	  also	  referred	  to	  as	  the	  “building	  blocks”	  
are:	  nanoparticles,	  carbon	  nanotubes	  and	  quantum	  dots.	  Other	  “makes”	  of	  nanomaterials	  
are	  developing	  rapidly.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25	  According	  to	  the	  Encyclopaedia	  Britannica:	  Van	  der	  Waals	  Attraction	  or	  Force	  is	  the	  sum	  of	  the	  attraction	  
and	  repulsion	  forces	  between	  atoms,	  molecules	  and	  surfaces	  and	  other	  intermolecular	  forces.	  See:	  
http://www.britannica.com/EBchecked/topic/622645/van-­‐der-­‐Waals-­‐forces	  (accessed	  24/08/2013)	  
	  26	  Nano	  Research	  Foundation	  http://www.nanotechnologyresearchfoundation.org/nanohistory.html	  
(accessed	  09/12/2012).	  Also	  see:	  Suprotec	  
http://www.suprotec.ie/estore/index.php?dispatch=pages.view&page_id=9	  (accessed	  09/12/2012)	  
	  27	  Suprotec	  http://www.suprotec.ie/estore/index.php?dispatch=pages.view&page_id=9	  (accessed	  
09/12/2012)	  	  28	  Nano	  Research	  Foundation	  http://www.nanotechnologyresearchfoundation.org/nanohistory.html	  
(accessed	  09/12/2012)	  	  	  29	  Pouris	  2010	  University	  of	  Pretoria	  21	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4.1. Nanoparticles	  	  
	  
These	  are	  particles	  that	  behave	  as	  a	  whole	  unit	  in	  terms	  of	  transport	  and	  properties.	  They	  
are	  classified	  according	  to	  size,	  between	  1-­‐100	  nm.	  But	  there	  is	  an	  important	  distinction	  
that	  must	  be	  taken	  into	  account,	  nanoparticles	  that	  have	  existed	  for	  decades,	  in	  the	  form	  of	  
antique	  ceramics	  and	  carbon	  black	  (the	  most	  abundant	  of	  these).	  However,	  these	  do	  not	  
fulfill	  definition	  given	  for	  nanoparticles	  namely	  the	  “planned”	  manipulation	  of	  atoms	  and	  
molecules	  as	  they	  occur	  naturally.30	  	  
	  
The	  large	  surface	  area	  is	  responsible	  for	  the	  improved	  performance	  of	  catalysis	  and	  
electrodes	  that	  are	  used	  in	  batteries	  and	  fuel	  cells.	  Due	  to	  the	  dimensions	  of	  nanoparticles	  
being	  below	  critical	  wavelenghs	  of	  light	  they	  are	  transparent	  and	  therefore	  appealing	  for	  
packaging,	  cosmetics,	  sunscreens	  and	  coatings.	  
	  
Examples	  of	  nanoparticles	  are	  metal	  oxide	  ceramic,	  zinc	  oxide,	  silicate	  and	  chitosan,	  which	  
is	  used	  in	  hair	  conditioners	  and	  skin	  products	  for	  better	  absorption.31	  	  	  
	  
4.2. Fullerenes	  	  
	  
Fullerenes	  are	  made	  entirely	  from	  carbon	  and	  there	  are	  two	  types;	  buckyballs	  and	  carbon	  
nanotubes.	  Carbon	  Nanotubes	  (CNT)	  are	  the	  most	  significant	  new	  nanomaterials.	  They	  are	  
long	  thin	  cylinders	  of	  atomic	  layers	  of	  graphite	  that	  come	  in	  a	  variety	  of	  structures,	  
possessing	  a	  wide	  variety	  of	  properties.	  Single	  walled	  carbon	  nanotubes	  (SWNT)	  consist	  of	  a	  
single	  cylindrical	  wall.	  And	  the	  multi-­‐walled	  carbon	  nanotubes	  (MWNT),	  have	  cylinders	  
within	  cylinders.32	  MWNT	  have	  the	  same	  properties	  and	  morphology,	  however	  their	  
resistance	  to	  chemicals	  is	  far	  superior.	  When	  a	  general	  reference	  is	  made	  to	  nanotubes,	  it	  is	  
usually	  the	  SWNT	  that	  are	  being	  referred	  to.	  Nanotubes	  are	  advantageous	  due	  to	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  30	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  6]	  	  
	  31	  Nanotechnology	  Now	  http://www.nanotech-­‐now.com/current-­‐uses.htm	  (accessed	  09/12/2012)	  
	  32	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  8-­‐10]	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following	  qualities	  they	  possess;	  high	  electrical	  conductivity,	  tensile	  strength,	  highly	  ductile,	  
high	  heat	  conductivity,	  mobility	  and	  they	  are	  relatively	  inactive	  chemically.33	  	  
	  
A	  drawback	  to	  using	  nanotubes	  is	  the	  difficulty	  with	  which	  they	  interact	  with	  other	  
materials.	  To	  fully	  exploit	  its	  strength	  in	  composite	  materials	  it	  needs	  to	  be	  attached	  to	  a	  
polymer.	  This	  unfortunately	  reduces	  the	  very	  properties	  they	  are	  used	  for.34	  Low	  yield	  is	  
another	  drawback,	  only	  once	  a	  system	  is	  devised	  to	  scale	  up	  production	  will	  this	  
nanomaterial	  be	  invaluable	  to	  any	  industry	  where	  strength	  and	  weight	  are	  factors	  in	  their	  
products.35	  Examples	  of	  ideal	  applications	  for	  carbon	  nanotubes	  include	  nanoelectrical	  and	  
nanomechanical	  devices.36	  
	  
4.3. Quantum	  dots	  	  
	  
Quantum	  dots	  are	  nanoparticles	  made	  from	  a	  semi	  conductor	  material,	  traditionally	  
chalcogenides	  of	  metals	  like	  zinc	  or	  cadmium.37	  They	  range	  from	  2-­‐10	  nm	  and	  display	  
optical	  and	  electrical	  properties	  that	  are	  different	  than	  those	  in	  bulk.38	  These	  structures	  are	  
capable	  of	  confining	  a	  single	  electron	  or	  a	  few	  thousand.	  The	  energy	  states	  of	  these	  
electrons	  can	  be	  controlled	  by	  applying	  a	  specific	  voltage.39	  When	  excited,	  photons	  are	  
emitted	  and	  this	  reaction	  is	  visible	  to	  us	  as	  light.	  This	  light	  can	  be	  controlled	  during	  
production	  to	  emit	  any	  colour	  of	  light.	  The	  ability	  to	  “tune”	  or	  control	  this	  emission	  from	  the	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  33	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  8-­‐10]	  
	  34	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  8-­‐10]	  	  35	  Nanotechnology	  Now	  http://www.nanotech-­‐now.com/current-­‐uses.htm	  (accessed	  09/12/2012)	  	  36	  IBM	  Research	  http://www.research.ibm.com/nanoscience/nanotubes.html	  (accessed	  12/12/2012)	  
	  37	  Nanoco	  Group	  PLC	  http://www.nanocotechnologies.com/content/AboutUs/AboutQuantumDots.aspx	  
(accessed	  12/12/2012)	  
	  38	  Nanoco	  Group	  PLC	  http://www.nanocotechnologies.com/content/AboutUs/AboutQuantumDots.aspx	  
(accessed	  12/12/2012)	  
	  39	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)[At	  10-­‐11]	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quantum	  dot	  is	  attained	  by	  changing	  its	  core	  size.	  This	  is	  called	  the	  “size	  quantisation	  
effect.”40	  	  The	  smaller	  the	  dot,	  the	  higher	  the	  energy	  and	  the	  closer	  it	  is	  to	  the	  blue	  end	  of	  
the	  spectrum.	  The	  bigger	  the	  dot,	  the	  lower	  the	  energy	  and	  the	  closer	  it	  is	  to	  the	  red	  end	  of	  
the	  spectrum.41	  Here	  the	  energy	  levels	  are	  more	  closely	  spaced.	  Quantum	  dots	  can	  also	  be	  
tuned	  beyond	  visible	  light	  and	  into	  infra-­‐red	  or	  ultra-­‐violet	  light.	  	  
	  
Full	  colour	  imagining	  is	  possible	  for	  biological	  samples	  and	  a	  large	  number	  of	  different	  sized	  
dots	  can	  be	  excited	  by	  a	  light	  source	  with	  a	  single	  wavelength.	  This	  is	  immensely	  
advantageous	  as	  current	  imaging	  is	  done	  using	  naturally	  florescent	  molecules,	  e.g.	  organic	  
dyes,	  each	  dye	  is	  attached	  to	  each	  kind	  of	  molecule	  in	  a	  sample.	  However,	  only	  about	  three	  
of	  these	  dyes	  emit	  light	  over	  a	  broad	  range	  of	  wavelengths	  resulting	  in	  their	  spectra	  
overlapping.	  In	  addition	  only	  about	  three	  different	  dyes	  can	  be	  used	  at	  the	  same	  time.42	  
	  
At	  the	  end	  of	  the	  production	  process	  quantum	  dots	  physically	  appear	  as	  powder	  or	  in	  a	  
solution.	  A	  small	  quanitity	  of	  quantum	  dots,	  for	  example,	  1	  kg	  will	  produce	  enough	  actual	  
quantum	  dots	  for	  industrial	  scale	  production.	  A	  company	  by	  the	  name	  of	  Nanoco	  
Technologies	  has	  patented	  this	  molecular	  seeding	  process	  thereby	  consistently	  producing	  
quantum	  dots	  for	  this	  large	  scale	  production.43	  
	  
Other	  possible	  applications	  include	  drug	  delivery,	  qubits	  in	  quantum	  computing	  and	  
photovoltaic	  cells.44	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  40	  Nanoco	  Group	  PLC	  http://www.nanocotechnologies.com/content/AboutUs/AboutQuantumDots.aspx	  
(accessed	  12/12/2012)	  	  	  41	  Nanotechnology	  Now	  http://www.nanotech-­‐now.com/current-­‐uses.htm	  (accessed	  9/12/2012)	  	  	  42	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  10-­‐11]	  	  	  43	  Nanoco	  Group	  PLC	  http://www.nanocotechnologies.com/content/AboutUs/AboutQuantumDots.aspx	  
(accessed	  12/12/2012)	  	  44	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  10-­‐11]	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5. ACTIVE	  AND	  PASSIVE	  NANOTECHNOLOGY	  	  	  	  	  
	  
James	  Tour	  made	  an	  important	  distinction	  between	  two	  areas	  in	  nanotechnology,	  namely	  
active	  and	  passive	  nanotechnology.	  A	  good	  example	  of	  passive	  nanotechnology	  would	  be	  
nanoparticles	  incorporated	  into	  sunscreen.	  The	  presence	  of	  the	  nanoparticles	  significantly	  
improves	  the	  performance	  of	  the	  product	  in	  which	  it	  is	  incorporated.	  Active	  nanotechnology	  
on	  the	  other	  hand,	  carry	  out	  complex	  functions.	  Here	  structures	  are	  able	  to	  perform	  
movements	  or	  dispense	  treatments,	  for	  example	  nanomachines	  or	  nanorobots.45	  	  
	  
6. TOOLS	  USED	  FOR	  NANOTECHNOLOGY	  
	  
There	  are	  two	  main	  types	  of	  microscopes	  used	  in	  nanotechnology	  that	  apply	  different	  
techniques,	  without	  which	  nanoparticles	  would	  remain	  invisible.	  The	  scanning	  electron	  
microscope	  (SEM)	  and	  transmission	  electron	  microscope	  (TEM),	  both	  apply	  the	  same	  
technique	  whereby	  the	  sample	  is	  stationary	  and	  in	  line	  with	  a	  high	  speed	  electron	  gun.	  The	  
other	  type	  or	  class	  of	  microscopes,	  where	  the	  microscope	  is	  stationary	  and	  the	  sample	  
moves,	  is	  the	  atomic	  force	  microscope	  (AFM)	  and	  the	  scanning	  tunnelling	  microscope	  
(STM).46	  This	  equipment	  is	  essential	  in	  understanding	  and	  developing	  nanomaterials	  and	  
building	  nanostructures.	  When	  using	  the	  SEM,	  TEM	  and	  STM	  microscopes,	  nanoscale	  
samples	  must	  be	  meticulously	  prepared,	  they	  must	  be	  electrically	  conductive	  and	  carefully	  
handled	  as	  they	  can	  easily	  be	  damaged	  by	  the	  high	  energy	  electrons	  that	  are	  fired	  at	  them.	  	  
	  
7. BUILDING	  NANOSTRUCTURES	  
	  
The	  diversity	  of	  nanotechnology	  ranges	  from	  extending	  and	  improving	  conventional	  device	  
physics	  to	  completely	  new	  revolutionary	  approaches	  based	  on	  molecular	  self-­‐assembly.	  
With	  this	  in	  mind	  there	  are	  two	  processes	  when	  building	  nanostructures,	  the	  “top-­‐down”	  
and	  the	  “bottom-­‐up”	  approach.	  When	  applying	  the	  top-­‐down	  approach	  bulk	  matter	  is	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  45	  Zech	  2009	  SCRIPTed	  150	  
	  46	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  11]	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processed	  by	  removing	  matter	  until	  only	  nanoscale	  features	  remain	  (namely,	  the	  process	  
described	  by	  Richard	  Feynman).47	  This	  is	  referred	  to	  as	  the	  traditional	  approach.	  
Nanopatterning	  is	  a	  generic	  term	  used	  to	  describe	  this	  process	  and	  nanolithography	  refers	  
to	  the	  fabrication	  of	  nanostructures,	  such	  as	  nanowires	  and	  quantum	  dots.	  A	  larger	  amount	  
of	  material	  is	  required	  which	  is	  then	  reduced	  in	  size.	  Unfortunately	  cast-­‐off	  material	  can	  
result	  in	  unnecessary	  waste.48	  The	  main	  problem	  with	  this	  approach	  is	  the	  imperfect	  surface	  
structures.	  These	  imperfections	  can	  cause	  further	  challenges	  in	  device	  design	  and	  
fabrication.49	  However,	  the	  top-­‐down	  approach	  is	  responsible	  for	  the	  bulk	  of	  production	  of	  
nanomaterials.	  
	  
The	  bottom-­‐up	  approach	  is	  more	  time	  consuming,	  nanostructures	  are	  built	  atom	  by	  atom,	  
molecule	  by	  molecule.	  This	  approach	  begins	  with	  constituent	  materials	  such	  as	  gases	  or	  
liquids	  and	  uses	  electrical,	  chemical	  or	  physical	  forces	  to	  “build	  up”	  the	  nanomaterial.	  This	  
method	  is	  used	  for	  creating	  nanowires,	  carbon	  nanotubes	  and	  quantum	  dots.	  The	  next	  
revolutionary	  step	  whereby	  materials	  will	  be	  created	  using	  this	  approach	  is	  by	  molecular	  
self-­‐assembly.50	  This	  is	  achieved	  by	  using	  attractive	  forces	  like	  static	  electricity,	  Van	  der	  
Waals	  forces	  and	  a	  variety	  of	  short	  range	  forces	  to	  position	  these	  constituent	  molecules	  in	  a	  
specific	  arrangement.51	  In	  other	  words	  by	  placing	  certain	  molecular	  scale	  components	  
together	  they	  will	  spontaneously	  self-­‐assemble	  from	  the	  bottom	  up	  into	  a	  specific	  ordered	  
structure	  without	  outside	  assistance.52	  This	  process	  promises	  a	  greater	  possibility	  of	  
producing	  nanostructures	  with	  an	  impressive	  level	  of	  customisability,	  having	  less	  defects	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  47	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  11-­‐12]	  
	  48	  Nano.gov	  http://www.nano.gov/nanotech-­‐101/what/manufacturing	  (accessed	  13/12/2012)	  
	  49	  Gitam.edu	  
http://www.gitam.edu/eresource/nano/nanotechnology/role_of_bottomup_and_topdown_a.htm	  (accessed	  
13/12/2012)	  
	  50	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  11-­‐12]	  	  
	  51	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  11-­‐12]	  
	  52	  Nano.gov	  http://www.nano.gov/nanotech-­‐101/what/manufacturing	  (accessed	  13/12/2012)	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and	  more	  consistent	  chemical	  compositions.53	  However,	  this	  process	  is	  difficult	  to	  control,	  
time	  consuming	  and	  capable	  of	  only	  producing	  simple	  structures	  and	  yielding	  very	  little.54	  
This	  concept	  is	  mostly	  at	  a	  theoretical	  stage.55	  	  
	  
8. APPLICATIONS	  AND	  OPPORTUNITIES	  FOR	  NANOTECHNOLOGY	  
	  
Existing	  industries	  will	  over	  the	  next	  few	  decades,	  if	  economically	  viable,	  dramatically	  
improve	  their	  existing	  products.	  The	  clothing,	  electronics,	  communications,	  
pharmaceuticals,	  healthcare	  and	  manufacturing	  industries	  will	  be	  strongly	  affected	  by	  the	  
advancements	  of	  nanotechnology.	  Energy	  technologies,	  chemical	  materials,	  national	  
security,	  and	  even	  space	  exploration	  will	  benefit	  from	  this	  technology.	  Mass-­‐produced	  
consumer	  products	  incorporating	  nanoparticles	  that	  are	  currently	  available	  to	  the	  public	  
include;	  applications	  in	  the	  car	  industry,	  glass	  for	  windows,	  lenses	  for	  sunglasses,	  
sunscreens	  and	  cosmetics,	  textiles,	  sports	  equipment	  and	  televisions.	  
	  
The	  short	  to	  long-­‐term	  opportunities	  within	  the	  field	  of	  nanotechnology	  are	  extensive.	  For	  
the	  purposes	  of	  this	  study	  I	  will	  focus	  on	  the	  fields	  of	  science	  South	  Africa	  considers	  
relevant.	  South	  Africa’s	  active	  projects	  and	  future	  goals	  will	  be	  discussed	  in	  chapter	  3.	  	  
	  
8.1. Application:	  Medicine	  
	  
Nanotechnology	  offers	  extraordinary	  opportunities	  in	  the	  field	  of	  medicine.	  New	  and	  
improved	  methods	  and	  approaches	  for	  the	  detection	  and	  treatment	  of	  diseases,	  viruses	  and	  
surgical	  procedures	  will	  be	  further	  explored	  in	  this	  section.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  53	  Gitam.edu	  
http://www.gitam.edu/eresource/nano/nanotechnology/role_of_bottomup_and_topdown_a.htm	  
(accessed	  13/12/2012)	  
	  54	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  12]	  	  
	  55	  Boysen	  and	  Muir	  http://www.dummies.com/how-­‐to/content/nanotechnology-­‐top-­‐down-­‐or-­‐bottom-­‐
up.html	  	  (accessed	  13/12/2012)	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a) Drug	  Delivery	  	  
	  
This	  is	  considered	  to	  be	  one	  of	  the	  most	  profitable	  applications	  of	  nanotechnology	  in	  
medicine.	  Nanoparticles	  have	  the	  ability	  to	  act	  as	  carriers	  for	  targeted	  drug	  delivery.	  Due	  to	  
the	  their	  small	  size,	  nanoparticles	  can	  interact	  at	  the	  same	  molecular	  and	  cellular	  level	  as	  
the	  cells	  in	  the	  body	  thereby	  gaining	  access	  to	  areas	  in	  the	  body	  that	  were	  otherwise	  
inaccessible.	  These	  particles	  are	  engineered	  so	  that	  they	  are	  attracted	  to	  diseased	  cells,	  
allowing	  for	  the	  direct	  treatment	  of	  only	  those	  cells.	  This	  technique	  reduces	  damage	  to	  
healthy	  cells	  in	  the	  body	  and	  allows	  for	  earlier	  detection	  of	  disease.	  Due	  to	  their	  size	  they	  
are	  able	  to	  penetrate	  certain	  protective	  membranes,	  this	  opens	  the	  possibility	  to	  treat	  
diseases	  precisely	  thereby	  hopefully	  reducing	  the	  side	  effects	  of	  traditional	  treatments	  and	  
minimizing	  damage	  to	  healthy	  cells.	  	  
	  
Nanoparticle	  encapsulation	  allows	  for	  the	  drug	  to	  be	  protected	  while	  it	  travels	  through	  the	  
body	  on	  route	  to	  the	  area	  targeted	  for	  treatment.	  The	  drug	  is	  contained	  in	  a	  capsule	  in	  
order	  to	  avoid	  damaging	  parts	  of	  the	  body	  it	  must	  travel	  through	  that	  are	  not	  affected	  by	  
the	  disease	  and	  for	  the	  purpose	  of	  maintaining	  its	  biological	  and	  chemical	  properties.56	  
Once	  the	  drug	  reaches	  its	  target,	  it	  is	  released	  at	  a	  rate	  that	  is	  appropriate	  for	  the	  effective	  
treatment	  of	  the	  disease.	  Nanotechnology	  can	  improve	  both	  the	  release	  of	  the	  medication	  
and	  degradation	  of	  the	  material	  of	  the	  capsule	  in	  the	  body	  thereby	  optimizing	  treatment.	  
This	  process	  is	  currently	  focused	  on	  treatment	  for	  diseases	  such	  as	  cancer	  but	  other	  
possible	  applications	  are	  being	  investigated	  such	  as	  the	  treatment	  for	  neurological	  disorders	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Other	  applications	  of	  nanocapsules	  include:	  	  
 The	  treatment	  of	  viruses,	  the	  nanocapsule	  will	  contain	  an	  enzyme	  that	  will	  prevent	  
the	  reproduction	  of	  virus	  molecules	  in	  the	  bloodstream,	  killing	  the	  virus	  before	  it	  
can	  multiply.57	  
 Severe	  burns	  can	  be	  treated	  with	  dressings	  coated	  with	  nanocapsules	  containing	  
antibiotics	  that	  will	  be	  released	  at	  the	  onset	  of	  an	  infection	  the	  bacteria	  will	  cause	  
the	  nanocapsules	  to	  open,	  releasing	  the	  medication.58	  
	  
b) Nanosensors	  and	  Lab-­‐on-­‐a-­‐chip	  Technologies	  	  
	  
Researchers	  are	  developing	  sensors	  that	  can	  be	  used	  to	  monitor	  the	  body	  in	  a	  variety	  of	  
ways	  thereby	  assisting	  in	  the	  early	  detection	  and	  identification	  of	  diseases.59	  For	  example,	  
subcutaneous	  chips	  are	  already	  being	  developed	  to	  continuously	  monitor	  key	  body	  
parameters	  including	  pulse,	  temperature	  and	  blood	  glucose.	  Optical	  micro-­‐sensors	  
implanted	  into	  the	  deep	  tissue	  can	  monitor	  tissue	  circulation	  after	  surgery.	  A	  micro-­‐
electromechanical	  system	  (MEMS)	  device	  and	  accelerometers	  can	  be	  used	  to	  measure	  
strain,	  acceleration,	  angular	  rate	  and	  related	  parameters	  for	  monitoring	  and	  treating	  
paralyzed	  limbs	  and	  for	  the	  improvement	  of	  artificial	  limbs.	  Implantable	  sensors	  can	  also	  
work	  with	  devices,	  like	  fluid	  injection	  systems	  that	  can	  administer	  treatment	  automatically	  if	  
required.	  Initial	  applications	  could	  include	  chemotherapy,	  directly	  targeting	  tumors	  and	  
dispensing	  precise	  amounts	  of	  medication	  at	  specific	  intervals	  that	  may	  be	  convenient	  for	  
the	  patient,	  for	  instance	  while	  they	  are	  asleep.60	  Sensors	  to	  monitor	  the	  hearts	  activity	  level	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can	  be	  achieved	  by	  implanting	  a	  defibrillator	  to	  regulate	  heartbeats.61	  	  
	  
c) Nano	  Devices	  
	  
Nanotechnology	  hopes	  to	  develop	  a	  new	  generation	  of	  smaller	  and	  more	  powerful	  devices	  
that	  will	  restore	  lost	  sight	  and	  hearing.	  Some	  of	  the	  approaches	  being	  investigated	  for	  sight	  




A	  miniature	  video	  camera	  attached	  to	  a	  blind	  person’s	  glasses	  will	  capture	  visual	  signals	  that	  
are	  then	  processed	  by	  a	  microcomputer	  worn	  on	  a	  belt.	  This	  microcomputer	  will	  then	  
transmit	  these	  signals	  to	  an	  array	  of	  electrodes	  that	  are	  placed	  in	  the	  eye.	  Another	  
approach	  is	  with	  a	  sub-­‐retinal	  implant	  that	  is	  designed	  to	  replace	  the	  photoreceptors	  in	  the	  
retina.	  This	  implant	  will	  use	  a	  microelectrode	  array	  that	  is	  that	  powered	  up	  to	  3,500	  




A	  transducer	  is	  implanted	  onto	  a	  bone	  in	  the	  inner	  ear,	  causing	  the	  bones	  to	  vibrate	  and	  
move	  the	  fluid	  in	  the	  ear	  stimulating	  the	  auditory	  nerve.	  An	  array	  at	  the	  tip	  of	  the	  device	  
uses	  up	  to	  128	  electrodes,	  five	  times	  higher	  than	  current	  devices	  and	  capable	  of	  stimulating	  
a	  fuller	  range	  of	  sounds.	  This	  implant	  is	  connected	  to	  a	  small	  microprocessor	  and	  
microphone	  in	  a	  device	  that	  can	  clip	  behind	  the	  ear.	  It	  will	  capture	  and	  translate	  sounds	  into	  
electric	  pulses	  transmitted	  by	  wire	  through	  a	  tiny	  hole	  made	  in	  the	  middle	  ear,	  enabling	  
hearing.	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d) Repair	  and	  Replacement	  of	  Damaged	  Tissue	  and	  Organs	  
	  
Currently	  damaged	  tissue	  and	  organs	  are	  replaced	  with	  artificial	  substitutes.	  Examples	  of	  
these	  conventional	  methods	  include	  pacemakers	  implanted	  in	  heart	  surgeries	  and	  
prosthetic	  limbs	  that	  replace	  natural	  limbs.	  Nanotechnology	  could	  offer	  a	  new	  range	  of	  
biocompatible	  coatings	  for	  implants,	  improving	  adhesion,	  durability	  and	  lifespan.	  	  
Nanopolymers	  could	  be	  used	  to	  coat	  devices	  such	  as	  artificial	  hearts	  or	  catheters	  that	  are	  in	  
contact	  with	  blood	  to	  disperse	  clots	  or	  even	  prevent	  them	  from	  forming.	  Research	  has	  also	  
been	  conducted	  in	  the	  following	  areas:	  tissue	  regeneration	  scaffolds	  with	  the	  ultimate	  goal	  
being	  to	  grow	  large	  complex	  organs.	  Other	  examples	  include	  nanoscale	  polymers	  that	  can	  
be	  moulded	  onto	  heart	  valves	  and	  polymer	  nanocomposites	  for	  bone	  scaffolds.	  These,	  
researchers	  hope,	  will	  be	  available	  within	  the	  next	  five	  to	  ten	  years.	  Bones	  can	  be	  regrown	  
using	  carbon	  nanotube	  scaffolds.	  	  Nanostructures	  are	  also	  promising	  for	  temporary	  
implants,	  whereby	  the	  implant	  will	  biodegrade	  avoiding	  the	  eventual	  removal	  in	  a	  
subsequent	  surgery.	  Flexible	  nanofiber	  membrane	  mesh	  can	  be	  applied	  to	  heart	  tissue	  in	  
open-­‐heart	  surgery.63	  This	  mesh	  can	  be	  infused	  with	  antibiotics,	  painkillers	  and	  other	  
medications	  that	  can	  be	  dispersed	  periodically	  in	  small	  quantities	  and	  directly	  applied	  to	  the	  
internal	  tissue.	  These	  nanofibers	  can	  also	  stimulate	  the	  production	  of	  cartilage	  in	  damaged	  
joints.64	  	  
	  
e) New	  Therapeutic	  Methods	  	  
	  
Other	  possible	  applications	  of	  nanotechnology	  include:	  
	  
 Nanoparticles	  could	  aid	  in	  the	  ultrasensitive	  detection	  of	  substances	  and	  potentially	  
deadly	  infections	  would	  be	  avoided.	  Recent	  findings	  revealed	  that	  with	  specially	  treated	  
nanoparticles,	  bacterial	  pathogens	  may	  be	  detected	  in	  very	  low	  concentrations.	  This	  will	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have	  massive	  implications	  for	  safety	  in	  medicine	  and	  food.65	  	  
 Imagining	  agents	  used	  to	  analyze	  biological	  samples	  can	  be	  used	  to	  detect	  tumors	  or	  
cancer	  in	  its	  earliest	  stages.66	  
 Nanobubbles	  are	  another	  new	  approach	  for	  the	  treatment	  of	  diseases;	  these	  are	  formed	  
around	  gold	  nanoparticles.	  There	  are	  two	  types	  that	  facilitate	  different	  functions.	  If	  the	  
nanobubble	  forms	  around	  a	  hollow	  gold	  nanoparticle	  and	  is	  heated	  with	  a	  laser,	  it	  can	  
destroy	  cancer	  cells.	  Applying	  the	  same	  process	  but	  forming	  the	  nanobubble	  around	  a	  
solid	  gold	  nanoparticle	  will	  cause	  a	  temporary	  opening	  in	  the	  cell	  wall	  thereby	  allowing	  
drugs	  to	  be	  injected	  into	  the	  cell.	  This	  technique	  could	  be	  used	  to	  destroy	  or	  modify	  
certain	  types	  of	  cells.67	  
 Eventually	  it	  is	  hoped	  to	  create	  nanostructures,	  nanorobots	  that	  can	  be	  programmed	  to	  
repair	  damaged	  cells	  in	  the	  body,	  mimicking	  the	  human	  bodies	  natural	  antibodies.68	  	  
	  
These	  new	  methods	  for	  the	  treatment	  of	  diseases	  can	  dramatically	  affect	  a	  patient’s	  quality	  
of	  life.	  It	  is	  hoped	  that	  these	  miracle	  drugs	  reach	  those	  who	  are	  adversely	  affected	  by	  some	  
of	  the	  above-­‐mentioned	  diseases.	  
	  
8.2. Application:	  Energy	  
	  
Globally,	  attention	  has	  been	  directed	  to	  the	  pending	  crisis	  the	  world	  is	  facing	  when	  it	  comes	  
to	  energy	  supply.	  Natural	  resources	  are	  quickly	  being	  depleted	  to	  the	  detriment	  of	  the	  
environment.	  This	  could	  have	  a	  serious	  ripple	  effect,	  affecting	  not	  only	  manufacturing	  
industries	  but	  also	  the	  availability	  of	  food	  and	  clean	  water.	  	  
	  
The	  burning	  of	  fossil	  fuels	  used	  to	  produce	  our	  energy	  supply	  continues	  to	  exacerbate	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another	  global	  problem,	  namely	  global	  warming.	  The	  challenge	  to	  discover	  alternative	  
renewable	  energy	  sources	  has	  become	  a	  worldwide	  priority.	  Ideally	  the	  objective	  is	  to	  
increase	  sustainable	  energy	  supply	  and	  decrease	  pollution	  by	  ensuring	  these	  new	  
technologies	  are	  for	  clean	  energy.	  Nanotechnology	  could	  be	  the	  answer	  to	  solving	  this	  
pending	  crisis	  with	  more	  efficient,	  less	  expensive	  and	  environmentally	  sound	  alternatives	  
that	  will	  optimize	  production,	  generation,	  distribution	  and	  storage	  methods	  from	  existing	  
energy	  sources.	  By	  applying	  nanotechnology,	  conventional	  energy	  sources:	  fossil,	  nuclear	  
fuels	  and	  renewable	  energy	  sources:	  geothermal	  energy,	  wind	  and	  hydro	  energy	  and	  
biomass	  can	  be	  greatly	  improved	  upon.	  
	  
Nanotechnology	  applications	  in	  the	  field	  of	  energy	  are	  discussed	  in	  further	  detail	  below:	  
	  
a) Fossil	  Fuels	  
	  
Nano	  coatings	  for	  the	  wear	  and	  protection	  of	  oil	  and	  gas	  drilling	  equipment	  will	  ensure	  a	  
longer	  lifespan	  and	  nanoparticles	  can	  be	  used	  to	  improve	  oil	  production.	  A	  gel-­‐based	  
nanocatalyst	  can	  liquefy	  coal	  and	  turn	  it	  into	  gas;	  this	  method	  can	  improve	  efficiency	  and	  
reduce	  cost.69	  
	  
b) Solar	  Energy	  
	  
Solar	  energy	  is	  an	  extraordinary	  method	  used	  to	  harness	  energy	  and	  is	  currently	  the	  most	  
important	  source	  of	  alternative	  energy.	  Due	  to	  the	  increased	  surface	  area	  to	  volume	  ratio,	  
nanoparticles	  can	  enhance	  the	  absorption	  of	  sunlight	  and	  increase	  conductivity,	  resulting	  in	  
a	  more	  efficient	  photovoltaic	  effect.70	  Materials	  traditionally	  used	  are	  expensive	  
consequently	  using	  nanostructured	  alternatives	  will	  greatly	  reduce	  these	  costs.71	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To	  maximize	  light	  yield,	  anti	  reflection	  coatings	  can	  be	  applied	  to	  solar	  panels.72	  This	  can	  be	  
achieved	  by	  scattering	  silver	  nanocubes	  over	  a	  thin	  gold	  layer.73	  	  
	  
Currently	  carbon	  nanotubes,	  quantum	  dots	  and	  fullerenes	  are	  being	  used	  to	  manufacture	  
solar	  cells,	  making	  these	  more	  efficient	  and	  less	  expensive.74	  Researchers	  are	  developing	  
dynamic	  solar	  cells	  whereby	  quantum	  dots	  are	  used	  for	  their	  ability	  to	  absorb	  different	  
wavelengths	  of	  light.75	  Current	  applications	  of	  nanotechnology	  to	  solar	  panels	  include,	  self-­‐
cleaning	  solar	  panels	  and	  dye	  enhanced	  solar	  cells.	  These	  dye-­‐enhanced	  solar	  cells	  
chemically	  mimic	  the	  biological	  process	  of	  photosynthesis;	  an	  organic	  dye	  monolayer	  is	  used	  
to	  help	  absorb	  sunlight,	  as	  a	  plant	  would.76	  	  
	  
By	  treating	  the	  glass	  in	  buildings	  with	  organic	  solar	  cells,	  energy	  consumption	  in	  buildings	  
will	  be	  greatly	  reduced.	  This	  new	  technology	  was	  announced	  by	  New	  Energy	  Technologies	  
and	  allows	  for	  glass	  to	  be	  coated	  with	  organic	  semiconductors	  that	  dissolve	  to	  create	  thin	  
photovoltaic	  cells.77	  This	  is	  achieved	  by	  combining	  silver	  nanowires,	  titanium	  dioxide	  
nanoparticles	  and	  polymer	  that	  absorbs	  infra	  red	  light.78	  This	  can	  then	  be	  spray	  painted	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c) Biomass	  
	  
Glucose	  is	  the	  most	  abundant	  form	  of	  energy	  available	  in	  bio-­‐systems.	  Glycolysis	  is	  based	  on	  
a	  form	  of	  cell	  respiration	  seen	  in	  animals.79	  Researchers	  have	  developed	  a	  nanowire	  biofuel	  
cell	  that	  will	  convert	  chemical	  energy	  from	  biofluids	  into	  electricity	  using	  glucose	  oxidase	  
and	  laccase	  as	  a	  catalyst.80	  This	  is	  a	  new	  approach	  for	  self-­‐powered	  nanotechnology;	  
generating	  electricity	  from	  the	  environment.	  This	  method	  can	  be	  applied	  to	  wireless	  
sensors,	  electronics	  and	  implantable	  biomedical	  devices.81	  	  
	  
d) Geothermal	  Energy	  
	  
Geothermal	  energy	  is	  a	  sustainable	  and	  a	  cost	  efficient	  source	  of	  energy.	  Nanotechnology	  
could	  increase	  the	  opportunities	  to	  develop	  geothermal	  resources	  by	  enhancing	  thermal	  
conductivity	  or	  facilitating	  in	  the	  development	  of	  non-­‐corrosive	  materials	  that	  could	  be	  used	  
for	  geothermal	  energy	  production.82	  For	  example	  nano-­‐coated	  wear	  resistant	  drill	  probes	  
could	  extend	  the	  lifespan	  and	  efficiency	  of	  systems	  for	  the	  cultivation	  of	  oil	  and	  natural	  gas	  
deposits,	  thereby	  being	  more	  cost	  effective.83	  
	  
Another	  possible	  application	  for	  nanotechnology	  is	  for	  the	  recovery	  of	  unconventional	  
sources	  of	  natural	  gas.	  Nano	  applications	  can	  aid	  in	  accessing	  and	  exploiting	  this	  energy	  
source.	  Nanocatalysts	  and	  nanoscale	  membranes	  could	  aid	  in	  gas	  to	  liquid	  production	  and	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separating	  different	  types	  of	  gases.84	  	  
	  
e) Heat	  Energy	  
	  
Energy	  that	  can	  otherwise	  be	  considered	  “wasted”	  could	  be	  harnessed	  and	  reused	  as	  fuel.	  
Most	  appliances	  and	  electronics	  radiate	  heat	  when	  used	  for	  a	  long	  period,	  e.g.	  a	  computer:	  
this	  simple	  observation	  has	  led	  researchers	  to	  develop	  electrical	  converters	  that	  convert	  
heat	  into	  electricity	  by	  using	  biological	  molecules.	  These	  molecules	  are	  abundant	  and	  
biodegradable.85	  Using	  carbon	  nanotube	  sheets	  would	  be	  very	  effective	  in	  harnessing	  this	  
energy;	  these	  sheets	  could	  be	  wrapped	  around	  the	  exhaust	  of	  a	  car	  or	  cover	  a	  geyser.86	  	  
	  
f) Wind	  and	  Hydro	  Energy	  
	  
Nanomaterials	  can	  be	  used	  for	  lighter,	  stronger	  and	  more	  resistant	  rotor	  blades	  for	  wind	  
and	  tide	  power	  plants.87	  For	  example	  nanotube	  filled	  epoxy	  rotor	  blades.88	  Providing	  better	  
wear	  and	  corrosive	  protection.	  Nanocoatings	  could	  be	  applied	  to	  the	  bearings	  and	  




More	  efficient	  hydrogen	  energy	  generation	  could	  be	  achieved	  with	  new	  processes	  and	  
nanocatalysts.	  Hydrogen	  could	  be	  used	  in	  nanoporous	  materials	  for	  the	  application	  in	  micro	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fuel	  cells	  used	  in	  mobile	  electronics	  and	  automobiles.90	  
	  
In	  terms	  of	  distribution,	  nanotube	  wiring	  will	  improve	  this	  as	  it	  provides	  increased	  strength,	  
conductivity	  and	  stability	  at	  very	  high	  temperatures	  reducing	  energy	  losses	  in	  current	  
transmission.91	  Ideally	  electric	  cables	  and	  pipelines	  should	  be	  replaced	  with	  carbon	  
nanotubes.92	  
Hydrogen	  is	  an	  atomic	  energy	  carrier;	  it	  is	  primarily	  a	  storage	  medium	  for	  energy.93	  This	  
energy	  can	  be	  converted	  into	  electrical	  and	  other	  sources	  of	  energy.	  It	  is	  advantageous	  in	  
that	  it	  can	  be	  transported	  over	  extended	  distances	  without	  losing	  much	  of	  its	  efficiency.94	  
Fullerenes	  are	  ideal	  to	  store	  large	  volumes	  of	  hydrogen	  as	  it	  can	  be	  condensed	  in	  high	  
densities	  in	  SWNT.	  A	  further	  development	  for	  storage	  is	  “nanoblades,”	  which	  are	  
exceptionally	  thin,	  uniform,	  with	  high	  surface	  areas.95	  	  
	  
Nanotechnology	  could	  enable	  cost	  effective	  generation,	  storage	  and	  transport	  for	  
geothermal	  energy	  production.	  
	  
h) Nuclear	  Energy	  
	  
Nuclear	  energy	  production	  leaves	  behind	  dangerous	  waste	  products	  that	  need	  to	  be	  safely	  
contained.	  Nanocomposites	  can	  be	  used	  in	  the	  form	  of	  radiation	  resistant	  containers	  that	  
will	  safely	  confine	  nuclear	  waste.96	  Nano	  engineered	  barriers	  can	  assist	  in	  preventing	  the	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migration	  of	  hazardous	  waste,	  i.e.	  in	  the	  case	  of	  an	  accidental	  leak.97	  Due	  to	  the	  
dangerously	  high	  levels	  of	  radiation,	  nanorobotics	  could	  also	  be	  useful	  in	  decontaminating	  a	  
nuclear	  accident	  site.	  
	  
i) Fuel	  Cells	  	  
	  
Properties	  of	  nanoparticles	  will	  improve	  energy	  and	  storage	  capacity	  and	  product	  service	  
life.98	  Nano	  optimized	  membranes	  and	  electrodes	  can	  enhance	  the	  efficiency	  of	  membranes	  
used	  in	  fuel	  cells	  to	  separate	  hydrogen	  ions	  from	  other	  gases	  (like	  oxygen)	  and	  reduce	  




Nanotechnology	  could	  be	  applied	  to	  create	  new	  types	  of	  batteries	  that	  will	  last	  far	  longer	  
than	  conventional	  batteries.	  The	  increased	  surface	  area	  of	  the	  nanoparticle	  results	  in	  
increased	  power	  density	  to	  battery	  size.101	  Further	  applications	  could	  include	  smaller	  
containers	  that	  are	  environmentally	  friendly,	  safe	  for	  humans	  and	  have	  the	  ability	  to	  
recharge	  batteries	  much	  faster.102	  
	  
Carbon	  nanotubes	  can	  be	  applied	  in	  supercapacitors	  as	  they	  yield	  higher	  energy	  
densities.103	  Possible	  applications	  of	  these	  batteries	  include	  mobile	  electronics	  and	  
automobiles.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  97	  Nanodeltech	  http://nanodeltech.com/nanotechnology/nanotechnology-­‐and	  -­‐energy.html	  (accessed	  
07/05/2012)	  	  
	  98	  Gardner	  2008	  PCOST	  9-­‐10	  	  
	  99	  Understandingnano	  Energy	  http://www.understandingnano.com/nanotechnology-­‐energy.html	  	  (accessed	  
07/05/2012)	  	  
	  100	  Dr.	  Luther	  http://www.hessen-­‐nanotech.de/mm/NanoEnergy_web.pdf	  (accessed	  14/12/2012)	  [At	  4]	  
	  101	  Gardner	  2008	  PCOST	  8	  	  
	  102	  Understandingnano	  Energy	  http://www.understandingnano.com/nanotechnology-­‐energy.html	  	  (accessed	  
07/05/2012)	  	  103	  Dr.	  Luther	  http://www.hessen-­‐nanotech.de/mm/NanoEnergy_web.pdf	  (accessed	  14/12/2012)	  [At	  30]	  	  
	   26	  
k) Other	  Nano	  Applications	  
	  
 Nanoparticle	  monitors	  could	  be	  used	  to	  detect	  any	  impurities	  in	  hydrogen	  and	  
ensure	  clean	  energy.104	  
 Lasers,	  microwaves	  or	  electromagnetic	  resonance	  based	  on	  nano-­‐optimized	  
components	  could	  be	  used	  for	  wireless	  power	  transmission.105	  	  
 Nanosensors	  could	  be	  used	  to	  manage	  highly	  decentralized	  power	  feeds.106	  
 Nanoporous	  foams	  and	  aerogels	  could	  be	  used	  for	  thermal	  insulation	  for	  buildings	  or	  
industrial	  processes.107	  	  
 Nanosensors	  that	  can	  control	  the	  release	  of	  pesticides	  and	  nutrients	  and	  specific	  
intervals	  for	  precision	  farming	  will	  optimize	  biomass	  energy	  production.108	  	  
 Inorganic	  buckyballs	  used	  in	  lubricants	  can	  reduce	  friction	  thereby	  reducing	  energy	  
consumption.109	  
	  
These	  applications,	  as	  discussed,	  illustrate	  the	  potential	  benefits	  that	  range	  from	  reducing	  
waste	  and	  pollution	  to	  creating	  more	  efficient	  resource	  technologies	  at	  a	  lower	  cost.	  
	  
8.3. Application:	  Water	  Sanitation	  
	  
The	  issue	  of	  clean	  water	  is	  of	  particular	  importance	  in	  developing	  countries.	  
Nanotechnology	  could	  contribute	  in	  providing	  less	  expensive,	  more	  durable	  and	  more	  
efficient	  water	  desalination	  methods.	  Some	  of	  these	  nanotechnology	  methods	  are	  already	  
available,	  while	  others	  are	  still	  being	  developed.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  104	  Gardner	  2008	  PCOST	  11	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Inexpensive	  methods	  of	  water	  filtration	  include	  the	  use	  of	  nanomembranes	  and	  nanoclays,	  
these	  systems	  are	  easy	  to	  clean	  and	  portable.110	  With	  these	  applications,	  water	  is	  purified	  
and	  depolluted	  more	  efficiently	  than	  with	  conventional	  filters.	  These	  nanomembranes	  have	  
tiny	  pores	  (>10	  nm);	  liquid	  is	  pressed	  through	  this	  membrane	  separating	  it	  from	  the	  
contaminants.111	  Nanotubes	  can	  be	  used	  for	  these	  nanoporous	  membranes	  on	  large-­‐scale	  
production	  of	  water	  desalination.	  Nanomesh	  is	  another	  filter	  option,	  made	  from	  carbon	  
nanotubes;	  it	  is	  flexible	  and	  can	  be	  placed	  on	  a	  flat	  substrate	  or	  wrapped	  around	  traditional	  
cylindrical	  filters	  or	  any	  other	  support.112	  This	  mesh	  allows	  the	  water	  to	  flow	  through,	  
thereby	  separating	  clean	  water	  from	  any	  parasites,	  microorganisms,	  fungi,	  viruses	  and	  
toxins	  that	  the	  water	  contained.	  
	  
Other	  methods	  include	  magnetic	  nanoparticles	  that	  remove	  heavy	  metal	  contaminants	  and	  
salts	  from	  liquids,	  and	  decompose	  organic	  pollutants.113	  Some	  of	  these	  contaminating	  
substances	  can	  then	  be	  collected	  and	  recycled.	  
	  
9. RISKS	  	  
	  
With	  all	  new	  technologies,	  the	  potential	  for	  new	  risks	  should	  also	  be	  taken	  into	  account.	  
When	  considering	  health	  and	  environmental	  risks,	  data	  collected	  in	  respect	  of	  the	  same	  
material	  on	  bulk	  scale	  seems	  inadequate	  to	  rely	  on	  as	  the	  same	  material	  at	  nanoscale	  can	  
have	  a	  very	  different	  effect.114	  With	  further	  research	  a	  greater	  understanding	  of	  
nanomaterials	  will	  be	  had	  resulting	  in	  the	  safe	  management	  of	  this	  material.	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9.1. Free	  and	  Fixed	  Nanoparticles	  
	  
Two	  types	  of	  nanostructures	  should	  be	  distinguished	  when	  addressing	  risks	  to	  health	  and	  
the	  environment.	  “Free	  nanoparticles”	  and	  “fixed	  manufactured	  nanoparticles.”115	  In	  the	  
latter	  instance,	  nanoscale	  particles	  are	  incorporated	  into	  a	  substance,	  material	  or	  device.	  
Therefore,	  no	  direct	  contact	  will	  be	  had	  by	  workers,	  consumers	  or	  the	  environment.116	  
These	  nanoparticles	  are	  immobilised	  and	  therefore	  pose	  no	  risk	  unless	  an	  accident	  were	  to	  
occur	  resulting	  in	  discarded	  or	  destroyed	  nanoparticles.	  Consequently	  concerns	  mainly	  
relate	  to	  free	  nanoparticles.	  
	  
Present	  nanotechnology	  focuses	  on	  the	  “planned”	  manipulation	  of	  materials	  and	  particles	  
on	  nanoscale.	  These	  can	  be	  produced	  from	  almost	  any	  chemical;	  those	  currently	  in	  use	  have	  
been	  made	  from	  transition	  metals,	  silicon,	  carbon	  (i.e.	  carbon	  black,	  carbon	  nanotubes,	  
quantum	  dots)	  and	  metal	  oxides.117	  Although	  several	  of	  these	  have	  been	  produced	  on	  an	  
industrial	  scale	  for	  decades	  (i.e.	  carbon	  black),	  quantum	  dots	  and	  carbon	  nanotubes	  have	  
only	  been	  around	  for	  the	  last	  two	  decades.	  The	  two	  distinguishing	  features	  of	  these	  
engineered	  nanoparticles	  are	  their	  specific	  physical	  size	  of	  less	  than	  100	  nm	  and	  the	  fact	  
that	  they	  are	  deliberately	  produced.	  Free	  nanoparticles	  on	  the	  other	  hand	  occur	  as	  a	  by-­‐
product	  at	  some	  stage	  of	  production	  or	  use,	  such	  as	  in	  the	  case	  of	  welding,	  sandblasting	  or	  
even	  diesel	  fuel.118	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9.2. Nanoparticles	  and	  the	  Human	  Body	  
	  
Thus	  far	  it	  has	  been	  established	  that	  nanoparticles	  can	  be	  toxic.	  As	  explained	  earlier	  the	  
larger	  surface	  area	  of	  the	  nanoparticle	  makes	  it	  more	  reactive,	  this	  characteristic	  could	  
make	  them	  more	  toxic	  than	  the	  same	  material	  on	  a	  larger	  scale.119	  However,	  it	  is	  also	  
argued	  that	  the	  specific	  nanostructure	  will	  have	  to	  be	  investigated,	  as	  the	  mere	  presence	  of	  
nanomaterial	  is	  not	  a	  threat	  in	  itself.	  To	  properly	  assess	  the	  health	  hazards	  of	  manufactured	  
nanoparticles	  the	  whole	  life	  cycle	  of	  these	  particles	  should	  be	  evaluated,	  including	  their	  
fabrication,	  storage	  and	  distribution,	  application	  and	  potential	  abuse,	  and	  their	  disposal.	  
Their	  impact	  on	  humans	  or	  the	  environment	  may	  vary	  at	  different	  stages	  of	  their	  life	  
cycle.120	  	  
	  
Due	  to	  their	  size,	  free	  nanoparticles	  can	  enter	  the	  body	  in	  various	  ways	  reaching	  and	  
compromising	  organs	  and	  tissue	  in	  the	  body.	  They	  can	  be	  inhaled,	  ingested	  and	  absorbed	  
via	  the	  skin.121	  If	  inhaled	  this	  could	  cause	  inflammation	  in	  the	  respiratory	  tract	  possibly	  
resulting	  in	  tissue	  damage	  and	  subsequent	  systemic	  effects.	  Also	  if	  inhaled	  it	  is	  possible	  for	  
the	  nanoparticle	  to	  be	  carried	  throughout	  the	  body	  via	  the	  bloodstream	  whereby	  other	  vital	  
organs	  and	  tissues	  can	  be	  compromised.122	  	  	  
	  
The	  effect	  of	  these	  nanoparticles	  being	  distributed	  in	  the	  body	  is	  highly	  dependant	  on	  the	  
specific	  nanoparticle.	  The	  shape,	  composition,	  size	  and	  surface	  characteristics	  (surface	  
coatings,	  surface	  chemistry)	  all	  have	  an	  influence	  on	  the	  behaviour	  of	  the	  nanoparticle	  and	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its	  mobility.123	  It	  is	  important	  to	  note	  that	  each	  nanostructure	  is	  engineered	  to	  perform	  a	  
specific	  function	  and	  therefore	  should	  be	  studied	  in	  light	  of	  its	  own	  unique	  biological	  or	  
ecological	  responses.124	  Therefore	  each	  specific	  class	  or	  group	  of	  nanoparticle	  will	  have	  to	  
be	  assessed.125	  A	  further	  investigation	  would	  need	  to	  be	  conducted	  into	  the	  life	  cycle	  of	  the	  
specific	  nanoparticle.	  By	  dissecting	  the	  different	  stages	  any	  changes	  that	  occur	  in	  the	  
nanomaterial	  will	  be	  revealed.	  This	  could	  assist	  in	  detecting	  and	  treating	  the	  indications	  of	  
the	  effects	  more	  efficiently,	  preventing	  permanent	  damage.	  	  
	  
9.3. Nanoparticles	  and	  the	  Environment	  
	  
Even	  if	  nanoparticles	  are	  not	  harmful	  to	  humans	  they	  could	  be	  to	  other	  species	  thereby	  
disrupting	  ecological	  balance.126	  This	  disruption	  could	  then	  in	  turn	  affect	  the	  food	  chain.	  
Nanoparticles	  can	  be	  released	  into	  the	  environment	  accidentally	  or	  gradually.	  Some	  of	  the	  
ways	  can	  include,	  leakage	  or	  emission	  during	  production,	  transportation	  or	  storage	  of	  the	  
raw,	  intermediate	  or	  finished	  products,	  the	  use	  of	  the	  product	  and	  finally	  when	  the	  product	  
is	  discarded	  as	  waste.	  Distribution	  and	  transformation	  in	  the	  air,	  soil	  and	  water	  are	  other	  
possibilities.127	  Products	  containing	  nanoparticles	  can	  be	  highly	  durable	  and	  could	  therefore	  
remain	  in	  the	  environment	  long	  after	  disposal;	  this	  can	  result	  in	  an	  accumulation	  of	  waste	  
that	  can	  harm	  the	  environment	  especially	  if	  they	  cannot	  be	  recycled.	  Therefore	  the	  
importance	  of	  considering	  the	  whole	  life	  cycle	  of	  the	  nanoparticle	  in	  the	  product	  or	  
application	  in	  which	  they	  are	  incorporated	  is	  emphasised	  when	  evaluating	  risk.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  123	  Maynard	  http://tinhoahoc.com/Nanotechnology/RiskRelatedResearch_Maynard_7-­‐06-­‐Final.pdf	  (accessed	  
12/12/2012)	  [At	  10-­‐12].	  Also	  see:	  Berger	  The	  Real	  Issues	  
http://www.nanowerk.com/spotlight/spotid=1781.php	  (accessed	  13/09/2012)	  
124	  Valverde	  and	  Linkov	  2011-­‐2012	  Nanotech.	  L.	  &	  Bus.	  31	  
125	  Gulumian	  “Proposals	  on	  the	  Implications	  of	  Nanotechnology	  Risks	  to	  South	  Africa.	  What	  are	  the	  urgent	  
research	  needs?”	  
http://www.csir.co.za/nre/pollution_and_waste/pdfs/Gulumian_Proposals%20on20%the%20implications.PDF	  
(accessed	  12/12/2012)	  [At	  16]	  [Hereinafter	  “Gulumian	  Nano	  Risks”]	  
	  126	  Maynard	  http://tinhoahoc.com/Nanotechnology/RiskRelatedResearch_Maynard_7-­‐06-­‐Final.pdf	  (accessed	  
12/12/2012)	  [At	  10-­‐12]	  	  	  	  127	  Berger	  The	  Real	  Issues	  
http://www.nanowerk.com/spotlight/spotid=1781.php	  (accessed	  13/09/2012)	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9.4. Risk	  Assessment	  	  
	  
Very	  little	  has	  been	  done	  in	  researching	  the	  potential	  hazard	  of	  nanomaterials	  and	  there	  is	  a	  
great	  deal	  of	  uncertainty	  surrounding	  their	  fate.	  It	  will	  take	  several	  years	  before	  reliable	  and	  
comprehensive	  risk	  assessment	  standards	  are	  established	  for	  this	  technology.128	  Efforts	  
have	  been	  made	  in	  this	  regard;	  the	  NNI	  has	  established	  a	  long-­‐term	  risk	  assessment	  
strategy.129	  However,	  an	  interim	  risk	  assessment	  strategy	  to	  manage	  the	  potential	  health	  
and	  environmental	  risks	  is	  very	  necessary.130	  Both	  the	  private	  and	  public	  sectors	  should	  
work	  together	  in	  researching	  and	  sharing	  their	  findings.	  	  
	  
Currently	  the	  traditional	  method	  of	  assessing	  risk	  is	  applied.	  These	  risk	  assessments,	  set	  for	  
the	  same	  matter	  in	  bulk	  should	  only	  apply	  as	  guidelines.	  It	  is	  imperative	  for	  regulators	  to	  
consider	  the	  implications	  of	  the	  unusual	  properties	  of	  these	  nanoparticles.	  To	  rely	  on	  
existing	  knowledge	  will	  create	  false	  assumptions	  of	  safety.131	  A	  new	  research	  approach	  may	  
be	  advantageous	  when	  determining	  the	  risks	  of	  this	  new	  technology	  as	  the	  current	  testing	  
methods	  to	  determine	  toxicity	  might	  not	  prove	  useful	  or	  sufficient.	  For	  example,	  the	  
manner	  in	  which	  nanoparticles	  can	  be	  absorbed	  by	  the	  body	  do	  not	  fall	  within	  the	  norms	  of	  
what	  toxicologists	  usually	  consider	  when	  evaluating	  exposure.132	  
	  
Billions	  are	  being	  invested	  to	  capitalise	  on	  this	  rapidly	  developing	  technology	  and	  with	  this,	  
research	  to	  explore	  the	  potential	  risks	  is	  sorely	  lagging	  behind.	  These	  risks	  need	  to	  be	  
assessed	  as	  soon	  as	  possible,	  before	  preventable	  and	  predictable	  problems	  result	  in	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  and	  Linkov	  2011-­‐2012	  Nanotech.	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  Bus.	  30	  
	  129	  Gulumian	  Nano	  Risks	  
http://www.csir.co.za/nre/pollution_and_waste/pdfs/Gulumian_Proposals%20on20%the%20implications.PDF	  
(accessed	  12/12/2012)	  [At	  2]	  
	  
130	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	  5]	  	  
	  131	  Maynard	  http://tinhoahoc.com/Nanotechnology/RiskRelatedResearch_Maynard_7-­‐06-­‐Final.pdf	  (accessed	  
12/12/2012)	  [At	  13]	  
	  132	  Valverde	  and	  Linkov	  2011-­‐2012	  Nanotech.	  L.	  &	  Bus.	  26	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setbacks	  that	  could	  otherwise	  be	  avoided.	  The	  goal	  should	  be	  to	  narrow	  the	  already	  wide	  
and	  growing	  gap	  between	  the	  lack	  of	  research	  and	  products	  already	  available	  commercially.	  	  
	  
In	  summary,	  findings	  based	  on	  bulk	  matter	  cannot	  be	  relied	  on	  entirely,	  not	  only	  due	  to	  
their	  size	  but	  also	  due	  to	  different	  interactions	  had	  with	  the	  body.	  Each	  nanoparticle	  should	  
be	  evaluated	  separately	  and	  at	  different	  stages	  of	  its	  lifecycle	  as	  changes	  in	  the	  
nanomaterial	  might	  affect	  exposure	  and	  risk.133	  The	  level	  of	  risk	  management	  also	  depends	  
on	  the	  relevant	  branch	  of	  industry	  in	  question.134	  	  
	  
9.5. Risk	  and	  Investment	  	  
	  
Another	  inherent	  risk	  of	  a	  new	  technology	  is	  that	  of	  investment.	  Due	  to	  the	  inherent	  
element	  of	  unpredictability	  associated	  with	  this	  technology	  it	  is	  imperative	  that	  reference	  is	  
made	  to	  the	  importance	  of	  drafting	  a	  high	  quality	  patent	  application	  (this	  aspect	  will	  be	  
discussed	  in	  detail	  in	  chapter	  2).	  Investment	  prospects	  are	  encouraged	  if	  a	  company	  can	  
show	  that	  the	  entire	  “value-­‐chain”	  of	  an	  invention	  has	  been	  protected.135	  Economic	  gain	  is	  a	  
primary	  incentive	  for	  innovation	  and	  as	  such	  this	  aspect	  should	  be	  mentioned.	  	  
	  
10. THE	  FUTURE	  OF	  NANOTECHNOLOGY	  	  
	  
Mihail	  Roco	  at	  the	  NNI,	  identifies	  the	  Four	  Generations	  of	  Nanotechnology	  as:136	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  (accessed	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  [At	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  134	  OECD	  http://www.oecd.org/science/safetyofmanufacturednanomaterials/44108334.pdf	  	  (accessed	  
08/09/2012)	  [At	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135	  Wild	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(accessed	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1. Passive	  Nanostructures:	  	   2000	  -­‐	  2010	  
	  
Here	  materials	  are	  designed	  to	  perform	  a	  specific	  task.	  Examples	  are:	  nanoparticles,	  
nanotubes,	  nanocomposites,	  nanocoatings	  and	  nanostructured	  materials.	  
	  
2. Active	  Nanostructures:	  	   2010	  -­‐	  2020	  
	  
We	  find	  ourselves	  in	  this	  generation	  of	  nanotechnology.	  Here	  nanomaterials	  are	  
used	  for	  multitasking.	  Examples	  include:	  electronics,	  sensors,	  targeted	  drugs	  and	  
adaptive	  structures.	  
	  
3. Systems	  of	  Nanosystems:	  	   2020	  -­‐	  2030	  
	  
Thousands	  of	  components	  interact	  with	  each	  other	  in	  the	  form	  of	  guided	  molecular	  
assembly,	  3D	  networking,	  robotics	  and	  supra	  molecules.	  
	  
4. Molecular	  Nanosystems:	  	   2030	  -­‐	  2040	  
	  
Here	  integrated	  molecular	  systems,	  including	  systems	  within	  systems	  that	  are	  
capable	  of	  accomplishing	  far	  more	  than	  we	  are	  currently	  able	  to.	  Examples	  are:	  
molecules	  “by	  design”,	  hierarchical	  functions	  and	  evolutionary	  systems.	  Examples	  
are:	  sophisticated	  molecules	  for	  manufacturing	  of	  genes	  inside	  the	  DNA	  of	  targeted	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CHAPTER	  2	  
IP	  &	  NANOTECHNOLOGY	  
	  
Nanotechnology	  is	  a	  unique	  and	  rapidly	  developing	  field;	  it	  is	  unlike	  any	  technology	  before	  
it:	  it’s	  unpredictable	  nature,	  complex	  characteristics,	  and	  cross-­‐industry	  application	  have	  
created	  a	  great	  deal	  of	  uncertainty	  amongst	  researchers,	  inventors	  and	  investors	  seeking	  to	  
develop,	  protect	  or	  invest	  in	  nanotechnology	  related	  products.	  The	  regulations	  and	  
procedures	  of	  patent	  law	  are	  not	  technology	  specific	  and	  apply	  to	  all	  technologies	  in	  the	  
same	  manner;	  however	  a	  new	  generation	  of	  technology	  will	  bring	  with	  it	  a	  new	  generation	  
of	  IP	  challenges.	  In	  order	  for	  a	  nanotechnology	  patent	  to	  be	  valid	  and	  adequately	  protected,	  
it	  is	  imperative	  that	  the	  technology	  is	  understood	  not	  only	  by	  the	  patent	  practitioner	  who	  is	  
responsible	  for	  ensuring	  that	  the	  inventor	  gains	  from	  the	  full	  use	  of	  his	  invention	  but	  also	  
the	  patent	  examiner	  who	  has	  the	  cumbersome	  duty	  of	  evaluating	  the	  validity	  of	  a	  
nanotechnology	  invention	  in	  light	  of	  the	  state	  of	  art	  and	  other	  substantive	  requirements	  set	  
by	  patent	  law.	  	  
	  
This	  chapter	  will	  explore	  the	  challenges	  facing	  new	  nanotechnology	  patent	  applications,	  
some	  of	  which	  originate	  from	  past	  nanotechnology	  patents,	  i.e.	  patented	  “building	  blocks”	  
and	  the	  use	  of	  overly	  broad	  claims.	  Others	  relate	  to	  the	  technology	  itself,	  i.e.	  the	  inherent	  
characteristics	  of	  nanotechnology,	  lack	  of	  standardised	  definitions	  and	  cross-­‐industry	  
application.	  Objections	  and	  criticism	  received	  by	  earlier	  patents	  serve	  as	  excellent	  insight	  to	  
drafting	  better	  patent	  specifications	  that	  are	  likely	  to	  succeed	  if	  submitted	  for	  re-­‐
examination	  or	  litigation.	  It	  is	  arguable	  that	  retrospectively	  many	  patents	  that	  were	  granted	  
for	  nanotechnology	  inventions	  in	  the	  past	  would	  have	  been	  rejected	  based	  on	  the	  
knowledge	  that	  has	  since	  been	  acquired.	  
	  
In	  light	  of	  this	  study,	  it	  is	  important	  to	  explore	  the	  differences	  and	  similarities	  in	  the	  
processes	  and	  requirements	  set	  for	  patents	  by	  different	  patent	  systems.	  The	  U.S.	  and	  
Europe	  have	  well-­‐developed	  IP	  systems	  and	  their	  patent	  systems	  are	  often	  used	  as	  models	  
for	  other	  countries	  to	  base	  their	  patent	  systems	  on.	  The	  requirements	  for	  a	  valid	  patent	  will	  
be	  addressed	  individually	  and	  important	  factors	  to	  consider	  when	  drafting	  the	  patent	  
application	  will	  be	  discussed	  throughout	  this	  chapter.	  This	  investigation	  will	  be	  conducted	  
	   35	  
within	  the	  context	  of	  the	  USPTO	  and	  EPO’s	  approach	  when	  examining	  the	  validity	  of	  
nanotechnology	  patents.	  In	  chapter	  3,	  these	  approaches	  will	  be	  compared	  to	  the	  South	  
African	  patent	  system	  and	  the	  present	  position	  South	  Africa	  finds	  itself	  in	  regarding	  
nanotechnology	  patent	  applications.	  
	  
1. SOME	  OF	  THE	  CHALLENGES	  OF	  NANOTECHNOLOGY	  IN	  PATENT	  LAW	  
	  
The	  primary	  objective	  of	  patent	  law	  is	  to	  encourage	  innovation	  for	  economic	  gain.	  Patent	  
systems	  are	  in	  place	  to	  give	  inventors	  the	  financial	  incentive	  to	  create	  products	  and	  
negotiate	  access	  to	  their	  technology	  by	  marketing	  their	  invention	  thereby	  contributing	  to	  
the	  economic	  development	  of	  the	  country.	  Nanotechnology	  has	  the	  potential	  to	  
significantly	  improve	  known	  technologies	  and	  create	  new	  technologies	  in	  varied	  fields,	  
ultimately	  having	  an	  immense	  impact	  on	  not	  only	  the	  economy	  but	  also	  on	  society’s	  quality	  
of	  life.	  With	  the	  promise	  of	  a	  better	  future	  an	  influx	  of	  nanotechnology	  patents	  was	  
experienced	  worldwide,	  resulting	  in	  some	  of	  the	  challenges	  currently	  facing	  new	  
nanotechnology	  patent	  applications.	  
	  
1.1. Patented	  “Building	  Blocks”	  
	  
Often	  referred	  to	  as	  the	  patent	  “land	  grab,”	  one	  of	  the	  main	  challenges	  facing	  present	  
nanotechnology	  patent	  applications	  is	  that	  many	  of	  the	  fundamental	  “building	  blocks”	  of	  
this	  science	  have	  already	  been	  patented	  forming	  part	  of	  prior	  art	  and	  preventing	  other	  
applications	  from	  ever	  becoming	  patents.137	  These	  patents	  comprise	  the	  fundamental	  
concepts	  upon	  which	  later	  developments	  are	  based	  and	  could	  cover	  a	  wide	  range	  of	  basic	  
nanotechnology	  inventions	  that	  could	  be	  applied	  to	  a	  broad	  spectrum	  of	  fields.138	  
Furthermore	  these	  early	  nanotechnology	  patents	  have	  very	  broad	  claims	  and	  are	  expected	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to	  overlap	  in	  scope	  with	  patents	  in	  other	  fields.139	  This	  after-­‐effect	  can	  be	  attributed	  to	  
nanotechnology’s	  vast	  cross-­‐industry	  application	  and	  that	  these	  patents	  were	  not	  examined	  
in	  light	  of	  different	  art	  units	  that	  may	  have	  been	  applicable	  to	  the	  particular	  invention.	  	  
	  
This	  issue	  is	  best	  illustrated	  with	  an	  example	  of	  how	  these	  patented	  nanotechnology	  
building	  blocks	  can	  result	  in	  infringements	  and	  impede	  further	  innovation.140	  Carbon	  
nanotubes	  (CNTs)	  are	  considered	  to	  be	  one	  of	  the	  most	  significant	  of	  the	  nanomaterials	  
discovered	  thus	  far,	  due	  to	  their	  incredible	  properties	  and	  vast	  commercial	  application.	  
They	  can,	  for	  example,	  be	  applied	  in	  materials	  and	  compounds	  for	  reinforcement	  used	  in	  
construction,	  the	  field	  of	  medicine	  and	  pharmaceuticals,	  nanoelectronics	  and	  
nanomechanical	  devices,	  biotechnology,	  agriculture,	  energy	  production,	  storage	  and	  
distribution	  and	  telecommunications.	  As	  a	  result	  of	  their	  enormous	  commercial	  appeal	  and	  
potential	  application,	  an	  enormous	  number	  of	  patents	  were	  sought	  for	  CNT	  based	  products.	  
These	  patents	  claimed	  nanotubes	  in	  compositions	  of	  matter,	  methods	  of	  production	  and	  
products	  containing	  or	  incorporating	  nanotubes	  thereby	  creating	  a	  dense	  patent	  thicket	  
whereby	  an	  inventor	  would	  have	  to	  reach	  licencing	  agreements	  for	  multiple	  patents	  from	  
multiple	  fields	  so	  as	  to	  avoid	  possible	  infringements	  from	  occurring.141	  	  
	  
These	  patents	  could	  claim	  CNT	  related	  inventions	  in	  a	  variety	  of	  ways.	  Drew	  Harris,	  a	  lawyer	  
and	  Managing	  Editor	  of	  Nanotechnology	  Law	  and	  Business	  explains	  that	  there	  are	  three	  
primary	  types	  of	  claims:142	  
	  
1. Composition	  of	  matter	  claims	  
2. Product,	  device,	  apparatus	  or	  systems	  claims	  
3. Method	  claims	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The	  term	  “building	  block”	  patent	  therefore	  refers	  to	  the	  above-­‐mentioned	  claims	  claiming	  
CNTs	  as	  the	  subject	  matter	  of	  the	  invention.	  In	  other	  words	  the	  application	  claims	  
nanotubes	  or	  nanotube	  based	  products	  or	  methods	  for	  making	  nanotubes	  or	  products	  
incorporating	  nanotubes	  as	  the	  invention.	  An	  infringement	  occurs	  when	  every	  element	  of	  
the	  claim	  or	  equivalent	  of	  the	  claim	  is	  found	  in	  the	  later	  claimed	  process	  or	  product	  of	  the	  
patent.143	  The	  claimed	  elements	  determine	  the	  scope	  of	  a	  patent.	  	  
	  
Harris	  further	  explains	  that	  CNT	  patents	  are	  divided	  into	  two	  categories,	  “basic	  building	  
block”	  patents	  and	  “applied	  building	  block”	  patents.	  The	  term	  “basic	  building	  block”	  patent	  
is	  used	  to	  describe	  patents	  claiming	  fundamental	  properties	  of	  CNTs	  such	  as	  nanotube	  
compositions	  of	  matter,	  general	  techniques	  applied	  in	  producing	  nanotubes	  and	  the	  tools	  
commonly	  used	  to	  change	  and	  manipulate	  nanotubes.	  This	  description	  would	  lead	  one	  to	  
assume	  that	  this	  general	  category	  of	  patents	  is	  likely	  to	  be	  infringed	  across	  a	  broad	  
spectrum	  of	  industries.	  On	  the	  other	  hand,	  the	  term	  “applied	  building	  block”	  patent	  refers	  
to	  patents	  claiming	  specific	  products	  incorporating	  CNTs	  and	  specific	  methods	  for	  
manufacturing	  those	  products.	  Examples	  include,	  apparatus	  and	  method	  claims	  directed	  to	  
nanotube	  transistors,	  nanotube	  based	  sensors	  and	  nanotube	  embedded	  in	  polymer	  resins.	  
In	  summary	  it	  can	  be	  said	  that	  due	  to	  the	  specificity	  of	  this	  category	  only	  a	  select	  number	  of	  
companies	  in	  specific	  industries	  would	  be	  affected	  by	  potential	  infringements.144	  	  
	  
Companies	  that	  have	  invested	  in	  conducting	  research	  of	  CNT	  based	  products	  are	  likely	  to	  
infringe	  these	  categories	  of	  CNT	  patents.	  The	  novelty	  of	  the	  invention	  and	  scope	  of	  the	  
claims	  will	  be	  argued	  thereby	  challenging	  the	  validity	  of	  the	  patent.	  Negative	  repercussions	  
of	  these	  thickets	  include	  legal	  uncertainty,	  significant	  legal	  costs	  and	  licencing	  costs	  for	  
companies	  seeking	  to	  manufacture	  and	  develop	  such	  products.	  Investment	  prospects	  and	  
mass	  production	  will	  also	  be	  adversely	  affected.145	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In	  the	  light	  of	  the	  example	  of	  CNTs,	  patent	  thickets	  could	  severely	  undermine	  the	  primary	  
incentive	  of	  patents	  viz.	  to	  provide	  the	  inventor	  with	  the	  exclusive	  monopoly	  to	  use	  and	  
commercialise	  the	  product	  or	  process	  in	  return	  for	  the	  public’s	  use	  thereof	  and	  could	  serve	  
as	  a	  deterrent	  to	  innovate.	  Furthermore	  innovation	  is	  limited	  rather	  than	  encouraged,	  as	  
inventors	  will	  attempt	  to	  create	  their	  inventions	  around	  existing	  patents.146	  It	  is	  necessary	  
to	  confront	  this	  complex	  nanotechnology	  patent	  landscape	  with	  meticulous	  review	  in	  order	  
to	  safeguard	  against	  new	  nanotechnology	  patents	  from	  infringing	  upon	  earlier	  patents.	  By	  
circumnavigating	  this	  labyrinth,	  uncertainty	  amongst	  researchers,	  developers,	  policy	  makers	  
and	  investors	  as	  to	  who	  owns	  which	  part	  of	  nanotechnology	  IP	  will	  be	  reduced.	  	  
	  
1.2. Broad	  Claiming	  	  
	  
As	  discussed,	  early	  nanotechnology	  patents	  not	  only	  claim	  fundamental	  concepts	  necessary	  
for	  further	  advances	  in	  the	  field	  but	  also	  tend	  to	  claim	  these	  concepts	  in	  an	  overly	  broad	  
manner	  thereby	  encompassing	  far	  more	  than	  the	  actual	  invention	  is	  capable	  of	  
accomplishing.	  The	  use	  of	  unduly	  broad	  claims	  in	  patent	  applications	  leads	  to	  uncertainty	  
regarding	  scope	  of	  coverage	  of	  the	  patent.147	  Inevitably	  these	  patents	  will	  overlap	  and	  
infringe	  upon	  earlier	  patents	  in	  other	  fields,	  eventually	  resulting	  in	  invalidation.	  Arguably	  
some	  of	  these	  early	  nanotechnology	  patents	  were	  unintentionally	  drafted	  with	  the	  use	  of	  
general	  and	  broad	  claims	  in	  the	  specification	  due	  to	  the	  newness	  of	  the	  technology,	  i.e.	  the	  
lack	  of	  standardised	  definitions	  and	  not	  fully	  comprehending	  the	  adaptability	  of	  this	  
discipline	  in	  multiple	  fields.	  These	  patents	  were	  consequently	  granted	  due	  to	  the	  lack	  of	  
prior	  art	  and	  knowledge	  necessary	  for	  the	  examiners	  to	  thoroughly	  and	  accurately	  
determine	  novelty	  and	  non-­‐obviousness.	  	  
	  
The	  issue	  of	  broad	  claiming	  can	  be	  described	  by	  referring	  back	  to	  the	  discussion	  on	  building	  
block	  patents,	  i.e.	  when	  nanotubes	  are	  claimed	  as	  the	  subject	  matter	  of	  the	  invention,	  the	  
claim	  is	  broad	  because	  it	  is	  claiming	  protection	  for	  all	  nanotubes	  or	  nanotube	  based	  
products	  and/or	  the	  methods	  for	  making	  nanotubes	  and/or	  products	  incorporating	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nanotubes	  as	  the	  invention.	  These	  patents	  receive	  protection	  for	  basic	  concepts	  that	  have	  
general	  application	  thereby	  hindering	  newer	  patent	  applications	  and	  creating	  an	  
“overlapping	  patent	  landscape”148	  for	  patents	  containing	  nanotubes	  as	  part	  of	  the	  
invention.	  Although	  desirable	  to	  the	  patent	  holder	  who	  stands	  to	  profit	  from	  his	  exclusive	  IP	  
rights,	  as	  he	  owns	  the	  monopoly	  to	  determine	  whom,	  when	  and	  how	  the	  technology	  can	  be	  
used	  irrespective	  of	  the	  field	  in	  which	  it	  is	  applied.	  He	  will	  also	  expose	  himself	  to	  a	  wider	  
range	  of	  potential	  infringers.	  	  
	  
Broad	  claims	  increase	  the	  risk	  of	  negative	  claim	  interpretation	  and	  there	  is	  also	  a	  greater	  
probability	  that	  the	  specification	  will	  not	  cover	  the	  entire	  width	  of	  the	  claimed	  invention	  
thereby	  putting	  into	  question	  the	  fulfillment	  of	  the	  enablement	  requirement.	  As	  seen	  in	  
earlier	  patents	  the	  use	  of	  overly	  broad	  claims	  will	  encourage	  litigation	  as	  broad	  claims	  are	  
often	  more	  easily	  challenged	  and	  investors	  will	  be	  hesitant	  to	  invest	  in	  a	  product	  with	  broad	  
claims	  even	  if	  that	  product	  will	  be	  profitable.149	  The	  patent	  practitioner	  can	  avoid	  these	  
costly	  and	  time	  consuming	  downstream	  problems,	  i.e.	  litigation	  and	  re-­‐examination,	  by	  
ensuring	  the	  claims	  are	  not	  broader	  than	  the	  description	  of	  the	  invention	  contained	  in	  the	  
specification,	  when	  drafting	  the	  patent	  application.	  Claims	  are	  only	  enforceable	  if	  they	  are	  
valid	  and	  they	  will	  only	  be	  valid	  if	  the	  breadth	  and	  scope	  of	  the	  claim	  is	  “enablingly”	  
disclosed,	  i.e.	  the	  invention	  can	  be	  worked	  across	  the	  entire	  width	  of	  the	  claims.	  Investors	  
will	  ultimately	  be	  assured	  of	  the	  defensibility	  and	  validity	  of	  a	  patent	  if	  care	  was	  taken	  to	  
submit	  an	  application	  with	  a	  focused	  claim.	  
	  
1.3. Problems	  with	  a	  Standardised	  Definition	  	  
	  
Another	  major	  challenge	  is	  the	  absence	  of	  a	  standardised	  definition	  for	  nanotechnology	  and	  
nanotech	  concepts.150	  There	  has	  been	  a	  great	  deal	  of	  criticism	  surrounding	  the	  lack	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  148	  The	  term	  “overlapping	  patent	  landscape”	  refers	  to	  a	  patent	  thicket,	  i.e.	  a	  dense	  maze	  of	  overlapping	  IP	  
rights.	  	  	  	  
149	  Wild	  http://www.iam-­‐magazine.com/issues/article.ashx?g=29c766f2-­‐a9b8-­‐4b94-­‐89d5-­‐d35b9ec8e614	  
(accessed	  31/07/2012)	  [At	  30-­‐31]	  
150	  Berger	  Nano	  Patent	  Land	  Rush	  http://www.nanowerk.com/spotlight/spotid=1919.php	  (accessed	  
02/05/2012).	  Also	  see:	  Chapter	  1,	  section	  entitled	  “1.	  NEW	  ADVANCEMENTS	  IN	  TECHNOLOGY:	  THE	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proficiency	  of	  patent	  examiners	  in	  the	  field	  of	  nanotechnology	  and	  for	  the	  absence	  of	  a	  
standardised	  definition	  reference.151	  As	  discussed	  briefly	  in	  the	  previous	  chapter,	  initiatives	  
by	  various	  organisations	  are	  in	  place	  to	  create	  a	  uniform	  definition	  for	  nanotechnology	  
terms.	  The	  EPO	  introduced	  the	  Y01N	  tagging	  system	  to	  classify	  nano-­‐related	  documents152	  
and	  in	  the	  US,	  experts	  in	  both	  the	  public	  sector,	  for	  example	  USPTO	  and	  private	  sector,	  The	  
Institute	  of	  Nanotechnology	  are	  collaborating	  to	  devise	  a	  first	  standard	  of	  nanotechnology	  
nomenclature.153	  	  
	  
In	  2004,	  the	  USPTO’s	  introduced	  Classification	  977	  as	  a	  cross-­‐referencing	  system	  that	  was	  
designed	  to	  aid	  in	  searching	  prior	  art	  related	  to	  nanotechnology	  and	  organise	  
nanotechnology	  related	  subject	  matter	  in	  a	  logical	  manner.	  This	  class	  contains	  263	  
subclasses	  and	  allows	  for	  patents	  to	  be	  referenced	  in	  two	  ways,	  firstly	  in	  an	  area	  related	  to	  
specific	  technology	  and	  then	  a	  supplemental	  search	  resource	  is	  provided	  for	  nanotech	  
classifications.154	  Class	  977	  has	  assisted	  in	  more	  efficient	  searches	  and	  reduced	  a	  great	  deal	  
of	  ambiguity	  relating	  to	  nanotechnology	  terms.	  Furthermore	  it	  has	  aided	  in	  eliminating	  
some	  of	  the	  uncertainty	  relating	  to	  the	  ownership	  rights	  of	  nanotechnology	  IP.155	  	  
	  
However	  despite	  the	  USPTO’s	  efforts	  there	  are	  still	  some	  problems	  with	  Class	  977,	  in	  
particular,	  inconsistencies	  regarding	  the	  definition	  and	  scope	  of	  the	  current	  definition	  given	  
to	  nanotechnology.	  This	  classification	  merely	  groups	  relevant	  patents	  together	  for	  prior	  art	  
searches.	  It	  fails	  to	  assess	  or	  communicate	  a	  relationship	  between	  these	  patents	  or	  identify	  
overlapping	  or	  infringing	  claims.	  As	  a	  result	  all	  pre-­‐2004	  patents	  were	  assessed	  at	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
DEFINITION	  AND	  SCOPE	  OF	  NANOTECHNOLOGY”	  and	  the	  USPTO,	  EPO	  and	  NNI	  nanotechnology	  definitions	  
provided	  in	  footnotes	  4,5	  and	  8.	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  O’Neil	  et	  al	  2007	  Nanotech.	  L.	  &	  Bus.	  597	  
154	  Paradise	  2012	  NJTIP	  170	  
	  155	  O’Neil	  et	  al	  2007	  Nanotech.	  L.	  &	  Bus.	  595	  and	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examiner’s	  discretion.156	  In	  2005	  USPTO	  enforced	  a	  stricter	  definition	  of	  nanotechnology	  
resulting	  in	  a	  decline	  of	  nano-­‐related	  patents	  received	  by	  the	  office.157	  	  
	  
A	  standardised	  reference	  of	  definitions	  and	  terminology	  is	  needed,	  especially	  due	  to	  the	  
multidisciplinary	  nature	  of	  nanotechnology.	  The	  same	  term	  can	  refer	  to	  significantly	  
different	  structures	  depending	  on	  the	  field	  it	  is	  applied	  to.	  The	  NNI	  and	  USTPO	  use	  similar	  
definitions	  but	  not	  all	  definitions	  have	  the	  same	  parameters.	  The	  same	  structure	  can	  be	  
described	  in	  various	  ways	  resulting	  in	  difficulty	  determining	  what	  is	  included	  and	  excluded	  
from	  a	  term	  used	  in	  a	  claim.158	  For	  example,	  silicon	  nanocrystals	  with	  the	  average	  diameter	  
of	  1-­‐30	  nm,	  as	  opposed	  to,	  nanocrystals	  light	  emitting	  a	  spectral	  range	  no	  greater	  than	  60	  
nm.	  The	  patent	  examiner	  must	  determine	  the	  scope	  of	  the	  claim	  therefore	  it	  is	  
recommended	  and	  in	  the	  best	  interest	  of	  the	  applicant	  to	  define	  the	  terms	  he	  uses	  to	  
describe	  the	  properties	  in	  his	  invention.	  If	  the	  applicant	  fails	  to	  do	  so	  the	  broadest,	  most	  
reasonable	  interpretation	  consistent	  with	  the	  specification	  will	  be	  given.159	  In	  other	  words	  
the	  terms	  used	  in	  the	  claim	  are	  interpreted	  within	  the	  context	  of	  any	  definition	  given	  in	  the	  
specification	  and	  if	  no	  definition	  is	  given,	  the	  “plain	  meaning”	  will	  be	  given,	  i.e.	  the	  meaning	  
a	  person	  skilled	  in	  the	  art	  of	  the	  relevant	  field	  would	  give	  the	  term	  when	  reading	  the	  
specification.160	  	  
	  
The	  field	  of	  nanotechnology	  poses	  a	  particular	  challenge	  when	  interpreting	  the	  terms	  of	  a	  
nanotechnology	  invention	  due	  to	  the	  many	  meanings	  that	  are	  available;	  the	  same	  structure	  
can	  have	  multiple	  terms	  describing	  it	  or	  the	  same	  term	  can	  have	  different	  meanings.161	  
Furthermore,	  cases	  where	  the	  applicant	  acts	  as	  his	  own	  lexicographer	  and	  defined	  unknown	  
terms	  could	  also	  make	  it	  difficult	  for	  the	  examiner	  to	  determine	  novelty.	  By	  creating	  a	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  156	  Paradise	  2012	  NJTIP	  170	  and	  184-­‐186	  
157	  Pouris	  2010	  University	  of	  Pretoria	  108-­‐109	  
158	  Mills,	  Fitzsimmons	  and	  Rodkey	  2010	  Nanotech.	  L.	  &	  Bus.	  223-­‐235	  
159	  In	  re	  Hyatt	  211	  F.3d	  1367,	  1372,	  54	  USPQ2d	  1664,	  1667	  (Fed.	  Cir.	  2000)	  
	  160	  MPEP	  §	  2111	  
161	  Mills,	  Fitzsimmons	  and	  Rodkey	  2010	  Nanotech.	  L.	  &	  Bus.	  233	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uniform	  definition	  reference	  for	  nanotechnology	  terms,	  confusion	  relating	  to	  similar	  terms	  
used	  in	  different	  fields	  will	  be	  reduced.	  	  
	  
It	  is	  maintained	  that	  many	  of	  the	  issues	  relating	  to	  nanotechnology	  patents	  stem	  from	  the	  
lack	  of	  a	  standardised	  definition	  therefore	  a	  uniform,	  standard	  reference	  would:	  limit	  broad	  
claims,	  simplify	  the	  task	  of	  the	  examiners	  when	  interpreting	  undefined	  terms	  and	  unify	  
concepts	  used	  in	  different	  fields	  thereby	  eliminating	  doubt	  and	  ultimately	  avoiding	  the	  
invalidation	  of	  patents	  at	  a	  later	  stage.	  	  
	  
1.4. The	  Multidisciplinary	  Application	  of	  Nanotechnology	  
	  
Nanotechnologies	  have	  a	  vast	  application	  enabling	  processes	  and	  products	  in	  multiple	  
fields.	  This	  was	  illustrated	  by	  the	  examples	  given	  regarding	  the	  many	  applications	  of	  carbon	  
nanotubes.162	  It	  is	  therefore	  imperative	  to	  have	  a	  comprehensive	  view	  of	  the	  
nanotechnology	  patent	  landscape	  when	  evaluating	  the	  validity	  of	  nanotechnology	  patent	  
applications.163	  	  
	  
Patent	  examiners	  are	  technically	  trained	  in	  a	  particular	  field	  and	  are	  tasked	  with	  evaluating	  
the	  validity	  of	  the	  invention	  claimed	  in	  the	  patent	  application.	  In	  the	  past	  inventions	  were	  
examined	  under	  a	  single	  classification	  or	  related	  classes	  of	  technology164	  whereas	  
nanotechnology	  inventions	  can	  combine	  different	  fields	  of	  science	  and	  technology	  and	  the	  
examiners	  are	  not	  necessarily	  equipped	  with	  the	  varied	  expertise	  required	  to	  examine	  such	  
an	  invention,	  as	  a	  result	  the	  risk	  of	  overlooking	  prior	  art	  in	  other	  relevant	  sectors	  is	  
increased	  and	  the	  granted	  patents,	  will	  in	  all	  probability	  be	  invalidated	  in	  court	  at	  a	  later	  
stage	  due	  to	  overlapping	  claims.165	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  162	  See:	  Chapter	  2,	  section	  entitled,	  “1.	  SOME	  OF	  THE	  CHALLENGES	  OF	  NANOTECHNOLOGY	  IN	  PATENT	  LAW:	  
1.1.	  Patented	  ‘Building	  Blocks’”	  	  	  163	  Watal	  and	  Faunce	  http://wipo.int/wipo_magazine/en/2011/02/article_0009.html	  (accessed	  02/05/2012)	  	  
	  164	  Gosain	  
http://www.daniel.adv.br/eng/articlesPublications/ranaGosain/NANOTECHNOLOGY_PATENT_PROTECTION_B
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  165	  Watal	  and	  Faunce	  http://wipo.int/wipo_magazine/en/2011/02/article_0009.html	  (accessed	  02/05/2012)	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The	  multidisciplinary	  application	  of	  this	  technology	  is	  of	  particular	  importance	  when	  
determining	  whether	  the	  requirements	  of	  novelty	  and	  non-­‐obviousness	  have	  been	  met.	  It	  is	  
problematic	  for	  the	  examiner	  to	  search	  for	  all	  of	  the	  relevant	  prior	  art	  due	  to	  the	  fact	  that	  
they	  may	  be	  located	  in	  various	  areas	  or	  fields	  of	  technology.166	  In	  an	  attempt	  to	  resolve	  this	  
issue	  the	  USPTO’s	  responded	  by	  appointing	  examiners	  from	  the	  various	  relevant	  fields	  
thereby	  creating	  a	  team	  to	  examine	  patents	  that	  incorporated	  more	  than	  one	  discipline,167	  
thus	  ensuring	  all	  of	  the	  potentially	  relevant	  prior	  art	  sectors	  be	  consulted.	  	  
	  
It	  is	  fair	  to	  conclude	  from	  the	  above	  that	  although	  the	  field	  of	  nanotechnology	  is	  new	  and	  
continues	  to	  be	  a	  challenge	  for	  examiners,	  who	  still	  have	  limited	  expertise	  and	  have	  to	  cope	  
with	  deficiencies	  of	  definitions,	  etc.,	  the	  Patent	  Offices	  have	  undertaken	  all	  the	  measures	  
necessary	  to	  minimize	  inadequate	  results	  of	  searches	  and	  examination.	  As	  in	  case	  of	  all	  new	  
technologies,	  it	  will	  probably	  still	  take	  some	  time	  to	  deal	  with	  nanotechnology	  the	  same	  
way	  as	  with	  other	  more	  traditional	  technologies.	  
	  
2. THE	  PATENT	  APPLICATION	  PROCESS	  
	  
The	  application	  process	  is	  the	  most	  important	  step	  in	  protecting	  an	  invention.	  In	  order	  to	  
maximise	  the	  inventions	  potential	  benefit,	  it	  is	  essential	  to	  ensure	  this	  step	  be	  dealt	  with	  
the	  greatest	  care	  and	  foresight	  so	  as	  to	  guarantee	  a	  strong	  and	  valid	  patent.	  	  
	  
2.1. The	  Claim/s	  
	  
The	  claim	  is	  the	  most	  valuable	  part	  of	  the	  patent	  application	  as	  it	  determines	  the	  scope	  of	  
the	  invention.168	  Two	  requirements	  must	  be	  met	  when	  drafting	  the	  claim,	  the	  subject	  
matter	  the	  inventor	  considers	  his	  invention	  to	  comprise	  of	  and	  the	  scope	  of	  what	  the	  
inventor	  includes	  as	  part	  of	  his	  invention	  must	  be	  described	  exactly	  as	  the	  inventor	  will	  only	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be	  protected	  in	  respect	  of	  the	  content	  of	  this	  disclosure.	  The	  protection	  he	  receives	  will	  
then	  prevent	  third	  parties	  from	  producing	  the	  same	  process	  or	  product	  the	  inventor	  has	  
claimed	  as	  his	  invention.	  Furthermore	  he	  should	  define	  the	  type	  of	  claim;	  by	  doing	  so	  the	  
extent	  of	  protection	  sought	  for	  his	  invention	  will	  be	  refined	  and	  this	  distinction	  can	  be	  
important	  when	  determining	  whether	  the	  invention	  was	  anticipated	  by	  prior	  art.	  By	  
disclosing	  all	  the	  elements	  of	  the	  invention	  claimed	  in	  each	  claim	  of	  the	  patent	  application,	  
the	  inventor	  will	  be	  able	  to	  rebut	  any	  objections	  of	  obviousness	  raised	  by	  providing	  the	  
limitations	  of	  his	  invention	  as	  evidence.	  	  
	  
a) Types	  of	  Claims	  
	  
 Species	  and	  Genus	  Claims	  	  	  
	  
A	  species	  claim	  defines	  one	  element	  at	  a	  time	  (it	  is	  specific)	  as	  opposed	  to	  a	  generic	  claim	  
where	  the	  element	  claimed	  is	  defined	  widely	  enough	  to	  include	  all	  of	  the	  species	  of	  that	  
genus	  (a	  general	  claim).169	  The	  inventor	  should	  claim	  as	  many	  species	  as	  possible	  of	  the	  
genus	  that	  is	  sought	  by	  the	  invention,	  including	  a	  description	  of	  the	  different	  types	  of	  
nanoscale	  structures	  the	  components	  can	  take:	  for	  example	  he	  should	  describe	  these	  
structures	  as	  nanoparticles,	  nanotubes	  or	  nanocrystals.170	  Furthermore,	  in	  order	  to	  avoid	  
including	  an	  infringing	  claim	  the	  applicant	  should	  also	  differentiate	  between	  the	  classes	  of	  
materials	  and	  give	  clear	  characteristics	  of	  the	  structure:	  for	  example	  a	  nanoparticle	  that	  is	  
60	  nm	  in	  all	  dimensions.171	  The	  inventor	  should	  also	  discuss	  how	  he	  measured	  and	  
characterized	  the	  subject	  matter	  by	  including	  the	  instruments	  he	  used.	  It	  is	  important	  to	  
describe	  the	  types	  of	  materials	  used	  to	  prepare	  the	  structure,	  for	  instance	  semiconductors	  
or	  metals.	  By	  giving	  more	  detailed	  information	  the	  applicant	  reduces	  his	  risk	  of	  the	  
examiner	  concluding	  the	  invention	  forms	  part	  of	  prior	  art.	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For	  example,	  a	  generic	  claim	  would	  be	  broad:	  “A	  composite	  material,	  comprising	  one	  or	  
more	  nanostructures,	  wherein	  one	  or	  more	  nanostructures	  comprise	  one	  or	  more:	  
nanocrystals	  or	  nanowires.”	  Whereas	  a	  species	  claim	  will	  include	  further	  limitations	  on	  the	  
above	  by	  adding:	  “A	  ‘nanostructure’	  is	  a	  structure	  having	  at	  least	  one	  characteristic	  
dimension	  of	  less	  than	  about	  100	  nm.”	  	  
	  
A	  further	  example	  is	  U.S.	  Patent	  7,101,761:	  “Method	  of	  fabricating	  semiconductor	  devices	  
with	  replacement,	  coaxial	  gate	  structure.”172	  Claim	  1	  reads:	  
	  
“The	  invention	  claimed	  is:	  	  
1. A	  method	  comprising:	  providing	  a	  nanostructure	  covered	  on	  a	  substrate;	  oxidizing	  a	  
first	  portion	  of	  the	  nanostructure	  to	  define	  a	  sacrificial	  layer	  between	  the	  substrate	  
and	  a	  second	  portion	  of	  the	  nanostructure;	  forming	  a	  first	  support	  structure	  over	  the	  
nanostructure;	  forming	  a	  second	  support	  structure	  over	  the	  nanostructure;	  and	  
removing	  the	  sacrificial	  layer	  from	  the	  nanostructure	  such	  that	  second	  portion	  of	  the	  
nanostructure	  is	  suspended	  a	  distance	  from	  a	  surface	  of	  the	  substrate	  between	  the	  
first	  and	  second	  support	  structure.”	  
	  
From	  this	  excerpt	  the	  term	  “nanostructure”	  seems	  broad	  enough	  to	  cover	  various	  types	  of	  
nanostructures.	  However	  dependent	  Claims	  5	  and	  7	  confine	  the	  term	  nanostructure	  to	  
include	  “nanowire	  structures”	  and	  “nanotube	  structures:”	  
	  
“5.	  The	  method	  of	  claim	  1,	  wherein	  the	  nanostructure	  comprises	  a	  nanowire	  structure.	  
	  
	  	  	  	  	  	  	  7.	  The	  method	  of	  claim	  1,	  wherein	  the	  nanostructure	  comprises	  a	  nanotube	  structure.”	  	  
	  
Despite	  these	  limitations,	  Claims	  5	  and	  7	  cannot	  be	  read	  into	  Claim	  1	  due	  to	  the	  doctrine	  of	  
claim	  differentiation,	  in	  terms	  of	  which	  Claims	  5	  and	  7	  cannot	  be	  used	  to	  narrow	  the	  scope	  
of	  the	  Claim	  1.173	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By	  referring	  to	  the	  specification,	  a	  more	  detailed	  description	  is	  given	  of	  the	  types	  of	  
nanostructures	  referred	  to	  in	  this	  patent	  and	  limits	  these	  nanostructures	  further	  by	  
referring	  to	  their	  size:	  	  
	  
“As	  used	  herein,	  the	  term	  nanostructure	  refers	  to	  any	  structure	  having	  a	  diameter	  less	  than	  
about	  50	  nm,	  such	  as	  a	  nanowire	  or	  a	  nanotube.	  The	  term	  nanowire	  is	  used	  herein	  to	  
describe	  any	  nanowires,	  including	  silicon	  nanowires.	  The	  term	  nanotube	  is	  used	  herein	  to	  
describe	  any	  nanotubes,	  including	  single-­‐walled	  or	  multiple-­‐walled	  carbon	  nanotubes.”	  
	  
Consequently	  the	  specification	  has	  narrowed	  and	  clarified	  the	  otherwise	  broad,	  generic	  
claim	  as	  described	  in	  Claim	  1	  by	  providing	  specific	  characteristics	  of	  the	  nanostructures.	  
	  
There	  are	  instances	  where	  the	  state	  of	  art	  disclosing	  a	  genus	  class	  will	  anticipate	  the	  species	  
claimed	  within	  that	  genus.	  Assessing	  whether	  the	  species	  was	  anticipated	  by	  prior	  art	  is	  
evaluated	  on	  a	  case-­‐by-­‐case	  basis	  by	  applying	  the	  doctrine	  of	  anticipation.174	  The	  courts	  
approach	  in	  assessing	  anticipation	  will	  be	  discussed	  in	  further	  detail	  under	  the	  section	  
regarding	  non-­‐obviousness.	  
	  
 Method	  versus	  Apparatus	  Claims	  	  	  	  	  	  	  	  	  	  
	  
Patent	  law	  distinguishes	  between	  two	  statutory	  classes,	  method	  claims	  and	  apparatus	  
claims.	  A	  product	  or	  apparatus	  claim	  refers	  to	  the	  device	  itself,	  for	  example	  a	  nanomachine.	  
Therefore	  an	  infringement	  will	  occur	  where	  third	  parties	  use	  all	  the	  elements	  of	  claimed	  
invention.	  A	  method	  or	  process	  claim	  comprises	  the	  various	  steps	  required	  to	  make	  or	  use	  
the	  invention.	  An	  infringement	  will	  occur	  where	  third	  parties	  perform	  each	  of	  the	  steps	  
claimed	  as	  the	  invention.175	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This	  distinction	  is	  important	  as	  these	  claims	  can	  sometimes	  be	  treated	  differently	  when	  
applying	  for	  a	  patent.	  A	  machine	  can	  be	  described	  as	  complex	  molecular	  structure,	  resulting	  
in	  uncertainty	  as	  to	  whether	  the	  invention	  should	  be	  treated	  as	  a	  compound	  or	  an	  
apparatus.	  The	  determining	  factor	  for	  interpreting	  the	  invention	  claimed	  will	  depend	  on	  the	  
manner	  in	  which	  the	  applicant	  describes	  the	  invention.176	  If	  the	  patent	  applicant	  describes	  
the	  invention	  as	  a	  nanomachine,	  i.e.	  an	  apparatus,	  it	  will	  be	  treated	  as	  such	  and	  vice	  versa	  
for	  compound	  claims.	  	  
	  
Furthermore	  the	  distinction	  can	  be	  relevant	  in	  determining	  whether	  the	  invention	  is	  
anticipated,	  for	  instance	  a	  prior	  art	  device	  can	  anticipate	  the	  claimed	  process.177	  This	  will	  
happen	  when	  a	  prior	  art	  device,	  in	  its	  normal	  and	  usual	  operation	  would	  perform	  the	  
method	  claimed.	  In	  other	  words	  where	  the	  prior	  art	  device	  and	  the	  device	  described	  in	  the	  
patent	  application	  responsible	  for	  effecting	  the	  process	  claimed	  are	  the	  same;	  it	  will	  be	  
assumed	  the	  prior	  art	  device	  will	  inherently	  perform	  the	  claimed	  process.	  Where	  applicable,	  
the	  applicant	  can	  claim	  both	  the	  use	  and	  the	  method	  of	  the	  invention,	  as	  this	  will	  ensure	  the	  
inventor	  receives	  the	  full	  benefit	  from	  his	  invention.	  However	  this	  will	  only	  be	  possible	  if	  
both	  the	  method	  and	  apparatus	  claimed	  are	  inventive.178	  	  
	  




The	  required	  contents	  for	  the	  specification	  are	  set	  out	  in	  §	  112	  Patent	  Act,179	  namely	  a	  full	  
written	  description	  of	  the	  subject	  matter	  that	  the	  inventor	  claims	  as	  his	  invention	  and	  these	  
claims	  must	  be	  expressed	  in	  “full,	  clear,	  concise,	  and	  exact	  terms.”	  Furthermore	  the	  
description	  must	  include	  the	  manner	  and	  process	  for	  making	  and	  using	  the	  invention	  so	  as	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  MPEP	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  Alstadt	  http://faculty.law.pitt.edu/alstadt/	  (accessed	  04/04/2013)	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to	  enable	  a	  person	  skilled	  in	  the	  pertinent	  art	  to	  make	  and	  use	  the	  same.	  Additionally	  the	  
best	  mode	  for	  doing	  so	  must	  be	  provided.	  	  
	  
Often	  patents	  believed	  to	  have	  complied	  with	  this	  section	  will	  be	  subjected	  to	  claim	  
interpretation	  by	  a	  court	  in	  order	  to	  determine	  their	  true	  scope.180	  A	  claim	  interpretation	  
hearing	  otherwise	  referred	  to	  as	  a	  “Markman”	  hearing,	  will	  outline	  the	  meaning	  of	  the	  claim	  
language,	  i.e.	  the	  claims	  in	  respect	  of	  which	  the	  inventor	  has	  described	  the	  subject	  matter	  
that	  comprises	  his	  invention.	  The	  judge,	  typically	  a	  lay-­‐person,	  with	  regards	  to	  the	  claimed	  
technology	  will	  review	  the	  claim	  terms	  for	  their	  intended	  meaning	  in	  order	  to	  determine	  the	  
scope	  of	  the	  claim.181	  The	  purpose	  of	  this	  procedure	  is	  to	  determine	  whether	  the	  inventor	  
has	  a	  valid	  claim	  and	  if	  valid,	  whether	  it	  has	  been	  infringed.	  The	  court	  therefore	  focuses	  on	  
the	  scope	  of	  the	  patent	  to	  determine	  infringement	  and	  if	  the	  scope	  is	  unclear,	  the	  patent	  
will	  have	  to	  be	  reviewed	  in	  order	  to	  determine	  the	  inventor’s	  intended	  meaning	  of	  the	  
terms	  used	  to	  claim	  his	  invention.	  
	  
The	  DuPont	  case	  is	  arguably	  one	  of	  the	  first	  nanotechnology	  cases	  and	  may	  be	  particularly	  
relevant	  to	  future	  nanotechnology	  related	  patent	  applications	  as	  it	  touches	  on	  the	  following	  
important	  issues:	  broad	  claims,	  non-­‐obviousness	  and	  the	  unpredictability	  of	  claim	  
construction.	  In	  this	  case,	  Cabot,	  the	  largest	  supplier	  of	  CMP	  slurries,	  sued	  DuPont	  in	  a	  five	  
patent	  suit	  for	  infringement	  relating	  to	  the	  ingredients	  and	  methods	  used	  in	  the	  chemical	  
mechanical	  polishing	  technique	  known	  as	  CMP.182	  This	  technique	  is	  used	  for	  planarization	  or	  
polishing	  the	  surface	  of	  a	  substrate,	  for	  example	  a	  semiconductor	  wafer,	  by	  way	  of	  
combining	  chemical	  and	  mechanical	  forces.	  The	  “slurry”	  comprises	  abrasive	  (nanoscale)	  
particles	  and	  a	  chemically	  reactive	  solvent	  that	  is	  deposited	  onto	  a	  rotating	  polishing	  pad,	  
which	  is	  then	  placed	  over	  a	  substrate.	  The	  chemical	  ingredient	  weakens	  the	  surface	  thereby	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  180	  O’Neil	  et	  al	  2007	  Nanotech.	  L.	  &	  Bus.	  598	  
181	  O’Neil	  et	  al	  2007	  Nanotech.	  L.	  &	  Bus.	  598-­‐599	  
182	  DuPont	  Air	  Products	  Nanomaterials	  L.L.C	  v.	  Cabot	  Microelectronics	  Corporation,	  Civil	  Action	  no.	  CV06-­‐2952-­‐
PHX-­‐ROS	  (D.	  Ariz.	  2006),	  Markman_Order_072508	  [At	  2-­‐3]	  [Hereinafter	  the	  DuPont	  case]	  	  
	   49	  
creating	  a	  thin	  layer	  of	  crust,	  which	  is	  then	  removed	  by	  the	  mechanical	  ingredient,	  i.e.	  the	  
rotating	  pad	  thereby	  flattening	  and	  polishing	  the	  surface	  of	  the	  wafer.183	  	  
	  
The	  Federal	  Circuit	  stated	  that	  claim	  construction	  is	  a	  question	  of	  law	  and	  referred	  to	  the	  
Markman	  case,	  in	  respect	  of	  which	  the	  term	  “Markman	  Hearing”	  was	  coined	  to	  describe	  a	  
pre-­‐trial	  phase	  to	  the	  hearing	  whereby	  the	  parties	  are	  given	  the	  opportunity	  to	  contest	  the	  
meaning	  of	  key	  terms	  and	  phrases	  in	  their	  patent	  applications.	  This	  case	  is	  particularly	  
significant	  because	  the	  court	  held	  that	  the	  language	  of	  a	  patent	  is	  a	  matter	  of	  law	  for	  a	  
judge	  to	  resolve	  (and	  not	  a	  matter	  of	  fact	  for	  a	  jury	  to	  decide	  on).	  Furthermore	  the	  court	  
recognized	  two	  categories	  of	  evidentiary	  roles,	  namely	  intrinsic	  evidence	  and	  extrinsic	  
evidence.184	  Intrinsic	  evidence	  refers	  to	  the	  specification,	  claims	  and	  the	  prosecution	  history	  
(viz.	  the	  negotiations	  between	  the	  USPTO	  and	  the	  inventor)	  of	  a	  specific	  patent.	  Extrinsic	  
evidence	  includes	  all	  other	  sources,	  for	  example	  expert	  testimony,	  dictionaries,	  treatises	  
and	  technical	  drawings.185	  	  
	  
Phillips	  v.	  AWH	  Corp.	  was	  also	  referred	  to,	  in	  terms	  of	  which	  the	  court	  revisited	  the	  rules	  on	  
claim	  construction	  and	  established	  an	  evidentiary	  priority	  method	  for	  interpreting	  claims.186	  
The	  court	  stated	  the	  importance	  of	  giving	  claim	  terms	  their	  ordinary	  meaning,	  if	  the	  
ordinary	  meaning	  is	  not	  clear	  to	  a	  lay	  judge	  the	  meaning	  should	  be	  understood	  in	  light	  of	  a	  
person	  skilled	  in	  the	  pertinent	  art.187	  In	  other	  words,	  the	  broadest,	  most	  reasonable	  
meaning	  understood	  by	  such	  a	  skilled	  person,	  that	  is	  consistent	  with	  the	  specification,	  
should	  be	  given.	  The	  court	  recognised	  that	  the	  applicant	  can	  act	  as	  his	  own	  lexicographer,	  
specifically	  defining	  the	  terms	  used	  to	  describe	  his	  invention.	  	  Should	  intrinsic	  sources	  of	  
evidence	  determine	  the	  “special	  meaning”	  of	  the	  claim	  terms,	  the	  inventor’s	  definitions	  will	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govern	  the	  interpretation.188	  The	  court	  stated	  that	  the	  prosecution	  history	  is	  not	  as	  useful	  as	  
other	  intrinsic	  evidence	  as	  it	  only	  represents	  the	  negotiations	  between	  the	  USPTO	  and	  the	  
inventor	  and	  can	  therefore	  lack	  clarity	  of	  the	  final	  claim	  language.	  However	  it	  can	  show	  how	  
the	  examiner	  understood	  the	  invention,	  which	  is	  helpful	  in	  determining	  the	  scope	  of	  the	  
invention.189	  If	  the	  terms	  are	  still	  unclear	  after	  this	  step,	  extrinsic	  evidence	  should	  be	  
consulted.	  The	  court	  emphasised	  that	  intrinsic	  evidence	  should	  be	  given	  greater	  weight	  
than	  extrinsic	  evidence	  as	  it	  is	  unlikely	  to	  be	  a	  reliable	  interpretation	  for	  the	  following	  
reason:	  extrinsic	  evidence	  is	  not	  part	  of	  the	  patent.	  Such	  an	  interpretation	  may	  be	  driven	  by	  
litigation,	  it	  might	  not	  reflect	  the	  understanding	  of	  the	  skilled	  artisans	  and	  it	  may	  change	  the	  
meaning	  that	  was	  otherwise	  indicated	  by	  intrinsic	  evidence.190	  The	  judge	  stated	  that	  claim	  
construction	  is	  similar	  to	  the	  determination	  of	  obviousness:	  it	  too	  is	  considered	  a	  factual	  
finding.	  Cabot	  acted	  as	  their	  own	  lexicographer	  and	  used	  terms	  that	  were	  within	  the	  
meaning	  of	  technical	  dictionaries	  in	  order	  to	  avoid	  uncertainties	  relating	  to	  the	  terms	  used	  
in	  their	  claim.	  At	  the	  Markman	  hearing	  the	  court	  favoured	  Cabot,	  accepting	  their	  definitions	  
given	  for	  specific	  terms.	  	  
	  
The	  Phillips	  case	  emphasises	  the	  relevance	  of	  the	  specification	  to	  the	  claim	  construction	  
examination	  and	  the	  court	  stated	  that	  it	  is	  the	  “single	  best	  guide	  to	  claim	  meaning”191	  due	  
to	  the	  fact	  that	  it	  describes	  the	  invention	  in	  full,	  clear,	  concise	  and	  exact	  terms.	  Furthermore	  
it	  may	  reveal	  specific	  definitions	  given	  by	  the	  inventor,	  especially	  where	  he	  acted	  as	  his	  own	  
lexicographer	  or	  reveal	  subject	  matter	  that	  he	  specifically	  wanted	  to	  exclude	  or	  include	  in	  
his	  claim.	  The	  court	  also	  noted	  that	  the	  specification	  must	  be	  interpreted	  within	  the	  context	  
of	  when	  the	  application	  was	  filed.	  	  
	  
Occasionally	  courts	  will	  apply	  the	  doctrine	  of	  claim	  differentiation	  to	  clarify	  the	  scope	  of	  the	  
coverage	  provided	  for	  by	  a	  patent	  claim.192	  It	  is	  assumed	  that	  two	  claims	  in	  the	  same	  patent	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are	  not	  intended	  to	  have	  the	  same	  scope.	  Therefore	  this	  doctrine	  disallows	  the	  broadening	  
of	  a	  claim	  beyond	  that	  which	  is	  disclosed	  in	  the	  specification	  and	  prohibits	  the	  narrowing	  of	  
broad	  claims	  by	  incorporating	  limitations	  of	  narrower	  claims.	  For	  example	  when	  a	  patent	  
describes	  a	  “table	  with	  plurality	  of	  legs”	  as	  the	  independent	  claim	  and	  the	  dependant	  claim	  
recites	  “legs.”	  The	  independent	  claim	  is	  not	  recited	  in	  the	  dependant	  claim	  and	  the	  
dependant	  claim	  will	  protect	  tables	  with	  four	  legs	  whereas	  the	  independent	  claim	  will	  
protect	  tables	  with	  four	  or	  more	  or	  less	  legs.	  Thereby	  ensuring	  the	  broad	  claim	  scope	  is	  





According	  to	  Article	  69	  of	  the	  European	  Patent	  Convention	  of	  1973,	  “The	  extent	  of	  the	  
protection	  conferred	  by	  a	  European	  patent	  or	  a	  European	  patent	  application	  shall	  be	  
determined	  by	  the	  claims.	  Nevertheless,	  the	  description	  and	  drawings	  shall	  be	  used	  to	  
interpret	  the	  claims.”	  In	  addition,	  “For	  or	  the	  period	  up	  to	  grant	  of	  the	  European	  patent,	  the	  
extent	  of	  the	  protection	  conferred	  by	  the	  European	  patent	  application	  shall	  be	  determined	  
by	  the	  claims	  contained	  in	  the	  application	  as	  published.	  However,	  the	  European	  patent	  as	  
granted	  or	  as	  amended	  in	  opposition,	  limitation	  or	  revocation	  proceedings	  shall	  determine	  
retroactively	  the	  protection	  conferred	  by	  the	  application,	  in	  so	  far	  as	  such	  protection	  is	  not	  
thereby	  extended.”	  	  
	  
The	  European	  Patent	  Convention	  of	  1973	  adopts	  a	  balanced	  approach	  when	  interpreting	  
the	  claims	  of	  the	  patent.	  The	  intention	  is	  to	  find	  balance	  between	  a	  strict,	  literal	  meaning	  
and	  using	  the	  claims	  as	  guidelines.	  According	  to	  the	  EPC’s	  Protocol	  on	  the	  Interpretation	  of	  
Article	  69,	  “it	  is	  to	  be	  interpreted	  as	  defining	  a	  position	  between	  these	  extremes	  which	  
combines	  a	  fair	  protection	  for	  the	  patent	  proprietor	  with	  a	  reasonable	  degree	  of	  legal	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This	  approach	  is	  appropriate	  when	  interpreting	  the	  claims	  of	  nanotechnology	  patents	  in	  
that	  the	  technology	  is	  new	  and	  adequate	  definitions	  have	  not	  yet	  been	  formulated.	  The	  
description	  and	  drawings	  included	  in	  the	  patent	  will	  be	  referred	  to	  clarify	  instances	  of	  
ambiguity	  regarding	  the	  claims.	  	  
	  
2.3. Drafting	  the	  Claim	  	  	  
	  
A	  claim	  cannot	  comprise	  entirely	  of	  “means	  plus	  function”	  (mpf)	  elements,	  these	  are	  well	  
known	  elements	  that	  form	  part	  of	  prior	  art.	  Examples	  are	  screws,	  nuts	  and	  bolts,	  glue	  or	  
Velcro.	  An	  invention	  will	  not	  be	  eligible	  for	  a	  patent	  if	  the	  application	  claims	  these	  elements	  
as	  the	  invention	  without	  describing	  a	  corresponding	  structure	  associated	  with	  the	  mpf	  




In	  light	  of	  the	  interpretation	  process	  adopted	  by	  the	  courts	  it	  is	  evident	  that	  claim	  
construction	  is	  extremely	  important	  when	  drafting	  a	  patent	  application	  as	  definitions	  of	  
technical	  terms,	  grammatical	  and	  semantic	  interpretation	  can	  all	  lead	  to	  uncertainty	  
regarding	  the	  scope	  of	  the	  invention.194	  A	  better	  understanding	  of	  the	  courts	  approach	  in	  
analysing	  and	  deciding	  the	  claim	  construction	  will	  allow	  for	  improved	  patent	  applications.	  
	  
As	  indicated	  by	  cases	  the	  claims	  and	  specification	  can	  provide	  important	  signs	  as	  to	  what	  
the	  intended	  meaning	  of	  the	  claim	  language	  may	  be.	  The	  patent	  practitioner	  should	  
meticulously	  check	  for	  “minor”	  differences	  in	  claim	  terms	  from	  one	  claim	  to	  another	  in	  
order	  to	  assure	  they	  accurately	  reflect	  the	  breadth	  and	  scope	  of	  the	  invention.195	  The	  claim	  
should	  be	  written	  with	  the	  broadest	  possible	  meaning	  supported	  by	  specification,196	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  193	  Crouch	  http://www.patentlyo.com/patent/2013/01/means-­‐plus-­‐function-­‐claiming.html	  (accessed	  
02/04/2013)	  
	  194	  Carvalho	  http://www.nanotech-­‐now.com/columns/?article=229	  (accessed	  31/07/2012)	  	  	  195	  Carvalho	  http://www.nanotech-­‐now.com/columns/?article=229	  (accessed	  31/07/2012)	  
	  196	  MPEP	  §	  2131	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balance	  should	  be	  the	  objective:	  it	  should	  be	  written	  broadly	  enough	  to	  adequately	  protect	  
the	  invention	  but	  also	  narrow	  enough	  to	  avoid	  including	  potential	  prior	  art,	  thereby	  risking	  
invalidity.197	  The	  claim	  should	  not	  be	  limited	  by	  specific	  uses	  and	  methods	  of	  processing,	  as	  
this	  will	  prevent	  the	  inventor	  from	  gaining	  from	  the	  full	  monopoly	  of	  his	  invention.198	  For	  
example	  where	  a	  patent	  for	  nanocomposite	  material	  used	  in	  coating	  applications	  is	  sought,	  
the	  patent	  attorney	  will	  not	  only	  claim	  the	  use	  of	  the	  material	  but	  also	  extend	  the	  scope	  of	  
the	  claim	  to	  include	  the	  material	  itself.	  Thereby	  extending	  the	  protection	  to	  all	  possible	  
fields	  that	  could	  use	  the	  invention,	  including	  those	  he	  did	  not	  consider.	  	  
	  
The	  inventor	  should	  define	  key	  terms	  used	  to	  describe	  the	  invention.	  By	  not	  defining	  
unknown	  terms,	  he	  runs	  the	  risk	  of	  a	  broad	  interpretation,	  which	  can	  result	  in	  structures	  in	  
the	  art	  being	  included	  that	  he	  would	  otherwise	  specifically	  exclude.	  Furthermore	  the	  court	  
could	  apply	  the	  plain	  meaning,	  i.e.	  the	  dictionary	  definition	  of	  the	  term	  and	  this	  could	  harm	  
the	  applicant’s	  application.	  The	  patent	  practitioner	  has	  the	  autonomy	  to	  define	  and	  use	  
claim	  terms	  in	  any	  way	  he	  chooses,	  therefore	  it	  is	  in	  the	  best	  interest	  of	  the	  applicant	  that	  
the	  terms	  are	  clearly	  defined.	  When	  defining	  terms	  conflict	  between	  dictionary	  meaning	  
and	  meaning	  from	  context	  of	  specification	  should	  be	  avoided	  (as	  done	  by	  Cabot	  in	  the	  
DuPont	  case).	  Using	  very	  broad	  claim	  language,	  such	  as	  “nanostructures”	  or	  
“nanoparticles”,	  increases	  the	  risk	  of	  terms	  being	  construed	  incorrectly,	  interpreting	  a	  
meaning	  not	  intended	  by	  the	  applicant.199	  	  
	  
Claim	  construction	  will	  determine	  the	  value,	  breadth,	  strength,	  validity	  and	  ultimately	  the	  
enforceability	  of	  the	  patent.	  By	  taking	  into	  account	  the	  above-­‐mentioned	  factors,	  a	  carefully	  
and	  well-­‐constructed	  high	  quality	  patent	  will	  be	  drafted.	  A	  strong	  patent	  will	  be	  easier	  to	  
enforce	  and	  more	  likely	  to	  receive	  protection	  for	  a	  variety	  of	  possible	  modifications,	  
improvements	  and	  other	  infringing	  products	  or	  methods	  using	  the	  basic	  knowledge	  applied	  
in	  the	  patented	  invention.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  197	  Alstadt	  http://faculty.law.pitt.edu/alstadt/	  (accessed	  04/04/2013)	  [*Select	  “claim	  drafting”	  to	  open	  this	  
document]	  [At	  30]	  
	  198	  Cisneros	  2009	  Nomos	  27-­‐28	  
	  199	  O’Neil	  et	  al	  2007	  Nanotech.	  L.	  &	  Bus.	  597	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II. EUROPE	  
	  
The	  same	  principles	  regarding	  drafting	  the	  claims,	  apply	  to	  European	  patents.	  Short	  of	  
repeating	  the	  above	  discussion,	  the	  claim	  must	  clearly	  and	  concisely	  define	  the	  subject	  
matter	  in	  respect	  of	  which	  protection	  is	  sought.200	  The	  claims	  must	  be	  supported	  by	  the	  
description,	  including	  a	  description	  of	  technical	  features	  of	  the	  claimed	  invention.	  These	  
technical	  features	  can	  be	  structural	  or	  functional.201	  	  
	  
The	  only	  contrasting	  feature	  is	  the	  form	  of	  a	  U.S.	  patent	  (i.e.	  the	  one-­‐part	  claim).	  European	  
applications	  normally	  contain	  the	  so-­‐called	  two-­‐part	  claim.202	  This	  means	  the	  claim	  is	  
interpreted	  by	  the	  examiner	  in	  two-­‐parts,	  initially	  the	  claim	  lists	  some	  features	  then	  
contains	  the	  phrase	  “characterised	  in	  that”	  or	  “	  with	  an	  improvement	  comprising,”	  after	  
which	  it	  lists	  one	  or	  more	  further	  features	  (the	  second	  part).	  The	  latter	  features	  are	  referred	  
to	  as	  characterising	  features	  and	  these	  features	  constitute	  the	  invention.	  This	  section	  of	  the	  
claim	  is	  referred	  to	  as	  the	  characterising	  portion.	  The	  former	  or	  pre-­‐characterising	  features	  
are	  found	  in	  the	  prior	  art	  and	  the	  examiner	  will	  firstly	  find	  the	  closest	  prior	  art,	  that	  is	  the	  
document	  that	  shares	  the	  most	  features	  with	  the	  invention	  and	  then	  request	  that	  the	  claim	  
be	  delimited	  therefrom.	  Should	  the	  applicant	  include	  a	  novel	  feature	  in	  the	  pre-­‐
characterising	  portion,	  he	  or	  she	  will	  be	  asked	  to	  remove	  it	  and	  this	  will	  not	  affect	  the	  
patentability	  of	  the	  invention.	  If	  a	  pre-­‐characterising	  feature	  was	  included	  in	  a	  U.S.	  patent	  
application,	  it	  may	  invalidate	  the	  application.	  
	  
3. REQUIREMENTS	  FOR	  A	  VALID	  PATENT	  
	  
The	  basic	  requirements	  for	  a	  valid	  nanotechnology	  patent	  will	  be	  addressed	  individually	  and	  
within	  the	  context	  of	  the	  USPTO	  and	  EPO	  respectively.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  200	  EPC	  Art	  84	  	  201	  EPC	  Rule	  43(1)	  	  202	  Ius	  Mentis	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I. TITLE	  35	  U.S.C.	  §101	  PATENTABILITY	  REQUIREMENTS	  	  
	  
In	  the	  USA,	  the	  requirements	  for	  a	  valid	  patent	  are:	  1)	  Novelty,	  2)	  Non	  Obviousness,	  3)	  
Utility,	  and	  4)	  Enablement.203	  	  
	  
The	  predictability	  of	  the	  field	  of	  technology	  influences	  the	  abovementioned	  requirements	  
therefore	  it	  is	  necessary	  to	  have	  a	  good	  understanding	  of	  this	  technology	  in	  order	  to	  
adequately	  protect	  nano-­‐related	  inventions.204	  The	  inherent	  nature	  of	  nanotechnology	  
presents	  a	  particular	  challenge	  when	  determining	  the	  predictability	  of	  an	  invention;	  it	  is	  
unpredictable	  in	  terms	  of	  its	  properties	  and	  relationships	  with	  other	  materials	  making	  it	  
difficult	  to	  protect.	  The	  predictability	  of	  an	  invention	  will	  influence	  the	  validity	  of	  the	  
patent;	  it	  is	  therefore	  a	  significant	  factor	  to	  consider	  when	  drafting	  the	  patent	  application.	  
This	  aspect	  will	  be	  discussed	  further	  under	  the	  requirement	  of	  non-­‐obviousness,	  utility	  and	  
enablement	  respectively.	  	  
	  
1) Excluded	  Subject	  Matter	  	  
	  
MPEP	  clearly	  sets	  out	  the	  guidelines	  regarding	  the	  eligibility	  of	  patentable	  subject	  matter.	  	  
Accordingly	  a	  patent	  cannot	  be	  obtained	  for	  an	  idea	  or	  suggestion,	  abstract	  ideas,	  physical	  
phenomena	  and	  laws	  of	  nature.205	  However	  there	  can	  be	  exceptions	  to	  these	  exclusions,	  for	  
example	  a	  novel	  quantum	  circuit	  can	  be	  patented	  but	  the	  quantum	  mechanic	  process	  
underlying	  the	  circuit	  is	  not	  patentable	  i.e.	  the	  theory	  motivating	  the	  end	  result.	  Several	  of	  
these	  ineligible	  topics	  will	  be	  discussed	  for	  the	  purposes	  of	  directly	  comparing	  the	  different	  
approaches	  adopted	  by	  the	  USPTO	  and	  EPO	  regarding	  the	  same	  subject	  matter.	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  2004	  STLR	  ¶3.	  Also	  see:	  Hicks,	  Grissett	  and	  Brown	  
http://www.wcsr.com/resources/pdfs/nano030310.pdf	  (accessed	  04/05/2012)	  [At	  4]	  and	  Mills,	  Fitzsimmons	  
and	  Rodkey	  2010	  Nanotech.	  L.	  &	  Bus.	  225	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  2010	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a) Scientific	  Theories	  	  
	  
The	  National	  Academy	  of	  Science	  (NAS)	  defines	  a	  scientific	  theory,	  “as	  a	  well-­‐substantiated	  
explanation	  of	  some	  aspect	  of	  the	  natural	  world,	  that	  can	  incorporate	  facts,	  laws	  inferences	  
and	  tested	  hypotheses.”206	  Scientific	  theories	  are	  based	  on	  a	  large	  body	  of	  knowledge	  that	  
has	  been	  repeatedly	  confirmed	  through	  observation	  and	  experimentation.	  	  
	  
From	  this	  definition	  it	  can	  be	  assumed	  that	  scientific	  theories	  are	  examples	  of	  law	  of	  nature	  
or	  natural	  phenomena	  and	  consequently	  excluded	  as	  patentable	  subject	  matter.207	  
Although	  not	  specifically	  excluded,	  some	  of	  the	  reasons	  relating	  to	  their	  ineligibility	  include:	  
	  
1. The	  U.S.	  Supreme	  Court	  describes	  four	  categories	  of	  invention	  types	  for	  utility	  
patents	  in	  terms	  of	  Title	  35	  U.S.C.	  §	  101;	  “any	  new	  and	  useful	  process,	  machine,	  
manufacture	  or	  composition	  of	  matter,	  or	  any	  new	  and	  useful	  improvement	  thereof”	  
can	  be	  patented.	  Scientific	  theories	  do	  not	  fall	  within	  any	  of	  these	  categories	  and	  
occur	  “without	  the	  hand	  of	  man.”208	  
2. Scientific	  theories	  lack	  novelty;	  a	  law	  of	  nature	  is	  assumed	  to	  have	  existed	  
irrespective	  when	  a	  person	  discovers	  it.209	  An	  invention	  must	  be	  new	  and	  not	  merely	  
unknown.	  (The	  principles	  relating	  to	  discoveries,	  discussed	  in	  the	  section	  that	  
follows,	  also	  apply	  to	  scientific	  theories).	  	  
3. Patent	  law	  is	  usually	  interested	  in	  the	  end	  result,	  the	  product	  or	  use	  of	  the	  invention	  
and	  not	  the	  theory	  or	  research	  leading	  to	  that	  end	  result.	  Scientific	  theories	  are	  
useful	  in	  that	  they	  are	  the	  foundations	  on	  which	  advancements	  in	  the	  field	  of	  
science	  and	  technology	  are	  made.	  However	  they	  lack	  a	  specific	  use,	  in	  other	  words	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  National	  Academy	  of	  Sciences	  http://www.nap.edu/openbook.php?record_id6024&page=2	  (accessed	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  [Page	  13	  at	  2]	  
	  207	  Gupta	  http://works.bepress.com/cgi/viewcontent.cgi?article=1000&context=deepak_gupta	  (accessed	  
24/04/2013)	  [At	  4-­‐5]	  	  208	  Association	  for	  Molecular	  Pathology	  et	  al.	  v.	  Myriad	  Genetics	  Inc.	  et	  al	  569	  US	  _	  (2011)	  [Hereinafter	  the	  
Myriad	  case]	  
	  209	  Mayo	  Collaborative	  Services	  v.	  Prometheus	  Laboratories	  Inc.	  566	  U.S.	  __,	  132	  S.Ct.	  1289	  (2012)	  [At	  1,	  (3)]	  
[Hereinafter	  the	  Mayo	  case]	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they	  have	  generic	  utility,210	  which	  arguably	  could	  stifle	  future	  developments	  in	  the	  
field	  of	  science	  and	  technology	  by	  creating	  a	  monopoly.	  Consequently	  they	  do	  not	  
fulfil	  the	  utility	  requirement.	  
	  
Here	  follows	  a	  hypothetical	  example	  illustrating	  this	  rationale;	  humans	  have	  been	  lighting	  
fires	  for	  centuries	  and	  this	  was	  done	  without	  realising	  oxygen	  fuels	  combustion.	  The	  first	  
person	  to	  discover	  the	  necessity	  of	  oxygen	  to	  create	  and	  maintain	  a	  flame	  would	  not	  have	  
been	  able	  to	  patent	  the	  method	  for	  making	  a	  fire	  because	  this	  occurrence	  is	  a	  law	  of	  nature.	  
It	  is	  fair	  to	  say	  that	  his	  observations	  resulted	  in	  understanding	  the	  importance	  of	  one	  
element,	  oxygen,	  to	  create	  the	  other,	  fire.	  However	  even	  if	  prior	  art	  did	  not	  disclose	  the	  
importance	  of	  oxygen	  to	  create	  a	  fire	  and	  a	  person	  skilled	  in	  the	  art	  was	  not	  aware	  of	  this	  
principle,	  the	  discoverer	  would	  still	  not	  have	  the	  right	  to	  preclude	  others	  from	  making	  fires.	  	  
	  
In	  the	  Mayo	  case,	  the	  patent	  at	  issue	  claims	  a	  diagnostic	  method	  that	  relies	  exclusively	  on	  a	  
law	  of	  nature,	  Claim	  1	  of	  the	  '623	  patent	  reads	  as:	  
	  
“A	  method	  of	  optimizing	  therapeutic	  efficacy	  for	  treatment	  of	  an	  immune-­‐mediated	  
gastrointestinal	  disorder,	  comprising:	  
(a)	  administering	  a	  drug	  providing	  6-­‐thioguanine	  to	  a	  subject	  having	  said	  immune-­‐
mediated	  gastrointesti-­‐nal	  disorder;	  and	  
(b)	  determining	  the	  level	  of	  6-­‐thioguanine	  in	  said	  subject	  having	  said	  immune-­‐
mediated	  gastrointesti-­‐nal	  disorder,	  
wherein	  the	  level	  of	  6-­‐thioguanine	  less	  than	  about	  230	  pmol	  per	  8x108	  red	  blood	  cells	  
indicates	  a	  need	  to	  increase	  the	  amount	  of	  said	  drug	  subsequently	  admin-­‐istered	  to	  said	  
subject	  and	  wherein	  the	  level	  of	  6-­‐thioguanine	  greater	  than	  about	  400	  pmol	  per	  8x108	  red	  
blood	  cells	  indicates	  a	  need	  to	  decrease	  the	  amount	  of	  said	  drug	  subsequently	  ad-­‐ministered	  
to	  said	  subject.”	  211	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The	  Supreme	  Court	  found	  this	  claim	  to	  be	  ineligible	  and	  stated,	  “if	  a	  law	  of	  nature	  is	  not	  
patentable,	  then	  neither	  is	  a	  process	  reciting	  a	  law	  of	  nature,	  unless	  that	  process	  has	  
additional	  features	  that	  provide	  practical	  assurance	  that	  the	  process	  is	  more	  than	  a	  drafting	  
effort	  designed	  to	  monopolize	  the	  law	  of	  nature	  itself.	  A	  patent,	  for	  example,	  could	  not	  
simply	  recite	  a	  law	  of	  nature	  and	  then	  add	  the	  instruction	  "apply	  the	  law.”212	  The	  claims	  in	  
this	  patent	  do	  not	  alter	  or	  transform	  the	  natural	  law	  that	  is	  applied,	  it	  simply	  describes	  the	  
relationships	  between	  the	  concentrations	  of	  certain	  metabolites	  in	  the	  blood	  and	  the	  
probability	  that	  a	  dosage	  of	  a	  thiopurine	  drug	  would	  either	  be	  ineffective	  or	  cause	  harm.	  
The	  three-­‐steps	  described	  in	  Claim	  1	  read	  as	  instructions	  for	  dosage.	  The	  way	  in	  which	  the	  
drug	  will	  be	  metabolized	  by	  the	  body	  depends	  on	  the	  individual	  and	  the	  method	  for	  
determining	  metabolite	  levels	  are	  considered	  well	  known	  by	  those	  in	  the	  relevant	  field	  of	  
art.213	  Consequently	  the	  diagnostic	  method	  claimed	  as	  the	  invention	  cannot	  be	  patented.	  
The	  Supreme	  Court	  also	  repeatedly	  emphasized	  that	  it	  would	  be	  incorrect	  to	  grant	  patents	  
for	  natural	  laws,	  referring	  to	  them	  as	  “the	  basic	  tools	  of	  scientific	  and	  technological	  work,”	  
as	  this	  would	  inhibit	  future	  discoveries	  from	  being	  made.214	  	  
	  
b) Discovery	  versus	  Invention	  	  
	  
U.S.	  patent	  law	  refers	  to	  an	  invention	  as	  an	  invention	  or	  discovery.	  In	  terms	  of	  §	  101,	  
“whoever	  invents	  or	  discovers	  a	  new	  and	  useful	  process,	  machine,	  manufacture,	  or	  
composition	  of	  matter,	  or	  any	  new	  and	  useful	  improvement	  thereof,	  may	  obtain	  a	  patent	  for	  
it	  subject	  to	  the	  conditions	  and	  requirements	  of	  this	  title.”	  	  Therefore	  a	  discovery	  can	  be	  
patented	  if	  the	  invention	  claimed	  fulfills	  the	  requirements	  set	  for	  any	  invention,	  i.e.	  novelty,	  
utility,	  non-­‐obviousness	  and	  enablement.	  
	  
Despite	  U.S.	  patent	  law	  stating,	  “invents	  or	  discovers”	  case	  law	  reveals	  that	  the	  courts	  have	  
differentiated	  between	  these	  two	  concepts.	  In	  Morton	  v.	  New	  York	  Eye	  Infirmary,	  the	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invention	  claimed	  was	  the	  use	  of	  ether	  to	  anesthetize	  patients	  during	  surgical	  procedures.	  
The	  court	  held	  that	  the	  use	  of	  this	  substance	  claimed	  was	  a	  discovery	  and	  not	  an	  invention	  
by	  explaining,	  “the	  discovery	  of	  a	  new	  principle,	  force,	  or	  law	  operating	  did	  not	  entitle	  the	  
discoverer	  to	  a	  patent	  unless	  he	  went	  beyond	  the	  mere	  domain	  of	  discovery	  and	  connected	  
the	  new	  principle,	  force,	  or	  law	  operating	  with	  some	  particular	  device	  which	  allowed	  him	  
exclusive	  control	  under	  patent	  law.”215	  The	  court	  concluded	  that	  the	  invention	  simply	  
claimed	  the	  use	  of	  the	  ether	  (a	  known	  substance)	  by	  a	  well-­‐known	  means	  to	  a	  new	  use.216	  
Therefore	  the	  invention	  lacked	  novelty;	  finding	  a	  new	  use	  for	  a	  known	  substance	  does	  not	  
within	  itself	  deserve	  the	  protection	  of	  a	  patent.	  If	  the	  inventor	  applies	  a	  principle	  to	  an	  
object,	  thereby	  going	  beyond	  the	  mere	  discovery	  of	  the	  substance,	  such	  an	  object	  may	  be	  
eligible	  for	  a	  patent.	  In	  relation	  to	  this	  case,	  the	  fact	  that	  ether	  can	  be	  applied	  during	  
surgical	  procedures	  does	  not	  make	  it	  more	  than	  a	  discovery.	  
	  
The	  Myriad	  case	  is	  a	  very	  recent	  case	  dealing	  with	  the	  patentability	  of	  naturally	  occurring	  
products	  or	  natural	  phenomena,	  which	  are	  considered	  to	  be	  discoveries.	  At	  issue,	  whether	  
human	  genes	  are	  patentable.	  Myriad	  was	  responsible	  for	  identifying	  two	  genes	  that	  
influence	  the	  possibility	  of	  developing	  breast	  or	  ovarian	  cancer,	  namely	  BRCA1	  and	  BRCA2.	  
Up	  until	  this	  time	  it	  was	  known	  that	  these	  types	  of	  cancer	  are	  hereditary	  but	  Myriad	  
established	  their	  precise	  location.	  Myriad	  held	  several	  patents	  relating	  to	  this	  discovery,	  
namely,	  methods	  for	  using	  the	  sequence	  of	  these	  mutations	  to	  test	  for	  breast	  cancer,	  a	  kit	  
to	  perform	  the	  test	  and	  the	  “genes”	  themselves.	  The	  latter	  was	  at	  issue.	  The	  Supreme	  Court	  
held	  that	  Myriad	  simply	  separated	  the	  gene	  from	  the	  surrounding	  genetic	  material	  and	  this	  
act	  did	  not	  amount	  to	  an	  invention.	  They	  did	  not	  create	  or	  alter	  the	  genetic	  information	  
encoded	  in	  BRCA1	  and	  BRCA2,	  nor	  the	  genetic	  structure	  of	  DNA.	  Therefore	  the	  genes	  were	  
not	  patentable	  as	  DNA	  fragments	  occur	  in	  nature.217	  The	  court	  concluded	  that	  a	  fragment	  of	  
a	  human	  genome	  is	  a	  product	  of	  nature.	  Furthermore	  they	  distinguished	  and	  discussed	  
cDNA	  (complementary	  DNA),	  which	  is	  derived	  from	  DNA	  however	  it	  does	  not	  occur	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  215	  Morton	  v.	  New	  York	  Eye	  Infirmary	  17	  F.	  Cas.	  879,	  844	  (S.D.N.Y.	  1862)	  U.S.	  (No	  9,8650)	  [Hereinafter	  the	  
Morton	  case]	  	  216	  Morton	  case	  [At	  810	  and	  813]	  	  	  217	  Myriad	  case	  [At	  II	  B]	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naturally,	  it	  is	  synthetic	  and	  is	  therefore	  patentable.218	  	  
	  
On	  13	  June	  2013,	  the	  Supreme	  Court	  ruled	  against	  this	  patent.	  If	  it	  had	  been	  found	  valid,	  it	  
would	  have	  meant	  Myriad	  would	  have	  had	  the	  exclusive	  rights	  to	  isolate	  an	  individual’s	  
BRCA1	  and	  BRCA2	  genes	  thereby	  being	  the	  only	  institution	  to	  test	  patients	  and	  preventing	  
further	  research	  on	  these	  genes	  by	  others.	  Furthermore	  they	  would	  have	  been	  able	  to	  
exclusively	  synthetically	  create	  BRCA	  cDNA.	  The	  Supreme	  Court	  held	  that	  the	  genes	  and	  the	  
information	  they	  hold	  is	  not	  patentable	  simply	  because	  it	  is	  isolated	  from	  surrounding	  
genetic	  material.219	  	  
	  
Therefore	  in	  both	  cases,	  the	  respective	  inventions	  claimed	  were	  simply	  discoveries,	  neither	  
had	  created	  or	  altered	  their	  discovery	  and	  although	  both	  were	  useful	  discoveries,	  their	  
actions	  did	  not	  amount	  to	  an	  act	  of	  an	  invention	  in	  light	  of	  the	  provisions	  of	  the	  U.S.C.	  
	  
 Naturally	  Occurring	  Products	  	  
	  
Nanotechnology	  often	  draws	  from	  “inventions”	  already	  existent	  in	  nature	  therefore	  it	  is	  
important	  to	  discuss	  the	  topic	  of	  naturally	  occurring	  products	  and	  their	  patentability.	  Laws	  
of	  nature,	  natural	  phenomena,	  and	  naturally	  occurring	  products	  are	  not	  patentable,	  
however	  there	  are	  exceptions.	  For	  example:	  
	  	  
1. If	  the	  inventor	  is	  able	  to	  isolate	  the	  substance	  and	  it	  is	  unknown	  to	  the	  public	  at	  this	  
date,	  it	  can	  be	  patented;	  	  
2. A	  variation	  of	  the	  substance	  that	  displays	  a	  substantial	  advantage	  over	  the	  naturally	  
occurring	  substance	  can	  be	  patented;220	  	  
3. Finding	  a	  new	  use	  for	  an	  old	  naturally	  occurring	  structure	  based	  on	  unknown	  
properties.	  However	  in	  this	  instance	  the	  patent	  will	  only	  protect	  the	  use	  and	  not	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  218	  Myriad	  case	  [At	  II	  C]	  	  219	  Myriad	  case	  [At	  III]	  	  220	  Tech	  Transfer	  http://www.techtransfer.umich.edu/resources/inventors/patents.php	  (accessed	  
07/04/2013)	  
	  
	   61	  
product	  itself.221	  This	  will	  be	  considered	  anticipated	  and	  not	  patentable	  if	  the	  use	  
claimed	  is	  aimed	  at	  a	  result	  or	  property	  of	  that	  composition	  or	  structure.	  	  
	  
Diamond	  v.	  Chakrabarty,	  was	  an	  influential	  case	  on	  the	  topic	  of	  modified	  naturally	  occurring	  
substances.222	  The	  subject	  of	  the	  patent	  was	  a	  bacterium	  developed,	  pseudomonas	  putida,	  
which	  was	  capable	  of	  breaking	  down	  crude	  oil.	  At	  issue	  was	  whether	  genetically	  modified	  
organisms	  could	  be	  patented	  in	  terms	  of	  Title	  35	  U.S.C.	  §	  101.	  Chakrabarty’s	  patent	  
comprised	  three	  types	  of	  claims:	  first,	  process	  claims	  for	  the	  method	  of	  producing	  the	  
bacteria;	  second,	  claims	  for	  an	  inoculum	  comprised	  of	  a	  carrier	  material	  floating	  on	  water,	  
such	  as	  straw	  and	  the	  new	  bacteria;	  and	  lastly,	  claims	  to	  the	  bacteria	  themselves.	  The	  
patent	  examiner	  allowed	  the	  first	  two	  claims,	  but	  rejected	  the	  third	  claim	  for	  the	  bacteria.	  
He	  reasoned:	  that	  microorganisms	  are	  “products	  of	  nature”,	  and	  as	  living	  things	  they	  are	  not	  
patentable	  subject	  matter	  under	  §	  101.	  	  
	  
The	  court	  not	  only	  discussed	  the	  provisions	  of	  §	  101	  in	  that	  bacteria	  (as	  a	  living	  organism)	  is	  
specifically	  excluded	  as	  patentable	  subject	  matter	  but	  also	  whether	  allowing	  the	  patent	  for	  
the	  bacteria	  itself	  would	  result	  in	  a	  monopoly	  thereby	  impeding	  further	  progress	  in	  the	  field	  
of	  scientific	  research.223	  The	  applicant	  argued	  that	  he	  produced	  the	  new	  bacterium	  with	  
distinctly	  different	  characteristics	  from	  any	  microorganism	  found	  in	  nature	  and	  this	  
developed	  bacteria	  had	  the	  potential	  for	  significant	  utility	  thereby	  fulfilling	  the	  provisions	  of	  
§	  101	  (as	  a	  non-­‐naturally	  occurring	  manufacture	  or	  composition	  of	  matter).	  Therefore	  this	  
was	  a	  product	  of	  human	  handiwork	  and	  not	  that	  of	  nature.224	  The	  court	  was	  satisfied	  with	  
Chakrabarty’s	  arguments.	  	  
	  
The	  Diamond	  case	  demonstrates	  how	  the	  inventor,	  by	  modifying	  the	  naturally	  occurring	  
substance,	  was	  able	  to	  make	  an	  otherwise	  un-­‐patentable	  object	  patentable.	  In	  contrast,	  the	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  221	  Funk	  Brothers	  Seed	  Co.	  v.	  Kalo	  Inoculant	  Co.	  333	  U.S.	  127,	  135	  (1948)	  [Hereinafter	  the	  Funk	  Bros.	  case]	  
	  222	  Diamond	  v.	  Chakrabarty	  447	  U.S.	  303,	  206	  USPQ	  193	  (1980)	  [Hereinafter	  the	  Diamond	  case]	  
	  223	  Diamond	  case	  [At	  319]	  
	  224	  Diamond	  case	  [At	  310]	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Myriad	  case	  (where	  identifying	  the	  exact	  location	  and	  isolating	  the	  BRCA1	  and	  BRCA2	  genes	  
did	  not	  qualify	  as	  an	  invention	  in	  light	  of	  §	  101)225	  and	  the	  Funk	  Brothers	  case	  (below)	  can	  
be	  referred	  to	  wherein	  neither	  of	  the	  patentees,	  in	  the	  respective	  cases	  could	  show	  that	  
they	  had	  done	  the	  same.	  
	  
In	  Funk	  Brothers	  Seed	  Co.	  v.	  Kalo	  Inoculant	  Co.,	  the	  invention	  claimed	  a	  method	  of	  
producing	  a	  multi-­‐purpose	  inoculant:	  a	  root-­‐nodule	  bacteria	  that	  was	  used	  and	  packaged	  
for	  sale	  to	  inoculate	  the	  seeds	  of	  leguminous	  plants.	  The	  use	  of	  the	  bacteria	  described,	  
Rhizobia,	  was	  well	  known	  and	  so	  was	  the	  method	  for	  selecting	  the	  strong	  strains	  and	  
producing	  the	  bacterial	  culture	  from	  them.	  Furthermore	  it	  was	  known	  that	  no	  single	  species	  
of	  this	  bacterium	  worked	  with	  all	  species	  of	  leguminous	  plants.	  The	  patentee	  however	  
discovered	  strains	  of	  each	  species	  of	  root-­‐nodule	  bacteria	  that	  could	  inoculate	  plants	  
belonging	  to	  different	  groups	  of	  plants.226	  He	  created	  and	  sold	  packages	  containing	  the	  
claimed	  invention:	  a	  mixture	  of	  different	  species	  of	  Rhizobia,	  suitable	  for	  a	  variety	  of	  plants.	  
Funk	  Brothers	  Seeds	  sold	  similar	  multi-­‐purpose	  inoculant	  packages	  thereby	  infringing	  the	  
patent	  held	  by	  Kalo	  (the	  patentee).	  The	  Supreme	  Court	  held	  that	  the	  properties	  in	  the	  
bacteria	  were	  a	  “work	  of	  nature”	  227	  and	  therefore	  not	  patentable,	  thereby	  reversing	  the	  
Court	  of	  Appeals	  opinion	  that	  the	  packaging	  of	  these	  strains	  together	  went	  beyond	  the	  laws	  
of	  nature	  and	  discovery.228	  Kalo	  did	  not	  alter	  the	  bacteria	  in	  any	  way	  (as	  opposed	  to	  
Chakrabarty)	  he	  merely	  discovered	  that	  certain	  strains	  of	  each	  species	  of	  these	  bacteria	  
could	  be	  mixed.	  The	  bacteria	  performed	  in	  its	  natural	  way	  independently	  from	  the	  
patentee’s	  actions.	  Therefore	  these	  packages	  could	  not	  be	  described	  as	  an	  invention	  within	  
the	  meaning	  given	  by	  patent	  law.	  The	  court	  stated,"if	  there	  is	  to	  be	  invention	  from	  [a	  
discovery	  of	  a	  law	  of	  nature],	  it	  must	  come	  from	  the	  application	  of	  the	  law	  of	  nature	  to	  a	  
new	  and	  useful	  end."229	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  225	  See:	  Section	  entitled	  “I.	  USPTO	  REQUIREMENTS:	  1)	  Excluded	  Subject	  matter:	  b)	  Discovery	  versus	  Invention”	  
(above)	  	  226	  Funk	  Bros.	  case	  [At	  132]	  	  227	  Funk	  Bros.	  case	  [At	  135]	  	  	  228	  Funk	  Bros.	  case	  [At	  133]	  	  	  229	  Funk	  Bros.	  case	  [At	  136]	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These	  cases	  clearly	  illustrate	  the	  Supreme	  Court’s	  interpretation	  and	  application	  of	  U.S.	  
patent	  laws	  provisions	  regarding	  naturally	  occurring	  products,	  i.e.	  that	  the	  manner	  of	  
implementing	  a	  natural	  principle	  must	  itself	  be	  patentable.	  Consequently	  a	  patent	  on	  a	  
machine,	  manufacture,	  or	  composition	  of	  matter	  that	  is	  based	  on	  a	  law	  of	  nature	  will	  be	  
possible	  since	  machines	  follow	  the	  laws	  of	  physics	  in	  their	  operation	  and	  chemical	  
compositions	  of	  matter	  follow	  the	  laws	  of	  chemistry.	  Where	  the	  underlying	  principles	  of	  
science	  are	  combined	  with	  human	  intervention,	  i.e.	  the	  processing	  of	  naturally	  occurring	  
materials,	  transforms	  these	  substances	  into	  an	  object	  for	  manufacture	  or	  composition	  of	  
matter	  or	  an	  improvement	  thereof,	  the	  result	  can	  be	  patented.230	  However	  the	  
requirements	  for	  novelty	  and	  non-­‐obviousness	  must	  also	  be	  met	  for	  a	  valid	  patent.231	  	  
	  
c) Selection	  Inventions	  
	  
It	  is	  highly	  probable	  for	  the	  subject	  matter	  of	  a	  nanotechnology	  patent	  to	  coincide	  with	  the	  
subject	  matter	  disclosed	  in	  prior	  art,	  for	  instance	  where	  an	  invention	  claims	  to	  use	  varying	  
sizes	  of	  nanoparticles	  thereby	  infringing	  upon	  those	  disclosed	  in	  the	  prior	  art	  while	  
simultaneously	  introducing	  new	  sizes	  that	  were	  not	  disclosed.	  In	  other	  words	  this	  patent	  
will,	  in	  a	  sense,	  “overlap”	  with	  the	  prior	  art.	  The	  question	  then	  arises	  whether	  such	  an	  
invention	  will	  still	  be	  patented.	  	  
	  
The	  EPO	  refers	  to	  these	  patents	  as	  “selection	  inventions,”	  U.S.	  statutory	  law	  on	  the	  other	  
hand,	  does	  not	  make	  this	  distinction	  consequently	  the	  USPTO	  examines	  all	  patents	  in	  the	  
same	  manner	  when	  determining	  their	  validity.	  Therefore	  the	  same	  principles	  discussed	  in	  
the	  above	  sections	  regarding	  patentable	  inventions	  will	  apply	  here	  (§	  101).	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  (accessed	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[At	  11]	  	  231	  Hollaar	  http://digital-­‐law-­‐online.info/lpdi1.0/treatise54.html	  (accessed	  07/04/2013)	  
	  
	   64	  
In	  terms	  of	  the	  provisions	  of	  patent	  law,	  there	  are	  no	  laws	  that	  prohibit	  new	  and	  non-­‐
obvious	  claims	  from	  overlapping	  with	  prior	  art.232	  The	  validity	  of	  overlapping	  patents	  will	  be	  
assessed	  within	  the	  scope	  of	  the	  patent	  and	  are	  decided	  on	  a	  case-­‐by-­‐case	  basis.	  	  
	  
Anticipation	  plays	  a	  significant	  role	  in	  assessing	  whether	  the	  overlap	  is	  sufficiently	  specified	  
in	  the	  claims.	  The	  term	  “anticipation”	  refers	  to	  a	  situation	  where	  each	  and	  every	  element	  of	  
the	  prior	  art	  is	  disclosed	  exactly	  in	  the	  claimed	  invention.233	  The	  content	  of	  the	  term	  
“sufficient	  specificity”	  is	  dependant	  on	  the	  facts	  of	  the	  case;	  if	  the	  claims	  are	  directed	  to	  a	  
narrow	  range	  and	  the	  reference	  teaches	  a	  broad	  range,	  depending	  on	  the	  other	  facts	  of	  the	  
case,	  it	  may	  be	  reasonable	  to	  conclude	  that	  the	  narrow	  range	  is	  not	  disclosed	  with	  
"sufficient	  specificity"	  to	  constitute	  an	  anticipation	  of	  the	  claims.234	  In	  other	  words	  if	  the	  
prior	  art	  discloses	  a	  range	  which	  overlaps	  with	  the	  claimed	  range	  and	  no	  specific	  examples	  
are	  given,	  for	  instance	  where	  the	  temperature	  range	  of	  100-­‐500	  °C	  does	  not	  describe	  a	  
claimed	  range	  of	  330-­‐450°C	  with	  sufficient	  specificity	  to	  conclude	  the	  claimed	  range	  was	  
anticipated	  by	  the	  prior	  art.	  Consequently	  despite	  the	  slight	  overlap,	  between	  the	  
reference’s	  preferred	  range	  (150-­‐350°C)	  and	  the	  claimed	  range,	  it	  is	  not	  sufficient	  for	  
anticipation.235	  	  
	  
Therefore	  overlapping	  patents	  may	  be	  valid	  when	  “prior	  art	  which	  teaches	  a	  value	  or	  range	  
that	  is	  very	  close	  to,	  but	  does	  not	  overlap	  or	  touch,	  the	  claimed	  range	  does	  not	  anticipate	  
the	  claimed	  range.”236	  Furthermore	  all	  inventions	  must	  fulfil	  all	  of	  the	  substantive	  
requirements	  of	  a	  valid	  patent.	  Novelty	  and	  non-­‐obviousness	  will	  be	  determined	  by	  
assessing	  the	  predictability	  of	  the	  invention	  claimed.	  Arguably	  it	  should	  be	  easier	  to	  obtain	  a	  
patent	  for	  a	  selection	  invention	  in	  an	  unpredictable	  field	  of	  art,	  such	  as	  nanotechnology	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Novelty	  is	  the	  primary	  obstacle	  for	  the	  patentability	  of	  a	  nanotechnology	  invention.	  
Nanomaterials	  can	  be	  objects	  of	  manufacture	  or	  compositions	  of	  matter	  and	  many	  
nanotechnology	  methods	  are	  associated	  with	  a	  machine	  or	  transform	  materials	  from	  one	  
form	  to	  another.238	  Nanotechnology	  is	  often	  referred	  to	  as	  a	  “refining”	  or	  “enabling”	  
technology	  as	  it	  improves	  existing	  technologies,239	  making	  it	  particularly	  difficult	  to	  
determine	  novelty.	  An	  invention	  will	  be	  considered	  novel	  if	  certain	  conditions	  are	  met,	  
namely,	  at	  the	  time	  the	  invention	  was	  made,	  it	  was	  not	  disclosed	  to	  the	  public	  thereby	  not	  
forming	  part	  of	  the	  state	  of	  art	  and	  was	  not	  anticipated	  by	  prior	  art.240	  Relevant	  prior	  art	  is	  
established	  by	  locating	  art	  that	  most	  closely	  resembles	  the	  invention	  and	  this	  will	  be	  used	  as	  
a	  comparison	  to	  determine	  novelty.	  In	  order	  for	  an	  invention	  to	  be	  anticipated,	  the	  
anticipation	  must	  be	  inherent,	  in	  other	  words	  the	  invention	  is	  an	  obvious	  progression	  from	  
prior	  art.	  	  
	  
Title	  35	  U.S.C.	  §	  102	  lists	  the	  conditions	  for	  novelty:	  
	  
“A	  person	  shall	  be	  entitled	  to	  a	  patent	  unless-­‐	  
a. The	  invention	  was	  known	  or	  used	  others	  in	  this	  country,	  or	  patented	  or	  described	  in	  a	  
printed	  publication	  in	  this	  or	  foreign	  country,	  before	  the	  invention	  thereof	  by	  the	  
applicant	  for	  patent,	  or	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  237	  AIPPI	  http://www.aippi-­‐us.org/images/GR209usa.pdf	  (accessed	  02/04/2013)	  [At	  1	  and	  6]	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b. The	  invention	  was	  patented	  or	  described	  in	  a	  printed	  publication	  in	  this	  or	  foreign	  
country	  or	  in	  public	  use	  or	  on	  sale	  in	  this	  country,	  more	  than	  one	  year	  prior	  to	  the	  
date	  of	  the	  application	  for	  patent	  in	  the	  United	  States,	  or	  
c. He	  has	  abandoned	  the	  invention	  
d. The	  invention	  was	  first	  patented…	  or	  was	  the	  subject	  of	  an	  inventor’s	  certificate…	  in	  
a	  foreign	  country	  prior	  to	  the	  date	  of	  the	  application	  for	  patent	  in	  this	  country	  on	  an	  
application	  for	  patent	  or	  inventor’s	  certificate	  filed	  more	  than	  twelve	  months	  before	  
the	  filing	  of	  the	  application	  in	  the	  United	  States,	  or	  
e. He	  did	  not	  himself	  invent	  the	  subject	  matter	  sought	  to	  be	  patented.”	  
	  
The	  above	  excerpt	  sets	  out	  five	  situations	  where	  an	  invention	  will	  not	  be	  considered	  novel.	  
Firstly,	  any	  printed	  publications	  are	  referred	  to	  as	  prior	  art	  references.	  This	  includes	  any	  
published	  written	  material,	  in	  any	  language,	  anywhere	  in	  the	  world.	  For	  example	  journals,	  
white	  papers,	  graduate	  theses,	  patents,	  published	  patent	  applications,	  web	  pages	  and	  
poster	  presentations	  given	  at	  meetings.	  Prior	  art	  references	  must	  disclose	  every	  element	  of	  
a	  claimed	  invention	  in	  order	  to	  anticipate	  it.241	  The	  doctrine	  of	  “inherent	  anticipation”	  may	  
apply	  where	  all	  the	  elements	  are	  not	  disclosed	  expressly,	  for	  instance	  the	  elements	  of	  the	  
claim	  may	  be	  inherent	  in	  a	  disclosed	  composition	  or	  process.242	  Hence	  this	  doctrine	  will	  
apply	  when	  an	  inherent	  prior	  art	  feature,	  process	  or	  product	  established	  to	  form	  part	  of	  the	  
state	  of	  art	  and	  neither	  the	  applicant	  nor	  the	  public	  were	  aware	  of	  this;	  the	  claimed	  
invention	  comprising	  of	  the	  inherent	  prior	  art	  features,	  process	  or	  product	  will	  not	  
necessarily	  be	  new	  and	  patentable	  based	  on	  this	  discovery.	  Therefore	  the	  patent	  can	  still	  be	  
anticipated	  irrespective	  of	  whether	  the	  inherent	  feature	  was	  known	  at	  the	  time	  of	  the	  
patent.	  This	  doctrine	  will	  not	  apply	  if	  prior	  art	  disclosing	  the	  claimed	  subject	  matter	  does	  so	  
accidentally	  or	  unwittingly.243	  Furthermore	  the	  anticipatory	  inherent	  feature,	  process	  or	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product	  must	  be	  foreseeable	  in	  the	  prior	  art,	  “probability”	  and	  “possibility”	  will	  not	  
suffice.244	  	  
	  
Additionally	  the	  inventor	  will	  lose	  his	  right	  to	  patent	  his	  invention	  if	  he	  delays	  filing	  his	  
application	  within	  the	  twelve-­‐month	  period	  granted.	  This	  consequence	  serves	  as	  
encouragement	  for	  an	  inventor	  to	  file	  within	  this	  grace	  period.	  He	  cannot	  abandon	  his	  
invention,	  this	  can	  happen	  for	  example	  when	  the	  inventor	  criticises	  his	  own	  work	  in	  a	  peer	  
reviewed	  journal	  or	  white	  paper.	  Furthermore,	  an	  invention	  will	  not	  be	  novel	  if	  the	  inventor	  
is	  prevented	  from	  filing	  a	  patent	  application	  in	  a	  foreign	  country	  more	  than	  one	  year	  prior	  
to	  filing	  a	  U.S.	  application.	  Finally,	  the	  inventor	  must	  invent	  the	  invention	  in	  respect	  of	  
which	  he	  seeks	  a	  patent;	  it	  cannot	  be	  copied	  from	  someone	  else.	  
	  
Recently	  significant	  changes	  were	  made	  to	  the	  provisions	  pertaining	  to	  the	  definition	  of	  
“prior	  art”	  in	  terms	  of	  §	  102.	  These	  changes	  were	  implemented	  by	  the	  America	  Invents	  Act	  
(AIA),	  which	  took	  effect	  on	  March	  16,	  2013.	  In	  terms	  §	  3	  of	  the	  AIA,	  the	  U.S.	  will	  adopt	  the	  
first-­‐to-­‐file	  system	  and	  the	  scope	  of	  prior	  art	  available	  whereby	  patent	  applications	  can	  be	  
rejected	  and	  patents	  invalidated	  is	  expanded.	  	  
	  
The	  new	  §	  102(a)	  states	  that	  a	  person	  shall	  be	  entitled	  to	  a	  patent	  unless:	  
	  
“(1)	  The	  claimed	  invention	  was	  patented,	  described	  in	  a	  printed	  publication,	  or	  in	  public	  use,	  
on	  sale,	  or	  otherwise	  available	  to	  the	  public	  before	  the	  effective	  date	  of	  the	  claimed	  
invention;	  or	  
(2)	  The	  claimed	  invention	  was	  described	  in	  [an	  issued	  U.S.	  patent],	  or	  in	  [a	  published	  U.S.	  
patent	  application	  or	  a	  published	  PCT	  application	  designating	  the	  U.S.],	  in	  which	  the	  patent	  
or	  application,	  as	  the	  case	  may	  be,	  names	  another	  inventor	  and	  was	  effectively	  filed	  before	  
the	  effective	  filing	  date	  of	  the	  claimed	  invention.”	  245	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  244	  MPEP	  §	  2112	  IV	  
	  245	  Leahy-­‐Smith	  America	  Invents	  Act	  of	  2011	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Differences	  between	  pre-­‐AIA	  provisions	  and	  the	  AIA	  provisions	  include:	  the	  former	  
definition	  distinguishes	  between	  prior	  art	  relating	  to	  the	  application	  filing	  date	  and	  other	  
prior	  art	  relating	  to	  the	  date	  of	  the	  invention.	  The	  new	  §	  102	  discards	  this	  distinction	  and	  
prior	  art	  is	  exclusively	  defined	  in	  terms	  of	  the	  effective	  filing	  date.	  The	  “effective	  filing	  date”	  
is	  the	  priority	  date	  of	  the	  application,	  such	  as	  the	  filing	  date	  of	  a	  parent	  patent	  
application,246	  a	  PCT	  application	  or	  a	  foreign	  patent	  application.247	  Furthermore	  it	  adds,	  “or	  
otherwise	  available	  to	  the	  public”	  thereby	  removing	  geographic	  limitations	  from	  what	  
constitutes	  prior	  art.	  	  
	  
Furthermore	  §	  102	  (b)	  describes	  certain	  exceptions	  for	  disclosures	  that	  are	  made	  within	  one	  
year	  of	  the	  effective	  filing	  date	  by	  the	  inventor	  or	  person	  who	  has	  derived	  his	  invention	  
from	  the	  inventor’s	  disclosure.248	  This	  grace	  period	  does	  not	  apply	  for	  sales	  or	  offers	  for	  sale	  
or	  public	  use	  and	  these	  limitations	  are	  extended	  worldwide.	  	  
	  
These	  changes	  could	  affect	  the	  difficulty	  with	  which	  an	  applicant	  will	  be	  able	  to	  obtain	  a	  
patent.	  By	  expanding	  the	  available	  prior	  art	  to	  include	  prior	  art	  patents	  and	  published	  
applications	  (including	  published	  PCT	  applications,	  only	  where	  the	  U.S.	  has	  been	  
designated)	  it	  may	  be	  more	  difficult	  to	  meet	  the	  requirements	  of	  novelty	  and	  non-­‐
obviousness.	  At	  present	  the	  AIA	  is	  not	  yet	  in	  force.	  
	  
A	  common	  misconception	  relating	  to	  nanotechnology	  inventions	  is	  that	  they	  are	  merely	  
miniaturized	  versions	  of	  prior	  art,	  i.e.	  they	  are	  smaller	  versions	  consisting	  of	  the	  same	  
subject	  matter	  as	  their	  larger	  scale	  versions.	  This	  reduction	  in	  size	  will	  only	  be	  novel	  if	  the	  
elements	  and	  features	  of	  the	  invention	  produce	  new,	  non-­‐obvious	  and	  unexpected	  
results.249	  Therefore	  size	  in	  itself	  does	  not	  necessarily	  establish	  novelty;	  the	  properties	  and	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  246	  A	  “parent	  patent	  application”	  is	  a	  divisional	  patent	  application	  that	  contains	  matter	  from	  a	  previously	  filed	  
application.	  
	  247	  USPTO.gov	  http://www.uspto.gov/aia_implementation/faqs_first_inventor.jsp	  (accessed	  13/06/2013)	  	  248	  IPO	  http://www.ipo.org/wp-­‐
content/uploads/2013/03/Patent_Reform_Chart_Comparison_of_AIA_and_Pre-­‐AIA_Laws_FINAL.pdf	  
(accessed	  13/06/2013)	  [At	  2]	  	  249	  Graham	  v.	  John	  Deere	  Co.	  of	  Kansas	  City	  383	  U.S.	  17-­‐18	  USPQ	  459	  (1966)	  [Hereinafter	  the	  John	  Deere	  case]	  
	   69	  
characteristics	  of	  nanomaterials	  that	  are	  often	  different	  to	  those	  of	  the	  same	  material	  in	  
bulk	  will	  determine	  novelty.	  For	  example	  electronic	  properties	  of	  nanoscale	  materials	  can	  in	  
bulk	  conduct	  electricity	  and	  be	  an	  insulator	  at	  nanoscale.	  The	  mechanical	  properties	  of	  
material	  are	  highly	  dependant	  on	  atomic	  scale	  effects,	  as	  the	  strength	  increases	  the	  
material	  generally	  becomes	  less	  ductile,	  for	  example	  graphite	  is	  usually	  soft	  and	  brittle	  but	  
carbon	  nanotubes	  are	  extremely	  strong.	  Chemical	  properties	  change	  as	  the	  size	  of	  the	  
material	  is	  reduced	  the	  ratio	  of	  the	  surface	  area	  to	  volume	  increases	  dramatically.	  Therefore	  
the	  reduction	  in	  size	  can	  change	  a	  material’s	  chemical	  structure	  and	  increase	  its	  chemical	  
reactivity.	  These	  examples	  illustrate	  how	  properties	  and	  materials	  at	  nanoscale	  can	  have	  




The	  requirement	  of	  non-­‐obviousness	  extends	  the	  inquiry	  of	  novelty	  by	  determining	  whether	  
the	  invention	  is	  adequately	  new.	  There	  must	  be	  a	  clear	  difference	  between	  the	  properties	  
of	  the	  claimed	  invention	  and	  those	  in	  relevant	  prior	  art	  in	  order	  for	  the	  invention	  to	  be	  
considered	  novel	  and	  non-­‐obvious.	  Once	  novelty	  is	  established	  it	  must	  then	  be	  determined	  
whether	  the	  invention	  is	  obvious	  to	  a	  person	  skilled	  in	  the	  pertinent	  art.	  If	  such	  a	  person	  
considers	  it	  to	  be	  obvious,	  the	  invention	  will	  not	  warrant	  a	  patent.	  A	  patent	  cannot	  be	  
obtained	  if	  the	  differences	  between	  the	  subject	  matter	  sought	  to	  be	  patented	  and	  the	  prior	  
art	  are	  such	  that	  the	  subject	  matter	  as	  a	  whole	  would	  have	  been	  obvious	  at	  the	  time	  the	  
invention	  was	  made	  to	  a	  person	  having	  ordinary	  skill	  in	  the	  art.250	  The	  phrase	  “subject	  
matter	  as	  a	  whole”	  is	  of	  particular	  importance,	  the	  scope	  and	  content	  of	  prior	  art	  and	  
differences	  between	  prior	  art	  and	  claimed	  invention	  and	  the	  level	  of	  ordinary	  skill	  in	  the	  
pertinent	  art	  must	  be	  compared.251	  	  
	  
Every	  element	  of	  the	  claim	  must	  have	  been	  publically	  known	  in	  the	  prior	  art	  at	  the	  time	  of	  
the	  patent	  application	  for	  the	  invention	  to	  be	  un-­‐patentably	  obvious.252	  “Ordinary	  skill”	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  250	  Title	  35	  U.S.C	  §	  103	  	  251	  MPEP	  §	  2131B	  
	  252	  MPEP	  §	  2131	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refers	  to	  a	  person	  who	  has	  ordinary	  skill	  in	  the	  field	  or	  area	  of	  the	  relevant	  invention.253	  The	  
area	  of	  the	  art	  will	  usually	  dictate	  the	  level	  of	  skill	  required	  for	  a	  person	  to	  be	  considered	  
skilled	  in	  that	  art.	  Some	  areas	  of	  art	  require	  a	  general	  knowledge	  and	  others	  require	  
industry	  specific	  experience	  or	  a	  certain	  qualification.254	  According	  to	  MPEP	  §	  2131,	  several	  
factors	  are	  considered	  to	  determine	  level	  of	  skill	  in	  the	  art:	  	  
	  
1. The	  type	  of	  problems	  encountered	  in	  the	  art;	  	  
2. Prior	  art	  solutions	  to	  those	  problems;	  	  
3. Rapidity	  with	  which	  innovations	  are	  made;	  
4. Sophistication	  of	  the	  technology;	  	  
5. Educational	  level	  of	  active	  workers	  in	  the	  field.	  	  
	  
This	  hypothetical	  person	  should	  have	  a	  special	  knowledge	  of	  all	  the	  prior	  art	  in	  the	  specific	  
field	  relevant	  to	  the	  invention,	  at	  the	  time	  of	  the	  patent	  application.	  Therefore	  if	  a	  person	  
skilled	  in	  the	  art	  who	  is	  working	  in	  the	  field	  of	  art	  at	  the	  time	  of	  the	  invention	  is	  able	  to	  
combine	  these	  known	  prior	  art	  elements	  using	  a	  known	  method	  and	  with	  no	  change	  to	  their	  
respective	  functions	  and	  this	  combination	  yields	  a	  predictable	  result,	  the	  invention	  will	  be	  
obvious.	  	  
	  
Examiners	  must	  consider	  the	  broad	  application	  of	  nanotechnology	  inventions	  when	  
considering	  relevant	  prior	  art.	  The	  examiner	  should	  have	  knowledge	  of	  all	  prior	  art	  
pertaining	  to	  the	  invention,	  however,	  with	  the	  possible	  convergence	  of	  various	  fields	  in	  one	  
invention	  the	  examiner	  may	  not	  have	  the	  necessary	  skill	  required	  to	  examine	  other	  relevant	  
art	  units	  or	  may	  overlook	  some	  of	  these.	  This	  will	  increase	  the	  risk	  of	  the	  invention	  
overlapping	  with	  patents	  in	  these	  overlooked	  fields.	  It	  is	  essential	  that	  examiners	  are	  able	  to	  
distinguish	  between	  inventions	  that	  are	  new	  and	  relevant	  prior	  art	  for	  a	  valid	  patent.	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  MPEP	  §	  2131	  C	  	  254	  Hicks,	  Grissett	  and	  Brown	  http://www.wcsr.com/resources/pdfs/nano030310.pdf	  (accessed	  04/05/2012)	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  7]	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Obviousness	  is	  a	  question	  of	  law	  based	  on	  underlying	  factual	  questions.	  In	  Graham	  v.	  John	  
Deere	  Co.	  of	  Kansas	  City,	  the	  Supreme	  Court	  coined	  this	  factual	  inquiry,	  the	  “Graham	  
factors.”	  These	  factors	  are	  intended	  to	  assist	  the	  examiner	  in	  determining	  obviousness	  
by:255	  	  	  
	  
1. Determining	  the	  scope	  and	  content	  of	  the	  prior	  art;	  
2. Ascertaining	  the	  differences	  between	  the	  claimed	  invention	  and	  the	  prior	  art;	  
3. The	  level	  of	  ordinary	  skill	  in	  the	  pertinent	  art.	  
	  
Furthermore	  secondary	  considerations,	  such	  as	  objective	  evidence,	  will	  be	  very	  persuasive	  
and	  must	  be	  included	  in	  the	  enquiry	  of	  obviousness.	  This	  includes	  commercial	  success,	  a	  
long-­‐felt	  but	  unsolved	  need,	  failure	  of	  others,	  evidence	  that	  the	  claimed	  invention	  was	  
copied	  by	  others	  and	  unexpected	  results	  or	  properties	  not	  in	  prior	  art.256	  This	  information	  
will	  “give	  light	  to	  the	  circumstances	  surrounding	  the	  origin	  of	  the	  subject	  matter	  sought	  to	  
be	  patented.”257	  This	  evidence	  can	  form	  part	  of	  the	  specification	  (as	  the	  declaration).	  	  	  
	  
In	  terms	  of	  commercial	  success,	  the	  success	  of	  the	  product	  must	  be	  as	  a	  result	  of	  the	  
invention	  claimed	  in	  the	  patent.	  It	  is	  necessary	  to	  determine	  reasonable	  expectation	  of	  
success	  in	  combination	  with	  prior	  art	  references	  in	  a	  manner	  suggested	  by	  the	  theory	  of	  
obviousness.	  Some	  degree	  of	  predictability	  is	  required,	  any	  evidence	  that	  shows	  that	  those	  
in	  the	  field	  would	  not	  consider	  reasonable	  expectation	  of	  success	  in	  that	  combination	  or	  
modification	  is	  important.	  There	  must	  be	  a	  link	  between	  this	  success	  and	  the	  invention	  
claimed.	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These	  factors	  were	  reaffirmed	  in	  the	  KSR	  case,	  whereby	  the	  following	  guidelines	  to	  establish	  
a	  prima	  facie	  case	  of	  obviousness	  were	  added.	  Obviousness	  will	  be	  established	  if	  the	  patent	  
application	  claims	  a	  combination	  of	  prior	  art	  elements	  whereby:258	  	  
	  
1. Combining	  prior	  art	  elements	  according	  to	  known	  methods	  to	  yield	  predictable	  
results;	  
2. Simple	  substitution	  of	  one	  known	  element	  for	  another	  to	  obtain	  predictable	  results;	  
3. Use	  of	  known	  technique	  to	  improve	  similar	  devices	  (methods,	  or	  products)	  in	  the	  
same	  way;	  	  
4. Applying	  a	  known	  technique	  to	  a	  known	  device	  (method,	  or	  product)	  ready	  for	  
improvement	  to	  yield	  predictable	  results;	  
5. 	  It	  would	  be	  “obvious	  to	  try.”	  Choosing	  from	  a	  finite	  number	  of	  identified,	  
predictable	  solutions,	  with	  a	  reasonable	  expectation	  of	  success;	  
6. Known	  work	  in	  one	  field	  of	  endeavor	  may	  prompt	  variations	  of	  it	  for	  use	  in	  either	  
the	  same	  field	  or	  a	  different	  one	  based	  on	  design	  incentives	  or	  other	  market	  forces	  if	  
the	  variations	  are	  predictable	  to	  one	  of	  ordinary	  skill	  in	  the	  art;	  
7. Some	  teaching,	  suggestion	  or	  motivation	  in	  prior	  art	  that	  would	  have	  led	  a	  person	  of	  
ordinary	  skill	  to	  modify	  the	  prior	  art	  reference	  or	  combine	  the	  prior	  art	  references	  to	  
arrive	  at	  the	  claimed	  invention.	  	  
	  
Non-­‐obviousness	  is	  possibly	  the	  most	  difficult	  barrier	  in	  determining	  the	  patentability	  of	  a	  
nanotechnology	  invention.	  As	  established	  from	  these	  guidelines,	  the	  element	  of	  
predictability	  plays	  a	  substantial	  role	  in	  determining	  non-­‐obviousness,	  usually	  if	  a	  person	  
skilled	  in	  the	  art	  can	  anticipate	  the	  effect	  of	  the	  change	  within	  the	  subject	  matter	  to	  which	  
the	  claimed	  invention	  pertains,	  the	  art	  is	  predictable.	  Within	  the	  context	  of	  nanotechnology,	  
nanoscale	  materials	  generally	  display	  different	  characteristics	  due	  to	  their	  increased	  surface	  
area	  to	  volume	  ratio	  than	  the	  same	  material	  in	  bulk.	  Nanomaterials	  are	  considered	  to	  be	  
inherently	  unpredictable,	  making	  it	  more	  difficult	  to	  determine	  the	  obviousness	  of	  a	  
nanotechnology	  invention.	  Therefore	  it	  should	  be	  relatively	  simple	  to	  corroborate	  non-­‐
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obviousness	  by	  showing	  a	  person	  skilled	  in	  the	  field	  would	  not	  combine	  the	  known	  
elements	  to	  yield	  the	  improvement	  due	  to	  the	  unpredictability	  of	  the	  field.	  
Generally	  an	  invention	  will	  be	  considered	  obvious	  if	  it	  is	  purely	  a	  smaller	  version	  of	  the	  prior	  
art,	  whereby	  it	  performs	  the	  same	  function	  and	  produces	  the	  same	  result.	  However,	  if	  prior	  
art	  does	  not	  enable	  a	  person	  skilled	  in	  the	  art	  to	  produce	  a	  version	  of	  the	  known	  device	  on	  
nanoscale,	  the	  nanoscale	  device	  will	  be	  non-­‐obvious	  even	  if	  the	  size	  is	  the	  only	  
difference.259	  A	  product	  is	  not	  obvious	  as	  a	  matter	  of	  law	  unless	  the	  process	  for	  making	  that	  
product	  is	  also	  obvious.260	  Furthermore	  an	  invention	  at	  nanoscale	  will	  not	  be	  obvious	  if	  it	  
produces	  new,	  improved	  properties	  or	  facilitates	  new	  uses	  for	  known	  compositions.	  The	  
patent	  can	  be	  obtained	  for	  the	  use	  of	  that	  known	  property	  in	  a	  particular	  environment.261	  
Another	  instance	  is	  if	  the	  invention	  claims	  to	  overcome	  a	  technical	  problem	  pertaining	  to	  
the	  prior	  art	  thereby	  affording	  a	  significant	  technological	  advantage	  over	  prior	  art,262	  the	  
solution	  can	  be	  claimed	  as	  the	  invention.	  	  
	  
The	  inventor	  is	  not	  obliged	  to	  submit	  data	  or	  other	  evidence	  showing	  these	  improved	  
results	  when	  he	  files	  his	  application,	  however	  by	  including	  this	  information	  he	  may	  avoid	  
the	  examiner	  assuming	  the	  invention	  is	  obvious.263	  	  This	  information	  is	  likely	  to	  be	  available,	  
especially	  if	  the	  inventor	  requested	  all	  the	  experimental	  data	  be	  kept	  and	  catalogued	  
properly.	  It	  serves	  as	  the	  best	  form	  of	  evidence	  to	  rebut	  a	  prima	  facie	  case	  of	  obviousness	  
especially	  if	  the	  patent	  practitioner	  anticipates	  this	  argument.	  He	  will	  also	  save	  an	  
enormous	  amount	  of	  time.	  Such	  evidence	  is	  of	  particular	  importance	  when	  applying	  for	  a	  
nanotechnology	  patent	  due	  to	  the	  unpredictable	  nature	  of	  this	  field.	  By	  anticipating	  
arguments	  for	  obviousness,	  the	  application	  can	  be	  drafted	  in	  such	  a	  way	  that	  the	  challenges	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faced	  by	  the	  inventor	  can	  be	  described	  and	  shown	  how	  they	  were	  overcome,	  thereby	  
reducing	  the	  need	  to	  argue	  unpredictability	  of	  art	  and	  lack	  reasonable	  expectation	  of	  
success.	  Therefore	  by	  considering	  the	  predictability	  of	  the	  invention,	  potential	  inquiries	  that	  
will	  be	  costly	  and	  delay	  the	  process	  can	  be	  circumvented	  and	  a	  clear,	  concise	  application	  
will	  be	  submitted.	  	  
	  
MPEP	  states	  that	  each	  case	  must	  be	  decided	  on	  its	  own	  facts	  and	  the	  Graham	  factors	  as	  
well	  as	  secondary	  considerations	  are	  part	  of	  the	  obvious	  analysis.	  In	  re	  Dillon,	  Dillon’s	  
invention	  claimed	  hydrocarbon	  fuel	  compositions	  containing	  these	  tetra-­‐orthoesters	  and	  
the	  method	  of	  reducing	  soot	  emissions	  during	  combustion	  by	  combining	  these	  esters	  with	  
the	  fuel	  before	  combustion.264	  The	  examiner	  rejected	  the	  application	  as	  obvious	  due	  to	  
similar	  prior	  art	  compositions	  and	  similar	  uses.	  The	  court	  stated	  "a	  prima	  facie	  case	  of	  
obviousness	  is	  not	  made	  unless	  both	  (1)	  the	  new	  compound	  or	  composition	  is	  structurally	  
similar	  to	  the	  reference	  compound	  or	  composition	  and	  (2)	  there	  is	  some	  suggestion	  or	  
expectation	  in	  the	  prior	  art	  that	  the	  new	  compound	  or	  composition	  will	  have	  the	  same	  or	  a	  
similar	  utility	  as	  that	  discovered	  by	  the	  applicant."265	  The	  court	  concluded	  there	  was	  no	  
suggestion	  in	  the	  prior	  art	  references,	  alone	  or	  in	  combination	  of	  the	  particulate-­‐reducing	  
property	  and	  use	  discovered	  by	  Dillon	  for	  her	  new	  compositions.	  Therefore	  a	  prima	  facie	  
case	  of	  obviousness	  was	  not	  made.266	  Dillon’s	  invention	  was	  not	  obvious,	  it	  claimed	  a	  new	  
method	  of	  reducing	  particulate	  emissions	  that	  was	  neither	  taught	  nor	  suggested	  by	  prior	  
art.	  
	  
It	  is	  important	  to	  mention	  the	  AIA	  has	  also	  altered	  §	  103,	  by	  changing	  the	  date	  on	  which	  to	  
assess	  the	  obviousness	  of	  an	  invention	  from	  the	  pre-­‐AIA	  criterion:	  "the	  time	  the	  invention	  
was	  made"	  to	  "before	  the	  effective	  filing	  date	  of	  the	  claimed	  invention."267	  Therefore	  the	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EPO’s	  approach	  (first-­‐to-­‐file)	  will	  be	  followed	  and	  the	  filing	  date	  of	  the	  patent	  application	  




An	  invention	  must	  be	  useful;	  it	  must	  perform	  some	  function	  or	  fulfil	  a	  specific	  need.	  The	  
term	  “useful”	  refers	  to	  the	  subject	  matter	  of	  the	  invention,	  it	  must	  have	  a	  useful	  purpose	  
including	  operativeness;	  i.e.	  the	  machine	  must	  perform	  its	  intended	  operation.268	  	  
	  
There	  are	  several	  challenges	  regarding	  nanotechnology	  and	  the	  requirement	  of	  utility.	  
These	  will	  be	  outlined	  in	  separate	  sections:269	  	  
	  
a) Nanotechnology’s	  Multidisciplinary	  Application	  	  
	  
When	  it	  comes	  to	  nanotechnology’s	  multidisciplinary	  application	  there	  is	  a	  divide	  between	  
theory	  and	  practice.	  Theoretically	  the	  utility	  requirement	  should	  be	  applied	  uniformly	  to	  all	  
technologies,	  however	  in	  practice,	  courts	  apply	  a	  more	  stringent	  standard	  in	  determining	  
the	  patentability	  of	  chemical	  inventions	  than	  that	  applied	  for	  mechanical	  inventions.	  As	  new	  
technologies	  emerge,	  they	  are	  placed	  in	  existing	  contexts	  by	  the	  courts	  rather	  than	  being	  
dealt	  with	  in	  their	  own	  right.	  An	  example	  of	  this	  “categorising”	  was	  seen	  with	  
biotechnology:	  it	  was	  compared	  to	  previous	  technologies	  and	  found	  to	  best	  suit	  the	  context	  
of	  chemical	  inventions	  by	  the	  Federal	  Circuit.	  Therefore	  it	  can	  be	  said	  that	  patent	  law	  can	  be	  
industry	  and	  technology	  specific.	  	  
	  
This	  treatment	  of	  new	  technologies	  can	  be	  problematic	  due	  to	  the	  unique	  challenges	  each	  
new	  technology	  brings	  with	  it.	  Nanotechnology	  obviously	  challenges	  this	  traditional	  practice	  
due	  to	  its	  multidisciplinary	  application;	  it	  can	  involve	  chemistry,	  biology,	  physics,	  computer-­‐
science,	  pharmaceutical	  drugs,	  varying	  fields	  of	  engineering	  and	  other	  disciplines.	  An	  
example	  of	  how	  all	  these	  fields	  can	  converge	  is	  best	  illustrated	  in	  medical	  treatment	  and	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diagnostics.	  Here	  nanotechnology	  can	  be	  applied	  to	  both	  scientific	  and	  industrial	  fields	  
thereby	  extending	  its	  breadth	  of	  application.	  The	  vast	  application	  of	  quantum	  dots	  further	  
illustrates	  this	  point	  as	  quantum	  dots	  can	  be	  applied	  within	  the	  pharmaceutical	  arts	  and	  in	  
several	  other	  arts	  making	  it	  difficult	  to	  place	  them	  in	  any	  single	  category.	  	  
	  
It	  is	  crucial	  that	  when	  nanotechnology	  inventions	  are	  examined,	  Patent	  Offices	  and	  courts	  
determine	  which	  context	  is	  appropriate	  by	  considering	  all	  disciplines	  and	  industries	  and	  the	  
scope	  of	  a	  new	  converging	  industry.	  In	  Fujikawa	  v.	  Wattanasin,	  the	  role	  of	  the	  utility	  
requirement	  was	  discussed	  in	  the	  context	  of	  “pharmaceutical	  arts.”	  Traditionally	  an	  
invention	  must	  show	  substantial	  or	  practical	  utility	  before	  the	  patent	  will	  be	  granted.	  The	  
court	  stated	  that	  practical	  utility	  is	  determined	  on	  a	  case-­‐by-­‐case	  basis.270	  Furthermore	  the	  
court	  confirmed	  the	  measure	  applied	  in	  the	  area	  of	  pharmaceutical	  arts,	  namely	  that	  the	  
applicant	  must	  provide	  sufficient	  evidence	  of	  pharmaceutical	  activity	  in	  order	  to	  constitute	  
adequate	  proof	  of	  practical	  utility	  of	  a	  compound	  and	  stated	  this	  evidence	  should	  eliminate	  
any	  doubt	  those	  skilled	  in	  the	  relevant	  art	  would	  have	  regarding	  the	  success	  of	  the	  
invention.271	  	  
	  
It	  is	  likely	  that	  the	  chemistry	  based	  utility	  context	  will	  be	  applied	  to	  nanotechnology	  
inventions.	  The	  reason	  being	  that	  despite	  its	  multidisciplinary	  application	  nanotechnology	  is	  
essentially	  the	  manipulation	  of	  molecules	  and	  atoms	  and	  chemistry	  is	  the	  area	  of	  science	  
that	  deals	  with	  the	  composition	  and	  change	  of	  matter	  from	  one	  form	  to	  another.	  Another	  
reason	  to	  apply	  this	  more	  demanding	  standard	  is	  the	  unpredictability	  factor	  of	  
nanotechnology.	  The	  mechanical	  based	  utility	  standard	  will	  probably	  be	  applied	  to	  
nanotechnology	  inventions	  that	  also	  involve	  mechanics	  and	  electronics.	  This	  would	  be	  
advantageous	  to	  the	  applicant	  as	  it	  is	  less	  demanding.	  It	  is	  also	  possible	  that	  the	  courts	  may	  
rely	  on	  both	  the	  chemistry-­‐based	  precedent	  and	  the	  mechanical-­‐based	  standard	  where	  
both	  would	  be	  applicable.272	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In	  summary	  nanotechnology’s	  interdisciplinary	  nature	  extends	  its	  technological	  and	  
industrial	  context	  making	  it	  difficult	  to	  determine	  which	  context	  best	  applies	  to	  an	  
invention.273	  A	  patent	  practitioner	  should	  contemplate	  the	  diverse	  fields	  in	  relation	  to	  which	  
the	  invention	  could	  be	  applied	  when	  drafting	  the	  patent	  application	  in	  order	  to	  ensure	  the	  
claim	  does	  not	  infringe	  upon	  prior	  art	  in	  a	  different	  field	  to	  that	  in	  which	  the	  inventor	  has	  
considered	  his	  invention	  to	  apply.	  	  
	  
b) The	  Invention	  must	  be	  Operable	  
	  
Inventions	  must	  work	  as	  the	  inventor	  has	  claimed	  it	  to	  work	  before	  the	  invention	  can	  be	  
patented.	  Should	  a	  person	  skilled	  in	  the	  art	  reasonably	  doubt	  the	  claimed	  utility	  of	  an	  
invention,	  the	  burden	  to	  provide	  evidence	  to	  sufficiently	  rebut	  this	  lies	  with	  the	  applicant.	  
Inoperability	  must	  be	  due	  to	  the	  impossible	  or	  inoperable	  nature	  of	  the	  inventions.	  An	  
impossible	  invention	  cannot	  be	  patented;	  in	  EMI	  Group	  North	  America,	  Inc.	  v.	  Cypress	  
Semiconductor	  Corp.,	  the	  invention	  claimed	  relied	  on	  a	  theoretical	  “vapour	  induced	  
explosion	  mechanism”	  which	  was	  found	  to	  lack	  utility	  because	  it	  relied	  on	  an	  impossible	  
mechanism.274	  This	  case	  features	  metallic	  fuses	  for	  semiconductor	  chips,	  these	  chips	  
typically	  have	  redundant	  circuitry	  due	  to	  the	  way	  they	  are	  manufactured.	  Each	  chip	  is	  tested	  
and	  the	  dysfunctional	  portions	  of	  the	  chip	  are	  disconnected	  whereby	  the	  redundant	  
circuitry	  takes	  over	  the	  function.	  The	  specification	  described	  this	  theoretical	  mechanism	  for	  
blowing	  the	  disclosed	  metallic	  fuse.	  An	  expert	  testified	  that	  this	  fuse	  simply	  could	  not	  
explode	  due	  to	  vapour	  pressure;	  the	  court	  accepted	  this	  testimony.	  Moreover	  Cypress’	  
fuses	  and	  processes	  could	  not	  infringe	  EMI’s	  patents	  because	  they	  did	  not	  explode	  
according	  to	  the	  claimed	  mechanism.	  The	  court	  stated;	  “when	  a	  claim	  itself	  recites	  incorrect	  
science	  in	  one	  limitation,	  the	  entire	  claim	  is	  invalid,	  regardless	  of	  the	  combinations	  of	  the	  
other	  limitations	  recited	  in	  the	  claim.”275	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Nanotechnology	  inventions	  are	  likely	  to	  confront	  similar	  objections	  as	  examiners	  who	  are	  
not	  experienced	  in	  this	  field	  may	  presume	  some	  inventions	  are	  unrealistic	  in	  their	  claims	  
resulting	  in	  improper	  evaluations.	  The	  operability	  of	  an	  invention	  must	  be	  evaluated	  
objectively.	  The	  standard	  is	  low	  therefore	  it	  is	  not	  an	  insurmountable	  issue.276	  Should	  the	  
examiner	  doubt	  the	  operability	  of	  the	  invention	  the	  inventor	  can	  simply	  supply	  additional	  
evidence	  (i.e.	  showing	  that	  the	  invention	  has	  a	  use)	  to	  refute	  this	  supposition.	  	  
	  
c) The	  Invention	  must	  be	  Practical	  
	  
The	  requirement	  of	  utility	  can	  be	  challenged	  if	  the	  practical	  use	  of	  the	  invention	  is	  
uncertain.	  Included	  in	  the	  utility	  requirement	  is	  the	  requirement	  of	  substantial	  utility	  or	  
practical	  utility.	  Practical	  utility	  denotes	  the	  public’s	  need	  to	  use	  the	  invention	  or	  benefit	  
from	  the	  invention	  in	  some	  practical	  way,	  i.e.	  a	  “real	  world	  use.”277	  Currently	  the	  
understanding	  of	  this	  standard	  comes	  from	  the	  PTO’s	  2001	  Utility	  Examination	  Guidelines	  
requiring	  all	  inventions	  to	  have	  a	  “well-­‐established	  utility.”278	  The	  asserted	  utility	  must	  be	  
specific	  and	  substantial.	  This	  occurs	  if	  a	  person	  of	  ordinary	  skill	  in	  the	  art	  would	  immediately	  
appreciate	  why	  the	  invention	  is	  useful	  and	  the	  utility	  is	  specific,	  substantial	  and	  credible.	  
Practical	  utility	  is	  easily	  shown	  in	  mechanical	  or	  electrical	  inventions.	  However	  it	  is	  not	  
always	  possible	  to	  show	  for	  in	  chemical	  inventions,	  as	  many	  of	  their	  uses	  are	  uncertain.	  In	  re	  
Ziegler,	  the	  practical	  use	  of	  the	  invention	  was	  not	  asserted,	  resulting	  in	  uncertainty	  as	  to	  its	  
usefulness	  and	  ultimately	  resulting	  in	  its	  rejection.279	  This	  case	  concerned	  polypropylene,	  a	  
polymer	  of	  propylene	  molecules	  wherein	  the	  applicant	  disclosed	  that	  solid	  granules	  of	  
polypropylene	  could	  be	  pressed	  into	  a	  flexible	  film	  that	  was	  “plastic-­‐like”	  without	  disclosing	  
the	  practical	  use	  for	  the	  polypropylene	  or	  its	  film.	  The	  court	  felt	  this	  disclosure	  was	  
insufficient	  to	  assert	  utility.	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An	  example	  illustrating	  uncertain	  uses	  for	  some	  nanotechnology	  inventions	  would	  be	  an	  
assembler.	  This	  nanomachine	  is	  capable	  of	  building	  other	  nanomachines	  and	  reproducing	  
itself	  in	  the	  same	  process.	  The	  fact	  that	  this	  nanorobot	  is	  far	  from	  existing	  makes	  its	  
potential	  use	  uncertain,	  as	  it	  is	  still	  unknown	  if	  and	  how	  it	  will	  work	  and	  what	  it	  will	  be	  used	  
for.	  This	  uncertainty	  makes	  it	  easy	  for	  examiners	  to	  assert	  lack	  of	  utility.	  The	  unpredictable	  
nature	  of	  nanotechnology	  leads	  to	  uncertainty	  regarding	  the	  actual	  use	  of	  nanotechnology	  
inventions.	  It	  is	  therefore	  important	  for	  the	  applicant	  to	  clearly	  show	  in	  their	  patent	  
application,	  specific	  real-­‐world	  use	  for	  their	  invention	  and	  show	  that	  the	  unique	  properties	  
of	  their	  nanotechnology	  invention	  are	  not	  too	  uncertain.	  Most	  nanotechnology	  inventions	  
have	  practical	  utility,	  however	  with	  overly	  broad	  claims,	  examiners	  may	  misunderstand	  the	  
invention	  in	  one	  of	  two	  ways:	  they	  could	  adopt	  a	  simplistic	  view	  in	  that	  nanotechnology	  is	  
merely	  a	  smaller	  version	  of	  pre-­‐existing	  technology	  or	  take	  the	  stance	  that	  as	  a	  result	  of	  
nanotechnology’s	  tendency	  to	  be	  unpredictable,	  it	  has	  no	  real	  world	  use.	  By	  clearly	  
describing	  the	  function	  or	  purpose	  of	  the	  nanotechnology	  invention,	  this	  requirement	  will	  
be	  met.	  	  
	  
d) Upstream-­‐research	  Problems	  Created	  by	  Patents	  at	  the	  Research	  Phase	  
	  
Traditional	  patent	  law	  focuses	  on	  the	  end	  result	  and	  not	  the	  research	  leading	  to	  that	  result.	  
An	  important	  consideration	  is	  that	  nanotechnology	  patent	  applications	  for	  upstream	  
research	  are	  likely	  to	  be	  basic	  because	  they	  are	  not	  fully	  developed	  final	  products.	  This	  
allows	  for	  overly	  broad	  claims	  to	  be	  made	  encompassing	  far	  more	  than	  what	  the	  final	  
product	  will	  actually	  offer.	  Although	  it	  is	  argued	  that	  the	  utility	  requirement	  limits	  patents	  
on	  research,	  this	  argument	  is	  unlikely	  to	  succeed	  in	  the	  case	  of	  nanotechnology	  inventions	  
as	  most	  of	  this	  technology	  is	  in	  a	  research	  phase.280	  
	  
An	  example	  of	  nanotechnology	  at	  an	  upstream	  research	  phase	  is	  that	  of	  dendrimers.	  They	  
are	  three-­‐dimensional	  molecules	  that	  have	  a	  hollow	  core	  capable	  of	  carrying	  other	  
molecules.	  It	  is	  a	  very	  versatile	  tool	  making	  it	  difficult	  to	  tell	  how	  potentially	  vast	  its	  
application	  will	  be.	  Possible	  applications	  include:	  drug	  delivery	  and	  sensor	  technologies,	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thereby	  spanning	  the	  medical,	  electronic	  and	  chemical	  industries.281	  It	  is	  difficult	  to	  
determine	  the	  scope	  of	  the	  patent	  when	  an	  invention	  can	  be	  applied	  to	  several	  different	  
fields	  of	  science	  and	  technology.	  As	  a	  result	  of	  nanotechnology	  being	  a	  relatively	  new	  field	  
without	  much	  prior	  art,	  researchers	  will	  not	  know	  how	  far	  the	  patent	  extends	  or	  whether	  
their	  actions	  are	  likely	  to	  infringe	  other	  patents.	  
	  
The	  patent	  entitled	  “Angiogenic	  Inhibitory	  Compounds”,	  illustrates	  this	  argument.	  The	  first	  
claim	  reads:	  
	  
1. “A	  method	  of	  prophylactic	  or	  therapeutic	  inhibition	  of	  angiogenesis	  in	  a	  patient,	  
which	  comprises	  administering	  to	  the	  patient	  of	  an	  effective	  amount	  of	  at	  least	  one	  
compound	  sufficient	  to	  inhibit	  or	  prevent	  angiogenesis,	  wherein	  said	  compound	  is	  a	  
dendrimer	  having	  a	  plurality	  of	  terminal	  groups	  and	  wherein	  at	  least	  one	  of	  said	  
terminal	  groups	  has	  an	  anionic-­‐	  or	  cationic-­‐containing	  moiety	  bonded	  or	  linked	  
thereto.”	  282	  
	  
Therefore	  the	  term	  “dendrimer”	  is	  understood	  in	  its	  broadest	  sense	  to	  include	  within	  its	  
scope	  all	  forms	  and	  compositions	  of	  these	  dendrimers.	  Thereby	  granting	  the	  holder	  of	  the	  
patent	  very	  broad	  rights	  over	  basic	  processes	  using	  dendrimers.	  This	  could	  consequently	  
have	  an	  adverse	  affect	  on	  further	  advancements	  from	  being	  patented.	  	  
	  
5) Enablement	  and	  Written	  Description	  (Specification)	  
	  
The	  bulk	  of	  patent	  applications	  comprises	  drawings	  and	  the	  specification	  that	  describes	  and	  
illustrates	  the	  invention,	  explaining	  how	  it	  works	  and	  how	  others	  can	  make	  use	  of	  it.	  	  
In	  terms	  of	  Title	  35	  U.S.C.	  §	  112(a)	  the	  requirements	  for	  the	  specification	  are	  as	  follows:	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a) A	  complete	  written	  description	  
b) Enablement	  	  
c) Best	  mode	  
	  
These	  will	  be	  discussed	  separately:	  
	  
a) Written	  Description	  
	  
A	  comprehensive	  written	  description	  of	  the	  invention	  must	  be	  included	  in	  the	  specification,	  
this	  includes	  complete	  details	  of	  how	  to	  make	  and	  use	  the	  invention.	  The	  purpose	  of	  this	  is	  
to	  ensure	  sufficient	  disclosure	  (is	  provided)	  to	  enable	  a	  person	  having	  ordinary	  skill	  in	  the	  
art	  to	  make	  and	  use	  the	  full	  scope	  of	  the	  claimed	  invention	  without	  undue	  
experimentation.283	  Particularly	  with	  a	  nanotechnology	  inventions,	  the	  inventor	  must	  
provide	  as	  much	  guidance	  as	  possible	  and	  demonstration	  in	  the	  specification,	  indicating	  
clearly	  and	  adequately	  how	  to	  make	  and	  use	  all	  the	  embodiments	  of	  the	  invention	  and	  how	  
all	  these	  embodiments	  may	  differ	  from	  each	  other	  and	  how	  the	  various	  embodiments	  solve	  
particular	  problems.284	  	  
	  
Not	  every	  description	  of	  the	  invention	  requires	  the	  same	  amount	  of	  detail.	  The	  standard	  for	  
written	  description	  is	  highly	  dependant	  on	  the	  complexity	  and	  the	  predictability	  or	  
unpredictability	  of	  the	  invention	  and	  the	  relevant	  field	  in	  which	  it	  is	  based.	  In	  other	  words	  
the	  level	  of	  complexity	  and	  predictability	  of	  the	  art	  will	  dictate	  if	  more	  teaching	  in	  the	  
specification	  is	  required.285	  Predictable	  fields	  such	  as	  traditional	  mechanical	  or	  industrial	  
applications	  will	  require	  a	  lower	  level	  of	  written	  description	  as	  more	  knowledge	  is	  available	  
in	  these	  fields.	  The	  field	  of	  nanotechnology	  on	  the	  other	  hand	  is	  a	  new,	  rapidly	  developing	  
field	  considered	  to	  be	  unpredictable,	  therefore	  more	  detail	  will	  be	  required	  in	  the	  written	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description	  of	  the	  invention	  as	  additional	  guidance	  or	  direction	  may	  be	  needed	  to	  enable	  
this	  more	  complex	  invention.	  By	  providing	  as	  much	  information	  as	  possible	  at	  this	  stage,	  
there	  will	  be	  less	  of	  a	  need	  to	  argue	  the	  knowledge	  of	  the	  person	  skilled	  in	  the	  art	  and	  state	  
of	  prior	  art	  should	  the	  inventor	  find	  himself	  defending	  his	  invention	  in	  court.286	  	  	  
	  
In	  brief	  the	  level	  of	  detail	  required	  varies	  depending	  on	  the	  scope	  of	  the	  claim	  and	  the	  
complexity	  and	  predictability	  of	  the	  relevant	  technology.	  The	  more	  that	  is	  known	  about	  the	  
field	  and	  nature	  of	  the	  invention,	  the	  less	  information	  that	  needs	  to	  be	  provided	  regarding	  
the	  manner	  in	  which	  to	  use	  and	  make	  the	  invention.	  The	  bar	  is	  set	  high	  when	  dealing	  with	  
nanotechnology	  inventions	  in	  meeting	  this	  requirement:	  it	  is	  therefore	  essential	  to	  describe	  
in	  detail	  nano-­‐related	  subject	  matter	  due	  to	  the	  inherent	  nature	  of	  nanotechnology	  which	  
makes	  for	  difficult	  predictions	  of	  properties	  and	  performance	  of	  nanoscale	  structures.	  A	  
nanotechnology	  invention	  can	  comprise	  more	  than	  one	  area	  of	  art	  accordingly	  the	  invention	  
must	  be	  disclosed	  adequately	  to	  allow	  for	  enablement	  in	  the	  various	  distinct	  areas	  of	  art.287	  
In	  other	  words	  a	  person	  skilled	  in	  each	  of	  the	  relevant	  technologies	  must	  be	  able	  to	  make	  or	  
use	  the	  invention	  for	  this	  requirement	  to	  be	  met.	  	  	  
	  
Moreover	  it	  is	  difficult	  to	  determine	  what	  constitutes	  a	  nanoscale	  structure	  due	  to	  the	  lack	  
of	  standardised	  definitions.	  Researchers,	  policy	  makers	  and	  institutions	  all	  struggle	  to	  
determine	  the	  scope	  of	  “nanotechnology”	  and	  it	  can	  be	  argued	  that	  as	  a	  result	  of	  this,	  it	  
requires	  the	  most	  description	  out	  of	  any	  technical	  field.	  Consequently	  it	  is	  important	  to	  use	  
general,	  well-­‐known	  terms	  of	  the	  art	  to	  describe	  the	  invention.	  Any	  unclear	  terms	  should	  be	  
defined;	  concise	  statements	  and	  the	  intended	  scope	  of	  these	  terms	  should	  be	  provided.	  
Due	  to	  the	  possibility	  of	  a	  nanotechnology	  invention	  having	  more	  than	  one	  application	  or	  
use,	  a	  well-­‐drafted	  specification	  supporting	  an	  interdisciplinary	  approach	  is	  essential	  to	  
ensure	  a	  variety	  of	  patentable	  claims	  will	  be	  supported	  and	  protected.288	  However,	  this	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disclosure	  should	  be	  limited	  to	  providing	  only	  enough	  information	  so	  as	  to	  enable	  the	  




Enablement	  is	  closely	  tied	  to	  utility.	  By	  providing	  working	  examples	  of	  the	  invention,	  the	  
applicant	  offers	  evidence	  that	  enablement	  is	  possible.289	  Occasionally	  it	  is	  difficult	  to	  
provide	  working	  examples	  of	  nanotechnology	  inventions,	  reasons	  for	  this	  include;	  the	  
instruments	  necessary	  to	  carry	  out	  the	  invention	  are	  still	  being	  developed	  or	  the	  invention	  
exists	  theoretically	  and	  not	  physically	  in	  a	  lab.	  Consequently	  this	  requirement	  is	  sometimes	  
not	  met,	  especially	  when	  dealing	  with	  unpredictable	  arts.	  Despite	  this	  situation	  it	  is	  possible	  
to	  enable	  with	  a	  prophetic	  example.290	  However,	  working	  examples	  will	  always	  provide	  
stronger	  evidence	  in	  overcoming	  the	  lack	  of	  enablement	  brought	  up	  by	  the	  examiner.	  The	  
applicant	  should	  provide	  as	  many	  working	  examples	  as	  possible	  especially	  when	  the	  claim	  is	  
broad.	  	  
	  
A	  person	  of	  ordinary	  skill	  must	  be	  able	  to	  make	  or	  use	  the	  invention	  without	  undue	  
experimentation,	  this	  means	  the	  skilled	  person	  should	  be	  able	  to	  make	  or	  use	  the	  invention	  
by	  way	  of	  the	  disclosures	  made	  by	  the	  inventor	  in	  the	  specification.291	  There	  are	  three	  tests	  
that	  are	  applied	  to	  determine	  undue	  experimentation:292	  
	  
1. Wands	  Test	  	  
2. Scripps	  Test	  
3. Subset	  Test	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The	  Wands	  Test	  has	  the	  widest	  application	  and	  is	  usually	  applied	  by	  the	  Federal	  Circuit	  in	  
cases	  involving	  new	  technologies,	  it	  comprises	  the	  following	  factors:293	  	  	  
	  
1. Quantity	  of	  experimentation	  required	  based	  on	  the	  content	  of	  disclosure	  provided	  
2. Amount	  of	  direction	  or	  guidance	  provided	  by	  the	  inventor	  
3. Presence	  or	  absence	  of	  working	  example	  
4. Nature	  of	  the	  invention	  
5. State	  of	  prior	  art	  
6. Relative	  skill	  of	  those	  in	  the	  art	  
7. Level	  of	  predictability	  or	  unpredictability	  of	  the	  art	  
8. Breadth	  of	  the	  claim	  
	  
The	  examiner	  cannot	  base	  his	  conclusion	  on	  only	  one	  of	  the	  above	  factors;	  he	  must	  consider	  
the	  evidence	  relating	  to	  each	  of	  these	  factors	  as	  a	  whole	  to	  determine	  whether	  the	  
invention	  is	  enabled.294	  
	  
In	  In	  re	  Kumar,	  the	  Kumar	  invention	  claimed	  aluminum	  oxide	  particles	  that	  were	  nano-­‐sized,	  
ideal	  for	  chemical	  mechanical	  polishing	  of	  ultra	  smooth	  surfaces.295	  The	  examiner	  allowed	  
the	  process	  to	  make	  the	  nanoparticles	  but	  rejected	  the	  product	  claimed	  as	  obvious	  in	  terms	  
of	  §	  103(a).	  Claim	  1	  and	  19	  of	  the	  Kumar	  patent	  reflected	  the	  overlap	  at	  issue:	  	  
	  
“1.	  A	  collection	  of	  particles	  comprising	  aluminum	  oxide,	  the	  collection	  of	  particles	  having	  an	  
average	  diameter	  of	  primary	  particles	  from	  about	  5	  nm	  to	  about	  500	  nm	  and	  less	  than	  
about	  one	  in	  106	  particles	  have	  a	  diameter	  greater	  than	  about	  three	  times	  the	  average	  
diameter	  of	  the	  collection	  of	  particles.	  
	  
19.	  A	  collection	  of	  particles	  comprising	  aluminum	  oxide,	  the	  collection	  of	  particles	  having	  an	  
average	  diameter	  from	  about	  5	  nm	  to	  about	  500	  nm	  and	  a	  distribution	  of	  particle	  sizes	  such	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that	  at	  least	  about	  95	  percent	  of	  the	  particles	  have	  a	  diameter	  greater	  than	  about	  40	  
percent	  of	  the	  average	  diameter	  and	  less	  than	  about	  160	  percent	  of	  the	  average	  
diameter.”296	  
	  
The	  claims	  at	  issue	  were	  directed	  at	  the	  particles	  themselves	  and	  not	  the	  method	  of	  
producing	  these	  particles.	  The	  Board	  of	  Appeals	  rejected	  Kumar’s	  claims	  on	  grounds	  of	  
obviousness	  and	  whether	  cited	  prior	  art	  was	  enabled.	  The	  prior	  art	  patent	  the	  courts	  
referred	  to	  in	  their	  assessment	  of	  the	  later	  patent	  (the	  “Kumar	  Patent”)	  was	  the	  “Rostoker	  
Patent.”	  The	  court	  based	  its	  decision	  on	  mathematical	  calculations,	  thereby	  comparing	  
Kumar’s	  product	  claims	  with	  the	  particles	  described	  in	  the	  Rostoker	  Patent	  in	  order	  to	  
determine	  the	  values	  between	  the	  nanoparticles	  size	  claimed	  and	  the	  prior	  art.297	  The	  
particles	  Kumar	  claimed	  overlapped	  in	  both	  particle	  size	  and	  size	  distribution	  with	  the	  
Rostoker	  particles,	  resulting	  the	  court’s	  decision	  of	  obviousness.	  Kumar	  argued	  the	  Rostoker	  
Patent	  did	  not	  disclose	  the	  method	  the	  Kumar	  patent	  applied	  to	  create	  the	  submicron	  sized	  
particles	  claimed	  in	  the	  Kumar	  invention.	  Therefore	  despite	  the	  Rostoker	  Patent	  disclosing	  a	  
method	  for	  making	  these	  particles,	  it	  was	  not	  the	  same	  method	  adopted	  by	  Kumar	  (i.e.	  laser	  
pyrolysis)298	  	  
	  
The	  Board	  of	  Appeals	  confirmed	  the	  examiners	  rejection	  however	  indicated	  that	  the	  USPTO	  
erred	  in	  their	  argument	  in	  respect	  of	  which	  they	  rejected	  the	  Kumar	  patent	  based	  on	  
obviousness.	  The	  USPTO	  had	  based	  their	  argument	  on	  the	  Rostoker	  Patent	  enabling	  the	  
Rostoker	  invention	  irrespective	  of	  whether	  the	  Rostoker	  Patent	  enabled	  the	  invention	  
claimed	  by	  the	  Kumar	  Patent.	  The	  court	  stated	  that	  in	  terms	  of	  obviousness,	  the	  enquiry	  is	  
based	  on	  whether	  the	  prior	  art	  enables	  a	  person	  skilled	  in	  the	  art	  to	  make	  or	  use	  the	  later	  
claimed	  invention.299	  In	  other	  words	  the	  pertinent	  question	  should	  be	  whether	  the	  Rostoker	  
Patent	  enabled	  a	  person	  of	  ordinary	  skill	  in	  the	  art	  to	  produce	  nanoparticles	  with	  the	  same	  
size	  and	  distribution	  as	  those	  claimed	  by	  Kumar.	  The	  Board	  of	  Appeals	  referenced	  the	  John	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Deere	  case	  in	  that	  obviousness	  is	  a	  legal	  conclusion	  based	  on	  underlying	  facts	  and	  stated	  
that	  a	  prima	  facie	  case	  of	  obviousness	  could	  be	  made	  when	  the	  only	  difference	  between	  the	  
invention	  claimed	  and	  the	  prior	  art	  is	  the	  range	  or	  value	  of	  a	  particular	  variable	  i.e.	  the	  
overlap.	  	  The	  court	  thereby	  concluded	  that	  the	  nanoparticles	  claimed	  by	  Kumar	  overlapped	  
in	  size	  and	  diameter	  with	  those	  claimed	  in	  Rostoker	  Patent.	  
	  
This	  case	  will	  be	  relevant	  to	  an	  applicant	  that	  may	  need	  to	  prove	  his	  nanotechnology	  
invention	  is	  not	  obvious.	  The	  applicant	  could	  argue	  that	  the	  examiner	  cannot	  render	  the	  
invention	  obvious	  if	  the	  prior	  art	  process	  applied	  is	  different	  from	  that	  applied	  in	  the	  later	  
claimed	  invention.	  Furthermore	  if	  the	  prior	  art	  process	  does	  not	  enable	  a	  person	  skilled	  in	  
the	  art	  to	  make	  the	  product	  claimed,	  the	  invention	  will	  not	  be	  obvious.300	  Consequently,	  the	  
difference	  in	  process	  applied	  to	  produce	  the	  invention	  can	  be	  used	  to	  argue	  the	  claim	  of	  
obviousness.	  A	  claim	  will	  not	  be	  obvious	  if	  prior	  art	  fails	  to	  show	  how	  to	  make	  and	  use	  an	  
invention	  at	  nanoscale.301	  	  
	  
c) Best	  Mode	  
	  
The	  inventor	  must	  also	  include	  a	  description	  of	  the	  best	  mode	  of	  the	  invention	  that	  he	  
knows	  at	  the	  time	  of	  filing	  for	  a	  patent,	  i.e.	  a	  description	  of	  what	  the	  inventor	  believes	  is	  the	  
best	  mode	  of	  his	  invention.	  This	  serves	  as	  a	  safeguard	  for	  full	  disclosure,	  thereby	  preventing	  
the	  inventor	  from	  keeping	  the	  best	  mode	  for	  himself	  and	  disclosing	  the	  second-­‐best	  
mode.302	  Examples	  and	  representative	  data	  such	  as	  diagrams,	  figures,	  formulas	  should	  be	  
provided	  to	  support	  the	  best	  mode	  of	  the	  invention.	  	  
	  
By	  disclosing	  the	  technological	  knowledge	  upon	  which	  the	  invention	  is	  based,	  the	  public	  is	  
placed	  in	  “possession”	  of	  what	  the	  inventor	  claims	  as	  his	  invention.	  A	  person	  having	  
ordinary	  skill	  in	  the	  art	  should	  reasonably	  conclude	  from	  this	  disclosure	  that	  the	  inventor	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had	  possession	  of	  claimed	  invention	  at	  the	  date	  the	  patent	  application	  was	  filed.	  The	  patent	  
application	  must	  be	  drafted	  so	  as	  to	  ensure	  the	  written	  description	  and	  enablement	  match	  
the	  breadth	  of	  the	  claims,	  i.e.	  the	  claim	  must	  be	  supported	  by	  the	  specification.303	  	  
	  
The	  patent	  practitioner	  responsible	  for	  drafting	  the	  patent	  application	  should	  be	  aware	  of	  
the	  challenges	  and	  common	  causes	  for	  rejection	  relating	  to	  nanotechnology	  inventions.	  
Broad	  claims,	  difficulty	  to	  prove	  the	  invention	  and	  insufficient	  details	  to	  enable	  the	  
reproduction	  of	  the	  invention	  claimed	  are	  some	  of	  the	  grounds	  in	  respect	  of	  which	  the	  
application	  can	  be	  rejected.	  The	  patent	  practitioner	  should	  apply	  his	  knowledge	  of	  the	  
examination	  process,	  common	  objections	  and	  understanding	  of	  the	  invention	  in	  relation	  to	  
which	  the	  application	  pertains	  in	  order	  to	  ensure	  the	  full	  scope	  of	  coverage	  of	  the	  invention	  
claimed	  is	  protected.	  He	  should	  advise	  and	  guide	  the	  inventor	  on	  any	  issues	  or	  shortfalls	  
that	  may	  need	  to	  be	  addressed	  and	  overcome	  these	  in	  the	  application.	  Furthermore	  the	  
patent	  practitioner	  together	  with	  the	  inventor	  should	  define	  the	  terms	  used,	  include	  all	  of	  
the	  limitations	  of	  the	  invention,	  ensure	  the	  level	  of	  detail	  required	  is	  met	  and	  guarantee	  the	  
specification	  supports	  the	  claim.	  Full	  disclosure	  should	  ensure	  the	  inventor	  does	  not	  claim	  
more	  than	  what	  he	  has	  actually	  invented	  and	  should	  leave	  the	  examiner	  trusting	  the	  validity	  
of	  the	  application.	  In	  instances	  where	  enablement	  is	  not	  satisfied	  but	  utility	  is	  established,	  
the	  patent	  will	  still	  be	  granted.	  For	  example	  where	  a	  person	  skilled	  in	  the	  art	  does	  not	  know	  
how	  to	  effect	  use	  of	  the	  invention.304	  
	  
The	  AIA	  has	  also	  impacted	  the	  provisions	  pertaining	  to	  “best	  mode”	  by	  relaxing	  this	  
requirement.	  A	  patent	  can	  no	  longer	  be	  invalidated	  or	  cancelled	  if	  the	  applicant	  fails	  to	  
disclose	  the	  best	  mode.305	  Consequently	  the	  applicant	  must	  still	  include	  this	  aspect	  of	  his	  
invention	  but	  the	  consequences	  for	  not	  disclosing	  the	  best	  mode	  will	  not	  invalidate	  his	  
application.	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II. EPC	  REQUIREMENTS	  FOR	  A	  PATENT	  
	  
In	  terms	  of	  the	  EPC,	  the	  requirements	  for	  a	  patent	  include;	  1)	  novelty,	  2)	  an	  inventive	  step,	  
and	  3)	  industrial	  application	  (i.e.	  the	  invention	  must	  relate	  to	  technically	  demonstrable	  
functioning	  products	  or	  production	  process	  in	  any	  field	  of	  technology).306	  	  
	  
1) Excluded	  Subject	  Matter	  	  
	  
The	  EPC	  excludes	  the	  following	  from	  being	  patentable:	  discoveries,	  scientific	  theories,	  
mathematical	  methods,	  aesthetic	  creations,	  presentations	  of	  information,	  schemes,	  rules	  
and	  methods	  for	  performing	  mental	  acts,	  playing	  games	  or	  doing	  business	  and	  programs	  for	  
computers.307	  	  
	  
The	  EPO’s	  treatment	  of	  natural	  scientific	  theories	  and	  discoveries	  will	  be	  discussed.	  
	  
a) Scientific	  Theories	  
	  
Referring	  back	  to	  the	  previous	  chapter	  and	  the	  distinction	  made	  between	  nanoscience	  and	  
nanotechnology;	  nanotechnology	  is	  based	  on	  the	  development	  of	  scientific	  research	  
therefore	  without	  further	  developments	  in	  the	  field	  of	  science	  many	  of	  the	  results,	  i.e.	  the	  
inventions,	  would	  not	  have	  been	  possible.	  Consequently	  devices	  and	  processes	  for	  
manufacturing	  that	  are	  based	  on	  scientific	  theories	  can	  be	  patented.	  
	  
The	  purpose	  of	  this	  exclusion	  is	  to	  avoid	  basic	  concepts	  of	  science	  and	  laws	  of	  nature	  from	  
being	  patented	  as	  these	  are	  considered	  to	  be	  part	  of	  the	  public	  domain.	  According	  to	  the	  
Manual	  for	  Examiners	  for	  the	  EPO,	  scientific	  theories	  are	  considered	  to	  be	  a	  more	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generalised	  form	  of	  discoveries.308	  The	  EPO	  has	  not	  defined	  the	  parameters	  of	  what	  either	  
comprise.	  Short	  of	  a	  formal	  definition,	  the	  eligibility	  of	  such	  research	  should	  be	  decided	  by	  
the	  TBA	  on	  a	  case-­‐by-­‐case	  basis	  and	  the	  same	  principles	  should	  apply	  to	  both.	  In	  certain	  
cases	  exceptions	  should	  be	  made	  and	  the	  research	  that	  is	  indispensable	  to	  the	  development	  
of	  nanotechnology	  products	  or	  uses	  should	  receive	  protection	  from	  patent	  law.	  	  
	  
b) Discovery	  versus	  Invention	  	  
	  
In	  contrast	  to	  U.S.	  patent	  law,	  the	  EPC	  expressly	  distinguishes	  between	  these	  two	  concepts.	  
The	  difference	  between	  a	  discovery	  and	  an	  invention	  will	  be	  discussed	  within	  the	  context	  of	  
naturally	  occurring	  products.	  
	  
 Naturally	  Occurring	  Products	  	  
	  
The	  principal	  inquiry,	  in	  terms	  of	  the	  EPC	  when	  dealing	  with	  a	  patent	  application	  that	  claims	  
a	  naturally	  occurring	  product	  as	  the	  invention	  relates	  to	  whether	  the	  invention	  claimed	  is	  
merely	  a	  discovery	  or	  whether	  the	  requirements	  of	  a	  valid	  patent	  have	  been	  met	  in	  terms	  of	  
Article	  52(1).	  An	  interesting	  example	  of	  a	  patentable	  nanotechnology	  invention	  that	  
imitates	  naturally	  occurring	  structures	  is	  that	  of	  CNTs.	  Some	  researchers	  believe	  these	  low	  
energy	  structures	  are	  present	  in	  nature	  as	  self-­‐generating	  structures	  however,	  it	  is	  argued	  
that	  other	  conditions	  are	  necessary	  for	  these	  phenomena	  to	  occur.	  Consequently	  it	  can	  be	  
said	  that	  CNTs	  are	  present	  in	  nature	  but	  no	  factual	  evidence	  exists	  to	  base	  the	  idea	  that	  
there	  are	  naturally	  generated	  CNTs.309	  With	  this	  example	  in	  mind,	  a	  discussion	  relating	  to	  
when	  a	  naturally	  occurring	  substance	  will	  be	  eligible	  for	  a	  patent,	  will	  follow.	  
	  
As	  established	  discoveries	  are	  specifically	  excluded	  from	  the	  EPC,310	  however	  
nanotechnology	  often	  blurs	  the	  line	  between	  what	  a	  discovery	  and	  invention	  comprise,	  as	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naturally	  occurring	  substances	  can	  concurrently	  be	  very	  complex	  nanomachines.311	  Part	  G,	  
Chapter	  II	  of	  The	  Manual	  for	  Examiners	  for	  the	  EPO	  provides;	  if	  a	  new	  property	  of	  a	  known	  
material	  or	  article	  is	  found,	  it	  is	  considered	  to	  be	  a	  discovery	  because	  it	  has	  no	  technical	  
effect	  thereby	  disqualifying	  it	  as	  an	  invention	  within	  the	  meaning	  of	  Article	  52(1).	  However,	  
it	  will	  still	  be	  possible	  to	  patent	  the	  invention	  if	  it	  has	  a	  practical	  use	  and	  all	  the	  
requirements	  for	  a	  valid	  patent	  are	  met	  (i.e.	  novelty,	  inventive	  step	  and	  industrial	  
application).	  Furthermore,	  finding	  a	  previously	  unrecognised	  substance	  occurring	  in	  nature	  
will	  also	  be	  considered	  a	  discovery	  unless	  it	  can	  be	  shown	  to	  produce	  a	  technical	  effect:	  this	  
effect	  may	  be	  patentable.	  For	  example,	  a	  substance	  occurring	  in	  nature	  is	  found	  to	  have	  an	  
antibiotic	  effect.	  Therefore	  the	  mere	  description	  of	  a	  naturally	  occurring	  substance	  denotes	  
a	  discovery	  and	  not	  an	  invention.312	  Discoveries	  are	  pure	  knowledge	  therefore	  only	  when	  
the	  inventor	  applies	  this	  knowledge,	  for	  example	  where	  he	  shows	  a	  way	  of	  providing	  the	  
substance	  and	  not	  merely	  describing	  it,	  can	  this	  applied	  knowledge	  be	  considered	  an	  
invention	  and	  subsequently	  its	  patentability	  determined,	  for	  instance	  where	  the	  inventor	  
discovers	  a	  means	  to	  synthesise	  or	  isolate	  such	  a	  substance	  by	  means	  of	  a	  technical	  
process.313	  Once	  the	  inventor	  is	  capable	  of	  showing	  that	  he	  has	  devised	  a	  means	  to	  
reproduce	  the	  substance,	  i.e.	  the	  invention,	  the	  novelty	  and	  inventiveness	  of	  the	  substance	  
claimed	  as	  the	  invention	  can	  be	  determined.	  The	  inventor	  must	  sufficiently	  describe	  the	  
method	  for	  reproducing	  the	  invention,	  particularly	  within	  the	  field	  of	  chemistry,	  so	  as	  to	  
meet	  the	  requirement	  of	  enablement,	  i.e.	  a	  skilled	  person	  in	  the	  pertinent	  art	  must	  be	  able	  
to	  prepare	  the	  compound	  according	  to	  the	  specification	  of	  the	  claimed	  invention.	  In	  other	  
words	  a	  simple	  disclosure	  of	  only	  the	  chemical	  formula	  would	  not	  suffice	  and	  the	  patent	  
may	  be	  invalidated.314	  Despite	  no	  existing	  separate	  provisions,	  in	  practice,	  chemical	  patents	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will	  contain	  examples	  describing	  the	  manner	  in	  which	  the	  compound	  claimed	  can	  be	  
made.315	  	  
	  
For	  the	  requirement	  of	  novelty	  to	  be	  met,	  neither	  a	  newly	  synthesised	  nor	  naturally	  
occurring	  substance	  can	  be	  part	  of	  the	  state	  of	  art	  at	  the	  time	  the	  invention	  is	  claimed.	  In	  
other	  words	  neither	  could	  previously	  have	  been	  made	  available	  to	  the	  public.	  The	  public’s	  
lack	  of	  knowledge	  of	  the	  existence	  of	  such	  substances	  does	  not	  negate	  its	  existence	  in	  
nature	  prior	  to	  its	  first	  discovery.	  It	  may	  be	  possible	  that	  the	  necessary	  instruments	  or	  
techniques	  were	  not	  available	  to	  enable	  an	  earlier	  discovery	  of	  such	  a	  substance	  from	  being	  
made.	  Once	  novelty	  is	  established	  the	  next	  part	  of	  the	  examination	  is	  to	  determine	  whether	  
the	  process	  to	  reproduce	  the	  substance	  involves	  an	  inventive	  step.	  This	  requirement	  is	  met	  
when	  the	  substance	  is	  artificially	  modified	  and	  this	  modification	  is	  inventive	  or	  the	  isolation	  
and	  synthesis	  of	  the	  newly	  discovered	  natural	  substance	  is	  inventive.316	  The	  standard	  
principles	  relating	  to	  all	  inventions	  when	  determining	  whether	  this	  requirement	  is	  met,	  will	  
apply	  here.	  	  
	  
The	  EPO	  allows	  for	  the	  substance	  itself	  and	  the	  new	  property	  to	  be	  patented.	  In	  other	  
words	  the	  use	  of	  the	  property	  and	  the	  subject	  matter	  that	  contains	  such	  property	  can	  be	  
patented.	  For	  example,	  if	  a	  microorganism	  is	  discovered	  to	  exist	  in	  nature	  and	  to	  produce	  
an	  antibiotic,	  the	  microorganism	  itself	  may	  also	  be	  patentable	  as	  one	  aspect	  of	  the	  
invention.	  The	  applicant	  should	  disclose	  the	  technical	  effect	  and	  claim	  every	  aspect	  of	  the	  
material	  including	  the	  material	  itself,	  supported	  by	  the	  use	  and	  the	  use	  of	  such	  matter	  in	  a	  
particular	  function.317	  By	  providing	  a	  description	  of	  the	  technical	  effect	  the	  inventor	  will	  
rebut	  any	  assumptions	  that	  the	  nanotechnology	  invention	  lacks	  an	  inventive	  step.	  	  In	  
practice,	  the	  TBA	  seems	  to	  set	  a	  further	  requirement	  to	  be	  met	  for	  this	  type	  of	  substance	  to	  
be	  patented,	  namely	  that	  the	  substance	  must	  be	  characterised	  by	  structure,	  generation	  
process	  or	  any	  other	  parameter.	  Additionally	  the	  substance	  must	  be	  new,318	  therefore	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naturally	  occurring	  nanomaterial	  can	  be	  patented	  if	  the	  description	  contains	  a	  
characterisation	  unknown	  and	  not	  previously	  available	  to	  the	  public.	  	  
	  
Lastly	  the	  isolated	  substance	  or	  substance	  that	  is	  produced	  by	  means	  of	  a	  technical	  process	  
must	  be	  susceptible	  of	  industrial	  application	  in	  order	  to	  be	  patentable.319	  This	  too	  must	  be	  
disclosed	  in	  the	  application.	  
	  
Two	  possible	  situations	  seem	  to	  emerge,	  namely	  where	  the	  researcher	  discovers	  a	  structure	  
originating	  in	  nature	  and	  patents	  it	  and	  secondly,	  where	  an	  invention	  is	  generated	  
independently,	  patented	  and	  the	  patent	  later	  declared	  invalid	  due	  to	  the	  discovery	  of	  the	  
same	  structure	  in	  nature.320	  In	  terms	  of	  European	  patent	  law,	  the	  inventor	  is	  not	  obliged	  to	  
disclose	  the	  motivation,	  origin	  or	  creative	  process	  that	  led	  to	  the	  conception	  of	  the	  
invention	  and	  the	  courts	  therefore	  do	  not	  distinguish	  between	  these	  two	  situations.	  
However,	  in	  many	  other	  jurisdictions,	  such	  as	  the	  U.S.,	  the	  inventor	  may	  be	  required	  to	  
disclose	  all	  relevant	  prior	  art	  known	  by	  him	  at	  the	  time	  the	  invention	  was	  made.	  Failure	  to	  
comply	  with	  this	  request	  could	  result	  in	  an	  invalid	  patent.	  It	  is	  therefore	  in	  the	  best	  interest	  
of	  the	  applicant	  to	  refer	  to	  natural	  substances	  when	  describing	  the	  state	  of	  art	  in	  such	  a	  way	  
that	  the	  examiner	  can	  thoroughly	  determine	  the	  novelty	  of	  the	  invention.	  	  	  
	  
In	   conclusion,	   an	   invention	   claiming	   naturally	   occurring	   substances	   as	   its	   subject	   matter	  
should	   display	   unexpected	   and	   or	   new	   technical	   effects.	   The	   patentability	   of	   such	   an	  
invention	  should	  be	  examined	  in	  the	  same	  manner	  and	  meet	  the	  same	  criteria	  as	  any	  other	  
area	  of	  technology.321	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c) Selection	  Inventions	  
	  
The	  EPC	  will	  treat	  patents	  that	  have	  subject	  matter	  overlapping	  with	  prior	  art	  as	  a	  separate	  
category	  of	  inventions;	  they	  are	  referred	  to	  as	  selection	  inventions.322	  This	  overlap	  
constitutes	  a	  selection	  of	  the	  prior	  art	  and	  if	  certain	  other	  conditions	  are	  met,	  the	  patent	  
will	  be	  granted.323	  When	  determining	  whether	  an	  invention	  overlaps	  with	  prior	  art,	  
European	  patent	  law	  focuses	  on	  the	  question	  of	  novelty	  and	  inventive	  step	  and	  not	  the	  
scope	  of	  the	  patent	  (as	  in	  U.S.	  patent	  law).	  When	  dealing	  with	  selection	  inventions,	  a	  three-­‐
part	  enquiry	  is	  applied:	  
	  
1. Determine	  whether	  the	  invention	  claimed	  is	  a	  discovery	  or	  an	  invention;	  
2. Assess	  the	  novelty	  of	  the	  invention	  claimed;	  and	  
3. Determine	  whether	  the	  invention	  has	  an	  inventive	  step.	  
	  
These	  applications	  are	  decided	  on	  a	  case-­‐by-­‐case	  basis.	  The	  same	  principles	  in	  determining	  
novelty	  and	  inventive	  step	  are	  applied	  in	  the	  case	  of	  overlapping	  ranges;	  the	  whole	  content	  
of	  the	  prior	  art	  document	  is	  taken	  into	  account.	  These	  overlapping	  ranges	  include	  numerical	  
ranges	  and	  chemical	  formulae.	  
	  
The	  EPO’s	  approach	  in	  assessing	  novelty	  in	  such	  applications	  involves	  determining	  whether	  
the	  selected	  elements	  are	  disclosed	  in	  an	  individualized	  form	  in	  the	  prior	  art.324	  A	  selection	  
from	  a	  single	  list	  of	  specifically	  disclosed	  elements	  does	  not	  confer	  novelty.	  When	  a	  
selection	  from	  two	  or	  more	  lists	  of	  a	  certain	  length	  is	  made	  in	  order	  to	  arrive	  at	  a	  specific	  
combination	  of	  features	  then	  the	  resulting	  combination	  of	  features,	  not	  specifically	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disclosed	  in	  the	  prior	  art,	  will	  confer	  novelty.325	  This	  is	  referred	  to	  as	  the	  "two-­‐lists	  
principle."	  In	  terms	  of	  the	  Manual	  for	  Examiners	  for	  the	  EPO,	  examples	  of	  selections	  from	  
two	  or	  more	  lists	  include	  the	  selection	  of:	  	  
	  
1. Individual	  chemical	  compounds	  from	  a	  known	  generic	  formula	  whereby	  the	  
compound	  selected	  results	  from	  the	  selection	  of	  specific	  substituents	  from	  two	  or	  
more	  "lists"	  of	  substituents	  given	  in	  the	  known	  generic	  formula.	  The	  same	  applies	  to	  
specific	  mixtures	  resulting	  from	  the	  selection	  of	  individual	  components	  from	  lists	  of	  
components	  making	  up	  the	  prior	  art	  mixture.	  
2. Starting	  materials	  for	  the	  manufacture	  of	  a	  final	  product.	  	  
3. Sub-­‐ranges	  of	  several	  parameters	  from	  corresponding	  known	  ranges.326	  
	  
The	  basis	  for	  this	  possibility	  is	  the	  practice	  that	  a	  prior	  art	  disclosure	  of	  a	  broad	  range	  does	  
not	  necessarily	  represent	  a	  disclosure	  of	  a	  sub-­‐range	  within	  that	  range.	  Novelty	  must	  be	  
determined	  by	  satisfying	  the	  following	  criteria:	  	  
	  
1. The	  overlap	  or	  selected	  sub-­‐range	  must	  be	  narrow	  when	  compared	  to	  the	  larger	  
known	  prior	  art	  range.	  
2. The	  selected	  sub-­‐range	  must	  be	  sufficiently	  far	  removed	  from	  any	  specific	  examples	  
disclosed	  in	  the	  larger	  known	  range	  and	  from	  the	  end	  points	  of	  the	  known	  range.	  
3. The	  selected	  range	  must	  result	  from	  a	  purposive	  selection;	  it	  must	  provide	  a	  new	  
technical	  teaching.	  The	  overlapping	  invention	  must	  be	  another	  invention;	  it	  cannot	  
merely	  embody	  the	  prior	  art	  description.	  It	  must	  not	  be	  an	  arbitrary	  specimen	  from	  
the	  prior	  art.327	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In	  terms	  of	  the	  first	  and	  second	  criteria,	  subjective	  reasoning	  can	  be	  applied	  to	  determine	  
whether	  an	  invention	  involving	  a	  sub-­‐range	  is	  distinguishable	  from	  the	  prior	  art	  
disclosure.328	  The	  meaning	  of	  “narrow”	  and	  "sufficiently	  far	  removed"	  has	  to	  be	  decided	  on	  
a	  case-­‐by-­‐case	  basis.329	  The	  new	  technical	  effect	  occurring	  within	  the	  selected	  range	  may	  
also	  be	  the	  same	  effect	  as	  that	  attained	  with	  the	  broader	  known	  range,	  but	  to	  a	  greater	  
extent.	  The	  third	  criterion	  is	  more	  difficult	  to	  determine	  due	  to	  ambiguity	  and	  uncertainty	  of	  
whether	  the	  technical	  effect	  occurred	  within	  the	  claimed	  sub-­‐range	  or	  the	  entire	  known	  
range.	  If	  a	  technical	  effect	  occurs	  only	  in	  the	  claimed	  sub-­‐range,	  this	  effect	  in	  itself	  does	  not	  
confer	  novelty	  on	  that	  sub-­‐range.	  However	  if	  a	  technical	  effect	  occurs	  in	  the	  selected	  sub-­‐
range	  and	  not	  in	  the	  whole	  of	  the	  known	  range,	  the	  third	  criterion	  is	  met	  and	  it	  can	  be	  
concluded	  that	  the	  invention	  is	  novel	  and	  not	  merely	  a	  specimen	  of	  the	  prior	  art.330	  The	  
state	  of	  the	  art	  must	  reveal	  the	  invention	  to	  the	  skilled	  person	  in	  a	  technical	  teaching	  and	  
must	  display	  new,	  unexpected	  or	  significantly	  improved	  effects	  within	  the	  selected	  sub-­‐
range.331	  In	  other	  words	  this	  sub-­‐range	  has	  been	  selected	  specifically	  to	  provide	  a	  technical	  
advantage	  or	  resolve	  a	  technical	  issue	  in	  prior	  art,	  making	  it	  novel.	  	  
	  
In	  addition	  to	  the	  above	  it	  must	  be	  determined	  whether	  a	  person	  expected	  to	  have	  the	  
necessary	  skill	  and	  knowledge	  in	  the	  applicable	  field	  of	  art	  would	  consider	  applying	  
technical	  teachings	  of	  prior	  art	  in	  the	  range	  of	  overlap.332	  If	  it	  can	  be	  fairly	  assumed	  he	  
would,	  the	  invention	  will	  lack	  novelty.	  Where	  prior	  art	  discloses	  sufficient	  information	  
enabling	  a	  person	  skilled	  in	  the	  art	  to	  replicate	  the	  invention,	  for	  example	  by	  defining	  the	  
particle	  size	  ranges,	  a	  patent	  claim	  within	  that	  range	  will	  be	  considered	  anticipated	  and	  the	  
patent	  will	  be	  invalid.	  Overlapping	  patents	  create	  a	  great	  deal	  of	  uncertainty	  regarding	  IP	  
rights	  and	  constrain	  the	  inventor	  to	  design	  around	  existing	  patents.	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  http://wipo.int/wipo_magazine/en/2011/02/article_0009.html	  (accessed	  02/05/2012)	  	  
	   96	  
In	  Smithkline	  Beecham	  Biologicals,	  the	  TBA	  applied	  the	  above	  criteria	  to	  the	  Smithkline	  
patent	  application	  on	  Hepatitis	  B	  vaccine	  adjuvant	  lipid	  measuring	  60-­‐120	  nm	  to	  determine	  
novelty.333	  An	  earlier	  patent	  had	  a	  similar	  adjuvant	  with	  particles	  measuring	  80-­‐500	  nm.	  The	  
TBA	  found	  the	  Smithkline	  patent	  to	  be	  novel	  because	  the	  overlap	  was:	  
	  
1. Narrow-­‐	  only	  10%	  of	  the	  larger	  range	  in	  the	  earlier	  patent	  	  
2. At	  the	  extreme	  lower	  end	  of	  the	  prior	  art	  range	  
3. Exhibited	  significantly	  improved	  adjuvancy;	  the	  smaller	  particles	  resulted	  in	  an	  
unexpected	  and	  favourable	  shift	  in	  immune	  response.	  
	  
In	  addition	  the	  prior	  art	  gave	  little	  guidance	  on	  how	  to	  prepare	  the	  smaller	  particles.	  A	  
skilled	  person	  who	  followed	  the	  vaccine	  supplier’s	  protocol	  would	  have	  produced	  particles	  
of	  between	  115-­‐952	  nm.	  The	  technical	  teachings	  in	  the	  prior	  art	  were	  therefore	  not	  
considered	  relevant	  to	  Smithkline	  patent	  application.	  	  	  
	  
In	  BASF	  v.	  Orica	  Australia,	  it	  was	  held	  that	  a	  prior	  patent	  held	  by	  BASF,	  disclosed	  polymer	  
nanoparticles	  larger	  than	  111	  nm	  did	  not	  destroy	  the	  novelty	  of	  a	  later	  application	  by	  Orica	  
that	  disclosed	  nanoparticles	  that	  were	  smaller	  than	  100	  nm.	  The	  claims	  of	  the	  case	  in	  
dispute	  were	  as	  follows:	  	  
	  
"1.	  Very	  small	  water-­‐insoluble	  polymer	  particles	  capable	  of	  forming	  a	  stable	  aqueous	  
dispersion	  wherein	  the	  particles	  have	  a	  maximum	  average	  diameter	  of	  100	  nm	  and	  a	  core-­‐
sheath	  structure	  in	  which	  the	  core	  contains	  addition	  polymer	  and	  the	  sheath	  contains	  
hydrophilic	  polyoxyalkylene	  chains	  containing	  an	  average	  of	  6	  to	  40	  oxyalkylene	  units	  per	  
chain	  characterized	  in	  that	  
(a)	  at	  least	  20	  wt%	  of	  the	  polyoxyalkylene	  chains	  are	  at[t]ached	  to	  the	  addition	  polymer	  of	  
the	  core	  via	  covalent	  bonds	  and	  
(b)	  the	  sheaths	  contain	  sufficient	  of	  the	  polyoxyalkylene	  chains	  for	  the	  mass	  ratio	  of	  the	  core	  
to	  sheath	  to	  be	  from	  98:2	  to	  60:40.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  333	  Smithkline	  Beecham	  Biologicals	  v.	  Wyeth	  Holdings	  Corporation	  Boards	  of	  Appeal	  of	  the	  EPO,	  T-­‐0552/00	  (30	  
October	  2003)	  (3D-­‐MPL/SMITHKLINE)	  [At	  25]	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10.	  A	  process	  for	  the	  preparation	  of	  a	  stable	  aqueous	  dispersion	  of	  water-­‐insoluble	  polymer	  
particles	  wherein	  the	  particles	  have	  a	  core-­‐sheath	  structure	  in	  which	  the	  core	  contains	  
addition	  polymer	  and	  the	  hydrophobic	  moiety	  of	  an	  amphiphile	  and	  the	  sheath	  contains	  
solvated	  hydrophilic	  polyoxyalkylene	  chains	  of	  the	  amphiphile	  and	  the	  polyoxyalkylene	  
chains	  have	  an	  average	  of	  6	  to	  40	  oxyalkylene	  units	  per	  chain	  characterised	  in	  that	  
(a)	  ethylenically	  unsaturated	  monomer	  is	  polymerised	  in	  an	  aqueous	  medium	  in	  the	  
presence	  of	  the	  amphiphile,	  
(b)	  the	  hydrophobic	  moiety	  of	  the	  amphiphile	  contains	  at	  least	  one	  ethylenic	  double	  bond	  
(c)	  sufficient	  polyalkylene	  chains	  are	  present	  in	  the	  aqueous	  medium	  to	  ensure	  that	  the	  mass	  
ratio	  of	  the	  cores	  to	  sheaths	  is	  from	  98:2	  to	  60:40	  and	  
(d)	  the	  polymerisation	  is	  initiated	  at	  under	  40°C.	  
	  
14.	  A	  stable	  aqueous	  dispersion	  of	  water-­‐insoluble	  polymer	  particles	  characterized	  in	  that	  
the	  dispersion	  contains	  particles	  as	  claimed	  in	  any	  one	  of	  Claims	  1	  to	  9	  or	  as	  made	  by	  a	  
process	  according	  to	  any	  one	  of	  Claims	  10	  to	  13.	  
	  
15.	  A	  coating	  composition	  containing	  film-­‐forming	  material	  characterized	  in	  that	  the	  film-­‐
forming	  material	  includes	  an	  aqueous	  dispersion	  as	  claimed	  in	  Claim	  14.	  
	  
Claims	  2	  to	  9	  are	  dependent	  on	  Claim	  1,	  Claims	  11	  to	  14	  are	  dependent	  on	  Claim	  10.”	  334	  
	  
BASF	  argued	  Orica’s	  patent	  disclosed	  all	  of	  the	  elements	  claimed	  by	  their	  patent	  thereby	  
destroying	  novelty.	  	  This	  disclosure	  included	  the	  description	  of	  aqueous	  dispersions	  having	  
all	  the	  features	  of	  the	  claimed	  polymer	  particles,	  their	  maximum	  diameter	  and	  the	  number	  
of	  oxyalkylene	  units	  comprised	  the	  sheath	  portion	  of	  the	  particles.	  Additionally,	  all	  the	  
features	  of	  the	  claimed	  method	  of	  preparation,	  including	  polymerization	  initiation	  
temperatures	  of	  below	  40	  °C	  of	  the	  respective	  dispersions	  were	  deemed	  identical	  and	  for	  
that	  reason,	  BASF	  argued	  the	  particle	  sizes	  of	  up	  to	  100	  nm,	  although	  not	  explicitly	  
mentioned	  in	  BASF’s	  patent,	  were	  implicitly	  disclosed	  in	  their	  patent.	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  of	  the	  EPO,	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  January	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BASF	  also	  contended	  that	  Orica’s	  patent	  was	  obvious	  to	  a	  person	  skilled	  in	  the	  art	  and	  
therefore	  lacked	  an	  inventive	  step.	  According	  to	  BASF,	  such	  a	  skilled	  person	  could	  achieve	  
the	  same	  beneficial	  properties	  from	  the	  sterically	  stabilized	  polymer	  dispersion	  by	  selecting	  
from	  the	  set	  of	  reaction	  conditions	  disclosed,	  which	  would	  result	  in	  the	  formation	  of	  
particles	  in	  the	  claimed	  size	  range	  up	  to	  100	  nm.	  In	  other	  words	  there	  was	  no	  inventive	  step	  
in	  achieving	  these	  improved	  smaller	  particles,	  “routine	  operations”	  would	  enable	  the	  same	  
outcome.	  Furthermore	  BASF	  concluded	  the	  results	  from	  Orica’s	  patent,	  i.e.	  improved	  gloss	  
was	  an	  obvious	  and	  immediate	  consequence	  of	  using	  dispersions	  with	  smaller	  particles,	  
which	  resulted	  in	  better	  penetration	  of	  such	  dispersion	  into	  a	  porous	  substrate.	  Therefore	  
Orica’s	  patent	  lacked	  an	  improvement	  of	  the	  rheological	  properties	  of	  the	  claimed	  
dispersions	  and	  the	  glossy	  coatings	  derived	  therefrom.	  
	  
Orica	  argued	  Claim	  1	  was	  novel	  as	  BASF’s	  patent	  did	  not	  disclose	  aqueous	  dispersions	  
comprising	  polymer	  particles	  having	  a	  maximum	  diameter	  of	  100	  nm,	  nor	  did	  it	  disclose	  that	  
the	  sheath	  portion	  of	  the	  particles	  comprised	  polyoxyalkylene	  chains	  containing	  an	  average	  
of	  6	  to	  40	  oxyalkylene	  units	  per	  chain.	  The	  lowest	  particle	  size	  disclosed	  was	  111	  nm	  and	  the	  
polymerisation	  initiation	  temperature	  used	  was	  higher	  than	  the	  maximum	  of	  40	  °C	  
permitted	  by	  Claim	  10	  of	  Orica’s	  patent.	  Furthermore	  they	  argued	  the	  claimed	  subject	  
matter	  was	  inventive	  over	  the	  closest	  prior	  art	  because	  BASF’s	  patent	  did	  not	  disclose	  the	  
solution	  of	  the	  existing	  technical	  problem,	  i.e.	  the	  provision	  of	  sterically	  stabilized	  
dispersions	  having	  an	  improved	  rheological	  properties	  at	  high	  solids	  content	  suitable	  for	  the	  
preparation	  of	  high	  gloss	  coatings.	  	  
	  
The	  appeal	  was	  dismissed,	  BASF	  failed	  to	  show	  their	  patent	  disclosed	  particles	  having	  a	  
maximum	  average	  diameter	  of	  100	  nm	  and	  a	  method	  for	  preparing	  these	  particles.	  The	  
court	  concluded	  the	  smaller	  nanoparticles	  claimed	  by	  Orica’s	  patent	  displayed	  greatly	  
improved	  technical	  properties,	  providing	  a	  significant	  technical	  advantage	  over	  the	  prior	  art	  
and	  this	  difference	  was	  held	  sufficient	  to	  satisfy	  the	  inventive	  step	  requirement.	  The	  Board	  
agreed	  with	  Orica	  in	  that	  the	  subject	  matter	  claimed	  was	  not	  obvious,	  the	  state	  of	  the	  art	  
did	  not	  suggest	  or	  specify	  the	  claimed	  solution	  to	  the	  technical	  problem	  existing	  with	  
respect	  to	  the	  closest	  prior	  art	  and	  a	  skilled	  person	  would	  not	  have	  expected	  the	  results	  
rendered	  by	  the	  claimed	  solution.	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It	  is	  therefore	  possible	  in	  certain	  instances	  for	  an	  invention	  to	  be	  deemed	  valid	  despite	  the	  
invention	  claimed	  containing	  small,	  unplanned	  or	  accidental	  amounts	  of	  a	  material	  or	  
substance	  that	  are	  part	  of	  the	  prior	  art.	  Interestingly,	  selection	  patents	  are	  usually	  rejected	  
by	  the	  German	  Federal	  Court	  of	  Justice	  due	  to	  the	  lack	  of	  novelty	  of	  the	  invention.	  The	  




The	  EPC	  states	  that	  a	  patent	  will	  be	  granted	  for	  any	  invention	  that	  is	  new;	  newness	  is	  
dependant	  on	  the	  invention	  not	  forming	  part	  of	  the	  state	  of	  art.336	  The	  invention	  must	  
possess	  an	  essential	  technical	  feature	  that	  differs	  from	  the	  technical	  features	  in	  the	  state	  of	  
art;	  that	  is	  “everything	  made	  available	  to	  the	  public	  by	  any	  means	  of	  written	  or	  oral	  
description,	  by	  use	  or	  in	  any	  other	  way,	  before	  the	  date	  of	  filing	  of	  the	  European	  patent	  
application.”337	  Consequently	  any	  product,	  substance	  or	  material	  containing	  the	  invention,	  
anywhere	  in	  the	  world	  and	  disclosed	  in	  any	  form	  will	  be	  included	  in	  the	  state	  of	  art.338	  	  
However	  an	  oral	  disclosure	  made	  to	  a	  non-­‐expert	  who	  is	  not	  able	  to	  communicate	  this	  
disclosure	  to	  experts	  or	  exploit	  it	  himself,	  will	  not	  destroy	  the	  novelty.339	  	  	  	  	  
	  
The	  availability	  of	  this	  information	  to	  the	  public	  should	  be	  interpreted	  as	  a	  hypothetical	  
possibility.340	  In	  other	  words	  irrespective	  of	  the	  public’s	  knowledge,	  interest	  or	  motive	  to	  
access	  such	  information,	  if	  it	  was	  available	  to	  the	  public	  at	  the	  time	  the	  patent	  application	  
was	  filed,	  the	  invention	  that	  incorporates	  the	  relevant	  prior	  art	  will	  also	  be	  part	  of	  the	  state	  
of	  art	  and	  the	  invention	  will	  lack	  novelty.	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  336	  EPC	  Art	  54	  (1)	  	  
	  337	  EPC	  Art	  54	  (2)	  	  
	  338	  Otherwise	  referred	  to	  as	  absolute	  novelty.	  (Art	  52(5))	  
339	  Singer	  and	  Stauder	  European	  Patent	  Convention	  107	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  Cisneros	  2009	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Assessing	  novelty	  not	  only	  comprises	  determining	  the	  facts	  available	  to	  the	  public	  before	  
the	  relevant	  date	  (i.e.	  the	  date	  the	  prior	  to	  which	  the	  application	  was	  filed)	  but	  also	  
assessing	  the	  information	  revealed	  by	  the	  technical	  teaching	  to	  a	  person	  skilled	  in	  the	  
pertinent	  art.	  Novelty	  will	  be	  determined	  by	  comparing	  each	  citation	  or	  known	  technical	  
teaching,	  individually	  and	  separately	  to	  the	  invention	  claimed	  (as	  opposed	  to	  determining	  
the	  inventive	  step	  where	  the	  mosaic	  approach	  can	  be	  applied).	  A	  citation	  will	  only	  be	  
considered	  part	  of	  the	  state	  of	  art	  if	  it	  is	  “reproducible”	  i.e.	  a	  person	  skilled	  in	  the	  art	  can	  
reproduce	  the	  invention.341	  	  	  
	  
3) Inventive	  Step	  
	  
The	  EPO	  uses	  the	  “problem-­‐and-­‐solution”	  approach	  to	  determine	  whether	  an	  invention	  
involves	  an	  inventive	  step.	  In	  terms	  of	  this	  approach,	  once	  novelty	  is	  established,	  the	  
invention	  must	  provide	  a	  solution	  to	  a	  technical	  problem	  in	  a	  non-­‐obvious	  way.342	  In	  other	  
words	  the	  invention	  must	  provide	  an	  advance	  over	  the	  state	  of	  art.343	  Assessing	  whether	  a	  
technical	  problem	  exists	  comprises	  the	  following	  structured	  objective	  enquiry:	  	  
	  
1. Firstly	  identify	  the	  prior	  art	  that	  most	  closely	  resembles	  the	  invention;	  	  
2. Determine	  the	  technical	  results	  achieved	  by	  the	  claimed	  invention	  when	  compared	  
to	  the	  closest	  prior	  art,	  i.e.	  define	  the	  technical	  problem;	  	  
3. Determine	  whether	  the	  invention	  claimed	  objectively	  overcomes	  this	  technical	  
problem	  	  (thereby	  ascertaining	  whether	  an	  inventive	  step	  exists);	  	  
4. Lastly,	  it	  must	  be	  determined	  in	  light	  of	  the	  prior	  art	  and	  the	  technical	  problem,	  
whether	  a	  person	  skilled	  in	  the	  pertinent	  art,	  “would	  have	  suggested	  the	  claimed	  
technical	  features	  for	  obtaining	  the	  results	  achieved	  by	  the	  claimed	  invention.”344	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  Singer	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  Convention	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  342	  Singer	  and	  Stauder	  European	  Patent	  Convention	  150	  	  
	  343	  Singer	  and	  Stauder	  European	  Patent	  Convention	  142	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  The	  Proctor	  &	  Gamble	  Company	  v.	  Unilever	  PLC	  /	  Unilever	  N.V.	  Boards	  of	  Appeal	  of	  the	  EPO,	  T-­‐0167/93	  (3	  
May	  1996)	  (Bleaching	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  [At	  4.3.1]	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The	  closest	  prior	  art	  is	  determined	  by	  comparing	  the	  invention	  claimed	  with	  each	  item	  of	  
prior	  art,	  the	  prior	  art	  document	  that	  discloses	  the	  most	  technical	  features	  in	  common	  with	  
the	  claimed	  invention	  will	  be	  used.	  There	  must	  be	  distinguishing	  technical	  features	  in	  order	  
for	  the	  invention	  claimed	  to	  be	  novel	  and	  the	  effects	  achieved	  by	  these	  features	  must	  be	  
compared	  and	  evaluated	  against	  the	  relevant	  prior	  art	  document.	  The	  differences	  will	  be	  
compared	  in	  order	  to	  determine	  whether	  a	  technical	  problem	  exists	  and	  whether	  the	  
claimed	  invention	  will	  provide	  a	  solution	  to	  this	  problem.	  This	  solution	  must	  significantly	  
improve	  the	  relevant	  prior	  art;	  a	  mere	  observation,	  for	  example	  will	  not	  sufficiently	  justify	  
the	  improvement	  as	  an	  invention.	  Furthermore	  this	  improvement	  cannot	  have	  been	  
anticipated	  by	  prior	  art.	  
	  
The	  “could-­‐would”	  test	  is	  applied	  once	  the	  technical	  problem	  to	  be	  solved	  has	  been	  
identified.	  The	  question	  is	  whether	  any	  teaching	  in	  the	  prior	  art	  as	  a	  whole,	  “would”	  (not	  
simply	  could,	  but	  would)	  have	  prompted	  the	  skilled	  person,	  faced	  with	  the	  objective	  
technical	  problem,	  to	  modify	  or	  adapt	  the	  closest	  prior	  art	  while	  taking	  that	  teaching	  into	  
consideration	  and	  thereby	  arriving	  at	  something	  falling	  within	  the	  terms	  of	  the	  claims	  and	  
achieving	  that	  which	  the	  invention	  achieves.	  In	  other	  words	  the	  prior	  art	  must	  have	  
prompted	  the	  skilled	  person	  to	  solve	  the	  technical	  problem.	  It	  is	  not	  simply	  whether	  the	  
skilled	  person	  would	  have	  arrived	  at	  the	  same	  result,	  i.e.	  the	  invention	  that	  solves	  or	  
improves	  the	  problem	  revealed	  by	  closest	  prior	  art	  but	  rather	  whether	  he	  was	  induced	  
towards	  the	  invention.	  This	  incitement	  could	  be	  implicit.	  Furthermore	  the	  skilled	  person	  
must	  have	  addressed	  this	  specific	  problem,	  arriving	  at	  the	  same	  solution	  as	  that	  claimed	  
before	  the	  filing	  or	  priority	  date	  of	  the	  claim	  under	  examination.345	  	  
	  
A	  “skilled	  person”	  for	  these	  purposes,	  is	  a	  person	  having	  a	  comprehensive	  general	  and	  
technical	  level	  of	  knowledge	  in	  the	  relevant	  field	  of	  art.	  He	  has	  no	  inventive	  capability	  and	  is	  
only	  expected	  to	  refer	  to	  close	  or	  neighbouring	  technical	  fields	  in	  order	  to	  determine	  
relevant	  prior	  art.346	  This	  comparison	  is	  different	  to	  that	  of	  novelty	  in	  that	  the	  novelty	  is	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  345	  EPO	  Guidelines	  Part	  G	  
http://documents.epo.org/projects/babylon/eponet.nsf/0/6c9c0ec38c2d48dfc1257a21004930f4/$FILE/guidel
ines_for_examination_2013_part_g_en.pdf	  (accessed	  20/04/2013)	  [Chapter	  VII	  at	  5.3]	  	  	  346	  Singer	  and	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  European	  Patent	  Convention	  144	  and	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determined	  by	  comparing	  the	  prior	  art	  document	  as	  a	  whole	  with	  that	  of	  the	  invention.	  
Inventiveness	  is	  determined	  by	  comparing	  each	  of	  the	  elements	  of	  the	  prior	  art	  with	  the	  
invention,	  elements	  from	  various	  documents	  can	  be	  combined	  (mosaic	  approach).	  The	  most	  
important	  consideration	  is	  whether	  the	  teaching	  acquired	  from	  the	  combination	  of	  features	  
in	  these	  documents	  or	  parts	  thereof	  is	  obvious	  to	  a	  person	  skilled	  in	  the	  art.347	  	  
	  
In	  the	  Blaschim	  case,	  the	  patent	  in	  suit	  related	  to	  a	  process	  of	  preparing	  2-­‐(6'-­‐methoxy-­‐2'-­‐
naphthyl)	  propionic	  acid	  and	  esters	  thereof	  via	  rearrangement	  of	  a	  ketal	  of	  2-­‐halo-­‐1-­‐
(6'methoxy-­‐2'-­‐naphthyl)-­‐propan-­‐1-­‐one.348	  	  	  
	  
Claim	  1	  reads:	  
	  
"1.	  A	  process	  for	  preparing	  products	  having	  general	  formula:	  
FORMULA	  
wherein	  
R	  is	  selected	  from	  the	  group	  comprising	  an	  hydrogen	  and	  a	  bromine	  atom;	  and	  
Y	  is	  selected	  from	  the	  group	  comprising	  an	  alkyl	  radical	  having	  from	  1	  to	  6	  carbon	  atoms,	  a	  
haloalkyl	  radical	  having	  from	  2	  to	  6	  carbon	  atoms	  and	  a	  benzyl	  radical;	  which	  comprises	  the	  
rearrangement	  of	  products	  having	  general	  formula	  
FORMULA	  
wherein	  
R	  has	  the	  above-­‐mentioned	  meaning;	  
R'	  is	  selected	  from	  the	  group	  comprising	  an	  alkyl	  radical	  having	  from	  1	  to	  6	  carbon	  atoms	  
and	  a	  benzyl	  radical;	  
R"	  is	  selected	  from	  the	  group	  comprising	  an	  alkyl	  radical	  having	  from	  1	  to	  6	  carbon	  atoms	  
and	  a	  benzyl	  radical;	  
R'	  and	  R",	  together,	  are	  an	  alkylene	  radical	  having	  2-­‐6	  carbon	  atoms	  which,	  together	  with	  
the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  347	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  348	  BLASCHIM	  S.p.A	  v.	  Syntex	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  International	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  BLASCHIM	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FORMULA	  
group,	  forms	  a	  heterocyclic	  ring;	  
X	  is	  a	  halogen	  atom	  in	  the	  presence	  of	  a	  Lewis	  acid,	  excluding	  Ag+."349	  	  	  
	  
The	  closest	  prior	  art,	  agreed	  to	  by	  the	  parties,	  was	  the	  rearrangement	  reaction	  in	  the	  Ag+	  
ions	  described	  in	  document	  (1).	  This	  document	  relates	  to	  reactions	  for	  preparing	  2-­‐(6'-­‐
methoxy-­‐2'-­‐naphthyl)	  propionic	  acid	  or	  esters	  thereof	  by	  rearrangement	  reaction	  of	  a	  1-­‐(6'-­‐	  
methoxy-­‐2'-­‐naphthyl)-­‐2-­‐halo-­‐propanone	  in	  the	  presence	  of	  a	  silver	  ion.	  Providing	  an	  
alternate	  process	  for	  preparing	  2-­‐(6'-­‐methoxy-­‐2'-­‐naphthyl)	  propionic	  acid	  or	  esters	  thereof	  
was	  considered	  to	  be	  the	  problem	  that	  needed	  to	  be	  solved.	  The	  solution	  was	  to	  convert	  
the	  ketone	  into	  a	  ketal,	  “which	  rearrangement	  reaction	  is	  conducted	  in	  the	  presence	  of	  a	  
metal	  salt	  in	  accordance	  with	  Claim	  1.”350	  	  
	  
The	  Board	  agreed	  in	  light	  of	  the	  examples	  provided	  in	  the	  patent	  in	  suit,	  the	  problem	  was	  
convincingly	  solved	  by	  their	  claimed	  solution.	  Subsequently	  the	  Board	  had	  to	  determine	  
whether	  or	  not	  it	  would	  have	  been	  obvious	  for	  a	  skilled	  person	  to	  substitute	  the	  silver	  (I)	  
salt	  by	  any	  of	  the	  metal	  salts	  mentioned	  in	  Claim	  1	  as	  a	  rearranging	  agent.	  
	  
The	  Appellant	  argued	  a	  skilled	  person	  would	  have	  recognized	  the	  particular	  metal	  salt	  used	  
in	  the	  claimed	  process	  as	  suitable	  for	  promoting	  the	  rearrangement.	  The	  Board	  disagreed,	  
referring	  to	  the	  cited	  documents	  and	  asserting	  no	  such	  suggestion	  or	  description	  had	  been	  
made.	  The	  Board	  went	  on	  to	  say,	  “in	  order	  to	  demonstrate	  obviousness	  it	  is	  not	  sufficient	  
that	  a	  skilled	  person	  could	  have	  interpreted	  document	  (1)	  in	  such	  a	  way	  that	  the	  silver	  (I)	  salt	  
was	  a	  Lewis	  acid,	  but	  it	  must	  be	  made	  credible	  that	  the	  skilled	  person	  would	  have	  
interpreted	  that	  document	  accordingly.	  Because,	  in	  the	  present	  case,	  there	  is	  not	  the	  
slightest	  hint	  in	  the	  prior	  art	  that	  a	  rearrangement	  reaction	  of	  alpha-­‐	  haloalkylarylketones	  or	  
ketals	  thereof	  could	  be	  assisted	  by	  any	  rearranging	  agent	  other	  than	  a	  silver	  salt,	  the	  skilled	  
man	  could	  deduce	  from	  this	  document	  only	  that	  silver	  ions	  were	  necessary	  to	  conduct	  the	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  349	  BLASCHIM	  case	  [At	  II.]	  	  350	  BLASCHIM	  case	  [At	  4.]	  
	  
	   104	  
rearrangement	  reaction	  and	  no	  reason	  can	  be	  seen	  why	  a	  skilled	  person	  would	  have	  
interpreted	  the	  reaction	  in	  such	  a	  way	  that	  the	  silver	  (I)	  ion	  is	  acting	  as	  a	  Lewis	  acid.”351	  
The	  Board	  concluded	  that	  it	  would	  not	  have	  been	  obvious	  to	  a	  skilled	  person	  to	  replace	  the	  
silver	  (I)	  salt	  in	  the	  reaction	  described	  in	  document	  (1)	  by	  any	  Lewis	  acid,	  let	  alone,	  by	  a	  salt	  
of	  one	  of	  the	  specific	  metals	  mentioned	  in	  Claim	  1	  of	  the	  patent	  at	  issue.	  
	  
The	  EPC	  also	  provides	  for	  instances	  when	  a	  previously	  unrecognised	  problem	  is	  discovered	  
and	  solved	  by	  the	  claimed	  invention	  despite	  appearing	  to	  be	  trivial	  and	  obvious	  in	  
retrospect.352	  The	  term	  used	  to	  describe	  this	  type	  of	  solution	  is	  a	  “problem	  invention”	  which	  
may	  be	  patentable	  under	  certain	  circumstances.	  The	  accepted	  understanding	  is	  that	  the	  
duty	  lies	  with	  a	  skilled	  person	  to	  improve	  and	  solve	  problems	  in	  the	  state	  of	  art	  therefore	  if	  
a	  solution	  follows	  in	  the	  course	  of	  routine	  work,	  this	  solution	  will	  generally	  not	  be	  
considered	  inventive.	  However,	  in	  such	  cases	  the	  question	  becomes	  whether	  the	  side	  effect	  
or	  “bonus”	  effect	  was	  expected	  by	  the	  skilled	  person.	  For	  instance	  in	  chemistry,	  “analogy	  
processes	  are	  only	  claimable	  as	  long	  as	  the	  problem,	  i.e.	  the	  need	  to	  provide	  certain	  
patentable	  products	  as	  their	  effect,	  is	  not	  yet	  within	  the	  state	  of	  the	  art.”353	  	  
	  
In	  the	  Rider	  case,	  the	  applicant	  altered	  a	  known	  layered	  tablet,	  containing	  simethicone	  and	  
antacids	  by	  providing	  a	  barrier	  between	  the	  layers	  of	  these	  two	  incompatible	  medicaments.	  
The	  problem	  in	  the	  state	  of	  art	  was	  the	  migration	  of	  silicone	  materials.	  The	  use	  of	  barriers	  
had	  been	  available	  and	  well	  known	  in	  the	  art	  to	  prevent	  interaction	  between	  two	  
incompatible	  ingredients.354	  However	  the	  trend	  in	  the	  art	  was	  to	  avoid	  barriers,	  
consequently	  other	  methods	  in	  the	  state	  of	  the	  art	  had	  been	  successfully	  used	  to	  keep	  
these	  ingredients	  separate.	  The	  effect	  of	  using	  a	  barrier	  to	  solve	  the	  well-­‐known	  problem	  
was	  known.355	  The	  Board	  held	  that	  the	  correct	  enquiry	  would	  not	  be	  whether	  a	  person	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  351	  BLASCHIM	  case	  [At	  4.4.6.]	  	  352	  Rider	  v.	  -­‐	  .	  Boards	  of	  Appeals	  of	  the	  EPO,	  T-­‐0002/83	  (15	  March	  1984)	  (Simethicone	  Tablet)	  [At	  I.]	  
[Hereinafter	  the	  Rider	  case]	  
	  353	  Rider	  case	  [At	  6.]	  	  354	  Rider	  case	  [At	  I.	  and	  II(c)]	  
	  355	  Rider	  case	  [At	  4.]	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skilled	  in	  the	  art	  would	  have	  provided	  the	  barrier	  between	  the	  layers	  but	  rather	  whether	  he	  
would	  have	  done	  so	  with	  the	  expectation	  of	  an	  improved	  or	  advantageous	  effect.	  	  
	  
The	  Board	  discussed	  that	  on	  the	  surface,	  the	  solution	  offered	  by	  inserting	  this	  barrier	  to	  
avoid	  the	  migration	  of	  the	  simethicone	  as	  “satisfactory”	  but	  “devoid	  of	  any	  technical	  effect”	  
and	  therefore	  obvious.356	  However,	  the	  applicants	  had	  discovered	  that	  the	  multilayered	  
tablet	  (the	  Yen	  tablet)	  lead	  to	  unexpected	  and	  substantial	  reduction	  of	  simethicone	  activity.	  
The	  applicant	  could	  not	  have	  expected,	  in	  light	  of	  the	  teaching	  of	  the	  prior	  art,	  the	  effects	  of	  
inserting	  a	  barrier	  in	  the	  multilayered	  tablet.	  On	  this	  basis	  and	  the	  fact	  that	  the	  Yen	  tablet	  
had	  not	  been	  part	  of	  the	  state	  of	  art	  at	  the	  priority	  date	  of	  the	  application,	  the	  Board	  
concluded	  this	  modification	  involved	  an	  inventive	  step.357	  	  
	  
This	  case	  illustrates	  the	  situation	  where	  the	  inventor	  had	  no	  choice	  in	  the	  way	  of	  improving	  
the	  known	  problem	  (the	  Board	  referred	  to	  this	  situation	  as	  a	  “one-­‐way	  street”),	  i.e.	  by	  using	  
a	  barrier,	  which	  was	  a	  known	  alternative,	  but	  also	  thereby	  solving	  an	  unknown	  problem,	  
namely	  the	  reduction	  of	  simethicone	  activity.358	  	  
	  
Other	  indicators	  that	  have	  been	  developed	  by	  the	  EPO	  to	  assist	  in	  determining	  whether	  an	  
inventive	  step	  exists,	  these	  include:359	  	  
	  
1. A	  long	  felt	  need	  
2. Commercial	  success	  
3. A	  surprising	  effect	  or	  unexpected	  result	  	  
4. Prejudices	  in	  the	  art	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  356	  Rider	  case	  [At	  II.	  and	  7.]	  	  357	  Rider	  case	  [At	  V(c),	  7.	  and	  8.]	  	  358	  Rider	  case	  [At	  6.]	  
359	  Singer	  and	  Stauder	  European	  Patent	  Convention	  161	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Evidence	  of	  a	  long-­‐felt	  need	  is	  often	  provided	  when	  no	  developments	  have	  been	  made	  
regarding	  the	  state	  of	  art	  or	  where	  repeated	  unsuccessful	  attempts	  to	  solve	  the	  technical	  
problem	  have	  been	  made	  over	  a	  long	  period	  of	  time.	  However	  the	  need	  must	  be	  general	  
and	  not	  a	  need	  had	  only	  by	  an	  individual.360	  	  
	  
The	  commercial	  success	  of	  the	  invention	  claimed	  is	  an	  additional	  consideration	  to	  
corroborate	  the	  existence	  of	  an	  inventive	  step.	  The	  commercial	  success	  of	  the	  invention	  
must	  originate	  from	  the	  technical	  features	  of	  the	  invention	  and	  not	  from	  other	  sources	  such	  
as	  marketing	  and	  advertising	  the	  invention.361	  However	  according	  to	  the	  jurisprudence	  of	  
the	  TBA,	  even	  if	  the	  commercial	  success	  is	  directly	  attributable	  to	  the	  claimed	  invention,	  this	  
will	  not,	  in	  itself,	  signify	  the	  presence	  of	  an	  inventive	  step.	  Commercial	  success	  is	  secondary	  
indicia	  and	  will	  not	  replace	  the	  objective	  conclusion	  of	  obviousness	  that	  was	  arrived	  at	  by	  
applying	  the	  problem-­‐solution	  approach.362	  	  
	  
Unexpected	  additional	  effects	  can	  be	  indicative	  of	  an	  inventive	  step.363	  The	  “effect”	  must	  
originate	  from	  the	  subject	  matter	  claimed	  and	  should	  not	  be	  treated	  as	  a	  side	  effect	  simply	  
because	  it	  is	  not	  expressly	  stated	  in	  the	  application.364	  However,	  in	  light	  of	  the	  state	  of	  art,	  if	  
this	  effect	  would	  have	  been	  obvious	  to	  a	  person	  skilled	  in	  the	  art,	  for	  instance	  due	  to	  a	  lack	  
of	  alternatives,	  i.e.	  the	  “one	  way	  street”	  situation,	  the	  unexpected	  effect	  that	  occurs	  
together	  with	  the	  expected	  effect	  (that	  which	  is	  expected	  to	  occur	  within	  the	  terms	  of	  the	  
claim),	  will	  be	  considered	  a	  bonus	  effect	  and	  will	  not	  confer	  inventiveness	  on	  the	  claimed	  
subject	  matter.365	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  360	  Singer	  and	  Stauder	  European	  Patent	  Convention	  165	  	  
361	  EPO	  Guidelines	  Part	  G	  
http://documents.epo.org/projects/babylon/eponet.nsf/0/6c9c0ec38c2d48dfc1257a21004930f4/$FILE/guidel
ines_for_examination_2013_part_g_en.pdf	  (accessed	  20/04/2013)	  [Chapter	  Vii	  at	  10]	  	  362	  ILPEA	  S.p.A	  v.	  REHAU	  AG	  &	  Co.	  Boards	  of	  Appeal	  of	  the	  EPO,	  T-­‐0005/91	  (24	  June	  1993)	  (Sealing	  
gasket/ILPEA)	  [At	  4.5]	  
	  363	  Biogen	  v.	  Boehringer	  Ingelheim	  Pharma	  AG	  Boards	  of	  Appeal	  of	  the	  EPO,	  T-­‐0301/87	  (16	  February	  1989)	  
(Alpha-­‐interferons)	  [At	  III	  (iv),	  V	  (d)	  and	  7.12-­‐7.14]	  
364	  Singer	  and	  Stauder	  European	  Patent	  Convention	  164	  	  
365	  Rider	  case	  [At	  6.]	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Prejudices	  in	  the	  art	  is	  an	  indicator	  similar	  to	  that	  of	  “long-­‐felt	  need.”	  References	  will	  be	  
made	  to	  a	  stagnating	  state	  of	  art	  or	  the	  age	  of	  the	  relevant	  citation.	  Only	  a	  generally	  
accepted	  technical	  prejudice	  or	  an	  obstacle	  substantiated	  by	  facts	  will	  be	  considered.	  For	  
instance,	  skilled	  people	  within	  a	  particular	  field	  will	  be	  able	  to	  assess	  whether	  the	  prejudice	  
exists.	  Evidence	  of	  prejudices	  can	  be	  found	  by	  referring	  to	  statements	  in	  standard	  works	  for	  
the	  field	  or	  textbooks	  that	  state	  the	  solution	  of	  the	  invention	  is	  impossible	  or	  overcome	  
with	  disadvantages.	  Relying	  on	  a	  single	  reference	  in	  another	  patent	  document	  that	  the	  
solution	  invention	  could	  not	  be	  achieved	  will	  not	  suffice.366	  
	  
Indicative	  evidence	  has	  a	  secondary	  function,	  i.e.	  an	  applicant	  will	  only	  need	  to	  rely	  on	  
indicative	  evidence	  to	  prove	  an	  inventive	  step	  if	  it	  has	  not	  been	  established	  in	  terms	  of	  the	  
problem-­‐solution	  approach.367	  	  
	  
Inventive	  step	  is	  based	  on	  a	  qualitative	  assessment	  and	  may	  be	  the	  most	  difficult	  
requirement	  to	  satisfy.	  It	  is	  highly	  probable	  that	  issues	  regarding	  nanotechnology	  inventions	  
failing	  to	  meet	  this	  requirement	  will	  be	  raised,	  an	  examiner	  could	  easily	  assume	  the	  
invention	  is	  simply	  the	  miniaturisation	  of	  a	  known	  structure	  i.e.	  where	  the	  size	  of	  a	  known	  
device,	  machine,	  material	  or	  physical	  structure	  is	  reduced	  in	  size.	  The	  mere	  reduction	  in	  size	  
of	  a	  known	  structure	  would	  render	  the	  invention	  obvious	  and	  therefore	  un-­‐patentable.	  
However	  it	  is	  possible	  to	  patent	  the	  miniaturised	  structure	  if	  the	  process	  in	  respect	  of	  which	  
this	  is	  achieved	  is	  novel	  or	  if	  the	  miniaturised	  material	  complies	  with	  the	  following	  factors:	  
	  
1. The	  material	  that	  was	  miniaturised	  displays	  new,	  improved	  or	  unexpected	  
properties	  that	  were	  not	  present	  in	  prior	  art.	  
2. These	  new	  properties	  solve	  an	  unknown	  or	  known	  technical	  problem	  
3. These	  new	  properties	  were	  not	  suggested	  by	  prior	  art,	  and	  
4. A	  person	  skilled	  in	  the	  art	  would	  not	  extrapolate	  teachings	  provided	  by	  prior	  art	  to	  
achieve	  this	  invention.	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  366	  Singer	  and	  Stauder	  European	  Patent	  Convention	  168-­‐	  170	  	  
	  367	  Singer	  and	  Stauder	  European	  Patent	  Convention	  162	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This	  discussion	  is	  illustrated	  well	  in	  Trustees	  of	  the	  University	  of	  Pennslyvania	  v.	  Affymetrix	  
Inc.,	  where	  the	  TBA	  recognized	  the	  general	  interest	  of	  downsizing	  and	  miniaturizing	  in	  the	  
field	  of	  biological	  analytical	  devices.	  The	  Board	  stated	  that	  the	  requirement	  of	  an	  inventive	  
step	  would	  only	  be	  met	  if	  an	  unexpected	  advantage	  or	  technical	  effect	  due	  to	  the	  reduced	  
dimensions	  of	  the	  material	  were	  to	  occur.	  In	  this	  case	  an	  analytical	  method	  differed	  from	  
the	  closest	  prior	  art	  in	  size	  of	  the	  flow	  channels	  for	  a	  specific	  analytical	  fluid.	  By	  reducing	  the	  
size	  of	  these	  flow	  systems,	  including	  flow-­‐inducing	  means	  allowed	  for	  the	  use	  of	  these	  
devices	  in	  diverse	  applications.	  The	  Board	  concluded	  this	  miniaturization	  solved	  the	  
technical	  problem	  existing	  in	  prior	  art	  and	  this	  improvement	  was	  not	  obvious	  in	  light	  of	  the	  
disclosures	  made	  in	  the	  relevant	  prior	  art	  to	  a	  person	  skilled	  in	  the	  pertinent	  art	  nor	  would	  
such	  a	  person	  anticipate	  this	  invention.368	  Therefore	  if	  the	  inventor	  is	  able	  to	  show	  that	  the	  
new	  material	  generates	  distinct	  properties	  that	  were	  not	  anticipated	  by	  prior	  art	  the	  
invention	  will	  not	  be	  considered	  obvious.	  The	  applicant	  should	  specify	  the	  advantageous	  
effects	  of	  the	  invention	  in	  the	  patent	  application,	  providing	  evidence	  of	  the	  closest	  prior	  art.	  
If	  the	  claim	  relates	  to	  a	  chemical	  invention,	  reports	  on	  comparative	  trials	  should	  be	  
provided	  during	  the	  examination	  proceedings	  (and	  opposition	  proceedings).369	  	  	  	  
	  
3) Industrial	  Application	  
	  
In	  terms	  of	  Article	  57	  of	  the	  EPC,	  “an	  invention	  shall	  be	  considered	  as	  susceptible	  of	  
industrial	  application	  if	  it	  can	  be	  made	  or	  used	  in	  any	  kind	  of	  industry,	  including	  agriculture.”	  
This	  requirement	  may	  be	  particularly	  difficult	  for	  the	  inventor	  to	  show	  in	  the	  case	  of	  
nanotechnology	  inventions	  as	  the	  invention	  may	  have	  multiple	  applications	  in	  various	  fields	  
of	  technology.	  With	  most	  of	  nanotechnology	  still	  at	  the	  early	  development	  stages	  
objections	  regarding	  whether	  the	  invention	  is	  merely	  a	  discovery	  may	  be	  raised.	  	  
	  
Thus,	  the	  inventor	  is	  simply	  required	  to	  disclose	  in	  the	  specification	  at	  least	  one	  practical	  
application	  of	  his	  invention	  in	  any	  industrial	  field	  that	  will	  enable	  a	  skilled	  person	  of	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  368	  Trustees	  of	  the	  University	  of	  Pennsylvania.	  v.	  Affymetrix	  Inc.	  T	  0070/99	  (23	  January	  2003)	  (Analytical	  
devices/UNIVERSITY	  OF	  PENNSYLVANIA)	  [At	  I.	  and	  1.3.]	  
	  369	  BLASCHIM	  S.p.A	  v.	  Syntex	  Pharmaceuticals	  International	  Limited	  Boards	  of	  Appeal	  of	  the	  EPO,	  T-­‐0597/92	  (1	  
March	  1995)	  [At	  4.4.7]	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relevant	  art	  to	  use	  or	  make	  the	  invention.370	  There	  can	  be	  more	  than	  one	  known	  use	  by	  the	  
inventor.	  However,	  he	  is	  merely	  required	  to	  disclose	  one	  of	  these	  and	  it	  need	  not	  be	  the	  
best	  one.371	  The	  inventor	  will	  receive	  protection	  for	  the	  infringement	  of	  his	  IP	  rights	  in	  the	  
event	  of	  third	  parties	  trying	  to	  use	  or	  make	  the	  same	  invention	  for	  any	  purpose,	  irrespective	  
of	  whether	  or	  not	  it	  was	  specifically	  disclosed	  by	  the	  inventor.372	  	  
	  
As	  indicated	  above,	  the	  standard	  to	  meet	  the	  requirement	  of	  industrial	  application	  could	  
possibly	  be	  applied	  more	  rigidly	  with	  nanotechnology	  inventions,	  especially	  when	  patent	  
applications	  relate	  to	  inventions	  to	  be	  applied	  for	  nanotechnology	  research.	  The	  applicant	  
may	  need	  to	  provide	  a	  more	  detailed	  disclosure	  with	  an	  extensive	  description	  and	  evidence	  
of	  the	  use	  of	  his	  invention	  in	  such	  cases.	  Recent	  case	  law	  has	  revealed	  the	  interpretation	  of	  
Article	  57,	  as	  adopted	  by	  the	  TBA	  in	  cases	  where	  it	  is	  difficult	  to	  determine	  the	  “industrial	  
applicability”	  of	  the	  invention	  claimed.	  	  
	  
In	  the	  Zymogenetics	  case,	  the	  application	  claimed	  a	  Zcytor1	  receptor	  as	  the	  invention,	  which	  
could	  be	  used	  in	  different	  screening	  methods	  and	  more	  specifically	  to	  "screen	  for	  ligands	  for	  
the	  receptor,	  including	  the	  natural	  ligand,	  as	  well	  as	  agonists	  and	  antagonists	  of	  the	  natural	  
ligand."373	  Unfortunately	  details	  relating	  to	  the	  biochemical	  activity	  and	  cellular	  function	  of	  
the	  Zcytor1	  receptor	  had	  not	  been	  clarified	  in	  the	  application	  resulting	  in	  the	  need	  for	  the	  
Board	  to	  examine	  the	  application	  further.	  The	  Board	  considered	  the	  treatments	  referred	  to	  
in	  the	  application	  and	  as	  a	  result	  of	  these	  applications	  (in	  the	  areas	  of	  rheumatoid	  arthritis,	  
multiple	  sclerosis,	  diabetes	  mellitus,	  etc.)	  being	  plausibly	  in	  relation	  to	  the	  function	  of	  the	  
molecule,	  the	  Board	  was	  able	  to	  clearly	  identify	  a	  therapeutic	  or	  diagnostic	  use	  for	  the	  
invention.	  Consequently	  the	  Zcytor1	  receptor	  and	  moreover	  the	  products	  related	  thereto,	  
i.e.	  the	  extracellular	  Zcytor1	  fragment	  were	  decided	  by	  the	  Board	  to	  have	  “a	  plausible	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
370	  EPC	  Art	  83	  	  
	  371	  Ius	  Mentis	  http://www.iusmentis.com/patents/uspto-­‐epodiff/	  (accessed	  07/12/2012)	  	  372	  Cisneros	  2009	  Nomos	  50	  	  
	  373	  Zymogenetics	  Inc.	  v.	  -­‐	  .	  Boards	  of	  Appeal	  of	  the	  EPO,	  T0898/05	  (3	  March	  2008)	  [At	  15]	  [Hereinafter	  
Zymogenetics	  case]	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application	  in	  an	  industrial	  (medico-­‐pharmaceutical)	  activity”	  thereby	  meeting	  the	  
necessary	  requirements.374	  	  
	  
The	  Board	  discussed	  other	  cases	  such	  as	  the	  Max-­‐Planck-­‐Gesellschaft	  case	  to	  arrive	  at	  their	  
decision.	  In	  respect	  of	  which	  it	  was	  held	  that	  “the	  mere	  fact	  that	  a	  substance	  (e.g.	  a	  
polypeptide)	  can	  be	  made	  in	  some	  way	  does	  not	  necessarily	  mean	  that	  the	  requirements	  of	  
Article	  57	  have	  been	  fulfilled,	  unless	  there	  is	  also	  some	  profitable	  use	  for	  which	  the	  
substance	  can	  be	  employed.”375	  In	  contrast	  to	  the	  previous	  case,	  no	  clear	  role	  was	  identified	  
for	  the	  claimed	  substance	  and	  the	  Board	  stated	  that	  “there	  must	  be	  a	  borderline	  between	  
what	  can	  be	  accepted,	  and	  what	  can	  only	  be	  categorized	  as	  an	  interesting	  research	  result	  
which	  per	  se	  does	  not	  yet	  allow	  a	  practical	  industrial	  application	  to	  be	  identified”	  and	  that	  
“even	  though	  research	  results	  may	  be	  a	  scientific	  achievement	  of	  considerable	  merit,	  they	  
are	  not	  necessarily	  an	  invention	  which	  can	  be	  applied	  industrially.”376	  	  
	  
Therefore	  a	  patent	  will	  not	  be	  granted	  for	  an	  invention	  that	  is	  purely	  speculative	  or	  
theoretical;	  it	  “	  must	  have	  such	  a	  sound	  and	  concrete	  technical	  basis	  that	  the	  skilled	  person	  
can	  recognise	  that	  its	  contribution	  to	  the	  art	  could	  lead	  to	  practical	  exploitation	  in	  industry,	  
i.e.	  to	  a	  concrete	  benefit,	  which	  is	  immediately	  derivable	  directly	  from	  the	  description,	  if	  it	  is	  
not	  already	  obvious	  from	  the	  nature	  of	  the	  invention	  or	  from	  the	  background	  art.	  It	  is	  
necessary	  to	  disclose	  in	  definite	  technical	  terms	  the	  purpose	  of	  the	  invention	  and	  how	  it	  can	  
be	  used	  in	  industrial	  practice	  to	  solve	  a	  given	  technical	  problem,	  this	  being	  the	  actual	  
concrete	  benefit	  or	  advantage	  of	  exploiting	  the	  invention.”377	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  374	  Zymogenetics	  case	  [At	  31] 	  
	  375	  Zymogenetics	  case	  [At	  2];	  Also	  see:	  Max-­‐Planck-­‐Gesellschaft	  zur	  Föderung	  der	  Wissenschaften	  e.V.	  v.	  -­‐	  
Boards	  of	  Appeal	  of	  the	  EPO,	  T870/04	  (11	  May	  2005)	  (BDP1	  Phosphatase/MAX-­‐PLANCK)	  [At	  Headnote] 	  
	  	  376	  Zymogenetics	  case	  [At	  3]	   	  377	  Zymogenetics	  case	  [At	  Headnote:	  1	  and	  5]	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Accordingly	  the	  issue	  as	  to	  whether	  the	  requirement	  of	  Article	  57	  is	  met,	  can	  only	  be	  
decided	  on	  a	  case-­‐by-­‐case	  basis	  and	  in	  relation	  to	  specific	  technical	  circumstances	  such	  as	  
background	  art,	  the	  extent	  of	  the	  disclosure	  and	  post-­‐published	  evidence.378	  	  
	  
4. PROPOSED	  SOLUTIONS	  TO	  OVERCOME	  SOME	  OF	  THESE	  CHALLENGES	  
	  
4.1. Specific	  Legislation	  	  
	  
Due	  to	  the	  complexities	  of	  nanotechnology,	  there	  has	  been	  doubt	  by	  experts	  regarding	  the	  
adequacy	  of	  current	  patent	  law	  provisions.	  This	  uncertainty	  extends	  to	  the	  manner	  in	  which	  
courts	  will	  deal	  with	  nanotechnology	  cases	  that	  appear	  before	  them.	  Critics	  have	  proposed	  
technology	  specific	  legislation	  as	  a	  solution	  for	  all	  things	  nano-­‐related.	  Specific	  legislation	  
would	  regulate	  the	  idiosyncrasies	  of	  this	  new	  technology	  with	  regard	  to	  IP	  law	  and	  risk	  
management.	  It	  is	  argued	  that	  many	  of	  the	  issues	  this	  technology	  raise	  are	  not	  adequately	  
dealt	  with	  within	  the	  scope	  of	  existing	  rules	  and	  regulations	  thereby	  demanding	  the	  need	  




Although	  limited,	  case	  law	  relating	  to	  nanotechnology	  has	  indicated	  that	  the	  CAFC	  will	  
continue	  to	  consistently	  apply	  the	  same	  standards	  they	  have	  in	  the	  past	  when	  confronted	  
with	  “new”	  technologies	  (for	  instance	  biotechnology	  in	  the	  past),	  that	  is	  to	  use	  the	  high	  
standard	  of	  enablement	  which	  is	  determined	  by	  applying	  the	  Wands	  Test.379	  Arguably	  one	  
of	  the	  most	  relevant	  nanotech	  cases	  the	  Federal	  Circuit	  adjudicated	  was	  In	  re	  Kumar,	  in	  
respect	  of	  which	  the	  court	  demonstrated	  its	  treatment	  of	  a	  nanotechnology	  patent.	  Here	  
the	  case	  was	  decided	  on	  procedural	  grounds:	  no	  special	  or	  additional	  rules	  were	  applied.	  It	  
was	  treated	  as	  any	  other	  case	  based	  on	  any	  other	  technology.380	  Therefore	  one	  can	  
conclude,	  based	  on	  the	  case	  law	  discussed	  throughout	  this	  chapter,	  that	  there	  is	  no	  real	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  378	  Zymogenetics	  case	  [At	  20]	  	  	  	  379	  Schwaller	  and	  Goel	  2006	  Nanotech.	  L.	  &	  Bus.	  147-­‐148	  	  
	  380	  In	  re	  Kumar	  418	  F.3d	  1368	  (Fed.	  Cir.	  2005).	  Also	  see:	  Baluch	  2005	  Nanotech.L.	  &	  Bus.	  346	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need	  for	  additional	  rules	  or	  legislation	  when	  nanotechnology	  related	  cases	  are	  the	  subject	  
of	  litigation.	  It	  appears	  the	  rules	  and	  regulations	  of	  patent	  law	  sufficiently	  protect	  




A	  study	  was	  conducted	  within	  the	  context	  of	  Germany	  and	  Europe	  as	  to	  whether	  a	  need	  for	  
nanotechnology	  legislation	  exists.381	  The	  findings	  based	  on	  this	  study	  revealed	  that	  existing	  
patent	  laws	  would	  sufficiently	  address	  any	  of	  the	  issues	  nanotechnology	  may	  present.382	  It	  
also	  commented;	  that	  despite	  patent	  law	  provisions	  having	  been	  developed	  to	  deal	  with	  
comparatively	  simple	  inventions	  these	  provisions	  still	  prove	  adequate	  when	  dealing	  with	  
new	  complex	  technologies.	  Almost	  all	  the	  challenges	  faced	  by	  nanotechnology	  patent	  
applications	  can	  be	  resolved	  within	  the	  parameters	  of	  existing	  laws	  and	  by	  carefully	  and	  
precisely	  drafting	  the	  claims	  of	  the	  patent	  application.	  The	  legal	  provisions	  pertaining	  to	  IP	  
law	  currently	  being	  applied	  to	  this	  new	  technology	  adequately	  cover	  the	  issues	  raised.	  
Therefore	  one	  can	  reasonably	  conclude	  that	  there	  is	  no	  need	  for	  extra	  technology	  specific	  
legislation.	  	  	  	  
	  
It	  is	  therefore	  unlikely	  that	  in	  the	  foreseeable	  future	  such	  legislation	  will	  be	  implemented.383	  
It	  is	  however	  possible	  that	  relevant	  individual	  legislative	  provisions	  may	  be	  “updated”	  to	  
provide	  for	  nano-­‐related	  subject	  matter.384	  	  
	  
4.2. Standard	  Definitions	  
	  
The	  USPTO,	  realising	  the	  need	  to	  improve	  on	  universally	  standardising	  nanotechnology	  
terms	  entered	  into	  trilateral	  discussions	  with	  the	  EPO	  and	  Japanese	  Patent	  Office	  with	  the	  
purpose	  of	  developing	  an	  effective	  and	  consistent	  international	  review	  of	  nanotechnology	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  381	  Beyerlein	  2006	  Nanotech.	  L.	  &	  Bus	  540	  	  382	  Beyerlein	  2006	  Nanotech.	  L.	  &	  Bus	  547-­‐	  549	  	  	  383	  Beyerlein	  2006	  Nanotech.	  L.	  &	  Bus	  548-­‐549	  	  	  384	  Beyerlein	  2006	  Nanotech.	  L.	  &	  Bus	  545	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patent	  applications	  and	  the	  development	  of	  classes	  and	  subclasses.385	  In	  2011,	  the	  
International	  Patent	  Classification	  (IPC)	  system	  introduced	  a	  new	  classification	  system	  to	  be	  
used	  by	  all	  patent	  offices	  worldwide	  for	  the	  uniform	  classification	  of	  nanotechnology.386	  The	  
EPO’s	  Y01N	  tagging	  system	  was	  replaced	  with	  the	  new	  symbol,	  B82B	  and	  B82Y.	  This	  new	  
symbol	  should	  make	  it	  easier	  to	  identify	  and	  retrieve	  relevant	  patent	  documents	  in	  this	  field	  
of	  technology.	  
	  
In	  addition	  to	  these	  large-­‐scale	  efforts	  the	  USPTO	  could	  improve	  on	  Class	  977	  by	  re-­‐
assessing	  the	  definitions	  and	  parameters	  of	  nanotechnology	  terms	  for	  the	  purpose	  of	  clarity	  
and	  certainty	  regarding	  eligible	  subject	  matter.	  The	  retrospective	  classification	  of	  all	  pre-­‐
2004	  nanotechnology	  patents	  could	  be	  another	  initiative	  whereby	  areas	  of	  science	  and	  
technology	  with	  the	  most	  active	  patent	  litigation	  would	  be	  given	  priority.387	  Reviewing	  the	  
patent	  landscape	  will	  remove	  any	  uncertainty	  regarding	  valid	  IP	  rights.	  
	  
In	  2013,	  the	  EPO	  and	  USPTO	  launched	  a	  global	  classification	  system	  for	  patent	  documents;	  
namely	  the	  Cooperation	  Patent	  Classification	  (CPC).	  The	  objective	  of	  the	  CPC	  is	  to	  combine	  
the	  best	  practices	  of	  both	  offices	  and	  create	  a	  common	  and	  internationally	  compatible	  
classification	  system.	  Worldwide	  patent	  examiners	  and	  patent	  users	  will	  be	  able	  to	  conduct	  
patent	  searches	  by	  accessing	  the	  same	  classified	  patent	  document	  collections	  which	  will	  
enhance	  the	  efficiency	  of	  prior	  art	  searches	  by	  eliminating	  unnecessary	  duplication	  of	  
work.388	  
	  
A	  uniform,	  consolidated	  database,	  comprising	  all	  the	  relevant	  prior	  art	  that	  is	  otherwise	  
dispersed	  across	  various	  fields	  would	  significantly	  optimize	  the	  examination	  process.	  By	  
having	  all	  nano-­‐related	  patent	  documents	  in	  one	  place,	  examiners	  are	  less	  likely	  to	  overlook	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  385	  Paradise	  2012	  NJTIP	  185	  	  386	  EPO	  “Nanotechnology:	  A	  Special	  Tagging	  System”	  http://www.epo.org/news-­‐
issues/issues/classification/nanotechnology.html	  (accessed	  31/07/2012)	  	  387	  Paradise	  2012	  NJTIP	  197-­‐198	  
	  388	  European	  Patents	  Office	  “EPO	  and	  USPTO	  Launch	  Cooperation	  Patent	  Classification”	  
http://www.epo.org/news-­‐issues/news/2013/20130102.html	  (accessed	  22/05/2013)	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any	  relevant	  prior	  art,	  which	  in	  turn	  will	  ensure	  the	  validity	  of	  future	  nanotechnology	  
patents.	  
	  
4.3. Training	  the	  Examiners	  
	  
It	  is	  fair	  to	  say	  that	  examiners	  have	  been	  at	  a	  disadvantage	  when	  examining	  the	  substantive	  
requirements	  of	  a	  nanotechnology	  patent	  application.	  The	  need	  for	  proficient	  examiners	  is	  
crucial	  in	  ensuring	  the	  quality	  and	  validity	  of	  granted	  nanotechnology	  patents.	  After	  having	  
received	  criticism	  for	  their	  examiners	  not	  being	  proficient	  in	  the	  field	  of	  nanotechnology,	  
the	  USPTO	  joined	  outside	  professionals	  and	  experts	  to	  aid	  in	  training	  and	  educating	  the	  
examiners	  on	  nanotechnology	  concepts	  and	  terms.	  Having	  a	  better	  understanding	  of	  this	  
science	  will	  assist	  them	  in	  carrying	  out	  more	  specialised	  prior	  art	  searches.389	  	  
	  
By	  appointing	  a	  team	  of	  scientists	  representing	  different	  scientific	  disciplines,	  a	  patent	  
application	  comprising	  more	  than	  one	  disciplinary	  component	  will	  be	  examined	  more	  
efficiently.390	  This	  will	  reduce	  the	  likelihood	  of	  relevant	  prior	  art	  in	  various	  fields	  applicable	  
to	  the	  invention	  from	  being	  overlooked.	  
	  	  
The	  USPTO	  activated	  a	  pilot	  programme	  whereby	  information	  on	  peer-­‐reviewed	  
publications	  and	  research	  in	  the	  public	  domain	  was	  collected.391	  In	  this	  way	  an	  “additional	  
source”	  is	  made	  available	  to	  examiners	  allowing	  them	  to	  locate	  prior	  art	  that	  might	  
otherwise	  not	  have	  been	  located	  during	  a	  typical	  patent	  examination	  process.	  This	  
programme	  was	  effective	  until	  about	  2011.	  A	  similar	  initiative	  should	  be	  activated	  for	  the	  
purpose	  of	  gathering	  information	  from	  outside	  sources,	  including	  agencies,	  companies,	  
researchers	  and	  investors.	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  Paradise	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  IP	  Issues	  http://nanowerk.com/news/newsid=1187.php	  (accessed	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4.4. Drafting	  
	  
a) Information	  Disclosure	  Statement.	  
	  
It	  is	  at	  the	  discretion	  of	  the	  applicant	  to	  submit	  an	  information	  disclosure	  statement,	  
however	  it	  is	  highly	  recommended	  when	  dealing	  with	  nanotechnology	  inventions.	  This	  
disclosure	  is	  considered	  a	  gesture	  of	  good	  faith	  and	  will	  demonstrate	  full	  disclosure	  of	  all	  
information	  known	  by	  the	  inventor	  or	  patent	  practitioner	  at	  the	  time	  of	  the	  patent	  
application.392	  This	  will	  give	  the	  examiner	  a	  better	  understanding	  of	  the	  technology	  and	  the	  
field	  it	  applies	  to	  thereby	  reducing	  the	  risk	  of	  rejection	  based	  on	  an	  otherwise	  superficial	  
search.	  	  
	  
Most	  patent	  applicants	  will	  cite	  other	  patents	  as	  prior	  art	  but	  with	  limited	  prior	  art,	  it	  is	  
suggested	  to	  extend	  the	  search	  to	  include	  scientific	  research	  papers	  and	  other	  published	  
articles.393	  The	  wider	  the	  prior	  art	  search,	  the	  stronger	  the	  patent	  and	  the	  greater	  the	  
probability	  the	  patent	  will	  overcome	  any	  opposition.394	  	  
	  
b) A	  Manual	  for	  Nanotechnology	  Patent	  Applications	  
	  
Patent	  Offices	  could	  develop	  and	  publish	  a	  manual	  for	  prospective	  patent	  applicants,	  
outlining	  guidelines	  as	  to	  the	  standard	  expected	  from	  a	  nanotechnology	  patent	  application.	  
This	  manual	  could	  advise	  the	  applicant	  on	  ways	  to	  circumvent	  some	  of	  the	  issues	  commonly	  
raised	  with	  nanotechnology	  patents.	  	  For	  instance,	  when	  drafting	  the	  application	  how	  the	  
invention	  should	  be	  described	  within	  the	  nanoscale	  range,	  thereby	  creating	  uniformity	  
regarding	  claim	  construction.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  392	  Hicks,	  Grissett	  and	  Brown	  http://www.wcsr.com/resources/pdfs/nano030310.pdf	  (accessed	  04/05/2012)	  
[At	  3]	  
	  393	  Almeling	  2004	  STLR	  ¶12-­‐	  ¶13	  	  
	  394	  Wild	  http://www.iam-­‐magazine.com/issues/article.ashx?g=29c766f2-­‐a9b8-­‐4b94-­‐89d5-­‐d35b9ec8e614	  
(accessed	  31/07/2012)	  [At	  32]	  	  
	   116	  
A	  universal	  reference	  will	  ensure	  nanotechnology	  patent	  applications	  will	  be	  consistently	  
drafted	  according	  to	  these	  high	  standards.	  
	  
c) Limiting	  the	  Scope	  of	  the	  Patent	  	  
	  
As	  discussed,	  nanotechnology	  is	  a	  relatively	  new,	  rapidly	  developing	  and	  a	  multidisciplinary	  
technology,	  where	  patents	  with	  overly	  broad	  product	  claims	  could	  easily	  cause	  serious	  
obstacles	  for	  innovative	  developments	  in	  a	  number	  of	  technological	  fields.	  It	  is	  therefore	  
essential	  that	  the	  scope	  of	  the	  allowed	  patent	  claims	  is	  strictly	  commensurate	  to	  the	  new	  
teaching	  of	  the	  patent,	  as	  enablingly	  disclosed	  in	  the	  patent	  specification.	  If	  this	  rule	  is	  
strictly	  applied	  and	  followed,	  the	  original	  patent	  holder	  will	  only	  be	  in	  position	  to	  control	  
improvements,	  which	  clearly	  use	  that	  teaching.	  In	  many	  cases	  further	  developments	  will	  
"escape"	  the	  claims	  and	  such	  inventions,	  if	  patented,	  will	  be	  treated	  as	  independent.	  
Particular	  attention	  has	  to	  be	  paid	  and	  restrictive	  practice	  followed,	  whenever	  the	  so-­‐called	  
"functional	  claims"	  are	  at	  stake.	  	  
	  
Because	  a	  holder	  of	  a	  product	  patent	  owns	  the	  right	  to	  the	  technology	  claimed	  in	  all	  the	  
industries	  in	  respect	  of	  which	  the	  invention	  can	  be	  applied	  and	  is	  in	  the	  position	  to	  grant	  
licenses	  for	  the	  production	  or	  use	  of	  his	  patent	  in	  any	  of	  these	  various	  fields,	  arguably	  the	  
claims	  could	  be	  limited	  to	  the	  uses	  he	  discloses	  and	  would	  not	  cover	  the	  general	  use	  of	  the	  
product.	  Consequently	  by	  limiting	  the	  protection,	  others	  are	  given	  the	  opportunity	  to	  
develop	  such	  improvements	  and	  further	  innovation	  within	  this	  field	  of	  technology.	  
Furthermore,	  as	  an	  interdisciplinary	  technology	  it	  seems	  increasingly	  appropriate	  to	  apply	  
this	  concept	  of	  limiting	  the	  scope	  of	  the	  patent	  thereby	  reducing	  the	  potentially	  negative	  
impact	  of	  broad	  product	  claims	  on	  R&D	  and	  competition.	  	  
	  
This	  can	  be	  achieved	  in	  cases	  where	  an	  invention	  can	  be	  used	  in	  several	  fields.	  The	  patent	  
holder	  owns	  the	  right	  to	  the	  technology	  claimed	  in	  all	  the	  industries	  in	  respect	  of	  which	  the	  
invention	  can	  be	  applied	  and	  is	  in	  the	  position	  to	  grant	  licences	  for	  the	  production	  or	  use	  of	  
his	  patent	  in	  any	  of	  these	  various	  fields.	  Arguably	  this	  power	  should	  be	  limited	  and	  the	  
patent	  holder	  should	  only	  be	  protected	  in	  relation	  to	  the	  uses	  he	  discloses	  and	  not	  the	  
general	  use	  of	  the	  product.	  By	  limiting	  the	  scope	  of	  the	  patent	  to	  only	  protect	  the	  specific	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use	  or	  uses	  described	  by	  the	  applicant,	  the	  relationship	  between	  the	  scope	  of	  the	  invention	  
and	  the	  rights	  granted	  by	  the	  patent	  will	  be	  improved.	  This	  will	  curb	  overly	  broad	  claims	  
from	  being	  included	  in	  patent	  applications,	  thereby	  achieving	  a	  better	  balance.	  The	  inventor	  
will	  no	  longer	  be	  able	  to	  own	  the	  rights	  to	  general	  concepts	  thereby	  encouraging	  
innovation.	  The	  appropriate	  scope	  for	  a	  nanotechnology	  patent	  is	  likely	  to	  be	  established	  as	  
this	  technology	  matures.	  	  
	  
This	  notion	  is	  further	  supported	  by	  the	  fact	  that	  companies	  will	  only	  invest	  in	  the	  R&D	  of	  
products	  that	  are	  commercially	  and	  economically	  valuable	  therefore	  they	  should	  be	  limited	  
by	  the	  uses	  they	  disclose.395	  Perhaps	  these	  limitations	  should	  only	  apply	  to	  specific	  
nanotechnology	  related	  cases,	  i.e.	  only	  those	  containing	  broad	  product	  claims,	  which	  would	  
have	  a	  negative	  impact	  on	  innovation.	  
	  
4.5. Patent	  Pools	  	  
	  
The	  so-­‐called	  Patent	  Pools	  could	  also	  provide	  some	  improvements.	  In	  reference	  to	  the	  CNT	  
building	  block	  patent	  example,396	  the	  establishment	  of	  a	  “Nanotube	  Patent	  Forum”	  was	  
proposed	  with	  the	  intention	  to	  simplify	  some	  of	  the	  complicated	  and	  unfamiliar	  future	  
patent	  issues	  that	  would	  have	  to	  be	  dealt	  with	  as	  more	  CNT	  based	  products	  are	  produced.	  	  
	  
The	  common	  incentive	  in	  creating	  a	  patent	  pool	  is	  to	  share	  technology.	  Due	  to	  the	  cross-­‐
industry	  application	  of	  nanotechnology	  a	  forum	  could	  bring	  together	  different	  patent	  
holders	  with	  companies	  developing	  and	  manufacturing	  similar	  nano-­‐based	  products,	  
thereby	  regulating	  cost-­‐effective	  licencing	  agreements	  that	  could	  be	  reached	  between	  
manufacturers	  and	  patent	  holders.397	  Participating	  patent	  holders	  could	  agree	  to	  license	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  395	  Cisneros	  2009	  Nomos	  53	  	  	  396	  See:	  Chapter	  1,	  section	  entitled	  “1.	  SOME	  OF	  THE	  CHALLENGES	  OF	  NANOTECHNOLOGY	  IN	  PATENT	  LAW:	  
1.1.	  Patented	  ‘Building	  Blocks’”	  	  	  	  397	  Berger	  Growing	  Nano	  Problems	  http://nanowerk.com/spotlight/spotid=1367.php	  (accessed	  02/05/2012)	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their	  technologies	  to	  one	  another	  in	  terms	  of	  a	  “joint	  licensing	  scheme”	  for	  example.398	  This	  
would	  benefit	  companies	  and	  patent	  seekers	  considering	  investment,	  by	  giving	  them	  insight	  
as	  to	  the	  costs	  involved	  in	  obtaining	  licences	  and	  making	  it	  easier	  for	  them	  to	  navigate	  the	  
complex	  patent	  landscape.399	  	  
	  
International	  collaborations	  seem	  to	  be	  a	  new	  trend	  and	  are	  established	  on	  a	  voluntary	  
basis	  whereby	  information	  and	  technologies	  can	  be	  shared	  by	  various	  technology	  holders	  
who	  appreciate	  the	  benefit	  of	  pooling	  technologies	  instead	  of	  the	  immediate	  advantage	  of	  
restricting	  access	  to	  their	  own	  technology.400	  Such	  collaborations	  will	  allow	  for	  separate	  
patented	  components	  held	  by	  separate	  entities	  to	  be	  joined.	  There	  are	  closed	  patent	  pools	  
whereby	  access	  will	  be	  limited	  to	  the	  technology	  and	  open	  patent	  pools	  where	  the	  converse	  
will	  apply.401	  This	  aspect	  will	  be	  discussed	  further	  regarding	  South	  Africa’s	  participation	  in	  











	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  398	  Wipo	  Magazine	  “Special	  Edition	  World	  Intellectual	  Property	  Day	  2009”	  
http://wipo.int/wipo_magazine/en/pdf/2009/wipo_pub_121_2009_02.pdf	  (accessed	  19/04/2012)	  [At	  6]	  
[Hereinafter	  “WIPO	  Intellectual	  Property	  Day”]	  	  
399	  WIPO	  Intellectual	  Property	  Day	  http://wipo.int/wipo_magazine/en/pdf/2009/wipo_pub_121_2009_02.pdf	  
(accessed	  19/04/2012)	  [At	  6]	  
400	  WIPO	  Intellectual	  Property	  Day	  http://wipo.int/wipo_magazine/en/pdf/2009/wipo_pub_121_2009_02.pdf	  
(accessed	  19/04/2012)	  [At	  4]	  	  401	  WIPO	  Intellectual	  Property	  Day	  http://wipo.int/wipo_magazine/en/pdf/2009/wipo_pub_121_2009_02.pdf	  
(accessed	  19/04/2012)	  [At	  6]	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CHAPTER	  3	  
SOUTH	  AFRICAN	  IP	  AND	  NANOTECHNOLOGY	  
	  
I. SOUTH	  AFRICAN	  PATENT	  LAW	  
	  
This	  chapter	  serves	  to	  uncover	  and	  discuss	  some	  of	  the	  differences	  and	  similarities	  between	  
the	  South	  African	  patent	  system	  and	  those	  of	  more	  developed	  jurisdictions,	  such	  as	  those	  
discussed	  in	  the	  previous	  chapter.	  South	  Africa	  is	  a	  developing	  country	  and	  the	  intention	  of	  
this	  comparison	  is	  to	  determine	  whether	  adopting	  international	  patent	  practices	  would	  
benefit	  the	  quality	  of	  the	  patents	  granted	  in	  South	  Africa	  or	  whether	  the	  current	  patent	  
practices	  suffice,	  especially	  when	  dealing	  with	  more	  complicated	  technologies	  such	  as	  
nanotechnology.	  
	  
1. THE	  PATENT	  APPLICATION	  PROCESS:	  Claim/s	  
	  
1.1. Interpretation	  of	  the	  Claims	  
	  
South	  Africa	  is	  a	  non-­‐examining	  country,	  meaning	  the	  merits	  of	  the	  invention	  claimed	  in	  a	  
patent	  application	  are	  not	  investigated	  when	  the	  patent	  application	  is	  filed.	  Consequently	  
there	  is	  no	  need	  to	  interpret	  and	  determine	  the	  scope	  of	  the	  claims	  at	  this	  stage.	  However	  
once	  granted,	  proceedings	  may	  arise	  challenging	  the	  validity	  of	  the	  patent	  and	  the	  scope	  of	  
the	  claims	  will	  then	  need	  to	  be	  determined	  (i.e.	  in	  post-­‐grant	  proceedings).	  
	  
This	  differs	  greatly	  from	  the	  U.S.	  and	  Europe,402	  both	  adopting	  an	  examining	  system	  
whereby	  the	  scope	  of	  the	  claims	  will	  be	  interpreted	  during	  the	  application	  process	  by	  the	  
examiners.	  Consequently	  aspects	  discussed	  in	  the	  previous	  chapter	  that	  would	  otherwise	  be	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  402	  However	  it	  should	  be	  noted	  that	  South	  Africa	  is	  not	  unique	  in	  this	  regard.	  Developed	  European	  countries	  
such	  as,	  Belgium,	  Italy	  and	  France	  also	  do	  not	  have	  an	  examining	  system.	  Consequently	  the	  national	  patents	  
for	  these	  European	  countries	  are	  not	  examined.	  The	  difference	  with	  South	  Africa	  exists	  in	  the	  extent	  that	  most	  
patents	  granted	  for	  those	  countries	  are	  granted	  by	  the	  EPO	  and	  therefore	  the	  substantive	  patentability	  
requirements	  are	  examined.	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considered	  when	  interpreting	  the	  claims	  of	  a	  patent,	  for	  instance	  the	  prosecution	  history,	  
will	  not	  be	  considered	  in	  post-­‐grant	  proceedings.403	  
	  
Case	  law	  is	  relied	  upon	  to	  determine	  the	  manner	  in	  which	  the	  scope	  of	  the	  claims	  will	  be	  
interpreted.	  The	  current	  approach	  adopted	  by	  the	  courts	  involves	  a	  more	  contextual	  or	  
purposive	  interpretation.	  The	  effect	  of	  this	  shift	  brings	  the	  former	  British	  textual	  
interpretation	  approach,	  referred	  to	  as	  the	  “pith	  and	  marrow”	  approach,404	  closer	  to	  the	  
former	  (i.e.	  before	  the	  harmonization	  with	  European	  patent	  law)	  and	  much	  more	  liberal	  
German	  approach.	  In	  respect	  of	  the	  latter	  approach,	  the	  courts	  applied	  so-­‐called	  “general	  
inventive	  idea”	  to	  determine	  the	  scope	  of	  the	  claims.	  The	  claims	  would	  be	  broadened	  to	  
include	  the	  general	  inventive	  idea	  in	  cases	  where	  the	  description	  and	  the	  claims	  of	  the	  
invention	  contained	  a	  “sufficient	  disclosure”	  to	  allow	  for	  a	  broader	  inventive	  idea	  to	  be	  
protected.405	  	  
	  
A	  relatively	  recent	  judgment	  reflecting	  this	  shift	  can	  be	  found	  in	  the	  Triomed	  case.	  At	  issue	  
was	   the	   infringement	  of	   a	  pharmaceutical	   product406	  containing	  omeprazole	   for	   inhibiting	  
gastric	  secretion.	  The	  oral	  dose	  of	  the	  drug	  is	  intended	  to	  pass	  through	  the	  stomach	  and	  be	  
delivered	  intact	  to	  the	  proximal	  part	  of	  the	  intestine,	  where	  it	  is	  rapidly	  dispersed	  so	  that	  it	  
can	   be	   absorbed	   through	   the	   wall	   of	   the	   intestine	   into	   the	   blood	   stream.	   The	   active	  
ingredient,	  omeprazole,	   is	   acid	   sensitive	  and	   therefore	  encapsulated	   in	  an	  enteric	   coating	  
that	  is	  resistant	  to	  dissolution	  in	  the	  stomach	  (by	  the	  stomach	  acids)	  but	  will	  dissolve	  in	  the	  
proximal	   part	   of	   the	   intestine.	   This	   coating	   is	   commonly	   used,	   however	   it	   is	   also	   acidic,	  
therefore	  to	  ensure	   it	  does	  not	  deteriorate,	   it	   is	  mixed	  with	  an	  alkaline	  compound.	  A	  sub-­‐
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  403	  Brunetti	  and	  Coertzen	  https://www.aippi.org/download/commitees/229/GR229south_africa.pdf	  (accessed	  
13/07/2013)	  [At	  2	  and	  5]	  	  404	  Brunetti	  and	  Coertzen	  https://www.aippi.org/download/commitees/229/GR229south_africa.pdf	  (accessed	  
13/07/2013)	  [At	  3]	  
	  405	  Dr.	  Pagenberg	  http://www.law.washington.edu/casrip/symposium/number8/CM%20-­‐
%20Pagenberg%20CASRIP%20Interpretation%20of%20Patent%20Claims.pdf	  (accessed	  07/10/2013)	  [At	  1]	  	  406	  South	  African	  Patent	  No.	  87/2378	  	  
	   121	  
coating	   layer	   of	   film	   forming	   alkaline	   compounds	   forms	   a	   barrier	   between	   the	   core	   of	  
omeprazole	  and	  the	  enteric	  coating	  thereby	  overcoming	  this	  problem.407	  	  
	  
At	  issue	  was	  the	  composition	  of	  this	  sub-­‐coating	  layer	  film.	  The	  respondent	  imported	  and	  
distributed	  a	  pharmaceutical	  preparation	  known	  as	  Ulzec,	  in	  10g	  and	  20g	  doses,	  which	  
allegedly	  infringed	  this	  patent.	  Claim	  1	  reads:	  
	  
“1.	  An	  oral,	  pharmaceutical	  preparation	  in	  the	  form	  of	  enteric	  coated	  tablets	  or	  pellets,	  
containing	  omeprazole	  as	  the	  active	  ingredient	  characterized	  in	  that	  it	  is	  composed	  of:	  
(a) alkaline	  core	  material	  containing	  omeprazole	  together	  with	  an	  alkaline	  reacting	  
compound,	  or	  an	  alkaline	  salt	  of	  omeprazole	  optionally	  together	  with	  an	  alkaline	  
reacting	  compound,	  and	  
(b) on	  said	  alkaline	  core	  material	  one	  or	  more	  inert	  reacting	  sub-­‐coating	  layers	  
comprising	  tablet	  excipients	  which	  are	  soluble	  or	  rapidly	  disintegrating	  in	  water,	  or	  
polymeric,	  water	  soluble,	  film-­‐forming	  compounds,	  optionally	  containing	  pH-­‐
buffering,	  alkaline	  compounds	  between	  the	  alkaline	  core	  material	  and	  
(c) an	  outer	  layer,	  which	  is	  an	  enteric	  coating.”408	  
	  
The	  active	  alkaline	  core	  of	  the	  respondent’s	  product,	  Ulzec,	  is	  sub-­‐coated	  with	  a	  single	  
compound	  (polyvinyl	  pyrrolidone,	  which	  is	  a	  water	  soluble,	  film-­‐forming	  polymer).	  
Therefore	  the	  allegedly	  infringing	  preparation	  differed	  from	  the	  claimed	  preparation	  only	  in	  
that	  the	  sub-­‐coating	  layer	  contained	  a	  single	  film-­‐forming	  compound.	  The	  question	  then	  
arose	  whether	  the	  applicant	  intended	  to	  exclude	  a	  sub-­‐coating	  consisting	  of	  only	  one	  
compound.	  
	  
In	  the	  court	  a	  quo,	  the	  Commissioner	  of	  Patents	  applied	  a	  purely	  textual	  interpretation	  of	  
the	  claim	  and	  held	  that	  the	  function	  of	  the	  claim	  is	  to	  describe	  the	  scope	  of	  the	  invention	  
claimed	  which	  will	  convey	  the	  limitations	  of	  the	  invention	  to	  others	  thereby	  ensuring	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  407	  Aktiebolaget	  Hässle	  and	  Another	  v.	  Triomed	  (Pty)	  Ltd	  2003	  (1)	  SA	  155	  (SCA)	  [At	  2	  and	  4]	  [Hereinafter	  the	  
Triomed	  case]	  	  408	  Triomed	  case	  [At	  5]	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infringements	  are	  avoided.	  He	  concluded	  that	  the	  patent	  had	  not	  been	  infringed	  because	  if	  
read	  grammatically	  and	  in	  the	  ordinary	  sense,	  the	  words,	  as	  quoted,	  meant	  that	  there	  must	  
be	  a	  plurality	  of	  film-­‐forming	  compounds	  of	  the	  type	  described.	  
	  
On	  appeal	  the	  judge	  disagreed	  with	  this	  literal	  interpretation	  of	  the	  claim	  and	  emphasized	  
the	  importance	  of	  the	  context,	  saying	  that	  “context	  is	  everything,”409	  when	  interpreting	  the	  
claim.	  The	  judge	  referred	  to	  the	  Catnic	  case,410	  in	  which	  Lord	  Diplock	  applied	  the	  purposive	  
approach:	  
	  
“…	  a	  patent	  specification	  is	  a	  unilateral	  statement	  by	  the	  patentee,	  in	  words	  of	  his	  own	  
choosing,	  addressed	  to	  those	  likely	  to	  have	  a	  practical	  interest	  in	  the	  subject	  matter	  of	  his	  
invention	  (i.e.	  ‘‘skilled	  in	  the	  art’’),	  by	  which	  he	  informs	  them	  what	  he	  claims	  to	  be	  the	  
essential	  features	  of	  the	  new	  product	  or	  process	  for	  which	  the	  letters	  patent	  grant	  him	  a	  
monopoly.	  It	  is	  those	  novel	  features	  only	  that	  he	  claims	  to	  be	  essential	  that	  constitute	  the	  so-­‐
called	  ‘‘pith	  and	  marrow’’	  of	  the	  claim.	  A	  patent	  specification	  should	  be	  given	  a	  purposive	  
construction	  rather	  than	  a	  purely	  literal	  one	  derived	  from	  applying	  to	  it	  the	  kind	  of	  
meticulous	  verbal	  analysis	  in	  which	  lawyers	  are	  too	  often	  tempted	  by	  their	  training	  to	  
indulge.	  The	  question	  in	  each	  case	  is:	  whether	  persons	  with	  practical	  knowledge	  and	  
experience	  of	  the	  kind	  of	  work	  in	  which	  the	  invention	  was	  intended	  to	  be	  used,	  would	  
understand	  that	  strict	  compliance	  with	  a	  particular	  descriptive	  word	  or	  phrase	  appearing	  in	  
a	  claim	  was	  intended	  by	  the	  patentee	  to	  be	  an	  essential	  requirement	  of	  the	  invention	  so	  that	  
any	  variant	  would	  fall	  outside	  the	  monopoly	  claimed,	  even	  though	  it	  could	  have	  no	  material	  
effect	  upon	  the	  way	  the	  invention	  worked.”411	  
	  
In	  cases	  of	  infringement,	  the	  infringing	  article	  or	  process	  must	  be	  compared	  to	  the	  language	  
of	  the	  claim;	  “the	  language	  of	  the	  claim	  should	  be	  construed	  purposively,	  so	  as	  to	  extract	  
from	  it	  the	  essence	  or	  the	  essential	  elements	  of	  the	  invention.”412	  The	  judge	  emphasized	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  409	  Triomed	  case	  [At	  1]	  	  410	  Catnic	  Components	  Ltd	  &	  Another	  v.	  Hill	  &	  Smith	  Ltd	  (1982)	  RPC	  183	  (HL)	  [Hereinafter	  the	  Catnic	  case]	  	  	  411	  Triomed	  case	  [At	  8]	  	  412	  Triomed	  case	  [At	  8]	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importance	  of	  the	  context	  when	  interpreting	  the	  language	  used	  in	  any	  document,	  whether	  
it	  is	  “a	  statute,	  or	  a	  contract,	  or,	  as	  in	  this	  case,	  a	  patent	  specification.”413	  The	  words	  should	  
not	  be	  read	  in	  isolation	  but	  viewed	  in	  the	  context	  of	  the	  invention	  as	  a	  whole.	  Claims	  3	  and	  
4	  provide	  as	  follows:	  
	  
“3.	  A	  preparation	  according	  to	  claim	  1	  wherein	  the	  sub-­‐coating	  comprises	  two	  or	  more	  sub-­‐
layers.	  
4.	  A	  preparation	  according	  to	  claim	  3	  wherein	  the	  sub-­‐coating	  comprises	  hydroxypropyl	  
methylcellulose,	  hydroxypropyl	  cellulose	  or	  polyvinylpyrrolidone.”414	  	  
	  
In	  light	  of	  Claims	  3	  and	  4	  the	  judge	  commented	  that	  the	  inventor	  was	  indifferent	  to	  the	  
composition	  of	  the	  sub-­‐coating	  layer	  as	  he	  only	  provided	  that	  it	  must	  have	  the	  functional	  
characteristics	  specified	  in	  the	  claim,	  thereby	  increasing	  doubt	  as	  to	  whether	  the	  inventor	  
intended	  that	  two	  or	  more	  excipients	  or	  compounds	  were	  essential	  elements	  of	  the	  
invention.	  The	  judge	  concluded	  there	  was	  no	  reason	  why	  it	  should	  not	  consist	  of	  any	  one	  of	  
those	  compounds	  alone	  and	  for	  this	  reason	  the	  respondent’s	  product	  did	  infringe	  the	  
patent.415	  	  
	  
1.2. Drafting	  the	  Claims	  
	  
In	  terms	  of	  section	  32(4)	  of	  the	  South	  African	  Patent	  Act,416	  the	  claims	  must	  be	  clear,	  
relating	  to	  a	  single	  invention	  and	  must	  be	  fairly	  based	  on	  the	  matter	  disclosed	  in	  the	  
specification.	  The	  Act	  however	  also	  states	  that	  a	  person	  will	  not	  be	  able	  to	  object	  to	  a	  
patent	  that	  comprises	  more	  than	  one	  invention.417	  In	  addition	  to	  this,	  Regulation	  30	  in	  the	  
Patent	  Regulations	  of	  1978	  can	  be	  referred	  to,	  stating,	  “each	  category	  of	  claims	  (product,	  
process,	  apparatus,	  use	  and	  the	  like)	  shall,	  as	  far	  as	  practicable,	  be	  arranged	  in	  order	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  413	  Triomed	  case	  [At	  1]	  	  414	  Triomed	  case	  [At	  12]	  	  415	  Triomed	  case	  [At	  11	  and	  16]	  
	  416	  Patent	  Act	  57	  of	  1978	  	  417	  Patent	  Act	  57	  of	  1978,	  section	  62	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decreasing	  scope.”	  
	  
There	  are	  no	  standard	  guidelines	  in	  place	  and	  in	  practice	  South	  African	  patent	  attorneys	  
may	  refer	  to	  European	  drafting	  guidelines	  when	  drafting	  a	  patent	  application,	  as	  South	  
African	  patent	  law	  is	  closer	  to	  European	  patent	  law	  than,	  for	  example,	  U.S.	  patent	  law.	  
However	  European	  drafting	  guidelines	  are	  not	  strictly	  adhered	  to.	  This	  approach	  is	  in	  stark	  
contrast	  to	  our	  overseas	  counterparts	  who	  place	  great	  emphasis	  on	  claim	  construction	  so	  as	  
to	  avoid	  any	  uncertainty	  relating	  to	  the	  scope	  of	  the	  patent	  and	  the	  consequences	  that	  
accompany	  a	  poorly	  drafted	  patent	  application.	  	  
	  
As	  discussed	  in	  the	  previous	  chapter,	  there	  is	  extensive	  literature	  relating	  to	  the	  importance	  
of	  claim	  construction	  and	  guidelines	  for	  drafting	  patent	  applications	  so	  as	  to	  maintain	  a	  high	  
standard.	  These	  guidelines	  serve	  to	  ensure	  that	  the	  patent	  application	  is	  drafted	  in	  
accordance	  with	  the	  manner	  in	  which	  it	  will	  be	  examined	  and	  interpreted	  by	  the	  Patent	  
Offices	  or	  courts	  respectively.	  The	  applicant	  must	  describe	  his	  invention	  in	  detail,	  supplying	  
sufficient	  information	  relating	  to	  what	  he	  includes	  as	  his	  invention	  and	  making	  certain	  the	  
scope	  of	  the	  claims	  match	  the	  specification.	  Claim	  construction	  directly	  affects	  the	  validity	  
of	  the	  claims	  and	  the	  extent	  of	  the	  protection	  afforded	  to	  the	  patent	  holder.	  The	  patentee	  
would	  not	  want	  to	  jeopardise	  his	  exclusive	  rights	  due	  to	  inadequately	  drafted	  claims	  (i.e.	  
narrow	  claims)	  or	  by	  using	  overly	  broad	  claims,	  which	  could	  result	  in	  infringement,	  thus	  
illustrating	  the	  need	  for	  a	  claim	  drafting	  policy	  in	  South	  Africa.	  	  
	  
Without	  regulated	  guidelines	  the	  language	  used	  in	  drafting	  the	  patent	  application	  may	  
encompass	  far	  more	  than	  the	  actual	  invention	  can	  enable	  thereby	  increasing	  the	  number	  of	  
claims	  sought	  to	  be	  patented.	  Furthermore	  by	  granting	  a	  patent	  that	  has	  more	  claims	  than	  
warranted	  by	  the	  claimed	  invention	  increases	  uncertainty	  relating	  to	  IP	  rights.	  The	  EPO	  
limits	  the	  number	  of	  claims	  to	  one	  independent	  claim	  in	  the	  same	  category	  in	  the	  patent	  
application.	  The	  USPTO	  sets	  different	  fees	  for	  the	  patents	  that	  have	  more	  than	  one	  
independent	  claim	  in	  the	  same	  patent.	  Independent	  claims	  “stand	  on	  their	  own”	  and	  
contain	  essential	  features	  relating	  to	  the	  invention.	  Independent	  claims	  must	  fulfil	  the	  
substantive	  requirements	  set	  for	  a	  valid	  patent.	  Dependant	  claims	  reference	  former	  claims	  
(i.e.	  it	  can	  refer	  to	  one	  or	  more	  independent	  claims;	  one	  or	  more	  dependant	  claims;	  or	  both	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independent	  claims	  and	  dependent	  claims)	  in	  the	  patent	  and	  will	  be	  interpreted	  in	  light	  of	  
the	  limitations	  included	  in	  the	  claim	  it	  refers	  to.418	  Either	  of	  these	  approaches	  could	  be	  
adopted	  by	  South	  Africa,	  which	  would	  then	  allow	  for	  more	  control	  regarding	  the	  breadth	  
and	  number	  of	  claims	  made	  in	  a	  patent	  application.419	  	  
	  
A	  patent	  application	  should	  be	  drafted	  according	  to	  the	  higher	  standard	  adopted	  by	  
countries,	  such	  as	  those	  discussed	  and	  comply	  with	  international	  standards	  to	  ensure	  a	  
higher	  quality	  of	  patents	  is	  achieved.	  This	  will	  also	  contribute	  to	  the	  priority	  of	  patent	  
applications	  filed	  first	  in	  South	  Africa	  and	  subsequently	  abroad.	  By	  reason	  of,	  differences	  in	  
priority	  applications	  often	  cannot	  be	  remedied	  later	  on.	  The	  applicant	  will	  benefit	  from	  a	  
well-­‐drafted	  application,	  as	  a	  poorly	  drafted	  one	  could	  result	  in	  the	  applicant	  not	  gaining	  
from	  the	  full	  monopoly	  of	  his	  invention.	  	  
	  
2. REQUIREMENTS	  FOR	  A	  VALID	  PATENT	  	  
	  	  
In	  terms	  of	  South	  African	  patent	  law	  the	  requirements	  for	  a	  valid	  patent	  include:	  1)	  novelty,	  
2)	  an	  inventive	  step	  and	  3)	  the	  invention	  must	  be	  capable	  of	  use	  or	  application	  in	  trade,	  
industry	  and	  agriculture.420	  These	  requirements	  are	  not	  dissimilar	  to	  those	  described	  for	  the	  
EPC	  as	  South	  African	  patent	  law	  is	  based	  on	  the	  EPC	  and	  relies	  on	  it	  to	  define	  the	  
undefined.421	  
	  
2.1. Excluded	  Subject	  Matter	  	  
	  
The	  Act	  specifically	  excludes:	  discoveries;	  scientific	  theories;	  mathematical	  methods;	  
schemes,	  rules	  or	  methods	  for	  performing	  mental	  acts,	  playing	  games	  or	  doing	  business;	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  418	  Guidelines	  for	  Examination	  in	  the	  European	  Patent	  Office,	  Part	  F	  “Independent	  and	  Dependent	  Claims”	  
http://www.epo.org/law-­‐practice/legal-­‐texts/html/guidelines/e/f_iv_3_4.htm	  (accessed	  07/10/2013)	  [Chapter	  
IV	  At	  3.4.]	  	  419	  Pouris	  2011	  S	  Afr	  J	  Sci	  9	  
	  420	  Patents	  Act	  57	  of	  1978,	  section	  25	  
	  	  421	  Bellman	  and	  Melendez-­‐Ortiz 	  (eds)	  Trading	  in	  Knowledge	  265	  and	  267	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computer	  programs;	  and	  presentation	  of	  information.422	  However	  section	  25(3)	  creates	  an	  
opportunity	  for	  otherwise	  excluded	  subject	  matter	  to	  be	  protected.	  It	  provides	  for	  any	  
ineligible	  subject	  matter	  from	  being	  treated	  as	  an	  invention,	  “only	  to	  the	  extent	  to	  which	  a	  
patent	  or	  an	  application	  relates	  to	  the	  particular	  thing	  as	  such.”	  Therefore	  it	  is	  possible	  for	  
the	  attorney	  responsible	  for	  drafting	  the	  claim	  to	  draft	  the	  application	  in	  such	  a	  way	  that	  an	  
otherwise	  ineligible	  invention	  may	  satisfy	  section	  25(3).	  For	  example	  by	  describing	  the	  
invention	  as	  a	  “method”	  or	  “process	  comprising	  of	  the	  following	  steps.”423	  Similar	  provisions	  
can	  be	  found	  in	  the	  EPC	  Article	  52(2)	  and	  (3).	  However	  it	  is	  important	  to	  mention	  that	  claim	  
drafting	  by	  itself	  cannot	  achieve	  this.	  	  	  	  
	  
a) Scientific	  Theories	  
	  
The	  EPO’s	  approach	  to	  scientific	  theories	  and	  the	  content	  therein	  can	  be	  referred	  to.424	  	  
	  
In	  summary,	  scientific	  theories	  are	  theories	  based	  on	  discoveries	  and	  discoveries	  are	  based	  
on	  nature’s	  creations.	  Only	  when	  a	  scientific	  theory	  is	  applied	  to	  create	  something,	  can	  that	  
product	  or	  process	  be	  patented.425	  This	  product	  or	  process	  must	  be	  novel,	  involve	  an	  
inventive	  step	  and	  be	  capable	  of	  use	  or	  application	  in	  trade,	  industry	  and	  agriculture.426	  	  
	  
In	  the	  Microsoft	  Corporation	  case,	  the	  invention	  was	  described	  as	  a	  rapid	  method	  for	  
updating	  probability	  distributions	  representing	  players’	  performance.	  This	  was	  achieved	  by	  
creating	  a	  factor	  graph	  and	  message	  passing	  algorithms.	  The	  technical	  effect	  of	  this	  
interaction	  between	  processor	  and	  players	  was	  that	  an	  accurate	  and	  timeously	  computation	  
could	  be	  had,	  allowing	  the	  system	  to	  manage	  millions	  of	  players.	  Although	  EPC	  Article	  52(2),	  
excludes	  all	  mathematical	  methods	  as	  patentable	  subject	  matter,	  it	  was	  argued	  that	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  422	  Patents	  Act	  57	  of	  1978,	  section	  25(2)	  
	  423	  Burrell	  Patent	  and	  Design	  Law	  [At	  1.26.1]	  	  424	  See:	  Chapter	  2,	  section	  entitled	  “II.	  EPC	  REQUIREMENTS:	  1)	  Excluded	  Subject	  matter:	  a)	  Scientific	  Theories”	  	  
	  425	  Burrell	  Patent	  and	  Design	  Law	  [At	  1.26.2]	  	  426	  Microsoft	  Corporation	  v.	  –	  Boards	  of	  Appeals	  of	  the	  EPO,	  T-­‐0042/10	  (28	  February	  2013)	  (Determining	  
relative	  skills/MICROSOFT)	  [At	  2.13.2].	  Also	  see:	  Gale’s	  Application	  [At	  324]	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mathematical	  method	  was	  applied	  to	  the	  measurement	  and	  use	  of	  a	  particular	  data	  
structure	  (i.e.	  the	  players	  skill)	  hence	  the	  mathematics	  was	  not	  purely	  abstract,	  it	  was	  
functional.427	  Claim	  1	  reads:	  
	  
“A	  computer-­‐implemented	  method	  of	  determining	  an	  indication	  of	  the	  relative	  skill	  (205)	  of	  
at	  least	  a	  first	  player	  and	  a	  second	  player	  of	  a	  game	  based	  on	  the	  outcome	  of	  one	  or	  more	  
such	  games	  involving	  those	  players	  said	  method	  comprising	  the	  steps	  of:	  
(i)	  arranging	  a	  processor	  (204)	  to,	  for	  each	  player,	  set	  statistics	  (200)	  describing	  a	  probability	  
distribution	  associated	  with	  skill	  of	  that	  player	  to	  default	  values;	  
(ii)	  at	  the	  processor	  (204)	  receiving	  information	  about	  the	  outcome	  (201)	  of	  one	  of	  the	  
games;	  
(iii)	  arranging	  the	  processor	  (204)	  to	  form	  and	  store	  a	  factor	  graph	  comprising	  variable	  
nodes	  and	  factor	  nodes,	  the	  factor	  nodes	  having	  associated	  calculation	  rules,	  said	  graph	  
being	  formed	  using	  the	  received	  information	  about	  the	  outcome,	  and	  arranging	  the	  
processor	  (204)	  to	  instantiate	  at	  least	  some	  of	  the	  variable	  nodes	  with	  the	  statistics;	  and	  
arranging	  the	  processor	  to	  form	  and	  store	  the	  factor	  graph	  such	  that	  it	  comprises	  a	  plurality	  
of	  first	  groups	  of	  nodes,	  each	  first	  group	  being	  associated	  with	  a	  particular	  player	  and	  
comprising	  nodes	  linked	  in	  series;	  and	  
(iv)	  arranging	  the	  processor	  (204)	  to	  update	  the	  statistics	  associated	  with	  each	  player	  by	  
applying	  message	  passing	  to	  the	  factor	  graph	  using	  the	  calculation	  rules;	  
(v)	  arranging	  the	  processor	  to	  repeat	  the	  process	  of	  updating	  the	  statistics	  as	  further	  game	  
outcomes	  are	  received.”428	  	  
	  
The	  Board	  referred	  to	  Re	  Gale's	  Application,	  although	  this	  case	  presented	  a	  slightly	  different	  
situation;	  Gale	  had	  found	  an	  algorithm	  (or	  particular	  method)	  for	  calculating	  a	  square	  root,	  
which	  he	  had	  implemented	  as	  a	  computer	  program.429	  The	  judge	  stated	  that	  the	  program	  
did	  not	  "embody	  a	  technical	  process	  which	  [existed]	  outside	  the	  computer"	  and	  that	  
although	  the	  computer	  "will	  be	  a	  better	  computer	  when	  programmed	  with	  Gale's	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  427	  Microsoft	  Corporation	  case	  [At	  VIII.]	  	  428	  Microsoft	  Corporation	  case	  [At	  V.]	  	  429	  Gale’s	  Application	  1991	  RPC	  305	  (CA)	  [At	  324-­‐327]	  [Hereinafter	  Gale’s	  Application]	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instructions,"	  it	  did	  not	  "solve	  a	  'technical'	  problem	  lying	  within	  the	  computer."430	  The	  
relevance	  of	  the	  comparison	  between	  these	  two	  cases	  lies	  within	  the	  same	  line	  of	  
questioning	  Lord	  Justice	  Nicholls	  applied	  in	  Re	  Gale’s	  Application,	  i.e.	  what	  is	  and	  what	  is	  not	  
technical	  about	  a	  computer-­‐implemented	  method.	  	  Therefore	  the	  relevant	  enquiry	  is,	  firstly:	  
“what	  does	  the	  method	  as	  a	  whole	  do,	  and	  does	  it	  produce	  an	  overall	  technical	  result?	  The	  
second	  is:	  if	  there	  is	  no	  overall	  technical	  result,	  does	  the	  method	  at	  least	  have	  a	  technical	  
effect	  within	  the	  computer?	  If	  both	  questions	  are	  answered	  in	  the	  negative,	  no	  technical	  
problem	  has	  been	  solved	  and	  there	  can	  be	  no	  inventive	  step.”431	  In	  line	  with	  this	  enquiry	  the	  
Board	  concluded	  the	  method,	  as	  defined	  in	  Claim	  1,	  did	  not	  involve	  an	  inventive	  step.432	  
Reasons	  for	  this	  were	  attributed	  to	  the	  fact	  that	  the	  aim	  of	  keeping	  players	  interested	  in	  the	  
game	  and	  assessing	  and/or	  comparing	  their	  performance	  did	  not	  solve	  a	  technical	  problem	  
existing	  in	  the	  state	  of	  art.	  Moreover	  the	  representation	  of	  performance	  by	  probability	  
distributions	  and	  the	  updating	  of	  them	  were	  mathematical	  methods	  (which	  are	  excluded	  in	  
terms	  of	  EPC	  Article	  52(2)).433	  Finally,	  the	  “processor”	  was	  the	  only	  technical	  feature	  in	  the	  
claim,	  which	  would	  have	  been	  obvious	  to	  a	  skilled	  person	  who	  had	  the	  task	  of	  implementing	  
the	  method	  to	  use	  a	  computer	  processor.434	  The	  method	  described	  involved	  the	  collection	  
of	  large	  amounts	  of	  data	  and	  the	  carrying	  out	  calculations	  on	  it,	  however,	  computer	  
processors	  were	  designed	  to	  achieve	  this	  hence	  it	  would	  have	  been	  obvious	  to	  use	  them	  for	  
his	  purpose.435	  	  
	  
b) Discovery	  versus	  Invention	  	  
	  
South	  Africa	  adopts	  the	  EPO’s	  approach	  regarding	  discoveries.	  That	  which	  exists	  in	  nature	  is	  
pure	  knowledge;	  it	  exists	  irrespective	  of	  man’s	  knowledge	  of	  it	  and	  cannot	  be	  invented	  only	  
discovered.	  However	  this	  knowledge,	  if	  applied	  to	  create	  a	  product	  or	  process	  (i.e.	  if	  applied	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  430	  Gale’s	  Application	  1991	  RPC	  305	  (CA)	  [At	  327]	  Also	  see:	  Microsoft	  Corporation	  case	  [At	  2.13.1]	  	  431	  Microsoft	  Corporation	  case	  [At	  2.13.2]	  	  	  432	  Microsoft	  Corporation	  case	  [At	  2.19]	  	  433	  Microsoft	  Corporation	  case	  [At	  2.14]	  	  434	  Microsoft	  Corporation	  case	  [At	  2.15]	  	  435	  Microsoft	  Corporation	  case	  [At	  2.16]	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practically)	  the	  discovery	  could	  constitute	  an	  invention.436	  In	  order	  for	  the	  discovery	  and	  
method	  to	  be	  protected	  it	  must	  also	  fulfil	  the	  substantive	  requirements	  for	  a	  valid	  patent.437	  
	  
c) Selection	  Inventions	  
	  
In	  terms	  of	  South	  African	  patent	  law	  no	  express	  provisions	  or	  case	  law	  appears	  to	  exist	  
relating	  to	  selection	  inventions.	  Selection	  inventions	  are	  not	  treated	  as	  a	  separate	  category	  
of	  patents	  and	  therefore	  one	  can	  assume	  the	  standard	  patentability	  criteria	  to	  determine	  
the	  validity	  of	  the	  patent	  will	  be	  applied	  equally	  in	  all	  cases.	  	  
	  
If	  we	  refer	  back	  to	  the	  previous	  chapter,	  the	  USPTO	  does	  not	  recognise	  selection	  inventions	  
as	  a	  separate	  category	  of	  inventions	  resulting	  in	  the	  same	  treatment	  of	  all	  inventions.438	  In	  
contrast,	  the	  EPO	  treats	  this	  as	  a	  separate	  category	  and	  adopts	  special	  rules	  in	  such	  
applications.439	  Consequently	  South	  African	  courts	  should	  adopt	  the	  same	  approach	  as	  that	  
of	  the	  USPTO	  in	  determining	  the	  validity	  of	  any	  invention	  claimed	  in	  a	  patent	  application.	  
	  
The	  advantages	  of	  addressing	  this	  issue	  on	  either	  a	  local	  or	  international	  level	  could	  provide	  
greater	  certainty	  regarding	  the	  treatment	  of	  these	  types	  of	  inventions	  by	  referring	  to	  clear	  
and	  consistent	  standards.440	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  436	  Burrell	  Patent	  and	  Design	  Law	  [At	  1.26.2].	  Also	  see:	  
	  Microsoft	  Corporation	  v.	  –	  Boards	  of	  Appeals	  of	  the	  EPO,	  T-­‐0042/10	  (28	  February	  2013)	  (Determining	  relative	  
skills/MICROSOFT)	  [At	  2.13.2]	  and	  Gale’s	  Application	  [At	  324]	  	  437	  Burrell	  Patent	  and	  Design	  Law	  [At	  1.26.2	  and	  1.25.12]	  	  438	  See:	  Chapter	  2,	  section	  entitled:	  “	  I.	  USPTO	  REQUIREMENTS:	  1)	  Excluded	  Subject	  matter:	  c)	  Selection	  
inventions”	  	  	  439	  See:	  Chapter	  2,	  section	  entitled:	  “II.	  EPC	  REQUIREMENTS:	  1)	  Excluded	  Subject	  matter:	  c)	  Selection	  
inventions”	  	  	  440	  It	  is	  therefore	  seemingly	  necessary	  to	  develop	  an	  international	  policy	  to	  deal	  with	  these	  types	  of	  inventions	  
and	  harmonise	  existing	  practices.	  This	  could	  be	  achieved	  by:	  	  
A. If	  recognised	  as	  a	  separate	  category	  of	  inventions:	  	  
1) Provision	  of	  a	  definition	  of	  “selection	  inventions”,	  including	  applicable	  fields	  of	  technology.	  In	  
other	  words	  will	  selection	  inventions	  be	  limited	  to	  specific	  fields	  of	  technology,	  such	  as	  
chemical	  and	  pharmaceutical	  fields	  or	  will	  all	  fields	  of	  technology	  be	  included.	  
2) Implementation	  of	  special	  rules	  or	  guidelines,	  for	  example:	  
 Standards	  to	  determine	  the	  novelty	  and	  inventiveness	  of	  a	  selection	  invention	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2.2. Novelty	  
	  
The	  product	  or	  process	  claimed	  as	  the	  invention	  must	  be	  new.	  “Newness”	  is	  established	  by	  
determining	  whether	  the	  invention	  forms	  part	  of	  the	  state	  of	  art	  immediately	  before	  the	  
priority	  date	  of	  that	  invention.441	  The	  “state	  of	  art”	  includes	  all	  matter	  that	  has	  been	  made	  
available	  to	  the	  public	  before	  the	  priority	  date	  of	  the	  patent,	  whether	  in	  South	  Africa	  or	  
elsewhere	  in	  the	  world,	  by	  written	  or	  oral	  description,	  by	  use	  or	  in	  any	  other	  way.442	  
Therefore	  South	  Africa	  follows	  the	  absolute	  novelty	  norm,	  i.e.	  “public”	  extends	  beyond	  
South	  African	  borders.443	  Furthermore	  it	  includes,	  matter	  contained	  in	  a	  patent	  application	  
in	  South	  Africa,	  which	  is,	  or	  will	  become,	  open	  to	  public	  inspection	  and	  where	  such	  matter	  
has	  an	  earlier	  priority	  date	  than	  that	  of	  the	  invention.444	  Consequently	  in	  the	  case	  of	  two	  
pending	  applications	  that	  relate	  to	  the	  same	  invention,	  the	  earlier	  application	  can	  be	  used	  
to	  destroy	  the	  novelty	  of	  the	  later	  application.	  A	  granted	  patent	  may	  be	  revoked	  if	  the	  
invention	  does	  not	  fulfil	  the	  patentability	  requirements	  in	  terms	  of	  section	  25.445	  	  	  
	  
The	  specific	  manner	  in	  which	  the	  disclosure	  occurs	  is	  irrelevant	  as	  the	  Act	  uses	  broad	  terms,	  
i.e.	  by	  way	  of	  written	  or	  oral	  description	  (section	  25(6)).	  The	  prior	  disclosure	  can	  take	  place	  
in	  any	  way	  preceding	  the	  date	  of	  filing	  the	  patent	  application	  but	  must	  include	  all	  of	  the	  
claimed	  novel	  features	  relating	  to	  the	  invention	  in	  order	  for	  this	  disclosure	  to	  destroy	  the	  
novelty	  of	  the	  invention	  claimed.446	  Furthermore	  no	  distinction	  is	  made	  regarding	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 Additional	  disclosures	  regarding	  the	  advantageous	  features	  of	  a	  selection	  invention	  and	  
instances	  where	  evidence	  to	  this	  effect	  must	  be	  produced.	  	  
B. If	  not	  recognised	  as	  a	  separate	  category	  of	  inventions:	  consensus	  regarding	  the	  equal	  treatment	  of	  all	  
inventions	  in	  respect	  of	  patentability	  criteria.	  	  	  441	  Patents	  Act	  57	  of	  1978,	  section	  25(5)	  	  442	  Patents	  Act	  57	  of	  1978,	  section	  25(6)	  
	  443	  Pechacek	  http://web.wmitchell.edu/cybaris/wp-­‐content/uploads/2012/09/Pechacek.pdf	  (accessed	  
03/07/2013)	  [At	  201]	  
	  444	  Patents	  Act	  57	  of	  1978,	  section	  25(7)	  	  445	  Patents	  Act	  57	  of	  1978,	  section	  61(c)	  	  	  	  446	  WIPO	  “Study	  on	  Patents	  and	  the	  Public	  Domain”	  
http://www.wipo.int/edocs/mdocs/mdocs/en/cdip_4/cdip_4_3_rev_study_inf_2.pdf	  (accessed	  12/07/2013)	  
[At	  59]	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person	  responsible	  for	  making	  the	  disclosure:	  it	  can	  be	  the	  inventor,	  applicant	  or	  an	  outside	  
person.447	  	  
	  
Certain	  instances	  are	  provided	  for	  when	  a	  disclosure	  will	  not	  affect	  or	  destroy	  the	  novelty	  of	  
the	  invention	  claimed;	  namely	  where	  knowledge	  was	  acquired	  or	  disclosure	  or	  use	  was	  
made	  prior	  to	  the	  filing	  date	  without	  the	  knowledge	  or	  consent	  of	  the	  inventor	  prior	  to	  the	  
priority	  date,	  provided	  the	  applicant	  files	  the	  application	  with	  reasonable	  diligence	  after	  
learning	  of	  the	  disclosure	  and	  “as	  a	  result	  of	  the	  invention	  being	  worked	  in	  the	  Republic	  by	  
way	  of	  reasonable	  technical	  trial	  or	  experiment	  by	  the	  applicant	  or	  patentee	  or	  the	  
predecessor	  in	  title	  of	  the	  applicant	  or	  patentee.”448	  The	  technical	  trial	  or	  experimentation	  
must	  be	  “reasonable”,	  in	  other	  words	  excessive	  and	  open	  disclosures	  would	  destroy	  the	  
novelty	  of	  the	  invention.	  	  
	   	  
2.3. Inventive	  Step	  
	  
An	  invention	  will	  have	  an	  inventive	  step	  if	  it	  “is	  not	  obvious	  to	  a	  person	  skilled	  in	  the	  art,	  
having	  regard	  to	  any	  matter	  which	  forms,	  immediately	  before	  the	  priority	  date	  of	  any	  claim	  
to	  the	  invention,	  part	  of	  the	  state	  of	  the	  art..."449	  The	  state	  of	  art	  will	  include	  subject	  matter	  
disclosed	  in	  a	  pending	  application	  within	  South	  Africa	  and	  an	  invention	  used	  secretly	  but	  on	  
a	  commercial	  scale	  in	  South	  Africa.450	  The	  criteria	  described	  in	  the	  context	  of	  the	  EPO’s	  
approach	  will	  be	  applicable	  here.451	  An	  invention	  will	  only	  have	  an	  inventive	  step	  if	  it	  
overcomes	  any	  technical	  problems	  facing	  the	  prior	  art.452	  If	  a	  patented	  invention	  is	  found	  to	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  447	  Dr.	  Gerntholtz	  Inc.	  	  http://www.gerntholtz.com/services/south-­‐african-­‐clients/patents#.UZy5SKX5ndk	  
(accessed	  22/05/2013)	  	  	  448	  Patents	  Act	  57	  of	  1978,	  section	  26(a)	  and	  (b)	  	  	  449	  Patents	  Act	  57	  of	  1978,	  section	  25(10)	  	  450	  Patents	  Act	  57	  of	  1978,	  section	  25(10),	  section	  25(7)	  and	  (8)	  	  451	  See:	  Chapter	  2,	  section	  entitled:	  “II.	  EPC	  REQUIREMENTS:	  3)	  Inventive	  Step”	  	  452	  	  See:	  Microsoft	  Corporation	  v.	  –	  Boards	  of	  Appeals	  of	  the	  EPO,	  T-­‐0042/10	  (28	  February	  2013)	  (Determining	  
relative	  skills/MICROSOFT)	  [At	  2.13.2].	  Also	  see:	  Gale’s	  Application	  [At	  324]	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be	  obvious,	  the	  patent	  will	  be	  revoked.453	  	  
	  
In	  Ensign-­‐Bickford	  case,	  the	  Court	  discussed	  the	  traditional	  three-­‐step	  test	  applied	  to	  
determine	  obviousness	  in	  relation	  to	  the	  South	  African	  patent	  no.	  79/3210	  entitled,	  "Low-­‐
energy	  fuse	  consisting	  of	  a	  plastic	  tube	  the	  inner	  surface	  of	  which	  is	  coated	  with	  explosive	  in	  
powder	  form."454	  	  
	  
Three-­‐step	  test	  is	  to	  determine	  whether:	  	  
	  
1. The	  invention	  claimed	  was	  part	  of	  the	  state	  of	  art	  in	  terms	  of	  section	  25(5)	  and	  (6)	  
on	  the	  effective	  date	  of	  the	  patent	  
2. The	  invention	  claimed	  is	  a	  step	  forward	  when	  compared	  to	  prior	  art,	  viz.	  does	  it	  
overcome	  any	  difficulty	  presented	  by	  the	  relevant	  prior	  art?	  	  
3. This	  “step”	  is	  inventive,	  in	  other	  words	  in	  light	  of	  the	  state	  of	  art	  would	  a	  person	  
skilled	  in	  pertinent	  art	  consider	  the	  invention	  obvious?	  	  
	  
	  This	  test	  has	  been	  applied	  in	  many	  cases	  as	  a	  useful	  measure	  to	  compare	  the	  differences	  
between	  prior	  art	  and	  the	  invention	  claimed.	  This	  enquiry	  is	  not	  limited	  to	  the	  claimed	  
invention	  but	  includes	  all	  the	  developing	  stages	  leading	  to	  the	  end	  result,	  i.e.	  the	  invention.	  
	  
The	  Ensign-­‐Bickford	  case	  is	  of	  particular	  significance	  because	  the	  judge	  felt	  the	  standard	  
three-­‐step	  enquiry	  required	  a	  more	  structured	  approach	  and	  therefore	  extended	  the	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  453	  Patents	  Act	  57	  of	  1978,	  section	  61(1)(c)	  	  
454	  Ensign-­‐Bickford	  (South	  Africa)	  (Proprietary)	  Limited	  &	  Others	  v.	  AECI	  Explosives	  &	  Chemicals	  Limited	  (21	  
September	  1998)	  [unreported	  judgement]	  [Hereinafter	  the	  Ensign-­‐Bickford	  case]	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1. What	  the	  inventive	  step	  is	  considered	  to	  be?	  
2. What	  was	  the	  state	  of	  the	  art	  relevant	  to	  that	  step,	  at	  the	  priority	  date?	  
3. In	  what	  respect	  does	  this	  “step”	  overcome	  the	  problem	  faced	  by	  relevant	  prior	  art.	  
In	  other	  words	  in	  what	  way	  does	  the	  claimed	  invention	  advance	  or	  differ	  from	  the	  
relevant	  state	  of	  the	  art?	  
4. Would	  this	  “step”	  be	  obvious	  to	  a	  person	  skilled	  in	  the	  pertinent	  art?455	  
	  
Although	  the	  content	  is	  similar,	  the	  effect	  of	  the	  change	  in	  the	  order	  of	  the	  steps	  of	  the	  
enquiry	  places	  the	  onus	  on	  the	  applicant	  to	  produce	  evidence	  showing	  the	  invention	  is	  non-­‐
obvious	  and	  to	  identify	  the	  differences	  between	  his	  invention	  and	  prior	  art	  thereby	  proving	  
it	  involves	  an	  inventive	  step	  rather	  than	  merely	  reviewing	  the	  prior	  art	  (as	  the	  first	  step	  of	  
the	  previous	  enquiry	  does).	  Consequently	  the	  court	  will	  review	  the	  relevant	  prior	  art	  after	  
the	  patentee	  has	  supplied	  the	  court	  with	  sufficient	  evidence	  showing	  the	  invention	  is	  
inventive.	  	  	  
	  
In	  terms	  of	  the	  “Three-­‐step”	  enquiry,	  the	  onus	  of	  proof	  rests	  with	  the	  person	  alleging	  the	  
invention	  to	  be	  obvious.	  This	  court	  referred	  to	  the	  Firestone	  case,	  illustrating	  the	  traditional	  
approach	  adopted	  by	  the	  courts;	  “the	  onus	  of	  proving	  that	  the	  patent	  in	  suit	  was	  invalid	  on	  
any	  of	  the	  alleged	  grounds	  rested	  on	  Firestone	  (the	  defendant),	  and	  that	  that	  onus	  could	  be	  
discharged	  on	  a	  balance	  of	  probabilities."456	  This	  principle	  viz.	  that	  the	  defendant	  is	  
responsible	  for	  proving	  the	  invention	  is	  invalid	  has	  been	  followed	  in	  many	  cases.457	  However	  
the	  Ensign-­‐Bickford	  case,	  exchanged	  the	  burden	  and	  the	  patentee	  became	  the	  party	  
responsible	  for	  producing	  evidence	  to	  support	  the	  inventiveness	  of	  the	  patent	  at	  issue.	  	  
	  	  	  
In	  the	  past,	  evidence	  in	  the	  form	  of	  testimony	  from	  a	  witness	  regarding	  the	  validity	  of	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
455	  	  Ensign-­‐Bickford	  case	  [At	  23	  of	  the	  unreported	  judgement]	  	  
	  456	  Gentiruco	  A.G.	  v.	  Firestone	  (South	  Africa)	  (Pty)	  Ltd	  1971	  BP	  58	  [At	  108B]	  	  	  457	  See:	  Kimberly-­‐	  Clark	  Corporation	  &	  Another	  v.	  Johnson	  &	  Johnson	  (Pty)	  Ltd	  1983	  BP	  160	  [At	  162A]	  "…the	  
onus	  of	  proof	  that	  the	  plaintiff’s	  patent	  is	  described	  in	  the	  Buell	  patent	  (an	  alleged	  prior	  disclosure	  of	  the	  
invention	  in	  issue)	  rests	  on	  the	  defendant…"	  and	  concluded	  that	  the	  defendant	  [emphasis	  added],	  by	  not	  
leading	  an	  expert	  to	  address	  invalidating	  Buell	  disclosures,	  had	  "…set	  itself	  an	  onus	  which	  is	  difficult	  to	  
discharge…”	  The	  validity	  of	  the	  patent	  was	  accordingly	  upheld.	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patent	  was	  considered	  irrelevant	  when	  determining	  whether	  the	  invention	  was	  inventive.	  In	  
this	  case	  however,	  the	  judge	  referred	  to	  the	  Mölnlyck	  v.	  Procter	  &	  Gamble	  case,458	  stating	  
that	  a	  court	  will	  almost	  invariably	  consult	  expert	  evidence.	  This	  primary	  evidence	  will	  be	  
used	  to	  determine	  whether	  or	  not	  in	  the	  opinion	  of	  the	  expert	  witness,	  the	  invention	  (or	  
relevant	  inventive	  step)	  would	  have	  been	  obvious	  to	  a	  person	  skilled	  in	  the	  pertinent	  art.	  
Expert	  evidence	  will	  be	  considered	  to	  determine	  the	  meaning	  of	  technical	  terms	  and	  
identify	  certain	  invalidating	  features	  disclosed	  in	  the	  prior	  art.	  All	  other	  evidence	  is	  
secondary.459	  Secondary	  evidence,	  including	  commercial	  success	  and	  “long	  felt	  want”	  will	  be	  
considered	  to	  assist	  the	  court	  in	  assessing	  the	  primary	  evidence.	  The	  judge	  considered	  the	  
“primary	  evidence”	  supplied	  by	  the	  patentee	  to	  be	  lacking.	  
	  
The	  principle	  that	  the	  onus	  rests	  with	  the	  patentee	  to	  challenge	  the	  arguments	  of	  the	  party	  
invoking	  the	  invalidity	  of	  the	  patent	  has	  been	  confirmed	  and	  followed	  in	  several	  other	  
cases.460	  This	  case	  also	  referred	  to	  the	  importance	  of	  the	  nature	  of	  the	  field	  in	  respect	  of	  
rebutting	  a	  prima	  facie	  case	  of	  obviousness.	  The	  court	  concluded	  that	  the	  patentee	  failed	  to	  
provide	  sufficient	  evidence	  thereby	  encouraging	  future	  patentees	  in	  similar	  circumstances	  
not	  to	  make	  the	  same	  mistake.	  In	  particular	  by	  providing	  the	  court	  with	  expert	  evidence	  to	  
support	  the	  inventive	  step	  claimed	  in	  the	  patent	  at	  issue.	  
	  
2.4. Application	  or	  Use	  in	  Industry,	  Trade	  or	  Agriculture	  
	  
The	  fact	  that	  South	  African	  patent	  law	  lists	  “trade,	  industry	  or	  agriculture”	  separately	  
suggests	  a	  need	  to	  determine	  the	  meaning	  of	  these	  terms.	  The	  Act	  does	  not	  define	  these	  
terms,	  however	  the	  source	  of	  this	  inclusion	  can	  be	  found	  in	  the	  Paris	  Convention.461	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  458	  Mölnlycke	  AB	  and	  Another	  v.	  Procter	  &	  Gamble	  Limited	  and	  Others	  (No.5)	  [1994]	  RPC	  49	  (CA)	  	  459	  Ensign-­‐Bickford	  case	  [At	  26	  of	  the	  unreported	  judgement]	  
	  460	  Also	  see:	  SmithKline	  Beecham	  plc.	  and	  Another	  v.	  Sandoz	  AG	  and	  Another	  (96/3472)	  [2010]	  ZACCP	  3	  (14	  
April	  2010)	  [At	  page	  22]	  and	  Sunsmart	  Products	  (Pty)	  Ltd	  v.	  Flag	  and	  Flagpole	  Industries	  (Pty)	  Ltd	  t/a	  National	  
Flag	  (97/10535,	  99/3281,	  7385/2004)	  [2005]	  ZACCP	  2	  (7	  November	  2005)	  [At	  9]	  
	  461	  Paris	  Convention	  for	  the	  Protection	  of	  Industrial	  Property	  (1883),	  Art	  1(3):	  “Industrial	  property	  shall	  be	  
understood	  in	  the	  broadest	  sense	  and	  shall	  apply	  not	  only	  to	  industry	  and	  commerce	  proper,	  but	  likewise	  to	  
agricultural	  and	  extractive…”;	  also	  see:	  Bodenhausen	  1967	  BIRPI	  1	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An	  invention	  simply	  cannot	  be	  the	  subject	  of	  a	  patent	  unless	  it	  can	  be	  applied	  or	  used	  in	  
trade,	  industry	  or	  agriculture.462	  This	  denotes	  that	  any	  invention	  not	  having	  a	  practical	  use	  
or	  that	  is	  not	  “useful”	  cannot	  be	  patented.	  However	  South	  African	  patent	  law	  does	  not	  
expressly	  include	  the	  same	  criteria	  as	  seen	  by	  the	  U.S.	  patent	  requirement	  of	  utility,	  namely	  
that	  an	  invention	  should	  have	  substantial	  or	  practical	  utility.	  Furthermore	  the	  applicant	  is	  
not	  obliged	  to	  disclose	  the	  best	  mode	  of	  the	  invention.	  The	  specification	  must	  fully	  describe	  
the	  invention	  and	  the	  manner	  in	  which	  a	  person	  skilled	  in	  the	  pertinent	  art	  can	  use	  or	  make	  
the	  invention.	  Failure	  to	  provide	  sufficient	  instruction	  to	  enable	  the	  invention	  in	  the	  
specification	  can	  result	  in	  invalidity.463	  	  A	  patent	  may	  be	  invalidated	  if	  the	  invention	  does	  
not	  perform	  in	  the	  manner	  or	  fulfil	  that	  which	  it	  has	  been	  described	  to	  do	  in	  the	  
specification.464	  The	  onus	  will	  rest	  on	  the	  person	  alleging	  the	  invention	  has	  no	  practical	  use.	  	  
	  
3. PROCEDURAL	  DIFFERENCES	  	  
	  
Despite	  some	  similarities	  to	  European	  patent	  law	  there	  are	  some	  important	  differences	  to	  
be	  noted	  with	  regard	  to	  the	  procedure	  followed	  by	  the	  South	  African	  patent	  system.	  	  
	  
3.1. Non-­‐examining	  System	  
	  
A	  significant	  difference	  between	  the	  procedure	  followed	  by	  Europe	  and	  the	  USA	  to	  that	  of	  
South	  Africa	  is	  the	  patent	  granting	  process.	  South	  Africa,	  as	  well	  as	  Belgium,	  France	  and	  Italy	  
employ	  the	  “Registration	  System”	  whereby	  patents	  are	  granted	  if	  the	  financial	  and	  
administrative/	  formal	  requirements	  are	  met.465	  In	  South	  Africa,	  the	  CIPC	  is	  responsible	  for	  
granting	  patents.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  462	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  463	  Ensign-­‐Bickford	  case	  [At	  36	  of	  the	  unreported	  judgement]	  	  464	  Patents	  Act	  57	  of	  1978,	  section	  32(3)(b)	  and	  section	  61(1)(d),	  (e)	  
	  465Access	  Campaign	  http://www.msf.org.za/publication/why-­‐south-­‐africa-­‐should-­‐examine-­‐pharmaceutical-­‐
patents	  (accessed	  22/05/2013)	  [At	  2]	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In	  a	  non-­‐examining	  patent	  system,	  the	  applicant	  is	  responsible	  for	  conducting	  the	  patent	  
search.	  The	  CIPC	  will	  merely	  verify	  the	  documents	  or	  forms	  but	  not	  the	  substance	  of	  the	  
product	  or	  process.	  Therefore	  it	  assumed	  that	  the	  invention	  claimed	  is	  valid	  and	  deserving	  
of	  a	  patent	  protection	  without	  examining	  the	  invention	  to	  ensure	  it	  satisfies	  the	  claim.	  	  
	  
Patents	  are	  more	  easily	  attainable	  in	  South	  Africa:	  they	  are	  also	  less	  expensive	  and	  readily	  
obtained	  in	  comparison	  to	  our	  overseas	  counterparts	  where	  the	  backlog	  and	  delay	  in	  
examining	  patent	  applications	  has	  been	  emphasised	  in	  various	  reports.466	  	  
	  
In	  summary:	  due	  to	  the	  fact	  that	  the	  invention’s	  novelty,	  inventiveness	  or	  usefulness	  is	  not	  
examined,	  the	  validity	  of	  the	  patent	  cannot	  be	  guaranteed	  unless	  the	  patent	  is	  later	  
challenged	  in	  court	  (post-­‐	  grant	  proceedings).	  An	  applicant	  will	  not	  invest	  in	  a	  frivolous	  
invention,	  however	  it	  is	  possible	  that	  an	  applicant	  may	  be	  unjustly	  awarded	  with	  IP	  rights	  to	  
the	  detriment	  of	  inventions	  potentially	  deserving	  patent	  protection.	  The	  breadth	  and	  scope	  
of	  the	  invention	  may	  be	  extended	  resulting	  in	  overly	  broad	  claims	  thereby	  creating	  more	  
uncertainty	  within	  the	  IP	  landscape	  and	  impeding	  further	  research	  or	  innovation	  in	  certain	  
fields.	  	  
	  
There	  should	  be	  checks	  and	  balances	  in	  place	  to	  assess	  the	  validity	  of	  a	  patent	  application	  
before	  it	  is	  granted.	  Without	  filtering	  South	  African	  patents,	  an	  inaccurate	  patent	  status	  is	  
depicted,	  as	  there	  may	  be	  many	  patents	  within	  those	  statistics	  that	  are	  not	  worthy	  of	  
patent	  protection.	  A	  commendable	  alternative	  to	  an	  examining	  body	  would	  be	  that	  adopted	  
by	  Turkey.	  Turkey	  does	  not	  have	  an	  examining	  body	  to	  investigate	  the	  substance	  of	  the	  
inventions	  in	  respect	  of	  which	  patents	  are	  sought.	  However	  the	  Turkish	  Patent	  Office	  sends	  
these	  applications	  to	  Russia,	  Sweden,	  EPO	  or	  Denmark	  for	  examination.467	  Other	  non-­‐
examining	  countries	  that	  have	  similar	  agreements	  in	  place	  with	  the	  EPO	  include	  Belgium,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  466	  For	  instance	  in	  2007,	  the	  total	  number	  of	  pending	  patents	  in	  the	  world	  was	  4.2	  million.	  The	  USPTO	  had	  the	  
largest	  backlog,	  28.4%	  of	  the	  total	  (1,178	  090	  pending	  patents)	  and	  the	  average	  pendency	  time	  was	  32	  
months.	  The	  EPO	  had	  550	  079	  pending	  patents	  with	  an	  average	  pendency	  time	  of	  45	  months.	  See:	  WIPO	  
“Intellectual	  Property	  Indicators”	  
http://www.wipo.int/export/sites/www/freepublications/en/intproperty/941/wipo_pub_941.pdf	  (accessed	  
12/10/2013)	  [At	  44-­‐45];	  Also	  see:	  Straus	  2008	  The	  Journal	  of	  World	  Intellectual	  Property	  60	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France	  and	  Italy.	  South	  Africa	  could	  establish	  similar	  agreements	  with	  the	  EPO	  or	  other	  
Patent	  Offices	  that	  would	  be	  willing	  to	  examine	  South	  African	  patent	  applications,	  thereby	  
improving	  the	  quality	  of	  the	  patents	  granted	  in	  South	  Africa	  and	  guaranteeing	  their	  validity.	  	  
	  
This	  suggested	  approach	  is	  further	  inspired	  by	  the	  inaccurate	  local	  CIPC	  database,	  in	  respect	  
of	  which,	  only	  the	  registration	  cover	  is	  provided	  and	  one	  would	  need	  to	  physically	  visit	  the	  
Office	  to	  find	  the	  relevant	  patent	  in	  the	  archives,	  as	  electronic	  versions	  are	  not	  available.	  
This	  makes	  it	  very	  difficult	  for	  interested	  stakeholders,	  abroad	  and	  locally,	  to	  check	  the	  
novelty	  of	  their	  invention.	  It	  is	  therefore	  encouraged	  that	  all	  the	  information	  pertaining	  to	  
South	  African	  patents	  be	  available	  online	  and	  updated	  regularly	  in	  the	  near	  future	  as	  the	  
current	  search	  system	  does	  not	  conform	  to	  international	  best	  practice	  nor	  does	  it	  meet	  the	  
requirements	  of	  public	  interest.468	  	  
	  
4. FILING	  FOR	  A	  SOUTH	  AFRICAN	  PATENT	  APPLICATION	  	  
	  
In	  practice	  the	  best	  approach	  to	  take	  when	  filing	  a	  national	  patent	  application	  would	  be	  to	  
file	  a	  provisional	  patent	  application.	  Upon	  filing	  the	  complete	  patent	  application	  a	  PCT	  
application	  should	  be	  filed	  simultaneously.	  The	  advantages	  of	  following	  this	  strategy	  allow	  
for	  improvements	  or	  developments	  relating	  to	  the	  invention	  to	  be	  included	  in	  the	  complete	  
specification	  and	  thereby	  also	  included	  in	  the	  PCT	  application.	  In	  other	  words	  by	  filing	  a	  PCT	  
application	  first,	  the	  applicant	  will	  not	  be	  able	  to	  benefit	  from	  these	  improvements.	  This	  is	  
an	  important	  consideration	  especially	  when	  dealing	  with	  nanotechnology	  related	  inventions	  
as	  it	  is	  an	  area	  predominately	  at	  the	  research	  phase	  and	  developments	  are	  rapid	  therefore	  
it	  is	  important	  to	  file	  a	  patent	  application	  as	  soon	  as	  possible	  to	  ensure	  protection	  with	  the	  
advantage	  of	  having	  the	  time	  to	  improve	  upon	  the	  invention	  and	  realise	  the	  full	  potential	  of	  
the	  invention	  claimed.	  
	  
The	  obligatory	  novelty	  search	  performed	  by	  International	  Search	  authorities	  (ISAs)	  can	  take	  
up	  to	  30-­‐31	  months:	  After	  30	  months	  from	  the	  priority	  date,	  the	  applicant	  must	  decide	  in	  
which	  PCT	  contracting	  states	  to	  further	  pursue	  the	  applications,	  i.e.	  pay	  the	  necessary	  fees,	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provide	  translations,	  etc.	  In	  those	  selected	  countries	  the	  national	  patent	  granting	  
proceedings	  will	  follow	  and	  patents	  will	  be	  granted	  or	  applications	  rejected.	  
Notwithstanding	  the	  intentions	  of	  the	  applicant	  to	  operate	  locally,	  it	  will	  be	  beneficial	  to	  
have	  the	  PCT	  examination	  report.	  
	  
II. SOUTH	  AFRICA’S	  EFFORTS	  IN	  THE	  FIELD	  OF	  NANOTECHNOLOGY	  
	  
South	  Africa,	  like	  the	  U.S.	  and	  Europe,	  took	  notice	  of	  the	  interest	  surrounding	  the	  field	  of	  
nanoscience	  and	  nanotechnology	  (NNT),	  appreciating	  the	  significant	  opportunities	  that	  
accompany	  this	  technology.	  With	  this	  realisation	  SANi	  was	  established	  which	  was	  formed	  
and	  commissioned	  in	  2002	  to	  set	  out	  the	  aims	  and	  objectives	  South	  Africa	  intends	  to	  
achieve	  by	  2014.469	  Together	  with	  the	  active	  involvement	  of	  the	  Department	  of	  Science	  and	  
Technology	  the	  National	  Nanotechnology	  Strategy470	  (NNS)	  was	  adopted	  in	  2005.	  This	  was	  
followed	  by	  a	  10	  year	  Research	  Plan	  on	  NNT,	  published	  in	  2010	  to	  ensure	  the	  successful	  
implementation	  of	  the	  NNS.471	  The	  government,	  namely	  the	  Department	  of	  Science	  and	  
Technology	  (DST),	  has	  made	  large	  financial	  contributions	  to	  fund	  the	  research	  and	  
development	  of	  nanotechnology.	  Furthermore	  universities,	  industrial	  companies	  and	  
science	  councils	  are	  actively	  participating	  in	  this	  endeavour.472	  South	  Africa	  has	  made	  a	  
long-­‐term	  investment	  in	  developing	  NNT	  in	  South	  Africa.	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  469	  Gulumian	  Nano	  in	  SA	  [At	  4]	  
http://www2.unitar.org/cwm/publications/event/Nano/Abidjan_25-­‐26_Jan_10/22_South_Africa.pdf	  
(accessed	  07/09/2012)	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1. SOUTH	  AFRICA’S	  NATIONAL	  NANOTECHNOLOGY	  STRATEGY	  
	  
The	  NNS	  sets	  out	  three	  generations	  of	  progress	  that	  South	  Africa	  expects	  to	  achieve	  over	  
the	  next	  decade	  or	  so:473	  
	  
 First	  Generation:	  	  	   	   Projected	  impact:	  1-­‐3	  years.	  
	  
Nanotechnology	  is	  already	  in	  use	  in	  the	  form	  of	  improvements	  on	  current	  technologies	  or	  
products	  that	  manipulate	  matter	  on	  nanoscale	  or	  use	  nanomaterials.	  Examples	  of	  these	  
applications	  include	  nanoparticles	  that	  are	  used	  in	  coatings,	  paints,	  sunscreens	  and	  
membranes	  for	  water	  purification.	  	  
	  
 Second	  Generation:	   	   Projected	  impact:	  3-­‐10	  years	  
	  
This	  phase	  includes	  new	  ways	  of	  making	  products	  or	  enhancing	  existing	  processes.	  
Examples	  include:	  	  
 The	  development	  of	  water	  treatment	  systems	  and	  secondary	  use	  of	  effluents	  to	  
make	  low	  cost	  nanoporous	  absorbents	  for	  brine	  stabilisation	  and	  water	  purification;	  
 Energy	  storage,	  conversion,	  distribution.	  Low	  cost	  solar	  and	  fuel	  cells,	  portable	  
power,	  intelligent	  materials	  and	  thermal	  regulation;	  	  
 Aerospace;	  	  
 Medicine	  (drug	  delivery	  systems	  and	  bioanalysis	  followed	  by	  prosthetics;	  
biopharmaceuticals,	  bio	  mimetic	  systems	  and	  cheaper,	  more	  portable	  nano-­‐analysis	  
tools	  and	  systems;	  	  
 Electronics	  (processor,	  memory	  and	  display	  technologies);	  
 ICT	  and	  associated	  technologies	  
 Cleaner	  process	  engineering	  will	  produce	  value	  added	  chemicals	  and	  speciality	  
products	  including	  bio	  catalytic	  systems	  and	  novel	  heterogeneous	  catalysts;	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 Value	  addition	  by	  beneficiation	  of	  gold,	  platinum	  group	  metals	  (PGM)	  and	  other	  
mineral	  resources	  as	  high	  performance	  catalysts,	  absorbents	  in	  polymer	  
nanocomposites	  and	  in	  energy	  saving	  materials;	  	  
 Smart	  and	  functional	  materials	  including	  lubricants	  and	  barrier	  coatings,	  ultra	  hard	  
and	  super	  strong	  materials,	  electro	  and	  photo-­‐chromic	  materials	  with	  applications	  in	  
all	  manufacturing	  sectors,	  industry,	  medical	  and	  domestic	  markets.	  
	  
 Third	  Generation:	  	  	   	   Projected	  impact:	  10	  years	  +	  
	  
This	  stage	  of	  development	  encompasses	  new	  ways	  of	  making	  entirely	  new	  products.	  
Examples	  include:	  	  
 Nanorobotics	  and	  self-­‐assembly	  sensors;	  	  
 Devices	  capable	  of	  monitoring	  health,	  food	  and	  the	  environment	  thereby	  pre-­‐
empting	  potential	  dangers	  such	  as	  pathogens;	  
 Powerful	  and	  inexpensive	  electronic	  devices	  incorporated	  into	  various	  household	  
appliances,	  for	  instance	  fridges	  with	  internet	  connectivity;	  	  
 Light	  and	  super	  strong	  materials	  for	  aircrafts	  and	  cars	  and	  many	  new	  applications;	  
 Intelligent	  medication	  for	  curing	  killer	  diseases,	  such	  as	  cancer	  etc.	  
	  
In	  terms	  of	  the	  NNS	  there	  are	  six	  focus	  areas	  pertinent	  to	  South	  Africa	  namely,	  the	  lack	  of	  
clean	  water,	  energy	  and	  health	  (in	  particular	  diseases	  such	  as	  TB).	  Therefore	  the	  field	  of	  
medicine	  and	  improved	  drug	  delivery	  systems,	  water	  desalination	  and	  other	  sustainable	  
energy	  sources	  are	  at	  the	  forefront	  of	  the	  research	  being	  conducted.	  In	  addition,	  the	  field	  of	  
mining	  is	  of	  great	  economic	  importance	  to	  South	  Africa,	  therefore	  the	  chemical	  and	  
bioprocessing,	  mining	  and	  minerals	  and	  advanced	  manufacturing	  are	  also	  being	  
researched.474	  These	  focus	  areas	  can	  be	  divided	  into	  two	  development	  clusters:	  social	  (the	  
first	  three	  listed)	  and	  industrial	  (the	  last	  three).475	  These	  areas	  were	  identified	  in	  NNS	  as	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  474	  Cele,	  Ray	  and	  Coville	  2009	  S	  Afr	  J	  Sci	  242.	  Also	  see:	  The	  Department	  of	  Science	  and	  Technology	  of	  South	  
Africa	  http://www.info.gov.za/view/DownloadFileAction?id=127107	  (accessed	  27/04/2012)	  [At	  13]	  
475	  Claassens	  and	  Motuku	  2006	  Nanotech.	  L.	  &	  Bus.	  221	  and	  223	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priorities	  in	  the	  development	  of	  nanoscience	  and	  nanotechnology	  in	  order	  to	  effect	  social	  
development	  in	  South	  Africa.	  	  
	  
1.1. Private	  and	  Public	  Sectors	  Contributing	  to	  R&D	  of	  Nanotechnology	  in	  South	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  Africa	  
	  
There	  is	  a	  flurry	  of	  activity	  in	  both	  the	  private	  and	  public	  sectors	  within	  South	  Africa.476	  In	  
2007,	  the	  following	  Nanotechnology	  Innovation	  Centres	  (NIC)	  were	  established:	  iThemba	  
Laboratories,	  and	  within	  well-­‐known	  institutions	  such	  as	  Mintek	  and	  the	  CSIR.477	  These	  
centres	  are	  determined	  to	  train	  and	  develop	  young	  scientists	  in	  order	  to	  stimulate	  
nanotechnology	  development	  in	  this	  country.478	  	  
	  
a) The	  Public	  Sector	  
	  
 The	  CSIR	  
	  
The	  National	  Centre	  for	  Nano	  Structured	  Material	  (NCNSM),	  within	  the	  CSIR,	  focuses	  on	  the	  
design	  and	  modelling	  of	  novel	  nanostructured	  materials	  and	  energy.479	  The	  acquisition	  of	  
modern	  facilities	  has	  improved	  the	  ability	  for	  the	  CSIR	  to	  fabricate	  a	  wide	  spectrum	  of	  
nanomaterials	  for	  both	  research	  and	  industrial	  applications.	  These	  include	  carbon	  
nanotubes,	  nanocomposites,	  polymers,	  quantum	  dots	  and	  metal	  nanoparticles	  such	  as	  
silicon	  and	  titanium	  dioxide	  (TiO2)	  and	  nano-­‐biotech.480	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  476	  Cele,	  Ray	  and	  Coville	  2009	  S	  Afr	  J	  Sci	  242	  
477	  Gulumian	  Nano	  in	  SA	  http://www2.unitar.org/cwm/publications/event/Nano/Abidjan_25-­‐
26_Jan_10/22_South_Africa.pdf	  (accessed	  07/09/2012)	  [At	  11]	  	  478	  Nanowerk	  News	  “South	  Africa	  Launches	  First	  Nanotechnology	  Innovation	  Centers”	  
http://www.nanowerk.com/news/newsid=3429.php	  	  (accessed	  07/11/2012)	  [Hereinafter	  “Nanowerk	  News	  
Innovation	  Centres”]	  
	  479	  Nanowerk	  News	  Innovation	  Centres	  http://www.nanowerk.com/news/newsid=3429.php	  	  (accessed	  
07/11/2012)	  	  480	  Gulumian	  2012	  S	  Afr	  Sci	  6	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Recent	  projects	  the	  CSIR	  focused	  on	  in	  its	  first	  three	  years	  include	  the	  following:	  	  
	  
1. Fabrication	  of	  selected	  novel	  nanostructured	  material	  for	  application	  on	  solar	  cells,	  
printed	  electronic	  devices,	  bio	  sensors	  and	  nanopolymers	  with	  the	  aim	  of	  developing	  
better	  and	  cheaper	  solar	  cells;	  
2. The	  synthesis	  and	  characterisation	  of	  quantum	  dots	  with	  application	  in	  medical	  
sensors,	  solid-­‐state	  lighting	  and	  optical	  devices;	  
3. Development	  and	  synthesis	  of	  polymer	  nanocomposites	  for	  a	  variety	  of	  applications;	  
4. The	  synthesis	  of	  nanostructured	  material	  for	  specific	  energy	  related	  applications;	  
5. Material	  modelling	  and	  stimulation	  with	  the	  aim	  of	  understanding	  and	  predicting	  
fundamental	  properties	  of	  nanomaterials.481	  
	  
An	  overview	  of	  the	  CSIR’s	  objectives	  was	  summarised	  by	  Prof	  Ray	  in	  2007,	  stating	  that	  
within	  the	  following:	  	  
	  
 5	  –	  10	  years:	  Sophisticated	  electronic	  devices	  that	  use	  nanoscale	  circuitry	  and	  
memory;	  	  
 10	  –	  15	  years:	  An	  introduction	  of	  pharmaceutical	  products,	  drug	  delivery	  and	  health	  
monitoring	  devices;	  and	  




Mintek	  is	  responsible	  for	  focusing	  their	  research	  on	  the	  following	  areas:	  mining	  and	  
minerals,	  health	  and	  water.483	  South	  Africa	  has	  a	  great	  wealth	  of	  minerals	  such	  as	  gold,	  
platinum,	  titanium,	  palladium;	  nanotechnology	  can	  add	  enormous	  value	  to	  these	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  481	  Nanowerk	  News	  Innovation	  Centres	  http://www.nanowerk.com/news/newsid=3429.php	  	  (accessed	  
07/11/2012)	  	  
	  482	  Nanowerk	  News	  Innovation	  Centres	  http://www.nanowerk.com/news/newsid=3429.php	  	  (accessed	  
07/11/2012)	  	  483	  Nanowerk	  News	  Innovation	  Centres	  http://www.nanowerk.com/news/newsid=3429.php	  	  (accessed	  
07/11/2012)	  
	  
	   143	  
minerals.484	  Mintek	  together	  with	  three	  gold	  mining	  houses	  have	  joined	  in	  researching	  the	  
use	  of	  gold	  in	  catalysis	  for	  the	  oxidation	  of	  carbon	  monoxide	  to	  carbon	  dioxide,	  molecular	  
diagnostics	  and	  metal–polymer	  composites.485	  Mintek	  is	  also	  responsible	  for	  developing	  
Point	  of	  Care	  Diagnostic	  Prototypes	  (POC).	  This	  project	  will	  be	  discussed	  in	  greater	  detail	  
further	  on.	  	  
	  
 Research	  Group	  iThemba	  LABS	  National	  Research	  Foundation	  
	  
The	  laboratories	  research	  focuses	  on	  nanoclusters	  and	  nanocomposites	  (silver,	  palladium,	  
copper)	  in	  terms	  of	  their	  mechanism	  of	  formation.486	  	  
	  
 Institutions	  of	  Higher	  Education	  
	  
Various	  South	  African	  Universities	  are	  cooperating	  with	  the	  NIC	  in	  conducting	  research	  in	  
various	  areas	  of	  nanotechnology.	  Some	  of	  these	  projects	  will	  be	  discussed	  further	  on.	  
	  	  
b) The	  Private	  Sector	  
	  
The	  commercial	  benefits	  of	  applying	  novel	  nanomaterials	  in	  the	  fabrication	  of	  products	  or	  
industrial	  processes	  has	  generated	  a	  tremendous	  amount	  of	  interest	  in	  various	  industrial	  
sectors	  resulting	  in	  existing	  companies	  such	  as	  SASOL,	  SAPI	  and	  Gold	  mines,	  such	  as	  Anglo	  
Gold,	  Harmony	  Gold,	  Goldfields,	  contributing	  to	  the	  advancements	  of	  research	  in	  the	  field	  
of	  nanotechnology	  in	  South	  Africa.487	   	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  484	  Science	  in	  Africa	  http://www.scienceinafrica.co.za/2003/november/nanotech.htm	  (accessed	  07/11/2012)	  
	  485	  Gulumian	  2012	  S	  Afr	  Sci	  6	  
	  	  	  486	  Gulumian	  Nano	  in	  SA	  http://www2.unitar.org/cwm/publications/event/Nano/Abidjan_25-­‐
26_Jan_10/22_South_Africa.pdf	  (accessed	  07/09/2012)	  [At	  13]	  	  487	  Gulumian	  Nano	  in	  SA	  http://www2.unitar.org/cwm/publications/event/Nano/Abidjan_25-­‐
26_Jan_10/22_South_Africa.pdf	  (accessed	  07/09/2012)	  [At	  13]	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2. SOUTH	  AFRICAN	  NANOTECHNOLOGY	  PATENTS	  
	  
2.1. The	  Definition	  Applied	  to	  “Nanotechnology”	  in	  South	  Africa	  
	  
According	  to	  the	  NNS,	  the	  term	  nanotechnology	  is	  defined	  in	  reference	  to	  scale	  only:	  “a	  
billionth	  of	  a	  metre.”	  488	  Therefore	  any	  object	  with	  this	  measurement	  will	  be	  classified	  as	  
nanotechnology.	  However,	  this	  is	  a	  very	  limited	  definition,	  a	  more	  detailed	  definition	  is	  
given	  by	  the	  IPC	  system	  in	  terms	  of	  class	  B82B	  and	  B82Y.489	  When	  determining	  the	  
appropriate	  class	  for	  nano-­‐related	  inventions,	  South	  African	  patent	  attorneys	  will	  refer	  to	  
this	  definition.	  	  	  
	  
2.2. Applications	  of	  Nanotechnology	  in	  South	  Africa	  
	  
South	  Africa	  actively	  began	  research	  in	  the	  field	  of	  nanotechnology	  in	  2005.	  Therefore	  when	  
examining	  South	  Africa’s	  position,	  we	  can	  refer	  back	  to	  the	  distinction	  made	  between,	  
“nanoscience”	  and	  “nanotechnology.”	  Nanotechnology	  related	  activities	  are	  limited	  to	  
research;	  they	  are	  not	  fully	  developed	  manufacturing	  technologies	  at	  this	  time.	  This	  can	  be	  
seen	  from	  the	  academic	  institutes	  and	  research	  centres	  conducting	  this	  research.	  	  
	  
It	  would	  be	  very	  difficult	  and	  unfair	  to	  compare	  South	  Africa’s	  level	  of	  competiveness	  on	  an	  
international	  scale	  especially	  with	  the	  leading	  countries	  having	  started	  their	  research	  in	  this	  
field	  approximately	  six	  years	  earlier	  than	  South	  Africa.490	  Therefore	  with	  regard	  to	  the	  
commercialisation	  of	  such	  research,	  it	  is	  hoped	  that	  this	  is	  realised	  by	  2015.491	  Some	  of	  the	  
current	  projects	  include:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  488	  The	  Department	  of	  Science	  and	  Technology	  of	  South	  Africa	  “National	  Nanotechnology	  Strategy”	  
http://www.info.gov.za/view/DownloadFileAction?id=127107	  (accessed	  27/04/2012)	  [At	  7]	  	  489	  Refer	  to	  the	  WIPO	  website	  for	  the	  comprehensive	  definition	  of	  B82B-­‐	  B82Y:	  
http://web2.wipo.int/ipcpub/#refresh=page&notion=scheme&version=20130101&symbol=B82	  (accessed	  
04/07/2013)	  
	  490	  Pouris	  2010	  University	  of	  Pretoria	  139	  
	  491	  Pouris	  2010	  University	  of	  Pretoria	  11	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a) Gold-­‐based	  Nanoparticles	  	  
	  
Much	  of	  the	  work	  conducted	  at	  Mintek	  is	  focused	  around	  semi	  commercial	  products	  in	  the	  
health	  sector.	  These	  products	  include	  the	  use	  of	  gold	  nanoparticles,	  relating	  to	  drug	  delivery	  
system	  research	  and	  quick	  diagnostic	  tests.	  Researchers	  have	  uncovered	  the	  extraordinary	  
optical,	  catalytic	  and	  magnetic	  properties	  of	  this	  precious	  metal,	  making	  them	  especially	  
appropriate	  for	  healthcare	  applications,492	  thereby	  placing	  the	  study	  of	  gold	  nanoparticles	  
at	  the	  forefront	  of	  nanotechnology	  research	  in	  both	  the	  industrial	  and	  academic	  sectors.	  
	  
Mintek	  and	  three	  major	  gold	  mining	  houses,	  namely	  AngloGold	  Ashanti,	  Gold	  Fields	  and	  
Harmony	  Gold	  have	  come	  together	  to	  establish	  the	  AuTEK	  Biomed	  consortium.493	  Research	  
projects	  include:	  
	  
1. The	  use	  of	  gold	  in	  catalysis	  for	  the	  oxidation	  of	  carbon	  monoxide	  to	  carbon	  dioxide	  
which	  can	  be	  applied	  to	  purify	  air	  at	  room	  temperature.494	  
2. The	  creation	  of	  gold-­‐based	  nano-­‐chemo-­‐therapeutics	  for	  the	  treatment	  of	  cancer,	  
malaria	  and	  Aids.495	  Despite	  the	  extended	  history	  of	  the	  use	  of	  gold	  colloids	  in	  
therapeutics,	  research	  has,	  in	  the	  past	  twenty	  years,	  focused	  on	  developing	  and	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drugs	  are	  currently	  being	  used.	  	  The	  use	  of	  gold	  in	  place	  of	  platinum	  could	  be	  highly	  
advantageous	  as	  gold	  drugs	  accumulate	  in	  the	  mitochondria.	  On	  accumulation,	  
these	  drugs	  become	  toxic	  and	  kill	  the	  cells.	  It	  has	  however	  been	  specified	  by	  the	  
head	  researcher,	  that	  these	  gold-­‐based	  drugs	  need	  to	  be	  modified	  so	  as	  to	  target	  
and	  destroy	  only	  the	  cancerous	  cells.497	  	  	  
3. In	  2005,	  research	  was	  conducted	  to	  see	  if	  gold	  compounds	  can	  act	  as	  inhibitors	  to	  
HIV.498	  	  
4. A	  remarkable	  development	  by	  Mintek	  is	  the	  portable	  test	  kits	  for	  advanced	  rapid	  
diagnostic	  testing	  of	  various	  infectious	  diseases.	  Research	  on	  both	  chemical	  and	  
electrochemical	  rapid	  diagnostic	  methods	  have	  been	  conducted	  for	  the	  testing	  of	  
both	  human	  and	  animal	  health	  diseases.	  A	  great	  deal	  of	  the	  focus	  has	  been	  on	  
developing	  low	  cost,	  stable	  and	  accurate	  point-­‐of-­‐care	  (POC)	  diagnostic	  tests	  kits	  for	  
TB	  and	  malaria.	  These	  gold-­‐based	  POC	  prototypes	  were	  tested	  using	  serum	  and	  
blood	  samples.	  These	  devices	  are	  simple	  enough	  to	  be	  used	  by	  any	  individual	  in	  the	  
comfort	  of	  their	  own	  home	  without	  the	  assistance	  of	  a	  trained	  professional	  to	  
diagnose	  the	  disease	  of	  interest.	  After	  clinical	  evaluations,	  these	  devices	  should	  be	  
available	  to	  the	  majority	  of	  the	  public	  thereby	  improving	  the	  quality	  of	  life	  by	  
diagnosing	  any	  relevant	  disease	  a	  person	  may	  have.499	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b) TB	  and	  Nanotechnology	  
	  
In	  2007,	  the	  WHO	  ranked	  South	  Africa	  fifth	  on	  the	  high	  burden	  TB	  countries	  in	  the	  world.500	  	  
The	  treatment	  for	  TB	  is	  the	  intake	  of	  four	  antibiotics:	  isoniazid,	  rifampicin,	  pyrazinamide	  and	  
ethambutol	  that	  are	  to	  be	  taken	  daily.	  This	  daily	  routine	  of	  taking	  each	  of	  these	  four	  
antibiotics	  for	  months	  can	  be	  grueling	  for	  many	  patients,	  who	  have	  to	  travel	  long	  distances	  
for	  a	  nurse	  to	  ensure	  that	  they	  get	  this	  medication.501	  When	  combining	  this	  with	  the	  side	  
effects	  of	  the	  medication,	  many	  patients	  despair	  before	  completing	  the	  course	  of	  
treatment,	  which	  then	  causes	  multidrug-­‐resistant	  strains	  to	  emerge,	  giving	  the	  disease	  
ample	  opportunity	  to	  spread.502	  The	  lack	  of	  healthcare	  staff	  to	  help	  administer	  the	  drugs	  on	  
a	  daily	  basis	  is	  yet	  another	  obstacle	  that	  arises	  with	  this	  treatment	  for	  TB.	  	  
	  
Researchers	  at	  the	  CSIR	  have	  incorporated	  these	  four	  antibiotics	  into	  nanoparticles	  which	  
are	  taken	  up	  by	  the	  white	  blood	  cells	  that	  effectively	  transport	  them	  throughout	  the	  body	  
while	  slowly	  releasing	  the	  antibiotics.	  According	  to	  the	  leading	  researcher,	  “these	  
nanoparticles	  have	  superior	  properties	  for	  absorption	  in	  the	  small	  intestine	  to	  improve	  bio-­‐
availability	  and	  uptake	  into	  circulation.”503	  The	  required	  dosage	  is	  every	  7-­‐10	  days,	  which	  
would	  increase	  the	  likelihood	  of	  the	  patient	  completing	  his	  or	  her	  treatment	  to	  the	  point	  
that	  the	  disease	  will	  be	  completely	  eliminated.504	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In	  2010,	  it	  was	  reported	  by	  this	  team	  that	  these	  drugs	  had	  been	  tested	  on	  TB-­‐infected	  mice	  
to	  determine	  whether	  this	  weekly	  nano-­‐dose	  was	  as	  effective	  as	  the	  conventional	  daily	  
treatment	  regiment.	  The	  preclinical	  trial	  data	  was	  promising:	  it	  revealed	  the	  nanoparticles	  
were	  absorbed	  by	  all	  the	  major	  tissues	  thereby	  matching	  the	  efficiency	  of	  the	  daily	  intake	  of	  
the	  drugs.505	  If	  successful,	  this	  new	  method	  for	  delivering	  TB	  drugs	  could	  overcome	  the	  
issues	  mentioned	  above,	  patients	  will	  complete	  their	  treatment,	  the	  need	  for	  healthcare	  
staff	  will	  only	  be	  required	  on	  a	  weekly	  basis	  as	  opposed	  to	  daily	  and	  all	  of	  this	  could	  be	  
achieved	  cost	  effectively.	  It	  is	  estimated	  that	  this	  project	  will	  complete	  preclinical	  trials	  by	  
2016.506	  	  
	  
c) Nanotechnology	  and	  Other	  Medical	  Treatment	  
	  
Treatments	  using	  nanocapusaltion,	  for	  example	  coating	  anti	  malaria	  drug	  chloroquine	  with	  
nanomaterials	  including	  liposomes	  which	  can	  deliver	  the	  drug	  by	  penetrating	  the	  cell	  
membrane	  thereby	  taking	  action	  on	  the	  diseased	  cells	  in	  a	  more	  targeted	  and	  efficient	  
way.507	  	  
	  
Examples	  of	  South	  African	  patent	  applications	  for	  targeted	  drug	  delivery	  include:	  	  
	  
 ZA	  2013/04573:	  “A	  drug	  delivery	  device”508	  	  
	  
The	  invention	  described	  in	  this	  patent	  relates	  to	  a	  biodegradable	  drug	  delivery	  device,	  
which	  is	  implanted	  in	  the	  cranium.	  Claim	  1	  reads:	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“1.	  An	  implantable	  intracranial	  device	  for	  the	  delivery	  of	  a	  pharmaceutically	  active	  agent	  to	  
a	  human	  or	  animal	  for	  treating	  a	  mental	  or	  neurological	  disorder,	  the	  device	  comprising:	  a	  
pharmaceutically	  active	  agent	  for	  treating	  the	  disorder;	  
polymeric	  nanoparticles	  into	  or	  onto	  which	  the	  pharmaceutically	  active	  agent	  is	  embedded;	  
and	  
a	  polymeric	  matrix	  incorporating	  the	  nanoparticles.”	  
	  
This	  invention	  is	  suitable	  for	  the	  treatment	  of	  mental	  or	  neurological	  disorders,	  such	  as	  
Alzheimer's	  disease,	  schizophrenia	  or	  other	  psychoses.	  
	  
 ZA	  2013/04634:	  “Polymeric	  matrix	  of	  polymer-­‐lipid	  nanoparticles	  as	  a	  pharmaceutical	  
dosage	  form”509	  	  
	  
Claim	  1	  reads:	  
	  
“1.	  A	  pharmaceutical	  dosage	  form	  for	  the	  release	  of	  at	  least	  one	  pharmaceutically	  active	  
ingredient,	  the	  pharmaceutical	  dosage	  form	  comprising:	  
a	  polymer	  matrix	  formed	  from	  at	  least	  two	  cross-­‐linked	  polymers;	  
polymer-­‐lipid	  nanoparticles	  formed	  from	  at	  least	  one	  polymer	  and	  at	  least	  one	  phospholipid	  
and	  which	  are	  incorporated	  within	  the	  polymer	  matrix;	  and	  
at	  least	  one	  pharmaceutically	  active	  ingredient.”	  
	  
This	  invention	  relates	  to	  a	  pharmaceutical	  dosage	  form	  for	  delivering	  a	  pharmaceutically	  
active	  ingredient	  having	  poor	  absorption	  in	  the	  body.	  Levodopa	  is	  an	  example	  of	  a	  poorly	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 ZA	  2013/04511:	  “An	  implant	  for	  the	  controlled	  release	  of	  pharmaceutically	  active	  
agents”510	  
	  
“1.	  A	  pharmaceutical	  composition	  for	  the	  delivery	  of	  a	  pharmaceutically	  active	  agent,	  the	  
composition	  comprising:	  
a	  thermoresponsive	  polymer	  composition	  which	  is	  in	  a	  liquid	  form	  at	  or	  about	  room	  
temperature	  and	  in	  a	  solid	  or	  gelatinous	  form	  at	  or	  about	  body	  temperature,	  wherein	  the	  
thermoresponsive	  polymer	  composition	  is	  formed	  from	  cross-­‐linked	  poly(methyl	  vinyl	  ether)	  
(PMVE)	  and	  an	  inorganic	  salt;	  and	  
a	  plurality	  of	  micro-­‐	  or	  nano-­‐particles	  which	  are	  pH	  responsive	  and	  which	  include	  at	  least	  
one	  pharmaceutically	  active	  agent;	  
wherein	  the	  micro-­‐	  or	  nano-­‐particles	  are	  suspended	  in	  the	  thermoresponsive	  polymer	  
composition.”	  
	  
The	  above	  invention	  describes	  a	  pharmaceutical	  composition	  or	  dosage	  form	  for	  the	  
constant	  and	  controlled	  delivery	  of	  at	  least	  one	  pharmaceutically	  active	  agent.	  The	  
pharmaceutical	  composition	  is	  injectable.	  Once	  injected,	  it	  can	  form	  an	  implant	  due	  to	  its	  
thermoresponsive	  nature	  (i.e.	  it	  contains	  pH	  responsive	  nanoparticles),	  which	  will	  respond	  
to	  the	  site	  of	  injection	  to	  release	  entrapped	  drugs.	  The	  composition	  can	  be	  used	  to	  treat	  any	  
disease	  or	  condition	  that	  results	  in	  a	  decrease	  in	  pH,	  for	  example	  the	  treatment	  of	  a	  solid	  
tumor,	  gout,	  acidosis	  or	  ketosis.	  
	  
 ZA	  2010/06639:	  “Nanoparticle	  carriers	  for	  drug	  administration	  and	  process	  for	  
producing	  same”511	  
	  
“The	  invention	  claimed	  is:	  
1.	  A	  process	  for	  the	  production	  of	  nanoparticles	  for	  drug	  delivery,	  said	  nanoparticles	  being	  
produced	  by:	  
preparing	  a	  double	  emulsion	  of	  water-­‐oil-­‐water	  including	  one	  or	  more	  polymers	  which	  form	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the	  basis	  of	  the	  nanoparticles;	  
blending	  the	  drug	  to	  be	  delivered	  into	  one	  of	  the	  emulsion	  phases;	  
doping	  either	  the	  oil-­‐phase	  or	  the	  outer	  water-­‐phase	  with	  a	  carbohydrate;	  
doping	  the	  oil-­‐phase,	  the	  outer	  water-­‐phase,	  the	  internal	  water-­‐phase,	  or	  both	  water	  phases	  
with	  a	  surfactant;	  and	  
spray	  drying	  the	  drug-­‐containing	  water-­‐oil-­‐water	  double	  emulsion	  having	  doped	  emulsion	  
phases	  to	  remove	  both	  the	  oil-­‐phase	  and	  the	  water-­‐phases	  simultaneously,	  thereby	  forming	  
nanoparticles	  having	  a	  particle	  size	  distribution	  of	  100	  nm	  to	  1000	  nm.”	  
	  
This	  application	  is	  partly	  a	  continuation	  of	  the	  PCT	  Application:	  PCT/ZA2008/000012	  and	  the	  
content	  thereof	  has	  been	  referred	  to	  in	  this	  application.	  The	  present	  invention	  relates	  to	  a	  
process	  for	  the	  production	  of	  nanoparticle	  carriers	  for	  oral	  administration.	  A	  spray	  drying	  
technique	  is	  used	  to	  produce	  nanoscale	  solid	  particles	  and	  solid	  lipid	  nanoparticles	  that	  are	  
laden	  with	  active	  agents	  that	  can	  be	  used	  as	  drug	  delivery	  systems	  for	  pulmonary	  airways.	  	  	  
	  
d) Water	  Sanitation	  	  
	  
South	  Africa	  has	  focused	  on	  water	  research	  for	  many	  years	  however	  with	  the	  addition	  of	  
nanomaterials	  a	  cheaper,	  more	  durable	  and	  efficient	  treatment	  of	  water	  may	  be	  realised	  to	  
reduce	  water-­‐borne	  diseases	  such	  as	  cholera	  and	  typhoid.	  The	  University	  of	  Johannesburg	  is	  
focused	  on	  developing	  novel	  solutions	  to	  treat	  water	  so	  as	  to	  meet	  drinking	  and	  
environmental	  quality	  standards.512	  Nanomaterials	  currently	  being	  used	  include,	  
nanomembranes	  for	  filtration,	  magnetic	  nanoparticles	  and	  nanofiber	  devices	  for	  toxic	  
elements	  and	  organic	  pollutant	  removal	  and	  nanostructured	  electro-­‐catalylic	  membranes	  
and	  zeolite	  absorbents	  for	  purification.513	  
	  
Prof	  Wei	  Hua	  Ho	  and	  Prof	  Vijaya	  Srinivasu	  Vallabhapurapu	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  Prof	  Ivan	  
William	  Hofsajer	  from	  Wits	  collaborated	  in	  the	  development	  of	  a	  water	  purification	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invention	  that	  could	  be	  mass-­‐produced.	  Consequently	  having	  great	  commercial	  value	  for	  
nanoparticle-­‐based	  water	  purification	  processes.	  This	  provisional	  patent	  application	  is	  
entitled	  “Method	  and	  Apparatus	  for	  Treating	  a	  Fluid”514	  and	  was	  lodged	  on	  14	  November	  
2012.	  	  
	  
This	  invention	  uses	  magnetic	  nanoparticles	  coated	  with	  a	  layer	  of	  material	  that	  removes	  
certain	  contaminants	  from	  the	  water.	  The	  use	  of	  magnetic	  nanoparticles	  to	  purify	  the	  water	  
is	  not	  novel,	  however	  the	  process	  in	  which	  they	  are	  applied	  is.	  	  Previously	  these	  magnetic	  
particles	  would	  separate	  the	  impurities	  after	  the	  purification	  process	  was	  completed.	  The	  
method	  used	  here	  incorporates	  the	  magnetic	  properties	  in	  the	  cleaning	  phase	  as	  well.	  A	  
chemical	  reaction	  is	  required	  for	  physical	  excitation	  of	  the	  particles	  in	  the	  water.	  Previously	  
this	  was	  done	  with	  a	  stirrer	  or	  similar	  device	  therefore	  the	  container	  and	  water	  would	  have	  
to	  be	  agitated.	  This	  invention	  shows	  that	  the	  same	  effect	  can	  be	  achieved	  by	  having	  a	  
moving	  magnetic	  field,	  as	  demonstrated	  by	  their	  small	  prototype.	  There	  are	  several	  
advantages	  in	  using	  this	  process:	  
	  
1. There	  are	  no	  moving	  parts,	  in	  contrast	  to	  the	  previous	  method	  (i.e.	  the	  stirrer)	  and	  
therefore	  there	  is	  no	  wear	  and	  tear	  thereby	  greatly	  reducing	  maintenance	  costs.	  
2. Only	  the	  particles	  are	  being	  agitated	  and	  not	  the	  container	  or	  water.	  This	  process	  
greatly	  reduces	  the	  energy	  required	  to	  achieve	  this	  agitation.	  
3. This	  electromagnetic	  technique	  moves	  the	  nanoparticles	  in	  the	  water,	  substituting	  
the	  mechanical	  stirring	  of	  the	  particles.	  Therefore	  the	  whole	  process	  can	  be	  
upgraded	  to	  an	  automated	  mass	  processing	  system.	  
	  
e) Scale	  Up	  	  
	  
The	  world	  is	  facing	  the	  same	  challenge	  when	  it	  comes	  to	  producing	  large	  quantities	  of	  
nanomaterials	  that	  meet	  certain	  quality	  standards.515	  These	  reproduction	  methods	  need	  to	  
be	  cost	  effective	  for	  commercial	  scale	  reproduction	  and	  environmentally	  friendly.	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Mintek	  has	  made	  significant	  progress	  in	  ensuring	  that	  nanoparticle	  products	  they	  produce	  
can	  be	  reproduced	  in	  large	  quantities.	  NIC	  are	  currently	  capable	  of	  producing	  20	  liters	  of	  
nanoparticles	  per	  batch.516	  This	  volume	  can	  easily	  be	  increased	  to	  meet	  supply	  and	  demand.	  	  
	  
 ZA	  2008/01689:	  “A	  process	  for	  producing	  carbon	  nanotubes”517	  
	  
According	  to	  Claim	  1,	  the	  invention	  is	  described	  as:	  
	  
“1.	  A	  process	  for	  producing	  carbon	  nanotubes	  which	  includes	  supplying	  a	  continuous	  
fluidized	  feed	  of	  a	  catalyst	  and	  at	  least	  one	  hydrocarbon	  to	  a	  reactor	  operating	  under	  
conditions	  suitable	  to	  produce	  carbon	  nanotubes	  and	  characterised	  in	  that	  fluid	  flow	  is	  non-­‐
laminar	  within	  the	  reactor	  and	  in	  that	  the	  internal	  surfaces	  of	  the	  reactor	  are	  cleaned	  of	  
deposits.”	  
	  
As	  previously	  commented,518	  processes	  currently	  adopted	  for	  batch	  production	  of	  CNTs	  
have	  their	  disadvantages,	  for	  example	  low	  yield	  and	  lack	  of	  industrial	  application	  or	  
efficiency.	  This	  invention	  relates	  to	  a	  process	  whereby	  some	  of	  these	  drawbacks	  are	  
reduced.	  
	  
 	  ZA	  2011/0535:	  “Method	  of	  producing	  nanoparticles”519	  	  
	  
Claim	  1	  reads:	  
	  
“1.	  A	  method	  of	  producing	  nanoparticles	  in	  the	  size	  range	  1	  nm	  to	  1000	  nm	  through	  the	  
synthesis	  of	  one	  or	  more	  precursor	  fluids,	  the	  method	  including	  providing	  a	  fluid	  medium	  
comprising	  at	  least	  one	  precursor	  fluid	  and	  generating	  an	  electrical	  spark	  within	  said	  fluid	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medium	  to	  cause	  pyrolysis	  of	  said	  at	  least	  one	  precursor	  fluid	  in	  a	  relatively	  hot	  plasma	  zone	  
to	  produce	  at	  least	  one	  radical	  species,	  and	  to	  form	  nanoparticles	  by	  nucleation	  in	  the	  fluid	  
medium	  in	  a	  cooler	  reaction	  zone	  about	  the	  plasma	  zone,	  wherein	  said	  at	  least	  one	  radical	  
species	  acts	  as	  a	  reactant	  or	  catalytic	  agent	  in	  the	  synthesis	  of	  material	  composing	  said	  
nanoparticles.”	  
	  
The	  process	  for	  the	  production	  of	  nanoparticles	  in	  relation	  to	  this	  invention	  involves	  
chemical	  vapour	  synthesis	  (CVS).	  Definitions	  for	  pyrolysis	  and	  CVS	  are	  provided	  for	  in	  the	  
application.	  
	  
e) Up-­‐	  and	  Down-­‐Conversions	  	  
	  
UNISA’s	  department	  of	  Physics	  is	  presently	  working	  on	  the	  synthesis	  of	  up-­‐conversion	  and	  
down-­‐conversion	  nanophosphors.	  These	  can	  be	  applied	  in	  biological	  labelling,	  solar	  cells,	  
solid-­‐state	  lighting	  and	  display	  technologies.	  Energy	  transfer	  from	  metal	  nanoparticles	  
attached	  to	  the	  surfaces	  of	  phosphor	  particles	  could	  enhance	  the	  intensity	  of	  the	  prepared	  
phosphor.	  Metal	  nanoparticles	  can	  be	  applied	  in	  DNA	  tagging,	  diagnostics	  to	  specific	  cells,	  
drug	  delivery	  (as	  discussed	  regarding	  gold-­‐nanoparticles	  in	  the	  treatment	  of	  TB),	  cancer	  cell	  
therapy,	  protein	  detection	  and	  tissue	  engineering.	  The	  optical	  properties	  of	  earth	  
phosphors	  can	  be	  applied	  to	  solar	  cells,	  sensors	  (for	  example	  methane	  sensors	  in	  mines),	  
memory	  chips	  and	  high-­‐speed	  transistors.520	  
	  
g) Fuel	  Cells	  and	  Nanotechnology	  
	  
Owing	  to	  the	  international	  energy	  crisis,	  UNISA	  has	  increased	  research	  outputs	  and	  focus	  
their	  research	  on	  the	  synthesis,	  characterisation	  and	  local	  production	  of	  membrane	  
electrode	  assembly	  for	  fuel	  cells.	  	  The	  intention	  is	  to	  develop	  technologically	  sound,	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  520	  According	  to	  the	  information	  circulated	  at	  UNISA’s	  BRICS	  International	  Symposium	  on	  Energy,	  Materials	  &	  
Innovation,	  2013.	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environmentally	  friendly	  and	  commercially	  viable	  fuel	  cells	  for	  industrial	  and	  domestic	  
use.521	  
	  
h) Quantum	  Dots	  
	  
The	  University	  of	  Zululand	  has	  mainly	  focused	  on	  quantum	  dots	  and	  other	  forms	  of	  
nanoparticles.	  This	  university	  is	  considered	  to	  be	  the	  leader	  in	  the	  research	  and	  fabrication	  
of	  quantum	  dots	  as	  these	  materials	  find	  applications	  in	  diagnostics,	  security	  systems,	  	  
biological	  probes,	  and	  optics.	  They	  are	  also	  responsible	  for	  the	  synthesis	  of	  nanoparticles	  for	  
drug	  delivery.522	  	  
	  
2.3. Patentability	  Issues	  Relating	  to	  South	  African	  Nanotechnology	  Patents	  	  
	  
Herein	  reference	  is	  specifically	  made	  to	  the	  provisional	  patent	  application	  of	  the	  water	  
desalination	  project	  and	  the	  six	  patent	  applications	  discussed.523	  In	  respect	  of	  the	  
provisional	  water	  desalination	  patent	  application,	  despite	  the	  invention	  not	  having	  been	  
classed	  yet,	  it	  is	  in	  the	  view	  of	  the	  attorneys	  responsible	  for	  this	  patent	  application	  that	  it	  
will	  probably	  be	  categorised	  in	  the	  “desalinisation”	  class	  (a	  general	  class)	  and	  only	  possibly	  
in	  addition,	  it	  may	  be	  filed	  in	  the	  “nanotechnology”	  class.	  	  In	  relation	  to	  the	  PCT	  patent	  
applications,	  only	  three	  of	  the	  six	  were	  classed	  in	  the	  B82Y	  class.	  Consequently	  if	  this	  is	  the	  
practice	  adopted	  in	  South	  Africa,	  inventions	  that	  would	  qualify	  as	  “nanotechnology”	  
inventions	  may	  not	  be	  filed	  as	  such,	  making	  it	  very	  difficult	  if	  not	  impossible	  to	  accurately	  
determine	  relevant	  prior	  art	  and	  the	  true	  status	  of	  nanotechnology	  patents	  in	  South	  
Africa.524	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  According	  to	  the	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  circulated	  at	  UNISA’s	  BRICS	  International	  Symposium	  on	  Energy,	  Materials	  &	  
Innovation,	  2013.	  
	  522	  Gulumian	  Nano	  in	  SA	  http://www2.unitar.org/cwm/publications/event/Nano/Abidjan_25-­‐
26_Jan_10/22_South_Africa.pdf	  (accessed	  07/09/2012)	  [At	  10]	  
	  523	  See:	  PA	  156	  843/P,	  ZA	  2010/06639,	  ZA	  2013/04573,	  ZA	  2013/04634,	  ZA	  2013/04511,	  ZA	  2008/01689	  and	  
ZA	  2011/0535.	  	  
	  524	  This	  idea	  is	  further	  corroborated	  by:	  Claassens	  and	  Motuku	  2006	  Nanotech.	  L.	  &	  Bus.	  226	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The	  challenges	  presented	  by	  nanotechnology	  when	  determining	  the	  patentability	  of	  a	  nano-­‐
related	  invention,	  was	  discussed	  extensively	  in	  the	  previous	  chapter.	  In	  South	  Africa,	  all	  
patent	  applications	  are	  treated	  equally,	  i.e.	  as	  long	  as	  the	  formal/	  administrative	  formalities	  
are	  complied	  with,	  the	  application	  will	  be	  granted.	  Consequently	  it	  is	  doubtful	  that	  
nanotechnology	  patent	  applications	  will	  face	  similar	  problems	  during	  the	  patent	  granting	  
phase	  but	  the	  validity	  may	  be	  challenged	  later	  on	  in	  court	  or	  if	  filed	  abroad	  in	  a	  country	  with	  
an	  examining	  body.	  	  
	  
Bearing	  in	  mind	  that	  in	  South	  Africa,	  at	  least	  at	  present	  and	  in	  foreseeable	  future,	  no	  
examination	  of	  patent	  applications	  as	  to	  the	  substance	  is	  carried	  out,	  South	  African	  
inventors/applicants	  in	  the	  area	  of	  nanotechnology	  should	  use	  the	  PCT	  System	  and	  select	  
either	  the	  USPTO	  or	  the	  EPO	  as	  the	  search	  and	  examining	  authorities.	  Depending	  on	  the	  
results	  of	  search	  reports	  and	  preliminary	  examination	  reports,	  then	  they	  can	  decide	  to	  
pursue	  their	  applications	  in	  the	  countries	  of	  particular	  interest	  and,	  of	  course,	  also	  in	  South	  
Africa.	  Needless	  to	  say	  that	  having	  a	  South	  African	  patent	  backed	  by	  either	  the	  USPTO	  or	  
EPO	  preliminary	  examination	  or	  even	  better,	  a	  U.S.	  or	  an	  EPO	  patent,	  will	  strengthen	  their	  
position	  in	  South	  Africa.	  	  
	  
2.4. The	  Status	  of	  Nanotechnology	  Patents:	  South	  Africa	  and	  Abroad	  	  
	  
	  WIPO’s	  statistics	  for	  the	  period	  of	  2009-­‐2010	  will	  be	  relied	  upon	  to	  give	  an	  overall	  
indication	  of	  patent	  applications	  filed	  for	  the	  above	  period.	  In	  2010,	  approximately	  1.98	  
million	  patents	  were	  filed	  globally.525	  This	  represents	  a	  7.2%	  increase	  in	  patent	  applications	  
filed	  worldwide	  from	  the	  previous	  year.526	  The	  top	  five	  Patent	  Offices	  included:	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  WIPO	  Economics	  &	  Statistics	  Series	  2012	  “WIPO	  IP	  Facts	  and	  Figures”	  
http://www.wipo.int/export/sites/www/freepublications/en/statistics/943/wipo_pub_943_2012.pdf	  
(accessed	  27/05/2013)	  [At	  17]	  [Hereinafter	  “WIPO	  Statistics	  2012”]	  	  526	  WIPO	  Statistics	  2012	  
http://www.wipo.int/export/sites/www/freepublications/en/statistics/943/wipo_pub_943_2012.pdf	  
(accessed	  27/05/2013)	  [At	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1.	  USA	   	   	   490,226	   (24.8%	  of	  the	  total	  patents	  filed	  for	  above	  period)	  
2.	  China	  	   	   391,177	   (19.8%	  of	  the	  total	  patents	  filed	  for	  above	  period)	  
3.	  Japan	  	   	   344,598	   (17.4%	  of	  the	  total	  patents	  filed	  for	  above	  period)	  
4.	  Republic	  of	  Korea	   170,101	  	   (8.6%	  of	  the	  total	  patents	  filed	  for	  above	  period)	  
5.	  EPO	   	   	   150,961	   (7.6%	  of	  the	  total	  patents	  filed	  for	  above	  period)527	  
	  
Therefore	  the	  USA,	  China	  and	  Japan	  were	  responsible	  for	  62%	  of	  the	  total	  patents	  filed	  in	  
2010.	  In	  the	  field	  of	  Chemistry,	  specifically	  Micro	  structural	  technology	  and	  
Nanotechnology,	  2,466	  patents	  were	  filed	  worldwide	  (0.2%	  share	  of	  the	  total	  patents	  filed	  
in	  2010).528	  	  
	  
In	  2010,	  6,383	  patent	  applications	  were	  filed	  in	  South	  Africa.529	  This	  computes	  to	  less	  than	  
1%	  share	  of	  the	  total	  patent	  applications	  filed	  in	  this	  period.	  However	  it	  was	  recorded	  as	  the	  
highest	  number	  of	  patent	  applications	  filed	  in	  relation	  to	  the	  20	  countries	  WIPO	  listed	  as	  
“Middle-­‐and-­‐Low	  income	  countries.”530	  Furthermore,	  5	  562	  of	  these	  patent	  applications	  
were	  filed	  by	  non-­‐residents.531	  In	  2011,	  WIPO	  statistics	  revealed	  319	  international	  
applications	  were	  filed	  in	  South	  Africa	  via	  the	  PCT	  system.	  To	  put	  this	  in	  perspective	  out	  of	  
the	  1.98	  million	  patent	  applications	  filed	  worldwide	  in	  2010,	  a	  total	  of	  182,112	  were	  filed	  via	  
the	  PCT	  system.532	  In	  relation	  to	  the	  South	  African	  patent	  applications	  filed	  by	  South	  African	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  Statistics	  2012	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(accessed	  27/05/2013)	  [At	  17	  and	  35-­‐	  38]	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  WIPO	  Statistics	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(accessed	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  529	  WIPO	  Statistics	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(accessed	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  38]	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(accessed	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  2012	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  Statistics	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applicants	  that	  were	  discussed:533	  PCT	  applications	  were	  filed	  for	  all	  six534	  and	  in	  two	  cases	  
applications	  further	  prosecuted	  in	  the	  USPTO	  and	  the	  EPO,	  where	  the	  South	  African	  
applicants	  were	  granted	  U.S.	  and	  EPO	  patents.	  CSIR	  was	  granted	  patents	  for	  “Nanoparticle	  
carriers	  for	  drug	  administration	  and	  process	  for	  producing	  same”	  (US	  851	  8450	  B2;	  
	  EP	  2249817	  A1)	  and	  the	  University	  of	  the	  Witwatersrand	  for	  “A	  process	  for	  producing	  
carbon	  nanotubes”	  (US	  20080247939	  A1;	  EP	  1919826	  A1	  20080514).	  These	  U.S.	  and	  EPO	  
patents	  of	  South	  African	  origin	  demonstrate	  that	  not	  only	  research	  currently	  being	  
conducted	  in	  South	  Africa	  is	  producing	  patentable	  results	  and	  thereby	  contributing	  
positively	  to	  the	  nanotechnology	  patent	  landscape,	  but	  could	  also	  contribute	  to	  
international	  competitiveness	  of	  South	  Africa.	  	  
	  
2.5. A	  Need	  for	  Nano	  legislation	  
	  
As	  the	  South	  African	  courts	  come	  to	  deal	  with	  nanotechnology	  patent	  infringement	  cases,	  it	  
will	  become	  obvious	  as	  to	  whether	  there	  will	  be	  a	  need	  for	  extra	  guidelines	  or	  legislation	  to	  
regulate	  nano-­‐related	  inventions.	  Presently	  no	  case	  law	  exists	  to	  base	  any	  projections	  on	  
the	  future	  of	  how	  nanotechnology	  patents	  will	  be	  dealt	  with	  in	  years	  to	  come.	  
	  
3. INTERNATIONAL	  COOPERATION	  
	  
Due	  to	  the	  limited	  expertise	  and	  resources	  in	  the	  field	  of	  nanotechnology,	  there	  is	  a	  need	  
for	  South	  Africa	  to	  collaborate	  with	  other	  countries	  already	  involved	  with	  this	  technology.	  
This	  would	  not	  only	  benefit	  current	  local	  research	  but	  also	  accelerate	  the	  process	  to	  
produce	  nano-­‐related	  products	  on	  a	  commercial	  scale.	  	  
	  
South	  Africa	  has	  collaborated	  internationally	  with	  other	  countries,	  such	  as	  ESTASAP	  
(European	  South	  African	  Science	  and	  Technology	  Advancement	  Programme),535	  BRICS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  533	  See:	  Chapter	  2,	  section	  entitled:	  “2.2.	  Applications	  of	  Nanotechnology	  in	  South	  Africa”	  	  	  	  534	  See:	  ZA	  2013/04573,	  ZA	  2013/04634,	  ZA	  2013/04511,	  ZA	  2011/0535,	  ZA	  2010/06639	  and	  ZA	  2008/01689	  
[the	  last	  two	  were	  filed	  with	  both	  the	  USPTO	  and	  EPO.	  See:	  Footnotes	  511	  and	  517]	  	  	  535	  Wolbring	  http://www.innovationwatch-­‐archive.com/choiceisyours/choiceisyours-­‐2008-­‐02-­‐15.htm	  
(accessed	  21/05/2012)	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(Brazil-­‐Russia-­‐India-­‐China-­‐South	  Africa)	  and	  IBSA	  (India-­‐Brazil-­‐South	  Africa).	  These	  bilateral	  
and	  multilateral	  agreements	  ensure	  South	  Africa	  receives	  cooperation	  in	  the	  field	  of	  
nanotechnology	  from	  countries	  that	  have	  better	  established	  centres.536	  	  
	  
South	  Africa	  joined	  BRICS	  in	  2010.	  Benefits	  of	  this	  cooperation	  in	  the	  field	  of	  
nanotechnology	  include	  a	  partnership	  with	  China	  who	  is	  currently	  leading	  in	  the	  field	  of	  
nanotechnology	  (in	  relation	  to	  the	  other	  BRICS	  countries).	  International	  cooperation	  is	  
mutually	  beneficial	  to	  all	  the	  countries	  collaborating	  as	  the	  R&D	  pool	  for	  nanotechnology	  
research	  becomes	  much	  larger	  and	  will	  allow	  scientists	  from	  various	  countries	  to	  come	  
together	  and	  share	  not	  only	  their	  significant	  research	  but	  also	  other	  resources,	  such	  as	  
scientific	  facilities,	  equipment	  and	  financial	  resources.	  Cooperating	  countries	  could	  assist	  
one	  another	  in	  large-­‐scale	  research	  projects	  that	  are	  far	  too	  large	  for	  one	  country	  alone.	  
Furthermore	  due	  to	  the	  scope	  and	  complexity	  of	  nanotechnology	  South	  Africa	  could	  also	  
benefit	  from	  the	  assistance	  of	  diversely	  skilled	  scientists	  from	  other	  countries.	  	  
	  
All	  of	  the	  member	  countries	  of	  both	  IBSA	  and	  BRICS	  are	  also	  members	  of	  WTO	  and	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  Cele,	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  and	  Coville	  2009	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  537	  This	  assumption	  is	  based	  on	  a	  publication	  on	  BRIC.	  See:	  Unilink	  http://www.ip-­‐
unilink.net/public_documents/Good_Practice_Guide_web.pdf	  (accessed	  09/10/2013)	  [At	  30-­‐31]	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CONCLUSIONS	  
	  
Nanotechnology	  is	  reshaping	  technology,	  as	  we	  know	  it.	  The	  benefits,	  as	  discussed,	  are	  
diverse	  and	  there	  are	  many	  opportunities	  that	  this	  research	  will	  afford	  South	  Africans	  and	  
South	  Africa	  as	  a	  developing	  country.	  It	  is	  therefore	  important	  to	  promote	  education	  and	  
create	  awareness	  so	  that	  a	  better	  understanding	  of	  NNT	  is	  had.	  Despite	  the	  fairly	  unknown	  
long	  term	  effects	  of	  this	  new	  technology	  on	  health	  and	  the	  environment	  it	  can	  be	  said	  that	  
the	  positive	  outcomes	  hoped	  to	  be	  achieved	  have	  the	  potential	  to	  not	  only	  solve	  urgent	  
issues	  such	  as	  providing	  the	  world	  with	  clean	  drinking	  water	  or	  sustainable	  energy	  
alternatives,	  but	  also	  treat	  diseases	  in	  a	  more	  effective	  and	  less	  invasive	  way.	  	  
	  
Patenting	  nanotechnology	  inventions	  under	  the	  EPC	  and	  Title	  35	  of	  the	  U.S.C.	  may	  present	  
some	  challenges.	  The	  unique	  and	  complex	  characteristics	  of	  this	  technology	  such	  as	  its	  
multidisciplinary	  application,	  has	  made	  the	  examination	  process	  more	  difficult.	  Previously	  
technologies	  were	  more	  conventional	  in	  that	  they	  could	  be	  placed	  in	  a	  single	  category	  and	  
the	  examiner	  would	  be	  skilled	  in	  that	  specific	  field.	  Examiners	  are	  now	  confronted	  with	  
inventions	  that	  have	  diverse	  applications	  resulting	  in	  the	  claims	  being	  applicable	  in	  multiple	  
fields.	  Furthermore	  the	  examiner	  may	  not	  have	  specialised	  knowledge	  in	  all	  of	  these	  fields	  
so	  as	  to	  fully	  understand	  the	  invention,	  resulting	  in	  some	  relevant	  areas	  of	  technology	  been	  
overlooked.	  Moreover	  nanotechnology	  is	  at	  the	  early	  stages	  of	  development,	  i.e.	  mainly	  
research	  phase	  and	  as	  such	  there	  is	  limited	  prior	  art	  and	  determining	  the	  utility	  of	  the	  
claimed	  invention	  may	  be	  difficult.	  Furthermore	  the	  lack	  of	  a	  uniform	  nanotechnology	  
definition,	  as	  given	  by	  various	  institutions	  complicates	  the	  matter	  in	  accurately	  examining	  a	  
nano-­‐related	  invention.	  However,	  despite	  these	  issues	  it	  was	  concluded	  from	  the	  research	  
presented,	  that	  there	  is	  no	  need	  for	  additional,	  specific	  legislation	  or	  rules	  pertaining	  to	  
nano-­‐related	  patent	  applications.	  Many	  of	  these	  challenges	  can	  be	  overcome	  in	  terms	  of	  
current	  patent	  law	  provisions	  as	  a	  well-­‐drafted	  patent	  application	  can,	  for	  example,	  indicate	  
whether	  a	  nano-­‐related	  invention	  fulfils	  the	  prescribed	  requirements	  for	  a	  valid	  patent.	  	  
	  
Although	  patents	  are	  deemed	  valid	  upon	  their	  issuance,	  their	  validity	  can	  be	  challenged	  on	  
the	  grounds	  that	  the	  patentability	  requirements	  were	  not	  met,	  whether	  in	  a	  re-­‐examination	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or	  opposition	  proceeding	  before	  the	  USPTO	  or	  EPO,	  or	  in	  an	  infringement	  suit	  (post-­‐grant	  
proceedings,	  by	  the	  respective	  counterclaims).	  	  A	  strong,	  well-­‐drafted	  patent	  application	  is	  
imperative	  and	  can	  be	  realised	  by	  carefully	  considering	  common	  objections	  and	  criticisms	  
made	  against	  nanotechnology	  patent	  applications	  in	  the	  past	  so	  as	  to	  avoid	  these	  same	  
objections	  being	  repeated.	  Due	  to	  the	  lack	  of	  any	  examination	  in	  South	  Africa,	  the	  
substance	  of	  the	  patent	  application	  is	  not	  assessed	  and	  many	  undeserving	  inventions	  may	  
receive	  patent	  protection.	  This	  in	  turn	  creates	  an	  unclear	  patent	  landscape	  and	  uncertainty	  
relating	  to	  IPR.	  By	  implementing	  drafting	  guidelines	  the	  quality	  of	  South	  African	  patent	  
applications	  will	  vastly	  improve	  thereby	  reducing	  uncertainty	  regarding	  the	  validity	  of	  the	  
patents	  produced	  by	  the	  country	  and	  clearly	  defining	  IPR.	  Furthermore	  the	  manner	  in	  which	  
information	  relating	  to	  South	  African	  patents	  can	  be	  reviewed	  should	  be	  significantly	  
improved,	  as	  it	  is	  a	  continuing	  struggle	  to	  access	  accurate	  and	  significant	  information	  
relating	  to	  the	  content	  of	  the	  specification	  and	  status	  of	  a	  South	  African	  patent	  application.	  
This	  can	  be	  achieved	  by	  implementing	  a	  stricter	  procedure	  whereupon	  the	  CIPC	  database	  
could	  be	  updated	  regularly	  thereby	  reflecting	  the	  true	  status	  of	  patent	  applications	  filed	  in	  
South	  Africa.	  In	  addition,	  providing	  an	  abstract	  of	  the	  invention	  would	  be	  invaluable	  to	  
those	  seeking	  information	  on	  the	  state	  of	  art.	  	  
	  
This	  study	  has	  compared	  the	  treatment	  of	  nanotechnology	  related	  inventions	  by	  the	  USPTO	  
and	  EPO	  to	  that	  of	  South	  Africa.	  Due	  to	  the	  examination	  of	  U.S.	  and	  European	  patent	  
applications,	  the	  validity	  of	  the	  invention	  claimed	  can	  be	  determined	  by	  addressing	  whether	  
the	  requirements	  for	  a	  valid	  patent	  have	  been	  met.	  In	  contrast,	  South	  Africa	  does	  not	  share	  
this	  examination	  approach	  and	  there	  are	  some	  foreseeable	  problems	  with	  this	  practice.	  For	  
instance,	  basic	  formal	  requirements	  for	  a	  valid	  patent	  may	  be	  overlooked;	  “double”	  patents	  
may	  be	  granted	  (double	  patents	  occur	  when	  a	  patent	  is	  granted	  for	  the	  same	  or	  a	  similar	  
subject	  matter	  found	  in	  an	  earlier	  patent).	  It	  was	  suggested	  that	  South	  Africa	  establish	  
agreements	  with	  the	  EPO	  or	  other	  Patent	  Offices	  that	  would	  be	  willing	  to	  examine	  South	  
African	  patent	  applications.	  
	  
However	  the	  South	  African	  government	  is	  in	  the	  process	  of	  reforming	  the	  current	  Patent	  Act	  
57	  of	  1978	  in	  the	  form	  of	  the	  Draft	  National	  Policy	  on	  Intellectual	  Property	  of	  South	  Africa,	  
which	  was	  published	  on	  4	  September	  2013.	  This	  progress	  indicates	  a	  local	  consciousness	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that	  current	  patent	  practices	  should	  be	  re-­‐addressed	  and	  potentially	  improved	  upon.	  Some	  
of	  the	  objectives	  of	  this	  policy	  include:	  strengthening	  the	  patentability	  criteria	  and	  
implementing	  an	  examination	  process:	  however	  this	  will	  be	  limited	  to	  pharmaceutical	  
products	  only.	  Despite	  the	  implementation	  of	  examination	  being	  limited	  to	  pharmaceutical	  
products,	  this	  policy	  is	  a	  positive	  step	  towards	  elevating	  current	  patent	  law	  practices.	  
	  	  
As	  nanotechnology	  is	  presently	  at	  its	  early	  stages	  of	  development,	  many	  of	  the	  unique	  
challenges	  facing	  nanotechnology	  inventions,	  for	  example	  definitional	  and	  prior	  art	  issues,	  
will	  be	  resolved	  as	  the	  courts	  face	  more	  infringement	  cases.	  This	  is	  likely	  to	  happen	  as	  more	  
products	  come	  into	  the	  market.	  In	  relation	  to	  South	  Africa	  specifically,	  it	  is	  suggested	  that	  
South	  African	  courts	  familiarize	  themselves	  with	  the	  case	  law	  of	  examining	  countries,	  such	  
as	  Germany	  and	  the	  United	  Kingdom	  or	  USA.	  Although	  it	  is	  entirely	  at	  the	  discretion	  of	  the	  
court	  to	  do	  so,	  this	  would	  provide	  valuable	  insight	  and	  guidance,	  as	  it	  is	  likely	  that	  foreign	  
courts	  will	  experience	  these	  issues	  first.	  	  	  
	  
Prospects	  for	  international	  harmonisation	  of	  practices	  amongst	  all	  Patent	  Offices	  around	  
the	  world	  would	  aid	  in	  reducing	  uncertainties	  regarding	  the	  extent	  of	  IP	  rights	  conferred	  by	  
nanotechnology	  patents,	  i.e.	  by	  adopting	  consistent	  and	  co-­‐ordinated	  patent	  application	  
practices,	  thereby	  simplifying	  the	  subsequent	  management	  of	  patents.	  Understandably	  this	  
will	  be	  a	  long	  process	  involving	  many	  compromises	  in	  respect	  of	  the	  different	  approaches	  
adopted	  by	  various	  countries,	  but	  would	  allow	  for	  new	  technologies,	  such	  as	  
nanotechnology,	  to	  be	  dealt	  with	  in	  the	  same	  consistent	  manner	  within	  a	  reliable	  
framework	  of	  standard	  practices.	  	  
	  
In	  the	  context	  of	  local	  developments,	  collaborations	  of	  CIPC	  with	  foreign	  agencies	  could	  
provide	  insight	  as	  to	  how	  some	  of	  the	  challenges	  presented	  by	  nanotechnology	  can	  be	  
overcome	  thereby	  improving	  existing	  practices.	  Should	  the	  present	  thesis	  contribute	  to	  a	  
better	  understanding	  of	  the	  problems	  addressed	  therein	  in	  South	  Africa	  and	  bring	  current	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